WSJ900801-0140 <DOCNO>
It <PRP>
would <MD>
also <RB>
clear <VB>
the <DT>
way <NN>
for <IN>
Schering-Plough <JJ>
Corp. <NNP>
to <TO>
market <NN>
the <DT>
biotechnology_product <NN>
for <IN>
a <DT>
form <NN>
of <IN>
the <DT>
disease <NN>
which <WDT>
is <VBZ>
formally <RB>
known <VBN>
as <IN>
chronic <JJ>
non-A <NNP>
, <,>
non-B <NNP>
hepatitis <VBZ>
. <.>
About <IN>
half_a <DT>
million <NN>
Americans <NNPS>
now <RB>
suffer <VBP>
this <DT>
form <NN>
of <IN>
liver_inflammation <NN>
, <,>
which <WDT>
is <VBZ>
spread <VBN>
by <IN>
tainted <VBN>
blood <NN>
transfusions <NNS>
, <,>
unclean_hypodermic <JJ>
needles <NNS>
and <CC>
sexual <JJ>
contact <NN>
. <.>
About <IN>
150 <CD>
, <,>
000 <CD>
new <JJ>
cases <NNS>
are <VBP>
diagnosed <VBN>
each <DT>
year <NN>
, <,>
of <IN>
which <WDT>
half <DT>
progress <NN>
to <TO>
a <DT>
state <NN>
of <IN>
chronic <JJ>
infection <NN>
. <.>
A <DT>
virus <NN>
responsible <JJ>
for_about <IN>
85 <CD>
% <NN>
of <IN>
such <JJ>
cases <NNS>
was <VBD>
recently <RB>
identified <VBD>
and <CC>
dubbed <VBN>
hepatitis <NNS>
C <NNP>
, <,>
making <VBG>
antibody_testing <NN>
possible <JJ>
. <.>
World-wide <JJ>
, <,>
the <DT>
number <NN>
of <IN>
cases <NNS>
of <IN>
the <DT>
disease <NN>
is <VBZ>
increasing <VBG>
and <CC>
has <VBZ>
assumed <VBN>
`` <``>
epidemic <JJ>
'' <''>
proportions <NNS>
in <IN>
Japan <NNP>
, <,>
according <VBG>
to <TO>
Robert_J._Spiegel <NNP>
, <,>
a <DT>
Schering <NNP>
vice_president <NN>
of <IN>
clinical <JJ>
research <NN>
. <.>
Chronic <NNP>
hepatitis <VBZ>
sufferers <NNS>
, <,>
who <WP>
are <VBP>
at <IN>
increased <VBN>
risk <NN>
of <IN>
death <NN>
from <IN>
cirrhosis <NN>
of <IN>
the <DT>
liver <NN>
or <CC>
liver <RB>
cancer <NN>
, <,>
would <MD>
be <VB>
candidates <NNS>
for <IN>
alpha_interferon_treatment <NN>
under <IN>
the <DT>
panel's <NNP>
recommendation <NN>
. <.>
Schering <VBG>
, <,>
based <VBN>
in <IN>
Kenilworth <NNP>
, <,>
N.J. <NNP>
, <,>
said <VBD>
it <PRP>
was <VBD>
'' <''>
immensely <RB>
pleased <VBN>
'' <''>
by <IN>
yesterday <NN>
's <POS>
action <NN>
, <,>
which <WDT>
virtually <RB>
ensures <VBZ>
a <DT>
much <JJ>
broader_market <NN>
for <IN>
interferon <NN>
. <.>
The <DT>
drug <NN>
previously <RB>
has <VBZ>
been_approved <VBN>
for <IN>
only <RB>
a <DT>
few_small <JJ>
niches <NNS>
, <,>
mostly <RB>
in <IN>
cancer_treatment <NN>
. <.>
The <DT>
action <NN>
also <RB>
marks <VBZ>
a <DT>
major <JJ>
milestone <NN>
in <IN>
the <DT>
evolution <NN>
of <IN>
biotechnology_industry <NN>
, <,>
where <WRB>
interferon <NN>
held <VBN>
the <DT>
rank <NN>
of <IN>
a <DT>
pioneer <NN>
, <,>
previously <RB>
consigned <VBD>
to <TO>
play <VB>
a <DT>
bit_part <NN>
, <,>
but <CC>
now <RB>
stepping <VBG>
up <RP>
to <TO>
fill <VB>
what <WP>
may <MD>
become <VB>
a <DT>
major <JJ>
role <NN>
. <.>
In <IN>
New_York_Stock_Exchange <NNP>
composite <JJ>
trading <NN>
, <,>
Schering <NNP>
closed <VBD>
at <IN>
$ <$>
48.875 <CD>
, <,>
up <RB>
37.5 <CD>
cents <NNS>
. <.>
To <TO>
win <VB>
the <DT>
panel <NN>
's <POS>
approval <NN>
, <,>
Schering <NNP>
scientists <NNS>
presented <VBD>
data <NNS>
on <IN>
more <JJR>
than <IN>
300 <CD>
patients <NNS>
, <,>
showing <VBG>
that <IN>
liver <JJR>
inflammation <NN>
subsided <VBD>
in <IN>
53 <CD>
% <NN>
of <IN>
the <DT>
patients <NNS>
treated <VBD>
with <IN>
alpha_interferon <NN>
, <,>
as <IN>
opposed <VBN>
to <TO>
7 <CD>
% <NN>
of <IN>
untreated <VBN>
patients <NNS>
. <.>
Conversely <RB>
, <,>
16 <CD>
% <NN>
of <IN>
the <DT>
untreated <VBN>
control_group <NN>
worsened <VBD>
during <IN>
the <DT>
study <NN>
, <,>
compared <VBN>
with <IN>
2 <CD>
% <NN>
of <IN>
the <DT>
treated <VBN>
group <NN>
. <.>
`` <``>
These <DT>
are <VBP>
impressive <JJ>
data <NNS>
, <,>
'' <''>
said <VBD>
Jordan_Gutterman <NNP>
, <,>
a <DT>
panel_member <NN>
and <CC>
a <DT>
pioneer_interferon_researcher <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
Texas <NNP>
's <POS>
M.D <JJ>
. <.>
Anderson_Cancer_Center <NNP>
. <.>
Side <NNP>
effects <NNS>
consisted <VBD>
mostly <RB>
of <IN>
flu-like <JJ>
symptoms <NNS>
including <VBG>
fatigue <NN>
and <CC>
nausea <NN>
. <.>
To <TO>
date <NN>
, <,>
interferon <NN>
has <VBZ>
received <VBN>
approval <NN>
for <IN>
use <NN>
in <IN>
a <DT>
rare_cancer <NN>
known <VBN>
as <IN>
hairy-cell <NNP>
leukemia <NN>
, <,>
which <WDT>
affects <NNS>
about <IN>
2 <CD>
, <,>
500 <CD>
people <NNS>
in <IN>
the <DT>
U.S. <NNP>
, <,>
and <CC>
in <IN>
Kaposi <NNP>
's <POS>
Sarcoma <NNP>
, <,>
an <DT>
AIDS-related <JJ>
malignancy <NN>
with <IN>
a <DT>
roughly <RB>
equal <JJ>
number <NN>
of <IN>
patients <NNS>
, <,>
Schering <NNP>
said <VBD>
. <.>
The <DT>
FDA <NNP>
has <VBZ>
also <RB>
approved <VBD>
its <PRP$>
use <NN>
in <IN>
treating_genital <NN>
warts <NNS>
. <.>
But <CC>
analysts <NNS>
said <VBD>
FDA <NNP>
approval <NN>
for <IN>
chronic <JJ>
non-A <NN>
, <,>
non-B <NNP>
hepatitis <VBZ>
would <MD>
expand <VB>
its <PRP$>
potential <JJ>
market <NN>
at <IN>
least <JJS>
five-fold <JJ>
. <.>
`` <``>
We <PRP>
see <VBP>
this <DT>
as <IN>
adding <NN>
another <DT>
$ <$>
100_million <CD>
to <TO>
Schering <NNP>
's <POS>
annual <JJ>
interferon <NN>
sales <NNS>
, <,>
'' <''>
doubling <VBG>
last <JJ>
year's <NNS>
level <NN>
, <,>
said <VBD>
Michael_Sorell <NNP>
, <,>
an <DT>
analyst <NN>
with <IN>
Morgan_Stanley <NNP>
in <IN>
New_York <NNP>
. <.>
Looking <VBG>
ahead <RB>
to <TO>
continuing <VBG>
studies <NNS>
in <IN>
other <JJ>
cancers <NNS>
, <,>
not <RB>
to <TO>
mention <VB>
in <IN>
AIDS <NNP>
and <CC>
hepatitis <VBZ>
B <NNP>
, <,>
Dr._Sorell <NNP>
predicted <VBD>
$ <$>
300_million <CD>
to <TO>
$ <$>
400_million <CD>
in <IN>
sales <NNS>
`` <``>
looks <NNS>
readily <RB>
achievable <JJ>
'' <''>
by <IN>
1993 <CD>
to <TO>
1994 <CD>
. <.>
In <IN>
the <DT>
evolution <NN>
of <IN>
biotechnology <NN>
, <,>
Schering <NNP>
's <POS>
Dr._Spielgel <NNP>
said <VBD>
, <,>
`` <``>
Interferon <NNP>
is <VBZ>
an <DT>
interesting <JJ>
story <NN>
as <IN>
the <DT>
pioneering_biotech_product <NN>
. <.>
`` <``>
It <PRP>
may <MD>
also <RB>
prove <VB>
to <TO>
be <VB>
a <DT>
classic <JJ>
case_history <NN>
of <IN>
the <DT>
new_biological <JJ>
agents <NNS>
which <WDT>
start <NN>
small <JJ>
, <,>
and <CC>
expand <NN>
to <TO>
fill <VB>
larger <JJR>
therapeutic <JJ>
roles <NNS>
as <IN>
scientific <JJ>
knowledge <NN>
about <IN>
their <PRP$>
activity <NN>
in <IN>
the <DT>
body <NN>
and <CC>
their <PRP$>
potential <JJ>
use <NN>
expands <NNS>
. <.>
Interferon <NNP>
was <VBD>
touted <VBN>
in <IN>
the <DT>
1970s <CD>
as <IN>
a <DT>
panacea <NN>
, <,>
only <RB>
to <TO>
prove <VB>
disappointing <JJ>
and <CC>
only_narrowly <RB>
useful <JJ>
at <IN>
first <JJ>
. <.>
`` <``>
A <DT>
few <JJ>
years <NNS>
ago <RB>
, <,>
when <WRB>
interleukin-2 <-NONE->
made <VBN>
the <DT>
headlines <NNS>
, <,>
people <NNS>
said <VBD>
: <:>
`Interferon <JJ>
-- <:>
so <IN>
what <WP>
? <.>
' <POS>
'' <''>
Dr._Spiegel <NNP>
said <VBD>
. <.>
`` <``>
But <CC>
it's <VBZ>
stood <NN>
the <DT>
test <NN>
of <IN>
time <NN>
, <,>
and <CC>
today <NN>
's <POS>
action <NN>
puts <NNS>
us <PRP>
in <IN>
a <DT>
whole_new <JJ>
league <NN>
. <.>
`` <``>
On <IN>
Monday <NNP>
, <,>
an <DT>
FDA <NNP>
panel <NN>
withheld <VBD>
approval <NN>
from <IN>
interleukin-2 <-NONE->
as <IN>
a <DT>
treatment <NN>
for <IN>
kidney_cancer <NN>
, <,>
demanding <VBG>
additional <JJ>
information <NN>
from <IN>
its <PRP$>
maker <NN>
, <,>
Cetus_Corp. <NNP>
of <IN>
Emeryville <NNP>
, <,>
Calif <NNP>
. <.>
In <IN>
a <DT>
separate <JJ>
action <NN>
, <,>
the <DT>
FDA <NNP>
advisory_panel <NN>
recommended <VBD>
that <IN>
the <DT>
agency_grant <NN>
Treatment_IND_( <NNP>
investigational_new <JJ>
drug <NN>
) <:>
status <NN>
to <TO>
Immunex_Corp. <NNP>
's <POS>
GM-CSF <JJ>
product <NN>
. <.>
GHM-CSF <JJ>
is <VBZ>
a <DT>
blood-cell <JJ>
growth_factor <NN>
that <IN>
shows <VBZ>
promise <NN>
as <IN>
a <DT>
treatment <NN>
for <IN>
bone_marrow_transplant_failure <NN>
in <IN>
cancer <NN>
patients <NNS>
and <CC>
those <DT>
suffering <NN>
certain <JJ>
kinds <NNS>
of <IN>
anemia <NN>
. <.>
However <RB>
, <,>
the <DT>
panel <NN>
asked <VBD>
Seattle-based <JJ>
Immunex <NNP>
for <IN>
more <JJR>
study <NN>
data <NNS>
before <IN>
making <VBG>
a <DT>
formal <JJ>
recommendation <NN>
to <TO>
the <DT>
FDA <NNP>
on <IN>
market_approval <NN>
. <.>
Treatment_IND <NNP>
status <NN>
would <MD>
make <VB>
the <DT>
drug <NN>
more <JJR>
widely <RB>
available_free <JJ>
of <IN>
charge <NN>
to <TO>
patients <NNS>
during <IN>
studies <NNS>
. <.>
About <IN>
5 <CD>
, <,>
000 <CD>
patients <NNS>
receive <JJ>
bone_marrow <NN>
transplants <NNS>
each <DT>
year <NN>
AP900419-0001 <DOCNO>
. <.>
A <DT>
single <JJ>
round <NN>
of <IN>
treatment <NN>
with <IN>
an <DT>
experimental_new <JJ>
medicine <NN>
appears <VBZ>
to <TO>
be <VB>
highly <RB>
effective <JJ>
against <IN>
a <DT>
rare_form <NN>
of <IN>
leukemia <NN>
and <CC>
may <MD>
help <VB>
fight <NN>
other <JJ>
kinds <NNS>
of <IN>
blood_cancer <NN>
as <IN>
well <RB>
, <,>
says <VBZ>
a <DT>
study <NN>
published <VBN>
today <NN>
. <.>
The <DT>
new <JJ>
drug <NN>
was <VBD>
developed <VBN>
at <IN>
Scripps_Clinic <NNP>
and <CC>
Research_Foundation <NNP>
in <IN>
La_Jolla <NNP>
, <,>
Calif. <NNP>
, <,>
where <WRB>
doctors <NNS>
tested <VBN>
it <PRP>
on <IN>
patients <NNS>
with <IN>
hairy_cell_leukemia <NN>
. <.>
In <IN>
almost <RB>
every <DT>
case <NN>
, <,>
the <DT>
medicine <NN>
erased <VBD>
all <DT>
signs <NNS>
of <IN>
the <DT>
disease <NN>
. <.>
Hairy <NNP>
cell <VBD>
leukemia <NN>
affects <NNS>
the <DT>
white <JJ>
blood <NN>
cells <NNS>
that <WDT>
make <VBP>
disease-fighting <JJ>
antibodies <NNS>
. <.>
Doctors <NNS>
are <VBP>
also <RB>
testing <VBG>
the <DT>
drug <NN>
against <IN>
chronic_lymphocytic <JJ>
leukemia <NN>
, <,>
non-Hodgkins <VBZ>
lymphoma <NN>
and <CC>
cutaneous <JJ>
T <NNP>
cell_lymphoma <NN>
. <.>
The <DT>
Scripps <NNP>
doctors <NNS>
concluded <VBD>
that <IN>
the <DT>
medicine <NN>
, <,>
called <VBN>
2-chlorodeoxyadenosine <CD>
, <,>
or <CC>
2-CdA <CD>
, <,>
`` <``>
may <MD>
well <RB>
be <VB>
the <DT>
drug <NN>
of <IN>
choice <NN>
in <IN>
the <DT>
treatment <NN>
of <IN>
hairy_cell_leukemia <NN>
. <.>
'' <''>
The <DT>
study <NN>
was <VBD>
directed <VBN>
by <IN>
Dr._Lawrence_D._Piro <NNP>
and <CC>
published <VBD>
in <IN>
the <DT>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
. <.>
In <IN>
their <PRP$>
study <NN>
, <,>
doctors <NNS>
gave <VBD>
the <DT>
drug <NN>
to <TO>
12 <CD>
patients <NNS>
. <.>
Of <IN>
these <DT>
, <,>
11 <CD>
have <VBP>
remained <VBN>
completely <RB>
free <JJ>
of <IN>
all <DT>
signs <NNS>
of <IN>
the <DT>
disease <NN>
for <IN>
periods <NNS>
up <IN>
to <TO>
four <CD>
years <NNS>
. <.>
The <DT>
doctors <NNS>
cautioned <VBD>
that <IN>
longer <JJR>
follow-up <JJ>
will <MD>
be <VB>
necessary <JJ>
before <IN>
they <PRP>
can <MD>
be <VB>
sure <JJ>
they <PRP>
have <VBP>
actually <RB>
cured <VBN>
the <DT>
disease <NN>
. <.>
Two <CD>
other <JJ>
treatments <NNS>
for <IN>
hairy_cell_leukemia <NN>
have <VBP>
been_developed <VBN>
in <IN>
recent <JJ>
years <NNS>
. <.>
They <PRP>
are <VBP>
interferon <RB>
and <CC>
deoxycoformycin <VB>
, <,>
a <DT>
drug <NN>
that <WDT>
is <VBZ>
similar <JJ>
to <TO>
2-CdA <CD>
. <.>
However <RB>
, <,>
interferon <NN>
is <VBZ>
less <JJR>
effective <JJ>
, <,>
and <CC>
both <DT>
of <IN>
those <DT>
treatments <NNS>
produce <VBP>
serious <JJ>
side <NN>
effects <NNS>
. <.>
By <IN>
contrast <NN>
, <,>
the <DT>
only_unwanted <JJ>
effect <NN>
of <IN>
2-CdA <CD>
was <VBD>
a <DT>
few <JJ>
days <NNS>
of <IN>
fever <NN>
. <.>
Patients <NNS>
experienced <VBD>
no <DT>
nausea <NN>
, <,>
hair_loss <NN>
, <,>
rashes <VBZ>
or <CC>
other <JJ>
symptoms <NNS>
typical <JJ>
of <IN>
cancer_therapy <NN>
. <.>
Also <RB>
unlike <VBP>
other <JJ>
treatments <NNS>
, <,>
this <DT>
one <CD>
appears <VBZ>
to <TO>
work <VB>
after <IN>
a <DT>
single <JJ>
seven-day_course <NN>
of <IN>
therapy <NN>
. <.>
The <DT>
Scripps_Clinic <NNP>
reached <VBD>
an <DT>
agreement <NN>
recently <RB>
with <IN>
Johnson <NNP>
& <CC>
amp <VB>
; <:>
Johnson <NNP>
's <POS>
Ortho <NNP>
Pharmaceuticals <NNPS>
to <TO>
produce <VB>
the <DT>
drug <NN>
, <,>
which <WDT>
is <VBZ>
not_yet <RB>
approved <VBD>
for <IN>
routine_use <NN>
AP900104-0061 <DOCNO>
. <.>
Chemotherapy <NNP>
drugs <NNS>
that <WDT>
were <VBD>
used <VBN>
to <TO>
treat <VB>
ovarian <JJ>
cancer <NN>
may <MD>
have <VB>
sharply <RB>
increased <VBN>
the <DT>
risk <NN>
of <IN>
leukemia <NN>
, <,>
a <DT>
study <NN>
has <VBZ>
found <VBN>
. <.>
Researchers <NNS>
found <VBD>
that_among <IN>
women <NNS>
treated <VBN>
between <IN>
1960 <CD>
and <CC>
1985 <CD>
, <,>
the <DT>
risk <NN>
of <IN>
leukemia <NN>
was <VBD>
12 <CD>
times <NNS>
higher <JJR>
in <IN>
those <DT>
who <WP>
received <VBN>
chemotherapy <VBP>
rather <RB>
than <IN>
surgery <NN>
alone <RB>
, <,>
according <VBG>
to <TO>
the <DT>
study <NN>
published <VBD>
in <IN>
today <NN>
's <POS>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
. <.>
Although <IN>
the <DT>
study <NN>
did <VBD>
not <RB>
measure <VB>
the <DT>
benefits <NNS>
of <IN>
treatment <NN>
, <,>
chemotherapy <NN>
drugs <NNS>
given <VBN>
during <IN>
that <DT>
time <NN>
frequently <RB>
failed <VBD>
to <TO>
stop <VB>
ovarian <JJ>
cancer <NN>
. <.>
But <CC>
doctors <NNS>
say <VBP>
that <IN>
newer <JJR>
drugs <NNS>
now <RB>
in <IN>
use <NN>
against <IN>
this <DT>
form <NN>
of <IN>
cancer <NN>
are <VBP>
more <RBR>
effective <JJ>
, <,>
and <CC>
their <PRP$>
benefits <NNS>
probably <RB>
outweigh <JJ>
their <PRP$>
risks <NNS>
. <.>
The <DT>
research <NN>
, <,>
directed <VBD>
by <IN>
Dr._John_M._Kaldor <NNP>
of <IN>
the <DT>
International_Agency <NNP>
for <IN>
Research <NNP>
on <IN>
Cancer <NNP>
in <IN>
Lyon <NNP>
, <,>
France <NNP>
, <,>
was <VBD>
based <VBN>
on <IN>
114 <CD>
women <NNS>
with <IN>
leukemia <NNS>
who <WP>
were <VBD>
among <IN>
99 <CD>
, <,>
113 <CD>
survivors <NNS>
of <IN>
ovarian <JJ>
cancer <NN>
in <IN>
seven <CD>
European <JJ>
countries <NNS>
and <CC>
Canada <NNP>
. <.>
Doctors <NNS>
have <VBP>
long <RB>
known <VBN>
that <IN>
the <DT>
powerful <JJ>
medicines <NNS>
used <VBN>
to <TO>
attack <VB>
cancer <NN>
may <MD>
also <RB>
cause <VB>
the <DT>
disease <NN>
. <.>
The <DT>
latest <JJS>
research <NN>
demonstrates <NNS>
the <DT>
magnitude <NN>
of <IN>
this <DT>
risk <NN>
. <.>
In <IN>
a <DT>
second <JJ>
study <NN>
, <,>
the <DT>
same <JJ>
researchers <NNS>
found <VBD>
that <IN>
the <DT>
risk <NN>
of <IN>
leukemia <NN>
is <VBZ>
also_substantially <RB>
increased <VBN>
in <IN>
people <NNS>
given <VBN>
chemotherapy <NN>
for <IN>
Hodgkin <NNP>
's <POS>
disease <NN>
, <,>
another <DT>
form <NN>
of <IN>
cancer <NN>
. <.>
But <CC>
since <IN>
Hodgkin <NNP>
's <POS>
disease <NN>
is <VBZ>
often <RB>
curable <JJ>
with <IN>
drugs <NNS>
, <,>
the <DT>
benefits <NNS>
of <IN>
treatment <NN>
clearly <RB>
outweigh <JJ>
the <DT>
risks <NNS>
. <.>
In <IN>
this <DT>
work <NN>
, <,>
the <DT>
doctors <NNS>
reviewed <VBD>
163 <CD>
cases <NNS>
of <IN>
leukemia <NN>
among <IN>
29 <CD>
, <,>
552 <CD>
Hodgkin <NNP>
's <POS>
disease <NN>
patients <NNS>
. <.>
They <PRP>
found <VBD>
that <IN>
the <DT>
risk <NN>
of <IN>
leukemia <NN>
was <VBD>
nine <CD>
times <NNS>
higher <JJR>
among <IN>
those <DT>
who <WP>
got <VBD>
chemotherapy <VBP>
instead <RB>
of <IN>
radiation_treatment <NN>
. <.>
`` <``>
The <DT>
risk <NN>
in <IN>
Hodgkin <NNP>
's <POS>
disease <NN>
is <VBZ>
well <RB>
worth <JJ>
it <PRP>
, <,>
because <IN>
the <DT>
treatment <NN>
does <VBZ>
extend_life <NN>
. <.>
In <IN>
ovarian <JJ>
cancer <NN>
, <,>
it <PRP>
's <VBZ>
not_necessarily <RB>
worth <JJ>
it <PRP>
, <,>
'' <''>
commented <VBD>
Dr._Charles_A._Coltman_Jr. <NNP>
of <IN>
the <DT>
University <NNP>
of <IN>
Texas_Health_Science_Center <NNP>
at <IN>
San_Antonio <NNP>
. <.>
Several <JJ>
of <IN>
the <DT>
cancer <NN>
drugs <NNS>
taken <VBN>
by <IN>
the <DT>
European <NNP>
women <NNS>
for <IN>
ovarian <JJ>
cancer <NN>
are <VBP>
no <RB>
longer <RBR>
used <VBN>
. <.>
`` <``>
Management <NN>
of <IN>
ovarian <JJ>
cancer <NN>
is <VBZ>
moving <VBG>
ahead_very_rapidly <RB>
, <,>
'' <''>
said <VBD>
Coltman <NNP>
. <.>
`` <``>
Some <DT>
of <IN>
the <DT>
more <RBR>
recent <JJ>
studies <NNS>
suggest <VBP>
an <DT>
impact <NN>
on <IN>
survival <NN>
'' <''>
that <WDT>
outweighs <VBZ>
the <DT>
increased <VBN>
risk <NN>
of <IN>
leukemia <NN>
AP880630-0223 <DOCNO>
. <.>
Scientists <NNS>
say <VBP>
they <PRP>
took <VBD>
a <DT>
step <NN>
toward <IN>
improving <VBG>
bone_marrow <NN>
transplants <NNS>
for <IN>
people <NNS>
with <IN>
cancer <NN>
and <CC>
radiation_sickness <NN>
by <IN>
purifying <NN>
, <,>
or <CC>
isolating <VBG>
, <,>
a <DT>
type <NN>
of <IN>
cell <NN>
crucial <JJ>
to <TO>
development <NN>
of <IN>
blood <NN>
and <CC>
immunity <NN>
in <IN>
mice <NN>
. <.>
Isolation <NN>
of <IN>
the <DT>
special <JJ>
cell_type <NN>
, <,>
called <VBN>
a <DT>
stem_cell <NN>
, <,>
eluded <VBD>
researchers <NNS>
for <IN>
30 <CD>
years <NNS>
until <IN>
achieved <JJ>
by <IN>
doctors <NNS>
at <IN>
Stanford_University_Medical_Center <NNP>
in <IN>
Northern_California <NNP>
and <CC>
Royal_Melbourne_Hospital <NNP>
in <IN>
Australia <NNP>
. <.>
The <DT>
research <NN>
is <VBZ>
outlined <VBN>
in <IN>
Friday <NNP>
's <POS>
issue <NN>
of <IN>
the <DT>
journal <NN>
Science <NNP>
. <.>
The <DT>
researchers <NNS>
are <VBP>
well <RB>
on <IN>
their <PRP$>
way <NN>
to <TO>
purifying_human_stem <NN>
cells <NNS>
and <CC>
growing <VBG>
them <PRP>
in <IN>
the <DT>
laboratory <NN>
, <,>
an <DT>
accomplishment <NN>
that <IN>
could <MD>
make <VB>
bone_marrow_transplantation_safer <NN>
and <CC>
more <JJR>
available <JJ>
, <,>
said <VBD>
Dr._Irving_Weissman <NNP>
, <,>
a <DT>
Stanford <NNP>
professor <NN>
of <IN>
pathology <NN>
and <CC>
cancer_biology <NN>
who <WP>
headed <VBN>
the <DT>
study_team <NN>
. <.>
Bone_marrow <NN>
transplants <NNS>
are <VBP>
used <VBN>
to <TO>
replace <VB>
damaged <JJ>
or <CC>
diseased <VBN>
marrow <NN>
, <,>
the <DT>
substance_inside <NN>
bones <NNS>
that <WDT>
produces <VBZ>
blood <NN>
and <CC>
provides <VBZ>
immunity <NN>
from <IN>
disease <NN>
. <.>
Transplant <NNP>
recipients <NNS>
include <VBP>
some <DT>
leukemia <NN>
patients <NNS>
, <,>
other <JJ>
cancer <NN>
patients <NNS>
made <VBN>
ill <NN>
by <IN>
chemotherapy <NN>
and <CC>
radiation_therapy <NN>
, <,>
people <NNS>
sickened <VBD>
by <IN>
accidental <JJ>
radiation_exposure <NN>
, <,>
and <CC>
those <DT>
with <IN>
certain <JJ>
disorders <NNS>
of <IN>
the <DT>
blood <NN>
and <CC>
the <DT>
immune_system <NN>
. <.>
Only <RB>
about <IN>
one <CD>
in <IN>
20 <CD>
, <,>
000 <CD>
cells <NNS>
in <IN>
bone_marrow <NN>
is <VBZ>
a <DT>
stem_cell <NN>
, <,>
said <VBD>
Weissman <NNP>
. <.>
But <CC>
the <DT>
rare <NN>
cells <NNS>
are <VBP>
ultimately <RB>
responsible <JJ>
for <IN>
making <VBG>
and <CC>
replacing <VBG>
other_short-lived <JJ>
blood <NN>
cells <NNS>
, <,>
including <VBG>
red <VBN>
cells <NNS>
, <,>
platelets <NNS>
and <CC>
the <DT>
B <NNP>
and <CC>
T <NNP>
types <NNS>
of <IN>
white <JJ>
blood <NN>
cells <NNS>
responsible <JJ>
for <IN>
immunity <NN>
. <.>
As <IN>
a <DT>
result <NN>
, <,>
stem <NN>
cells <NNS>
are <VBP>
the <DT>
most <RBS>
important <JJ>
part <NN>
of <IN>
transplanted <VBN>
bone_marrow <NN>
. <.>
But <CC>
such <JJ>
transplants <NNS>
often <RB>
fail <VBP>
unless <IN>
the <DT>
donor <NN>
and <CC>
recipient <JJ>
are <VBP>
matched <VBN>
closely <RB>
. <.>
That <DT>
's <VBZ>
because <IN>
some <DT>
white <JJ>
blood <NN>
cells <NNS>
in <IN>
donor_marrow_attack <NN>
the <DT>
recipient <JJ>
's <POS>
tissues <NNS>
in <IN>
a <DT>
sort <NN>
of <IN>
reverse_rejection <NN>
called <VBN>
graft-versus-host <-NONE->
disease <NN>
. <.>
If <IN>
human <JJ>
stem <NN>
cells <NNS>
can <MD>
be <VB>
purified <VBN>
, <,>
they <PRP>
might <MD>
be <VB>
transplanted <VBN>
without <IN>
other <JJ>
cells <NNS>
in <IN>
bone_marrow <NN>
, <,>
thus <RB>
avoiding <VBG>
the <DT>
failure <NN>
of <IN>
the <DT>
transplants <NNS>
, <,>
Weissman <NNP>
said <VBD>
. <.>
Purified <NNP>
human_stem <NN>
cells <NNS>
also <RB>
could <MD>
eliminate <VB>
the <DT>
need <NN>
to <TO>
find <VB>
closely <RB>
matched <VBN>
marrow <NN>
donors <NNS>
, <,>
making <VBG>
marrow <NN>
transplants <NNS>
more <RBR>
widely <RB>
available <JJ>
, <,>
he <PRP>
added <VBD>
. <.>
Pure_stem <NN>
cells <NNS>
also <RB>
could <MD>
make <VB>
it <PRP>
safer <JJR>
for <IN>
leukemia <NN>
patients <NNS>
to <TO>
have <VB>
some <DT>
of <IN>
their <PRP$>
own <JJ>
marrow <NN>
removed <VBD>
and <CC>
then <RB>
have <VBP>
it <PRP>
replaced <VBD>
later <JJ>
after <IN>
they <PRP>
have <VBP>
been_subjected <VBN>
to <TO>
radiation_therapy <NN>
. <.>
Radiation <NN>
kills <NNS>
the <DT>
remaining <VBG>
marrow <NN>
at <IN>
the <DT>
same <JJ>
time <NN>
it <PRP>
kills <VBZ>
cancer <NN>
cells <NNS>
in <IN>
marrow <NN>
, <,>
he <PRP>
said <VBD>
. <.>
When <WRB>
leukemia <NN>
patients <NNS>
have <VBP>
some <DT>
marrow <NN>
removed <VBD>
and <CC>
later <JJ>
replaced <VBD>
, <,>
it <PRP>
can <MD>
contain <VB>
some <DT>
cancer <NN>
cells <NNS>
, <,>
which <WDT>
spur_recurrence <NN>
of <IN>
the <DT>
leukemia <NN>
, <,>
or <CC>
blood_cancer <NN>
. <.>
By <IN>
separating_stem <NN>
cells <NNS>
from <IN>
the <DT>
extracted <VBN>
marrow <NN>
, <,>
the <DT>
stem <NN>
cells <NNS>
can <MD>
be <VB>
reimplanted <VBN>
free <JJ>
of <IN>
any <DT>
cancer <NN>
cells <NNS>
, <,>
preventing <VBG>
the <DT>
cancer <NN>
from <IN>
recurring <VBG>
, <,>
Weissman <NNP>
said <VBD>
. <.>
The <DT>
researcher <NN>
also <RB>
said <VBD>
that_in <IN>
several <JJ>
years <NNS>
, <,>
purifying <VBG>
human_stem <NN>
cells <NNS>
could <MD>
speed <VB>
development <NN>
of <IN>
gene_therapy <NN>
for <IN>
inherited <VBN>
blood <NN>
diseases <NNS>
. <.>
Gene <NNP>
therapy <NN>
involves <VBZ>
the <DT>
replacement <NN>
of <IN>
disease-causing <JJ>
genes <NNS>
_ <NNP>
the <DT>
basic <JJ>
units <NNS>
of <IN>
heredity <NN>
_ <NNP>
with <IN>
healthy <JJ>
genes <NNS>
AP900405-0064 <DOCNO>
. <.>
Medical <JJ>
experts <NNS>
expressed <VBN>
skepticism <NN>
about <IN>
reports <NNS>
that <IN>
a <DT>
licensed <JJ>
drug <NN>
alleviated <VBD>
AIDS <NNP>
patients <NNS>
' <POS>
symptoms <NNS>
after <IN>
it <PRP>
was <VBD>
prepared <VBN>
in <IN>
a <DT>
novel_way <NN>
. <.>
Researchers <NNS>
said <VBD>
data <NNS>
is <VBZ>
too <RB>
inconclusive <JJ>
to <TO>
embrace <VB>
the <DT>
results <NNS>
reported <VBD>
on <IN>
Wednesday <NNP>
by <IN>
Dr._Joseph_M._Cummins <NNP>
, <,>
head <NN>
of <IN>
the <DT>
Amarillo_Cell_Culture_Co._Inc._Cummins <NNP>
said <VBD>
that <IN>
alpha_interferon <NN>
given <VBN>
to <TO>
patients <NNS>
in <IN>
a <DT>
wafer_form <NN>
in <IN>
small <JJ>
amounts <NNS>
`` <``>
has <VBZ>
reduced <VBN>
the <DT>
symptoms <NNS>
of <IN>
a <DT>
person_suffering <NN>
from <IN>
AIDS <NNP>
. <.>
'' <''>
A <DT>
veterinarian <JJ>
, <,>
Cummins <NNP>
said <VBD>
he <PRP>
began <VBD>
experiments <NNS>
with <IN>
interferon <NN>
to <TO>
treat <VB>
illnesses <NNS>
in <IN>
cattle <NN>
. <.>
He <PRP>
offered <VBD>
a <DT>
pure_form <NN>
of <IN>
the <DT>
drug <NN>
to <TO>
Dr._Davy_K._Koech <NNP>
, <,>
the <DT>
director <NN>
of <IN>
the <DT>
Kenyan_Medical_Research_Institute <NNP>
in <IN>
Nairobi <NNP>
, <,>
for <IN>
use <NN>
on <IN>
AIDS <NNP>
patients <NNS>
. <.>
`` <``>
Dr._Koech <NNP>
was <VBD>
desperate <JJ>
enough <RB>
to <TO>
try <VB>
something <NN>
new <JJ>
, <,>
'' <''>
Cummins <NNP>
said <VBD>
Wednesday <NNP>
. <.>
`` <``>
And <CC>
he <PRP>
is <VBZ>
reporting <VBG>
positive <JJ>
results <NNS>
with <IN>
every <DT>
patient <NN>
he <PRP>
has <VBZ>
treated <VBN>
. <.>
'' <''>
In <IN>
the <DT>
current <JJ>
issue <NN>
of <IN>
Biotechnology_Newswatch <NNP>
, <,>
Koech <NNP>
reported <VBD>
that_within <IN>
days <NNS>
of <IN>
taking <VBG>
oral <JJ>
alpha_interferon <NN>
all <DT>
of <IN>
his <PRP$>
99 <CD>
AIDS <NNP>
patients <NNS>
in <IN>
the <DT>
test_group <NN>
developed <VBD>
an <DT>
appetite <NN>
. <.>
Fever <RB>
, <,>
diarrhea <NN>
and <CC>
fungal <JJ>
infections <NNS>
and <CC>
other <JJ>
symptoms <NNS>
subsided <VBD>
, <,>
the <DT>
report <NN>
said <VBD>
. <.>
Dr._Anthony_S._Fauci <NNP>
, <,>
head <NN>
of <IN>
the <DT>
National <NNP>
Institutes <NNPS>
of <IN>
Allergy <NNP>
and <CC>
Infectious_Disease <NNP>
in <IN>
Bethesda <NNP>
, <,>
Md. <NNP>
, <,>
said <VBD>
Wednesday <NNP>
the <DT>
results <NNS>
from <IN>
Africa <NNP>
were <VBD>
`` <``>
astounding <VBG>
and <CC>
very <RB>
difficult <JJ>
to <TO>
believe <VB>
, <,>
'' <''>
but <CC>
`` <``>
you <PRP>
have <VBP>
to <TO>
keep <VB>
an <DT>
open <JJ>
mind <NN>
. <.>
'' <''>
Dr._Sidney_Wolfe <NNP>
, <,>
director <NN>
of <IN>
the <DT>
Health_Research_Group <NNP>
in <IN>
Washington <NNP>
, <,>
D.C. <NNP>
, <,>
said <VBD>
there <EX>
is <VBZ>
not_enough <RB>
data <NNS>
on <IN>
the <DT>
tests <NNS>
to <TO>
make <VB>
an <DT>
opinion <NN>
. <.>
Cummins <NNS>
agreed <VBD>
that <IN>
more <JJR>
tests <NNS>
need <VBP>
to <TO>
be <VB>
done <VBN>
. <.>
`` <``>
People <NNS>
do <VBP>
n't <RB>
have <VB>
to <TO>
believe <VB>
it <PRP>
, <,>
but <CC>
let <VB>
's <VBZ>
test <NN>
it <PRP>
, <,>
'' <''>
he <PRP>
said <VBD>
. <.>
`` <``>
We <PRP>
need <VBP>
to <TO>
see <VB>
if <IN>
it <PRP>
's <VBZ>
a <DT>
true <JJ>
and <CC>
natural <JJ>
way <NN>
to <TO>
treat <VB>
AIDS <NNP>
. <.>
'' <''>
Koech <NNP>
's <POS>
research <NN>
showed <VBD>
interferon <NN>
led <VBN>
to <TO>
a <DT>
significant <JJ>
increase <NN>
in <IN>
the <DT>
number <NN>
of <IN>
CD4 <NNP>
lymphocytes <VBZ>
, <,>
the <DT>
white <JJ>
blood_cell <NN>
destroyed <VBD>
by <IN>
the <DT>
HIV <NNP>
virus <VBZ>
, <,>
which <WDT>
causes <NNS>
acquired <VBD>
immune <JJ>
deficiency_syndrome <NN>
. <.>
Alpha <NNP>
interferon <VBD>
has <VBZ>
been_scrutinized <VBN>
for <IN>
its <PRP$>
antiviral <JJ>
activity <NN>
since <IN>
its <PRP$>
discovery <NN>
more <JJR>
than <IN>
30 <CD>
years <NNS>
ago <RB>
. <.>
The <DT>
U.S._Food <NNP>
and <CC>
Drug_Administration <NNP>
has <VBZ>
approved <VBN>
alpha_interferon <NN>
to <TO>
treat <VB>
Kaposi <NNP>
's <POS>
sarcoma <NN>
, <,>
a <DT>
cancer <NN>
that <WDT>
occurs <VBZ>
commonly <RB>
among <IN>
people <NNS>
with <IN>
AIDS <NNP>
. <.>
But <CC>
the <DT>
drug <NN>
has <VBZ>
not_generally <RB>
been_tested <VBN>
in <IN>
pill_form <NN>
because_of <IN>
the <DT>
belief <NN>
it <PRP>
would <MD>
be <VB>
destroyed <VBN>
by <IN>
stomach_acid <NN>
. <.>
Koech <NNP>
prepared <VBD>
the <DT>
drug <NN>
in <IN>
wafer_form <NN>
so <RB>
that <IN>
small <JJ>
doses <NNS>
could <MD>
be <VB>
absorbed <VBN>
through <IN>
the <DT>
mouth <NN>
. <.>
Cummins <NNS>
said <VBD>
a <DT>
veterinarian <JJ>
called <VBN>
him <PRP>
last <JJ>
year <NN>
seeking <VBG>
interferon <NN>
`` <``>
to <TO>
treat <VB>
a <DT>
big <JJ>
dog <NN>
for <IN>
leukemia <NN>
. <.>
'' <''>
Cummins <NNP>
later <JJ>
learned <VBD>
the <DT>
man <NN>
had <VBD>
AIDS <NNP>
and <CC>
was <VBD>
using <VBG>
the <DT>
interferon <NN>
to <TO>
treat <VB>
himself <PRP>
. <.>
The <DT>
man <NN>
agreed <VBD>
to <TO>
talk <VB>
to <TO>
The <DT>
Associated_Press <NNP>
upon <IN>
condition <NN>
of <IN>
anonymiity <NN>
. <.>
The <DT>
47-year-old <JJ>
man <NN>
said <VBD>
interferon <NN>
was <VBD>
keeping <VBG>
him <PRP>
alive <JJ>
. <.>
`` <``>
I <PRP>
contracted <VBD>
AIDS <NNP>
along_with <IN>
three <CD>
other <JJ>
people <NNS>
who <WP>
split <NN>
infected <VBD>
blood <NN>
during <IN>
a <DT>
transfusion <NN>
, <,>
'' <''>
he <PRP>
said <VBD>
Wednesday <NNP>
. <.>
`` <``>
They <PRP>
are <VBP>
both <DT>
dead <JJ>
and <CC>
I <PRP>
am <VBP>
still_here <RB>
. <.>
'' <''>
The <DT>
man <NN>
, <,>
who <WP>
said <VBD>
he <PRP>
was <VBD>
diagnosed <VBN>
with <IN>
AIDS <NNP>
three <CD>
years <NNS>
ago <RB>
, <,>
said <VBD>
the <DT>
drug <NN>
stimulated <VBD>
his <PRP$>
appetite <NN>
, <,>
boosted <VBD>
his <PRP$>
low <JJ>
CD4 <NNP>
count <NN>
and <CC>
eradicated <VBD>
fever <RB>
blisters <NNS>
. <.>
Dr._Jordan_U._Gutterman <NNP>
, <,>
an <DT>
interferon_expert <NN>
at <IN>
the <DT>
M.D <JJ>
. <.>
Anderson_Center <NNP>
in <IN>
Houston <NNP>
, <,>
said <VBD>
Wednesday <NNP>
that <IN>
Cummins <NNPS>
' <POS>
use <NN>
of <IN>
interferon <NN>
to <TO>
treat <VB>
animals <NNS>
with <IN>
leukemia <NN>
produced <VBN>
`` <``>
some <DT>
intriguing <JJ>
results <NNS>
. <.>
'' <''>
`` <``>
We <PRP>
are <VBP>
going <VBG>
to <TO>
start <VB>
studies_ourselves <NNS>
with <IN>
interferon <NN>
for <IN>
cancer_treatment <NN>
, <,>
'' <''>
Gutterman <NNP>
said <VBD>
. <.>
`` <``>
More <JJR>
studies <NNS>
need <VBP>
to <TO>
be <VB>
done <VBN>
to <TO>
provide <VB>
confirmation <NN>
for <IN>
the <DT>
results <NNS>
being <VBG>
reported <VBN>
. <.>
AP901008-0062 <DOCNO>
'' <''>
Dr._E._Donnall_Thomas <NNP>
, <,>
who <WP>
blazed <VBN>
a <DT>
new <JJ>
path <NN>
for <IN>
the <DT>
treatment <NN>
of <IN>
leukemia <NN>
when <WRB>
he <PRP>
performed <VBD>
the <DT>
first <JJ>
human_bone_marrow_transplant <NN>
in <IN>
1956 <CD>
, <,>
said <VBD>
today <NN>
he <PRP>
always <RB>
considered <VBN>
the <DT>
Nobel_Prize <NNP>
`` <``>
a <DT>
long <JJ>
shot <NN>
at <IN>
best <JJS>
. <.>
'' <''>
Thomas <NNP>
, <,>
70 <CD>
, <,>
of <IN>
Bellevue <NNP>
, <,>
Wash. <NNP>
, <,>
and <CC>
Joseph_E._Murray <NNP>
, <,>
71 <CD>
, <,>
were <VBD>
awarded <VBN>
the <DT>
Nobel_Prize <NNP>
in <IN>
medicine_today <NN>
, <,>
officials <NNS>
in <IN>
Stockhom <NNP>
, <,>
Sweden <NNP>
announced <VBD>
. <.>
Murray <NNP>
, <,>
affiliated <VBD>
with <IN>
Brigham <NNP>
and <CC>
Women <NNP>
's <POS>
Hospital <NNP>
in <IN>
Boston <NNP>
, <,>
was <VBD>
recognized <VBN>
for <IN>
his <PRP$>
discovery <NN>
of <IN>
a <DT>
method <NN>
to <TO>
prevent <VB>
tissue_rejection <NN>
when <WRB>
organs <NNS>
are <VBP>
transplanted <VBN>
in <IN>
people <NNS>
. <.>
Thomas <NNP>
, <,>
with <IN>
the <DT>
Fred_Hutchinson_Cancer_Research_Center <NNP>
in <IN>
Seattle <NNP>
, <,>
said <VBD>
he <PRP>
learned <VBD>
of <IN>
the <DT>
good <JJ>
news <NN>
when <WRB>
awakened <VBN>
by <IN>
a <DT>
reporter <NN>
's <POS>
telephone_call <NN>
early <RB>
this <DT>
morning <NN>
. <.>
`` <``>
I <PRP>
really <RB>
thought <VBD>
this <DT>
work <NN>
was <VBD>
too <RB>
clinical <JJ>
to <TO>
ever <RB>
win <VB>
the <DT>
prize <NN>
, <,>
'' <''>
Thomas <NNP>
said <VBD>
. <.>
`` <``>
There <EX>
are <VBP>
many <JJ>
scientist-researchers <NNS>
out <IN>
there <RB>
who <WP>
are <VBP>
eligible <JJ>
for <IN>
this <DT>
prize <NN>
. <.>
`` <``>
It <PRP>
's <VBZ>
a <DT>
long <JJ>
shot <NN>
at <IN>
best <JJS>
, <,>
and <CC>
it <PRP>
would <MD>
be <VB>
a <DT>
mistake <NN>
to <TO>
waste <VB>
time <NN>
thinking <VBG>
about <IN>
winning <VBG>
it <PRP>
. <.>
'' <''>
The <DT>
prize <NN>
shared <VBD>
by <IN>
Murray <NNP>
and <CC>
Thomas <NNP>
, <,>
worth <NN>
$ <$>
695 <CD>
, <,>
000 <CD>
, <,>
is <VBZ>
endowed <VBN>
by <IN>
the <DT>
will <MD>
of <IN>
dynamite <JJ>
inventor <NN>
Alfred_Nobel <NNP>
, <,>
who <WP>
died <VBD>
in <IN>
1896 <CD>
. <.>
Thomas <NNP>
said <VBD>
he <PRP>
has <VBZ>
n't <RB>
had <VBD>
time <NN>
yet <RB>
to <TO>
think <VB>
of <IN>
what <WP>
he <PRP>
will <MD>
do <VB>
with <IN>
the <DT>
money <NN>
. <.>
Thomas <NNP>
, <,>
who <WP>
took <VBD>
after <IN>
his <PRP$>
father <NN>
and <CC>
fulfilled <VBD>
his <PRP$>
childhood_desire <NN>
to <TO>
become <VB>
a <DT>
doctor <NN>
, <,>
performed <VBN>
the <DT>
first <JJ>
human_bone_marrow_transplant <NN>
in <IN>
Cooperstown <NNP>
, <,>
N.Y. <NNP>
, <,>
in <IN>
1956 <CD>
. <.>
The <DT>
surgical <JJ>
procedure <NN>
has <VBZ>
become <VBN>
standard <JJ>
treatment <NN>
for <IN>
many <JJ>
sufferers <NNS>
of <IN>
leukemia <NN>
and <CC>
lymphoma <NN>
, <,>
which <WDT>
are <VBP>
types <NNS>
of <IN>
cancer <NN>
. <.>
Thomas <NNP>
joined <VBD>
the <DT>
University <NNP>
of <IN>
Washington <NNP>
faculty <NN>
in <IN>
1963 <CD>
and <CC>
went <VBD>
to <TO>
the <DT>
Hutchinson <NNP>
center <NN>
when <WRB>
it <PRP>
opened <VBD>
in <IN>
1975 <CD>
. <.>
The <DT>
center <NN>
is <VBZ>
now <RB>
one <CD>
of <IN>
the <DT>
world'sleading <JJ>
cancer_treatment <NN>
and <CC>
research <NN>
institutions <NNS>
. <.>
`` <``>
I <PRP>
think <VBP>
it <PRP>
's <VBZ>
a <DT>
recognition <NN>
of <IN>
a <DT>
lot <NN>
of <IN>
work <NN>
by <IN>
a <DT>
lot <NN>
of <IN>
people <NNS>
who <WP>
have <VBP>
worked <VBN>
on <IN>
the <DT>
problems <NNS>
over <IN>
the <DT>
years <NNS>
. <.>
I <PRP>
have <VBP>
a <DT>
medical <JJ>
team <NN>
here <RB>
of <IN>
some <DT>
50 <CD>
physicians <NNS>
and <CC>
Ph.D.s <NNS>
who <WP>
now <RB>
work <VBP>
with <IN>
me <PRP>
on <IN>
this <DT>
. <.>
It <PRP>
's <VBZ>
been <VBN>
very <RB>
gratifying <VBG>
to <TO>
see <VB>
the <DT>
procedure_become <NN>
accepted <VBD>
as <IN>
the <DT>
primary <JJ>
form <NN>
of <IN>
treatment <NN>
for <IN>
leukemia <NN>
, <,>
'' <''>
Thomas <NNP>
said <VBD>
. <.>
In <IN>
a <DT>
bone_marrow_transplant <NN>
, <,>
the <DT>
patient <NN>
's <POS>
diseased <VBN>
marrow <NN>
is <VBZ>
destroyed <VBN>
by <IN>
chemotherapy <NN>
and <CC>
radiation <NN>
. <.>
Disease-free <JJ>
marrow <NN>
is <VBZ>
removed <VBN>
by <IN>
needle <NN>
from <IN>
the <DT>
hip_bone <NN>
of <IN>
a <DT>
donor <NN>
, <,>
often <RB>
a <DT>
relative <JJ>
, <,>
and <CC>
dripped <VBD>
intravenously <RB>
into <IN>
the <DT>
patient <NN>
. <.>
In <IN>
time <NN>
, <,>
the <DT>
transplanted <VBN>
cells <NNS>
begin <VBP>
to <TO>
grow <VB>
in <IN>
the <DT>
patient <NN>
's <POS>
marrow <NN>
and <CC>
produce <VB>
new_white <JJ>
and <CC>
red <VBD>
blood <NN>
cells <NNS>
and <CC>
platelets <NNS>
AP900727-0024 <DOCNO>
. <.>
Researchers <NNS>
have <VBP>
been <VBN>
unable <JJ>
to <TO>
definitively <RB>
link <VB>
fallout_from <IN>
atomic <JJ>
explosions <NNS>
in <IN>
Nevada <NNP>
during <IN>
the <DT>
1950s <CD>
to <TO>
the <DT>
higher <JJR>
than <IN>
normal <JJ>
leukemia_rate <NN>
in <IN>
neighboring <VBG>
Utah <NNP>
, <,>
although <IN>
a <DT>
new <JJ>
study <NN>
does <VBZ>
suggest <VBP>
a <DT>
link <NN>
. <.>
Weapons_tests <NNS>
in <IN>
Nevada <NNP>
by <IN>
the <DT>
old <JJ>
U.S._Atomic_Energy_Commission <NNP>
may <MD>
have <VB>
caused <VBN>
the <DT>
higher <JJR>
cancer_rate <NN>
in <IN>
the <DT>
neighboring_state <NN>
, <,>
but <CC>
the <DT>
evidence <NN>
is <VBZ>
weak <JJ>
, <,>
according <VBG>
to <TO>
a <DT>
study <NN>
conducted <VBN>
by <IN>
University <NNP>
of <IN>
Utah <NNP>
researchers <NNS>
to <TO>
be <VB>
published <VBN>
in <IN>
next <JJ>
week's <NNS>
Journal <NNP>
of <IN>
the <DT>
American_Medical_Association <NNP>
. <.>
`` <``>
The <DT>
excess <NN>
of <IN>
acute <NN>
leukemias <NNS>
in <IN>
southwestern <NN>
Utah <NNP>
is <VBZ>
probably_not <RB>
due <JJ>
to <TO>
chance <NN>
and <CC>
may <MD>
be <VB>
attributable <JJ>
to <TO>
fallout <VB>
radiation <NN>
. <.>
However <RB>
, <,>
the <DT>
estimated <VBN>
number <NN>
of <IN>
cases <NNS>
attributable <JJ>
to <TO>
fallout <VB>
in <IN>
this <DT>
region <NN>
is <VBZ>
small <JJ>
, <,>
and <CC>
these <DT>
cases <NNS>
are <VBP>
indistinguishable <JJ>
from <IN>
other <JJ>
factors <NNS>
, <,>
'' <''>
the <DT>
study <NN>
said <VBD>
. <.>
If <IN>
a <DT>
direct <JJ>
relationship <NN>
could <MD>
have <VB>
been_established <VBN>
between_fallout <IN>
and <CC>
leukemias <NNS>
`` <``>
there <EX>
would <MD>
also <RB>
have <VB>
been <VBN>
a <DT>
substantial <JJ>
number <NN>
of <IN>
cases <NNS>
attributable <JJ>
to <TO>
fallout <VB>
in <IN>
the <DT>
rest <NN>
of <IN>
the <DT>
state <NN>
, <,>
because_of <IN>
its <PRP$>
much <JJ>
larger_population <NN>
, <,>
'' <''>
the <DT>
study <NN>
said <VBD>
. <.>
But <CC>
no <DT>
such <JJ>
increased <VBN>
risk <NN>
was <VBD>
found <VBN>
outside <IN>
southwest <JJS>
Utah <NNP>
, <,>
it <PRP>
said <VBD>
. <.>
`` <``>
There <EX>
was <VBD>
an <DT>
excess <JJ>
of <IN>
acute <JJ>
leukemia <NN>
cases <NNS>
, <,>
but <CC>
it <PRP>
was <VBD>
not_statistically <RB>
significant <JJ>
, <,>
'' <''>
concluded <VBD>
Dr._Joseph_L._Lyon <NNP>
, <,>
one <CD>
of <IN>
the <DT>
researchers <NNS>
with <IN>
the <DT>
University <NNP>
of <IN>
Utah <NNP>
's <POS>
Department <NNP>
of <IN>
Family <NNP>
and <CC>
Preventative_Medicine <NNP>
. <.>
The <DT>
U.S._House <NNP>
last <JJ>
month <NN>
approved <VBD>
a <DT>
bill <NN>
creating <VBG>
a <DT>
$ <$>
100_million <CD>
trust_fund <NN>
to <TO>
compensate <VB>
those <DT>
living <VBG>
downwind <NN>
from <IN>
the <DT>
Nevada <NNP>
test_site <NN>
for <IN>
alleged <JJ>
radiation <NN>
injuries <NNS>
. <.>
Up <IN>
to <TO>
1 <CD>
, <,>
300 <CD>
alleged <VBN>
fallout <IN>
victims <NNS>
could <MD>
collect <VB>
up <RP>
to <TO>
$ <$>
50 <CD>
, <,>
000 <CD>
each <DT>
under <IN>
the <DT>
legislation <NN>
, <,>
now <RB>
being <VBG>
considered <VBN>
by <IN>
the <DT>
Senate <NNP>
. <.>
More <JJR>
than <IN>
100 <CD>
atomic <JJ>
bombs <NNS>
were <VBD>
set <VBN>
off <RP>
above <IN>
ground <NN>
in <IN>
Nevada <NNP>
between <IN>
1951 <CD>
and <CC>
1958 <CD>
, <,>
researchers <NNS>
said <VBD>
. <.>
Fallout_from <IN>
those <DT>
blasts <NNS>
spread <VBP>
across <IN>
southwestern <JJ>
Utah <NNP>
. <.>
In <IN>
one <CD>
county <NN>
, <,>
the <DT>
average <JJ>
resident <NN>
was <VBD>
exposed <VBN>
to <TO>
nearly <RB>
30 <CD>
times <NNS>
as <RB>
much <JJ>
radiation <NN>
as <IN>
occurred <VBN>
naturally <RB>
, <,>
researchers <NNS>
found <VBD>
. <.>
But <CC>
because <IN>
leukemia_leaves <NNS>
no <DT>
traces <NNS>
as <IN>
to <TO>
its <PRP$>
source <NN>
, <,>
it <PRP>
was <VBD>
impossible <JJ>
to <TO>
determine <VB>
whether <IN>
individual <JJ>
deaths <NNS>
were <VBD>
caused <VBN>
by <IN>
exposure <NN>
to <TO>
fallout <VB>
, <,>
Lyon <NNP>
said <VBD>
Thursday <NNP>
. <.>
`` <``>
You <PRP>
ca <MD>
n't <RB>
say <VB>
this <DT>
leukemia <NN>
was <VBD>
caused <VBN>
by <IN>
smoking <NN>
, <,>
this <DT>
one <CD>
was <VBD>
caused <VBN>
by <IN>
radiation <NN>
_ <NNP>
there <EX>
's <VBZ>
nothing <NN>
in <IN>
the <DT>
disease <NN>
that <IN>
says <VBZ>
what <WP>
it <PRP>
was <VBD>
caused <VBN>
by <IN>
. <.>
You <PRP>
ca <MD>
n't <RB>
sort <VB>
out <RP>
the <DT>
random <NN>
cases <NNS>
from <IN>
those <DT>
involving <VBG>
fallout <IN>
, <,>
'' <''>
Lyon <NNP>
said <VBD>
. <.>
Researchers <NNS>
analyzed <VBD>
more <JJR>
than <IN>
6 <CD>
, <,>
500 <CD>
deaths <NNS>
in <IN>
Utah <NNP>
between <IN>
1952 <CD>
and <CC>
1981 <CD>
for <IN>
the <DT>
$ <$>
6.8_million <CD>
, <,>
federally <RB>
funded <VBN>
study <NN>
. <.>
They <PRP>
confined <VBD>
their <PRP$>
analysis <NN>
to <TO>
members <NNS>
of <IN>
the <DT>
Mormon_Church <NNP>
, <,>
because <IN>
church <NN>
records <NNS>
could <MD>
be <VB>
used <VBN>
to <TO>
determine <VB>
who <WP>
had <VBD>
died <VBN>
and <CC>
moved <VBD>
into <IN>
or <CC>
out_of <IN>
the <DT>
area <NN>
during <IN>
the <DT>
testing_period <NN>
. <.>
Earlier <JJR>
studies <NNS>
indicated <VBD>
the <DT>
state <NN>
's <POS>
leukemia_rate <NN>
was <VBD>
1.45 <CD>
times <NNS>
higher <JJR>
than <IN>
that <DT>
across <NN>
the <DT>
country <NN>
, <,>
and <CC>
2.45 <CD>
times <NNS>
higher <JJR>
for <IN>
children <NNS>
. <.>
But <CC>
those <DT>
studies <NNS>
did <VBD>
n't_directly <RB>
link <VB>
that <IN>
higher <JJR>
rate <NN>
to <TO>
radiation <NN>
fallout <IN>
, <,>
Lyon <NNP>
said <VBD>
. <.>
The <DT>
study <NN>
did <VBD>
show <NN>
an <DT>
apparently <RB>
significant <JJ>
link <NN>
between_fallout <IN>
and <CC>
leukemia <NN>
among <IN>
those <DT>
who <WP>
were <VBD>
younger <JJR>
than <IN>
20 <CD>
when <WRB>
they <PRP>
were <VBD>
exposed <VBN>
to <TO>
the <DT>
radiation <NN>
. <.>
In <IN>
Washington_County <NNP>
, <,>
where <WRB>
the <DT>
highest <JJS>
radiation <NN>
levels <NNS>
were <VBD>
recorded <VBN>
, <,>
there <EX>
were <VBD>
17 <CD>
leukemia_deaths <NNS>
. <.>
Five <CD>
were <VBD>
among <IN>
people <NNS>
younger <JJR>
than <IN>
20 <CD>
when <WRB>
exposed <VBN>
, <,>
making <VBG>
them <PRP>
nearly <RB>
eight <CD>
times <NNS>
more <JJR>
likely <JJ>
to <TO>
die <VB>
from <IN>
acute <JJ>
leukemia <NN>
than <IN>
others <NNS>
their <PRP$>
age <NN>
. <.>
But <CC>
researchers <NNS>
said <VBD>
that <IN>
study <NN>
sample <NNS>
was <VBD>
too <RB>
small <JJ>
to <TO>
be <VB>
significant <JJ>
WSJ880803-0161 <DOCNO>
. <.>
In <IN>
your <PRP$>
second-front-page_article <NN>
`` <``>
Approved <JJ>
Drugs <NNS>
Find_Unapproved_Uses <NNP>
'' <''>
( <:>
July <NNP>
12_) <CD>
, <,>
your <PRP$>
approach <NN>
to <TO>
the <DT>
problem <NN>
of <IN>
Food <NNP>
and <CC>
Drug_Administration <NNP>
approval <NN>
of <IN>
medicines_fails <NNS>
to <TO>
take <VB>
into <IN>
account <NN>
the <DT>
complexities <NNS>
of <IN>
modern <JJ>
medicine <NN>
. <.>
For <IN>
example <NN>
, <,>
picture <NN>
yourself <PRP>
sitting <VBG>
in <IN>
front <NN>
of <IN>
me <PRP>
in <IN>
my <PRP$>
office <NN>
. <.>
`` <``>
Mr._X <NNP>
, <,>
'' <''>
I <PRP>
might <MD>
begin <VB>
, <,>
`` <``>
you <PRP>
unfortunately <RB>
have <VBP>
a <DT>
rare_cancer <NN>
of <IN>
the <DT>
adrenal <JJ>
gland <NN>
. <.>
Treatment <NNP>
of <IN>
this <DT>
is <VBZ>
very <RB>
difficult <JJ>
, <,>
and <CC>
up <RP>
to <TO>
this <DT>
point <NN>
, <,>
all <DT>
patients <NNS>
with <IN>
this <DT>
have <VBP>
died <VBN>
. <.>
However <RB>
, <,>
at <IN>
one <CD>
of <IN>
our <PRP$>
recent <JJ>
cancer <NN>
meetings <NNS>
, <,>
there <EX>
were <VBD>
two <CD>
reports <NNS>
that <WDT>
a <DT>
combination <NN>
of <IN>
the <DT>
chemotherapy <NN>
drugs <NNS>
etoposide <VBP>
and <CC>
cisplatin <NN>
were <VBD>
able <JJ>
to <TO>
shrink <VB>
this <DT>
cancer <NN>
in <IN>
10 <CD>
of <IN>
11 <CD>
patients <NNS>
. <.>
These <DT>
are <VBP>
not <RB>
experimental <JJ>
drugs <NNS>
, <,>
but <CC>
drugs <NNS>
well <RB>
known <VBN>
to <TO>
us <PRP>
for <IN>
the <DT>
treatment <NN>
of <IN>
other <JJ>
cancers <NNS>
. <.>
Unfortunately <RB>
, <,>
these <DT>
drugs <NNS>
are <VBP>
not <RB>
approved <VBN>
for <IN>
this <DT>
cancer <NN>
, <,>
since <IN>
adrenocortical <JJ>
cancer <NN>
strikes <VBZ>
only <RB>
a <DT>
few <JJ>
hundred <VBN>
patients <NNS>
a <DT>
year <NN>
. <.>
``_`` <``>
Well <NNP>
, <,>
Doc <NNP>
, <,>
'' <''>
you <PRP>
answer <JJR>
, <,>
`` <``>
I <PRP>
'll <MD>
go <VB>
ahead <RB>
and <CC>
take <VB>
the <DT>
drugs <NNS>
anyway <VBP>
; <:>
those <DT>
odds <NNS>
sound <VBP>
pretty <RB>
good <JJ>
. <.>
``_`` <``>
Yes <VBZ>
, <,>
they <PRP>
do <VBP>
, <,>
Mr._X <NNP>
. <.>
Unfortunately <RB>
, <,>
your <PRP$>
insurer <NN>
does <VBZ>
not <RB>
pay <VB>
for <IN>
any <DT>
medicines <NNS>
given <VBN>
for <IN>
'unapproved <JJ>
' <''>
indications <NNS>
. <.>
Since <IN>
you <PRP>
have <VBP>
a <DT>
rare_disease <NN>
, <,>
you <PRP>
certainly <RB>
can <MD>
not <RB>
expect <VB>
these <DT>
drug <NN>
companies <NNS>
to <TO>
spend <VB>
millions <NNS>
of <IN>
dollars <NNS>
to <TO>
get <VB>
approval <NN>
for <IN>
such <JJ>
a <DT>
rare_problem <NN>
, <,>
can <MD>
you <PRP>
? <.>
If <IN>
you <PRP>
owned <VBN>
stock <NN>
in <IN>
them <PRP>
, <,>
you <PRP>
'd <MD>
throw <VB>
the <DT>
management <NN>
out <IN>
. <.>
I <PRP>
'd <MD>
like <VB>
to <TO>
give <VB>
you <PRP>
the <DT>
drugs <NNS>
, <,>
but <CC>
since <IN>
you <PRP>
live <VBP>
in <IN>
Massachusetts <NNP>
, <,>
your <PRP$>
insurer <NN>
makes <VBZ>
me <PRP>
take <VBP>
assignment <NN>
for <IN>
your <PRP$>
treatment <NN>
, <,>
and <CC>
not_only <RB>
will <MD>
they <PRP>
not <RB>
pay <VBP>
me <PRP>
, <,>
by <IN>
law <NN>
you <PRP>
ca <MD>
n't <RB>
pay <VB>
me <PRP>
out <RP>
of <IN>
your <PRP$>
pocket_either <NN>
. <.>
These <DT>
are <VBP>
expensive <JJ>
drugs <NNS>
, <,>
and <CC>
we <PRP>
ca <MD>
n't <RB>
give <VB>
them <PRP>
away <RB>
. <.>
``_`` <``>
But <CC>
Doc <NNP>
, <,>
you <PRP>
're <VBP>
an <DT>
expert <NN>
in <IN>
cancer_medicine <NN>
; <:>
certainly <RB>
if <IN>
you <PRP>
tell <VBP>
the <DT>
insurer <NN>
that <IN>
this <DT>
is <VBZ>
the <DT>
best <JJS>
thing <NN>
for <IN>
me <PRP>
, <,>
it <PRP>
will <MD>
be <VB>
OK. <NNP>
'' <''>
`` <``>
I <PRP>
wish <VBP>
it <PRP>
were <VBD>
that <IN>
simple <JJ>
, <,>
Mr._X <NNP>
, <,>
'' <''>
I <PRP>
go <VBP>
on <IN>
, <,>
`` <``>
but <CC>
your <PRP$>
policy <NN>
clearly <RB>
states <VBZ>
that <IN>
only <RB>
drugs <NNS>
approved <VBN>
by <IN>
the <DT>
FDA <NNP>
for <IN>
that <DT>
disease <NN>
can <MD>
be <VB>
reimbursed <VBN>
; <:>
how <WRB>
else <RB>
can <MD>
they <PRP>
hold <VBP>
down <RP>
runaway <NN>
costs <NNS>
? <.>
But <CC>
do <VBP>
n't <RB>
feel <VB>
bad <JJ>
; <:>
you <PRP>
're <VBP>
not_alone <RB>
. <.>
Why <WRB>
, <,>
when <WRB>
etoposide_first <JJ>
came <NN>
out <IN>
every <DT>
oncologist <NN>
already <RB>
knew <VBD>
that <IN>
it <PRP>
was <VBD>
the <DT>
best <JJS>
single <JJ>
drug <NN>
for <IN>
small <JJ>
cell_lung_cancer <NN>
. <.>
There <EX>
are <VBP>
a <DT>
lot <NN>
of <IN>
those <DT>
patients <NNS>
( <VBP>
why <WRB>
could <MD>
n't <RB>
you <PRP>
get <VB>
a <DT>
common <JJ>
disease <NN>
? <.>
) <NN>
and <CC>
it <PRP>
only <RB>
took <VBD>
the <DT>
FDA <NNP>
a <DT>
few <JJ>
years <NNS>
to <TO>
approve <VB>
the <DT>
application <NN>
for <IN>
that <DT>
use <NN>
. <.>
Of <IN>
course <NN>
, <,>
the <DT>
average <JJ>
patient <NN>
with <IN>
that <DT>
disease <NN>
lived <VBD>
only <RB>
11 <CD>
months <NNS>
then <RB>
, <,>
but <CC>
what <WP>
are <VBP>
10 <CD>
, <,>
000 <CD>
or <CC>
20 <CD>
, <,>
000 <CD>
lives <NNS>
compared <VBN>
with <IN>
the <DT>
safety <NN>
of <IN>
a <DT>
whole <JJ>
country <NN>
, <,>
not <RB>
to <TO>
mention <VB>
the <DT>
asset_base <NN>
of <IN>
the <DT>
insurance <NN>
companies <NNS>
? <.>
``_`` <``>
Well <NNP>
, <,>
I <PRP>
certainly <RB>
understand <VBP>
the <DT>
problem <NN>
, <,>
Doc <NNP>
. <.>
Let <NNP>
's <POS>
just <RB>
write <JJ>
to <TO>
the <DT>
FDA <NNP>
, <,>
tell <VBD>
them <PRP>
the <DT>
facts <NNS>
you <PRP>
told <VBD>
me <PRP>
, <,>
and <CC>
they <PRP>
'll <MD>
approve <VB>
it <PRP>
. <.>
``_`` <``>
You <PRP>
may <MD>
understand <VB>
your <PRP$>
problem <NN>
, <,>
Mr._X <NNP>
, <,>
but <CC>
you <PRP>
do <VBP>
n't <RB>
understand <VB>
the <DT>
FDA <NNP>
. <.>
First <NNP>
of <IN>
all <DT>
, <,>
they <PRP>
require <VBP>
a <DT>
fairly <RB>
large <JJ>
amount <NN>
of <IN>
data <NNS>
to <TO>
approve <VB>
a <DT>
drug <NN>
, <,>
but <CC>
there <EX>
are <VBP>
n't <RB>
enough <JJ>
cases <NNS>
of <IN>
your <PRP$>
disease <NN>
in <IN>
a <DT>
year <NN>
to <TO>
give <VB>
a <DT>
large <JJ>
enough <RB>
data <NNS>
base <NN>
. <.>
Second <JJ>
, <,>
only <RB>
the <DT>
company <NN>
that <WDT>
manufactures <VBZ>
the <DT>
drug <NN>
can <MD>
apply <VB>
for <IN>
approval <NN>
. <.>
As <IN>
we <PRP>
discussed <VBD>
, <,>
that <IN>
usually <RB>
requires <VBZ>
several <JJ>
years <NNS>
and <CC>
costs_tens <NNS>
of <IN>
millions <NNS>
of <IN>
dollars <NNS>
. <.>
Once <RB>
a <DT>
drug <NN>
is <VBZ>
on <IN>
the <DT>
market <NN>
for <IN>
a <DT>
common <JJ>
disease <NN>
, <,>
why <WRB>
on <IN>
earth <JJ>
should <MD>
they <PRP>
spend <VBP>
the <DT>
money <NN>
for <IN>
a <DT>
rare_disease <NN>
? <.>
They <PRP>
'd <MD>
never <RB>
make <VB>
back <RB>
their <PRP$>
investment <NN>
. <.>
``_`` <``>
But <CC>
, <,>
Doc <NNP>
, <,>
I <PRP>
'm <VBP>
going <VBG>
to <TO>
die <VB>
of <IN>
this <DT>
, <,>
'' <''>
you <PRP>
plead <VBP>
. <.>
`` <``>
This <DT>
just <RB>
is <VBZ>
n't <RB>
fair <JJ>
. <.>
Anyway <NNP>
, <,>
my <PRP$>
insurance_broker <NN>
always <RB>
told <VBD>
me_it <PRP>
would <MD>
pay <VB>
for <IN>
everything <NN>
. <.>
``_`` <``>
I <PRP>
sympathize <VBP>
, <,>
but <CC>
think <VBP>
of <IN>
the <DT>
whole <JJ>
country <NN>
. <.>
Why <WRB>
, <,>
this <DT>
policy <NN>
has <VBZ>
saved <VBN>
thousands <NNS>
from <IN>
damaging <VBG>
their <PRP$>
scalps <NNS>
trying <VBG>
to <TO>
grow <VB>
hair <NN>
with <IN>
minoxidil <NN>
. <.>
Anyway <NNP>
, <,>
this <DT>
morning <NN>
already <RB>
, <,>
I <PRP>
've <VBP>
had <VBN>
to <TO>
tell <VB>
one <CD>
women <NNS>
with <IN>
chronic_myelocytic <JJ>
leukemia <NN>
that <WDT>
I <PRP>
would <MD>
like <VB>
to <TO>
treat <VB>
her <PRP$>
with <IN>
alpha-interferon <JJ>
, <,>
but <CC>
unfortunately <RB>
she <PRP>
did <VBD>
n't <RB>
have <VB>
hairy <JJ>
cell_leukemia <NN>
. <.>
Another <DT>
woman <NN>
with <IN>
breast <JJ>
cancer <NN>
needed <VBN>
mitoxantrone <NN>
, <,>
and <CC>
I <PRP>
tried <VBD>
to <TO>
figure <VB>
out <RP>
how <WRB>
I <PRP>
could <MD>
convince <VB>
her <PRP>
insurer <JJR>
that <IN>
she <PRP>
had <VBD>
acute <JJ>
leukemia <NN>
. <.>
``_`` <``>
Doc <NNP>
, <,>
at <IN>
least <JJS>
my <PRP$>
insurance <NN>
premiums <NNS>
have <VBP>
been_held <VBN>
down <RP>
. <.>
But <CC>
how <WRB>
could <MD>
we <VB>
have <VBP>
come <VBN>
to <TO>
something <NN>
like <IN>
this <DT>
, <,>
in <IN>
this <DT>
day <NN>
and <CC>
age <NN>
? <.>
I <PRP>
figured <VBD>
that_by <IN>
1990 <CD>
we <PRP>
'd <MD>
have <VB>
thought <VBN>
about <IN>
it <PRP>
. <.>
``_`` <``>
Well <NNP>
, <,>
at <IN>
least <JJS>
you <PRP>
wo <MD>
n't <RB>
have <VB>
to <TO>
worry <VB>
about <IN>
the <DT>
side <NN>
effects <NNS>
. <.>
`` <``>
Joseph_J._Muscato_M.D <NNP>
. <.>
Columbia <NNP>
, <,>
Mo <NNP>
WSJ880128-0006 <DOCNO>
. <.>
More <JJR>
evidence <NN>
emerged <VBD>
that <IN>
a <DT>
cancer_virus <NN>
is <VBZ>
contaminating <VBG>
the <DT>
nation <NN>
's <POS>
supply <NN>
of <IN>
banked <VBN>
blood <NN>
. <.>
Researchers <NNS>
in <IN>
New_York_City <NNP>
reported <VBD>
evidence <NN>
that <IN>
some <DT>
hospital <JJ>
patients <NNS>
who <WP>
had <VBD>
received <VBN>
multiple_blood <NN>
transfusions <NNS>
had <VBD>
been_infected <VBN>
with <IN>
the <DT>
virus <NNS>
. <.>
This <DT>
follows <VBZ>
other <JJ>
, <,>
tentative <JJ>
reports <NNS>
in <IN>
recent <JJ>
months <NNS>
hinting <VBG>
that <IN>
1 <CD>
% <NN>
to <TO>
4 <CD>
% <NN>
of <IN>
blood <NN>
donors <NNS>
in <IN>
some <DT>
localities <NNS>
and <CC>
as <IN>
many <JJ>
as <IN>
9 <CD>
% <NN>
of <IN>
drug <NN>
addicts <NNS>
tested <VBD>
in <IN>
New_York_City <NNP>
may <MD>
be <VB>
infected <VBN>
with <IN>
the <DT>
virus <NNS>
. <.>
Such <JJ>
reports <NNS>
prompted <VBD>
the <DT>
American_Red_Cross <NNP>
last <JJ>
November <NNP>
to <TO>
urge <VB>
rapid <JJ>
development <NN>
and <CC>
federal <JJ>
approval <NN>
of <IN>
a <DT>
definitive <JJ>
test <NN>
that <WDT>
could <MD>
be <VB>
used <VBN>
to <TO>
screen <VB>
blood <NN>
donors <NNS>
for <IN>
evidence <NN>
of <IN>
infection <NN>
by <IN>
the <DT>
cancer <NN>
virus <VBZ>
. <.>
The <DT>
cancer <NN>
virus_is <VBZ>
related <VBN>
to <TO>
the <DT>
AIDS <NNP>
virus <VBZ>
and <CC>
is <VBZ>
believed <VBN>
to <TO>
be <VB>
spread <VBN>
by <IN>
the <DT>
same <JJ>
routes <NNS>
, <,>
that <IN>
is <VBZ>
, <,>
by <IN>
blood <NN>
transfusions <NNS>
, <,>
sexual <JJ>
contact <NN>
and <CC>
the <DT>
sharing <NN>
of <IN>
contaminated <VBN>
needles <NNS>
among <IN>
drug <NN>
addicts <NNS>
. <.>
The <DT>
virus <NN>
is <VBZ>
known <VBN>
to <TO>
cause <VB>
a <DT>
rare <NN>
but <CC>
rapidly <RB>
fatal <JJ>
type <NN>
of <IN>
leukemia <NN>
that <IN>
, <,>
until <IN>
now <RB>
, <,>
has <VBZ>
been_confined <VBN>
largely <RB>
to <TO>
southern <VB>
Japan <NNP>
, <,>
and <CC>
certain <JJ>
areas <NNS>
in <IN>
Africa <NNP>
and <CC>
the <DT>
Caribbean <NNP>
. <.>
It <PRP>
also <RB>
has <VBZ>
been_linked <VBN>
to <TO>
a <DT>
multiple_sclerosis <NN>
-- <:>
like <IN>
nerve_ailment <NN>
, <,>
called <VBN>
tropical_spastic <JJ>
paraparesis <NN>
, <,>
occurring <VBG>
in <IN>
children <NNS>
in <IN>
the <DT>
Caribbean <NNP>
. <.>
The <DT>
virus <NN>
is <VBZ>
known <VBN>
as <IN>
HTLV-1 <-NONE->
, <,>
for <IN>
human_T-cell <JJ>
leukemia <NN>
virus <VBZ>
. <.>
The <DT>
presence <NN>
of <IN>
the <DT>
virus <NN>
in <IN>
the <DT>
blood_supply <NN>
poses <NNS>
an <DT>
unusual_public <JJ>
health_dilemma <NN>
. <.>
Although <IN>
only <RB>
1 <CD>
% <NN>
of <IN>
people <NNS>
infected <VBN>
with <IN>
the <DT>
virus <NNS>
develop <VBP>
leukemia <NN>
, <,>
the <DT>
blood_cancer <NN>
does <VBZ>
n't <RB>
occur <VB>
until <IN>
many <JJ>
years <NNS>
, <,>
perhaps <RB>
decades <VBZ>
, <,>
after <IN>
the <DT>
initial <JJ>
infection <NN>
. <.>
An <DT>
increase <NN>
in <IN>
the <DT>
incidence <NN>
of <IN>
leukemia <NN>
that <IN>
would <MD>
confirm <VB>
that <IN>
the <DT>
virus <NN>
is <VBZ>
spreading <VBG>
among <IN>
Americans <NNPS>
might <MD>
n't <RB>
occur <VB>
for <IN>
another <DT>
decade <NN>
. <.>
By <IN>
that <DT>
time <NN>
, <,>
millions <NNS>
might <MD>
have <VB>
become_infected <VBN>
, <,>
leading <VBG>
to <TO>
an <DT>
epidemic <JJ>
of <IN>
tens <NNS>
of <IN>
thousands <NNS>
of <IN>
cases <NNS>
lasting <VBG>
well <RB>
into <IN>
the <DT>
next <JJ>
century <NN>
. <.>
The <DT>
newest <JJS>
evidence <NN>
of <IN>
the <DT>
virus <NN>
's <POS>
presence <NN>
in <IN>
the <DT>
blood_supply <NN>
was <VBD>
reported <VBN>
in <IN>
the <DT>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
by <IN>
a <DT>
research_team <NN>
at <IN>
Memorial_Sloan-Kettering_Cancer_Center <NNP>
in <IN>
New_York <NNP>
. <.>
They <PRP>
tested <VBD>
blood <NN>
samples <NNS>
from <IN>
211 <CD>
patients <NNS>
who <WP>
had <VBD>
been_treated <VBN>
at <IN>
the <DT>
center <NN>
for <IN>
various <JJ>
types <NNS>
of <IN>
leukemia <NN>
. <.>
None <NN>
of <IN>
the <DT>
patients <NNS>
suffered <VBD>
the <DT>
T-cell <NNP>
type <NN>
of <IN>
leukemia <NN>
caused <VBN>
by <IN>
the <DT>
virus <NN>
, <,>
but <CC>
all <DT>
had <VBD>
received <VBN>
multiple <NN>
transfusions <NNS>
of <IN>
blood <NN>
during <IN>
their <PRP$>
therapy <NN>
. <.>
Six <CD>
of <IN>
the <DT>
patients <NNS>
had <VBD>
antibodies <NNS>
to <TO>
HTLV-1 <-NONE->
, <,>
indicating <VBG>
they <PRP>
had <VBD>
been_exposed <VBN>
to <TO>
the <DT>
virus <NN>
. <.>
All <DT>
of <IN>
these <DT>
patients <NNS>
died <VBD>
of <IN>
their <PRP$>
blood <NN>
cancers <NNS>
long <RB>
before <IN>
there <EX>
was <VBD>
any <DT>
chance <NN>
of <IN>
developing <VBG>
disease <NN>
from <IN>
the <DT>
HTLV-1 <NN>
. <.>
The <DT>
researchers <NNS>
said <VBD>
they <PRP>
could <MD>
n't <RB>
determine <VB>
when <WRB>
the <DT>
six <CD>
patients <NNS>
had <VBD>
been_infected <VBN>
. <.>
The <DT>
tests <NNS>
were <VBD>
run <VBN>
on <IN>
blood <NN>
samples <NNS>
that <WDT>
had <VBD>
been_taken <VBN>
and <CC>
stored <VBD>
for <IN>
other <JJ>
reasons <NNS>
. <.>
But <CC>
in <IN>
three <CD>
of <IN>
the <DT>
patients <NNS>
, <,>
samples <NNS>
were <VBD>
available <JJ>
that <IN>
were <VBD>
taken <VBN>
before <IN>
the <DT>
transfusions <NNS>
. <.>
These <DT>
were <VBD>
negative <JJ>
for <IN>
the <DT>
virus <NN>
antibodies <NNS>
, <,>
while <IN>
samples <NNS>
from <IN>
the <DT>
same <JJ>
patients <NNS>
taken <VBN>
after <IN>
transfusions <NNS>
were <VBD>
positive <JJ>
. <.>
There <EX>
was <VBD>
n't <RB>
any <DT>
way <NN>
of <IN>
determining <VBG>
who <WP>
donated <VBN>
the <DT>
contaminated <VBN>
blood <NN>
. <.>
Last <JJ>
fall <NN>
, <,>
the <DT>
Red_Cross <NNP>
said <VBD>
it <PRP>
had <VBD>
completed <VBN>
preliminary <JJ>
screening <NN>
of <IN>
blood <NN>
from <IN>
40 <CD>
, <,>
000 <CD>
healthy <JJ>
donors <NNS>
and <CC>
found <VBN>
10 <CD>
who <WP>
might <MD>
be <VB>
positive <JJ>
for <IN>
HTLV-1 <-NONE->
exposure <NN>
. <.>
More <JJR>
elaborate <JJ>
and <CC>
time-consuming <JJ>
tests <NNS>
now <RB>
are <VBP>
being <VBG>
done <NN>
to <TO>
check <VB>
the <DT>
accuracy <NN>
of <IN>
this <DT>
preliminary <JJ>
screening <NN>
. <.>
This <DT>
prevalence <NN>
, <,>
though <IN>
tiny <JJ>
, <,>
is <VBZ>
about <IN>
the <DT>
same <JJ>
as <IN>
the <DT>
prevalence <NN>
of <IN>
the <DT>
acquired <VBN>
immune_deficiency_syndrome <NN>
virus <VBZ>
in <IN>
donated <VBN>
blood <NN>
before <IN>
screening <VBG>
programs <NNS>
began <VBD>
. <.>
Studies <NNS>
in <IN>
Japan <NNP>
have <VBP>
confirmed <VBN>
that <IN>
HTLV-1 <-NONE->
can <MD>
be <VB>
transmitted <VBN>
by <IN>
blood <NN>
transfusions <NNS>
, <,>
but <CC>
so_far <RB>
there <EX>
are <VBP>
n't <RB>
any <DT>
known <VBN>
cases <NNS>
of <IN>
T-cell <NNP>
leukemia <NN>
developing <VBG>
in <IN>
people <NNS>
so <IN>
infected <JJ>
. <.>
The <DT>
New_York <NNP>
scientists <NNS>
noted <VBD>
, <,>
however <RB>
, <,>
that <IN>
patients <NNS>
such <JJ>
as <IN>
theirs <NNS>
, <,>
who <WP>
receive <JJ>
multiple <NN>
transfusions <NNS>
, <,>
can <MD>
serve <VB>
as <IN>
a <DT>
`` <``>
sensitive <JJ>
indicator <NN>
'' <''>
of <IN>
the <DT>
virus <NN>
's <POS>
presence <NN>
in <IN>
the <DT>
blood_supply <NN>
AP880607-0013 <DOCNO>
. <.>
A <DT>
new <JJ>
treatment <NN>
is <VBZ>
available <JJ>
for <IN>
the <DT>
estimated <VBN>
8_million <CD>
Americans <NNS>
who <WP>
suffer <VBP>
each <DT>
year <NN>
from <IN>
genital <JJ>
warts <NNS>
. <.>
The <DT>
Food <NNP>
and <CC>
Drug_Administration <NNP>
announced <VBD>
Monday <NNP>
that <IN>
it <PRP>
has <VBZ>
OK_'d <NNP>
direct <JJ>
injection <NN>
of <IN>
genetically <RB>
engineered <VBN>
alpha_interferon <NN>
into <IN>
the <DT>
warts <NNS>
. <.>
The <DT>
FDA <NNP>
said <VBD>
a <DT>
study <NN>
of <IN>
192 <CD>
patients <NNS>
showed <VBD>
they <PRP>
exhibited <VBD>
marked <VBN>
improvement <NN>
after <IN>
receiving <VBG>
interferon <NN>
injections <NNS>
three <CD>
times <NNS>
a <DT>
week <NN>
for_up <IN>
to <TO>
three <CD>
weeks <NNS>
. <.>
Of <IN>
the <DT>
192 <CD>
, <,>
42 <CD>
percent <NN>
experienced <VBD>
complete <JJ>
clearing <NN>
of <IN>
all <DT>
their <PRP$>
treated <VBN>
warts <NNS>
, <,>
24 <CD>
percent <NN>
had <VBD>
a <DT>
75 <CD>
percent <NN>
to <TO>
99 <CD>
percent_reduction <NN>
in <IN>
the <DT>
size <NN>
of <IN>
their <PRP$>
treated <VBN>
warts <NNS>
and <CC>
18 <CD>
percent <NN>
had <VBD>
a <DT>
50 <CD>
percent <NN>
to <TO>
74 <CD>
percent_reduction <NN>
in <IN>
the <DT>
size <NN>
of <IN>
their <PRP$>
treated <VBN>
warts <NNS>
, <,>
the <DT>
FDA <NNP>
said <VBD>
. <.>
Previously <RB>
, <,>
the <DT>
most <RBS>
effective <JJ>
treatments <NNS>
were <VBD>
painful <JJ>
and <CC>
potentially <RB>
scarring <VBG>
removal <NN>
by <IN>
freezing <NN>
or <CC>
burning <VBG>
. <.>
Some <DT>
types <NNS>
of <IN>
genital <JJ>
warts <NNS>
can <MD>
be <VB>
treated <VBN>
with <IN>
direct <JJ>
application <NN>
of <IN>
conventional_anti-infective <JJ>
drugs <NNS>
, <,>
but <CC>
this <DT>
treatment <NN>
often <RB>
is <VBZ>
not <RB>
effective <JJ>
. <.>
Alpha <NNP>
interferon_was <VBD>
first <JJ>
approved <VBN>
in <IN>
June <NNP>
1986 <CD>
as <IN>
a <DT>
treatment <NN>
for <IN>
hairy_cell_leukemia <NN>
_ <NNP>
a <DT>
rare_form <NN>
of <IN>
leukemia <NN>
. <.>
Although <IN>
the <DT>
presence <NN>
of <IN>
genital <JJ>
warts <NNS>
is <VBZ>
more <RBR>
distressing <VBG>
than <IN>
health-threatening <JJ>
, <,>
some <DT>
studies <NNS>
have <VBP>
suggested <VBN>
there <EX>
could <MD>
be <VB>
a <DT>
relationship <NN>
in <IN>
women <NNS>
between <IN>
the <DT>
warts <NNS>
and <CC>
later <JJ>
development <NN>
of <IN>
cervical <JJ>
cancer <NN>
. <.>
Adverse <NNP>
reactions <NNS>
experienced <VBD>
during <IN>
clinical <JJ>
trials <NNS>
were <VBD>
mild <VBN>
flu-like <JJ>
symptoms <NNS>
. <.>
The <DT>
drug <NN>
is <VBZ>
not <RB>
recommended <VBN>
for <IN>
use <NN>
in <IN>
pregnant <JJ>
women <NNS>
since <IN>
animal <JJ>
studies <NNS>
have <VBP>
shown <VBN>
the <DT>
treatment <NN>
may <MD>
cause <VB>
abortions <NNS>
. <.>
Schering <VBG>
Corp. <NNP>
of <IN>
Kenilworth <NNP>
, <,>
N.J. <NNP>
, <,>
will <MD>
market <VB>
the <DT>
alpha_interferon_treatment <NN>
under <IN>
the <DT>
Intron-A <NNP>
brand_name <NN>
WSJ900419-0016 <DOCNO>
. <.>
The <DT>
results <NNS>
need <VBP>
to <TO>
be <VB>
replicated <VBN>
by <IN>
other <JJ>
researchers <NNS>
before <IN>
definitive <JJ>
conclusions <NNS>
can <MD>
be <VB>
made <VBN>
, <,>
and <CC>
the <DT>
long-term <JJ>
effect <NN>
of <IN>
the <DT>
treatment <NN>
remains <VBZ>
unknown <NN>
. <.>
But <CC>
the <DT>
initial <JJ>
experience <NN>
with <IN>
the <DT>
compound <NN>
is <VBZ>
especially <RB>
promising <VBG>
, <,>
and <CC>
an <DT>
apparent <JJ>
improvement <NN>
over <IN>
other <JJ>
therapy <NN>
for <IN>
the <DT>
disease <NN>
, <,>
scientists <NNS>
said <VBD>
. <.>
`` <``>
There <EX>
are <VBP>
n't <RB>
many <JJ>
{ <:>
drugs <NNS>
} <VBP>
where <WRB>
you <PRP>
can <MD>
administer <VB>
one <CD>
course <NN>
of <IN>
treatment <NN>
and <CC>
have <VB>
the <DT>
disease_go <NN>
away <RB>
and <CC>
stay <NN>
away <RB>
for <IN>
as <RB>
long <JJ>
as <IN>
four <CD>
years <NNS>
, <,>
'' <''>
says <VBZ>
Lawrence_Piro <NNP>
, <,>
chief <NN>
of <IN>
cancer_research <NN>
at <IN>
Scripps_Clinic <NNP>
& <CC>
amp <VB>
; <:>
Research_Foundation <NNP>
, <,>
La_Jolla <NNP>
, <,>
Calif. <NNP>
, <,>
where <WRB>
the <DT>
drug <NN>
was <VBD>
developed <VBN>
. <.>
`` <``>
The <DT>
leukemia <NN>
has <VBZ>
n't <RB>
come <VBN>
back <RB>
in <IN>
any <DT>
of <IN>
the <DT>
patients <NNS>
we <PRP>
treated <VBD>
. <.>
`` <``>
The <DT>
study <NN>
is <VBZ>
published <VBN>
in <IN>
today <NN>
's <POS>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
. <.>
`` <``>
It <PRP>
is <VBZ>
without <IN>
doubt <NN>
the <DT>
most <JJS>
effective <JJ>
treatment <NN>
for <IN>
hairy-cell <JJ>
leukemia <NN>
, <,>
in <IN>
terms <NNS>
of <IN>
rapidity <NN>
of <IN>
response <NN>
, <,>
'' <''>
adds <VBZ>
Elihu_H._Estey <NNP>
, <,>
a <DT>
cancer_researcher <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
Texas-M.D <JJ>
. <.>
Anderson_Cancer_Center <NNP>
, <,>
Houston <NNP>
. <.>
Dr._Estey <NNP>
recently <RB>
began <VBD>
treating <VBG>
patients <NNS>
with <IN>
2-CdA <CD>
and <CC>
has <VBZ>
had <VBN>
similar <JJ>
results <NNS>
with <IN>
five <CD>
patients <NNS>
. <.>
`` <``>
It <PRP>
's <VBZ>
a <DT>
striking <JJ>
finding <NN>
, <,>
'' <''>
he <PRP>
says <VBZ>
. <.>
`` <``>
It <PRP>
's <VBZ>
very_unlikely <RB>
to <TO>
be <VB>
a <DT>
fluke <NN>
. <.>
`` <``>
Hairy-cell <JJ>
leukemia <NN>
, <,>
so-called <JJ>
because_of <IN>
the <DT>
appearance <NN>
of <IN>
the <DT>
cancerous <JJ>
cells <NNS>
under <IN>
the <DT>
microscope <NN>
, <,>
affects <NNS>
about <IN>
6 <CD>
, <,>
000 <CD>
people <NNS>
in <IN>
the <DT>
U.S. <NNP>
, <,>
with <IN>
600 <CD>
new <JJ>
cases <NNS>
a <DT>
year <NN>
. <.>
As <IN>
the <DT>
disease <NN>
progresses <VBZ>
, <,>
patients <NNS>
become <VBP>
anemic <JJ>
, <,>
are <VBP>
vulnerable <JJ>
to <TO>
infection <NN>
and <CC>
often <RB>
need <VBP>
blood <NN>
transfusions <NNS>
. <.>
Until <IN>
the <DT>
mid-1980s <NNS>
, <,>
treatments <NNS>
were <VBD>
ineffective <JJ>
, <,>
and <CC>
patients <NNS>
often <RB>
died <VBD>
of <IN>
blood <NN>
problems <NNS>
and <CC>
infections <NNS>
. <.>
Since <IN>
then <RB>
, <,>
alpha_interferon <NN>
, <,>
a <DT>
drug <NN>
sold <VBN>
by <IN>
Hoffmann-La_Roche_Inc. <NNP>
and <CC>
Schering-Plough <JJ>
Corp. <NNP>
and <CC>
an <DT>
experimental <JJ>
drug <NN>
called <VBN>
deoxycoformycin <NN>
have <VBP>
significantly <RB>
reduced <VBN>
death <NN>
rates <NNS>
from <IN>
hairy-cell <NNP>
leukemia <NN>
. <.>
Hoffmann-La <NN>
Roche <NNP>
is <VBZ>
the <DT>
U.S. <NNP>
subsidiary <NN>
of <IN>
F._Hoffmann-La_Roche <NNP>
& <CC>
amp <VB>
; <:>
Co. <NNP>
of <IN>
Switzerland <NNP>
. <.>
But <CC>
neither <DT>
drug <NN>
is <VBZ>
as <RB>
effective <JJ>
as <IN>
2-CdA <CD>
appears <NNS>
to <TO>
be <VB>
in <IN>
low <JJ>
doses <NNS>
and <CC>
both <DT>
can <MD>
cause <VB>
such <PDT>
side <NN>
effects <NNS>
as <IN>
nausea <NN>
, <,>
vomiting <VBG>
, <,>
skin <NN>
rashes <NNS>
and <CC>
nervous-system <JJ>
disorders <NNS>
, <,>
researchers <NNS>
say <VBP>
. <.>
`` <``>
With <IN>
the <DT>
lack <NN>
of <IN>
toxicity <NN>
and <CC>
the <DT>
ease <NN>
with <IN>
which <WDT>
people <NNS>
go <VBP>
into <IN>
remission <NN>
{ <:>
with <IN>
2-CdA_} <CD>
, <,>
I <PRP>
think <VBP>
there's <JJ>
something <NN>
really <RB>
going <VBG>
on <IN>
here <RB>
, <,>
'' <''>
says <VBZ>
Ellin_Berman <NNP>
, <,>
a <DT>
staff_leukemia_doctor <NN>
at <IN>
Memorial_Sloan_Kettering_Cancer_Center <NNP>
, <,>
New_York <NNP>
. <.>
Scripps <NNS>
said <VBD>
it <PRP>
negotiated <VBD>
an <DT>
agreement <NN>
with <IN>
a <DT>
subsidiary <NN>
of <IN>
Johnson <NNP>
& <CC>
amp <VB>
; <:>
Johnson <NNP>
, <,>
New_Brunswick <NNP>
, <,>
N.J. <NNP>
, <,>
to <TO>
produce <VB>
and <CC>
distribute <VB>
2-CdA <CD>
to <TO>
other <JJ>
centers <NNS>
for <IN>
broader <JJR>
clinical <JJ>
trials <NNS>
. <.>
The <DT>
researchers <NNS>
said <VBD>
the <DT>
drug <NN>
is <VBZ>
easy <JJ>
to <TO>
produce <VB>
and <CC>
thus <RB>
is <VBZ>
likely <JJ>
to <TO>
be <VB>
less <JJR>
expensive <JJ>
than <IN>
other <JJ>
cancer <NN>
treatments <NNS>
. <.>
In <IN>
the <DT>
12-patient <JJ>
study <NN>
, <,>
2-CdA <CD>
, <,>
short <JJ>
for <IN>
2-chlorodeoxyadenosine <CD>
, <,>
was <VBD>
administered <VBN>
continuously <RB>
for <IN>
seven <CD>
days <NNS>
to <TO>
patients <NNS>
aged <VBN>
36 <CD>
to <TO>
61 <CD>
. <.>
Within <NNP>
eight <VBD>
to <TO>
10 <CD>
weeks <NNS>
, <,>
11 <CD>
of <IN>
the <DT>
patients <NNS>
had <VBD>
no <DT>
trace <NN>
of <IN>
cancer <NN>
in <IN>
their <PRP$>
blood <NN>
or <CC>
bone_marrow <NN>
; <:>
the <DT>
12th <JJ>
had <VBD>
a <DT>
small <JJ>
amount <NN>
remaining <VBG>
in <IN>
the <DT>
marrow <NN>
, <,>
but <CC>
he <PRP>
declined <VBD>
further <RB>
bone_marrow <NN>
monitoring <VBG>
, <,>
Dr._Piro <NNP>
said <VBD>
. <.>
His <PRP$>
blood <NN>
tests <NNS>
are <VBP>
normal <JJ>
, <,>
Dr._Piro <NNP>
added <VBD>
. <.>
None <NN>
of <IN>
the <DT>
patients <NNS>
have <VBP>
had <VBN>
a <DT>
relapse <NN>
; <:>
complete <JJ>
remission <NN>
has <VBZ>
lasted <VBN>
from <IN>
seven <CD>
to <TO>
46 <CD>
months <NNS>
after <IN>
treatment <NN>
, <,>
according <VBG>
to <TO>
the <DT>
study <NN>
. <.>
`` <``>
When <WRB>
you <PRP>
can <MD>
make <VB>
all <PDT>
the <DT>
disease_go <NN>
away <RB>
with <IN>
a <DT>
single <JJ>
infusion <NN>
of <IN>
therapy <NN>
, <,>
you <PRP>
have <VBP>
a <DT>
disease <NN>
which <WDT>
may <MD>
be <VB>
able <JJ>
to <TO>
be <VB>
cured <VBN>
, <,>
'' <''>
Dr._Piro <NNP>
said <VBD>
. <.>
But <CC>
because <IN>
hairy-cell <JJ>
leukemia <NN>
proliferates <NNS>
slowly <RB>
, <,>
a <DT>
relapse <NN>
could <MD>
occur <VB>
long <JJ>
after <IN>
treatment <NN>
. <.>
Longer_follow-up <NNP>
is <VBZ>
necessary <JJ>
to <TO>
determine <VB>
whether <IN>
2-CdA <CD>
actually <RB>
cures <VBZ>
the <DT>
disease <NN>
. <.>
The <DT>
drug <NN>
was <VBD>
first <JJ>
made <VBN>
about <IN>
10 <CD>
years <NNS>
ago <RB>
at <IN>
Scripps <NNP>
by <IN>
Dennis_A._Carson <NNP>
, <,>
who <WP>
studied <VBN>
severe <JJ>
combined <VBN>
immunodeficiency_disease <NN>
, <,>
made <VBN>
famous <JJ>
a <DT>
few <JJ>
years <NNS>
ago <RB>
by <IN>
the <DT>
Texas <NNP>
boy <NN>
that <WDT>
lived <VBD>
in <IN>
a <DT>
bubble <JJ>
. <.>
People <NNS>
with <IN>
that <DT>
disease <NN>
lack <VBP>
an <DT>
enzyme <NN>
that <IN>
processes <NNS>
deoxyadenosine <VBP>
, <,>
a <DT>
chemical <JJ>
that <IN>
, <,>
without <IN>
the <DT>
enzyme <NN>
, <,>
builds <VBZ>
up <RP>
in <IN>
infection-fighting_white <JJ>
blood <NN>
cells <NNS>
and <CC>
kills <NNS>
them <PRP>
. <.>
Since <IN>
cancer <NN>
patients <NNS>
have <VBP>
the <DT>
enzyme <NN>
, <,>
Scripps <NNP>
scientists <NNS>
developed <VBD>
a <DT>
compound <NN>
that <WDT>
mimics <NNS>
deoxyadenosine <VBP>
, <,>
but <CC>
tricks <NNS>
the <DT>
enzyme <NN>
so <RB>
it <PRP>
ca <MD>
n't <RB>
be <VB>
processed <VBN>
. <.>
The <DT>
compound <NN>
then <RB>
kills <VBZ>
the <DT>
white <JJ>
blood <NN>
cells <NNS>
, <,>
including <VBG>
those <DT>
that <WDT>
are <VBP>
cancerous <JJ>
. <.>
New <NNP>
, <,>
normal_white <JJ>
cells <NNS>
are <VBP>
then <RB>
generated <VBN>
in <IN>
the <DT>
bone_marrow <NN>
. <.>
Because <IN>
hairy-cell <JJ>
leukemia <NN>
is <VBZ>
rare <JJ>
, <,>
a <DT>
12-patient <JJ>
study <NN>
'' <''>
is <VBZ>
considered <VBN>
a <DT>
pretty <RB>
good <JJ>
series <NN>
, <,>
'' <''>
says <VBZ>
Sloan-Kettering's <-NONE->
Dr._Berman <NNP>
. <.>
`` <``>
It <PRP>
's <VBZ>
ironic <JJ>
that <IN>
we <PRP>
have <VBP>
three <CD>
active <JJ>
drugs <NNS>
for <IN>
a <DT>
disease <NN>
that <WDT>
's <VBZ>
fairly <RB>
rare <JJ>
, <,>
but <CC>
for <IN>
some <DT>
of <IN>
the <DT>
more <RBR>
common <JJ>
forms <NNS>
of <IN>
leukemia <NN>
, <,>
we <PRP>
do <VBP>
n't_yet <RB>
have <VB>
good <JJ>
treatments <NNS>
. <.>
`` <``>
Dr._Piro <NNP>
said <VBD>
2-CdA <CD>
has <VBZ>
also <RB>
been_used <VBN>
effectively <RB>
in <IN>
initial <JJ>
trials <NNS>
to <TO>
treat <VB>
more <JJR>
common <JJ>
cancers <NNS>
, <,>
including <VBG>
chronic_lymphocytic <JJ>
leukemia <NN>
, <,>
non-Hodgkins <VBZ>
lymphoma <NN>
and <CC>
cutaneous <JJ>
T-cell_lymphoma <NN>
. <.>
About <IN>
50 <CD>
% <NN>
to <TO>
60 <CD>
% <NN>
of <IN>
patients <NNS>
-- <:>
most <JJS>
of <IN>
whom <WP>
had <VBD>
failed <VBN>
other <JJ>
treatments <NNS>
-- <:>
responded <VBD>
to <TO>
the <DT>
drug <NN>
, <,>
some <DT>
with <IN>
complete <JJ>
remission <NN>
, <,>
he <PRP>
said <VBD>
. <.>
`` <``>
Now <RB>
, <,>
we <PRP>
will <MD>
use <VB>
{ <:>
2-CdA_} <CD>
as <IN>
a <DT>
first <JJ>
treatment <NN>
to <TO>
see <VB>
if <IN>
response <NN>
and <CC>
remission <NN>
are <VBP>
higher <JJR>
, <,>
'' <''>
he <PRP>
said <VBD>
. <.>
Meanwhile <RB>
, <,>
researchers <NNS>
at <IN>
University <NNP>
of <IN>
California <NNP>
at <IN>
San_Francisco <NNP>
are <VBP>
testing <VBG>
2-CdA <CD>
on <IN>
AIDS-related <JJ>
lymphoma <NN>
AP881122-0017 <DOCNO>
. <.>
Alpha <NNP>
interferon <VBD>
, <,>
a <DT>
natural <JJ>
disease_fighter <NN>
already <RB>
used <VBN>
to <TO>
treat <VB>
leukemia <NN>
, <,>
can <MD>
now <RB>
be <VB>
used <VBN>
to <TO>
battle <VB>
Kaposi's <JJ>
sarcoma <NN>
, <,>
a <DT>
cancer <NN>
that <WDT>
primarily <RB>
attacks <VBZ>
AIDS <NNP>
patients <NNS>
. <.>
The <DT>
Food <NNP>
and <CC>
Drug_Administration <NNP>
announced <VBD>
Monday <NNP>
that <IN>
alpha_interferon <NN>
was <VBD>
shown <VBN>
in <IN>
tests <NNS>
to <TO>
be <VB>
effective <JJ>
against <IN>
Kaposi <NNP>
's <POS>
and <CC>
now <RB>
is <VBZ>
approved <VBN>
for <IN>
treatment <NN>
of <IN>
the <DT>
cancer <NN>
that <IN>
has <VBZ>
become <VBN>
common <JJ>
among <IN>
AIDS <NNP>
victims <NNS>
. <.>
Alpha <NNP>
interferon <VBD>
is <VBZ>
a <DT>
disease-fighter <JJ>
that <IN>
is <VBZ>
present <JJ>
in <IN>
the <DT>
body <NN>
naturally <RB>
in <IN>
small <JJ>
amounts <NNS>
, <,>
but <CC>
has <VBZ>
been <VBN>
artifically <RB>
produced <VBN>
in <IN>
large <JJ>
quantities <NNS>
in <IN>
recent <JJ>
years <NNS>
through <IN>
the <DT>
use <NN>
of <IN>
gene-splicing <JJ>
techniques <NNS>
. <.>
It <PRP>
previously <RB>
had <VBD>
been_approved <VBN>
for <IN>
treatment <NN>
of <IN>
hairy-cell <NNP>
leukemia <NN>
and <CC>
for <IN>
genital <JJ>
warts <NNS>
. <.>
Frank_E._Young <NNP>
, <,>
FDA <NNP>
commissioner <NN>
, <,>
said <VBD>
approval <NN>
of <IN>
the <DT>
man-made <JJ>
alpha_interferon <NN>
`` <``>
shows <VBZ>
biotechnology <NN>
's <POS>
emerging_role <NN>
in <IN>
helping_modern_medicine_fight <NN>
some <DT>
of <IN>
the <DT>
most <RBS>
serious <JJ>
diseases <NNS>
which <WDT>
plague <JJ>
mankind <NN>
. <.>
'' <''>
Kaposi <NNP>
's <POS>
sarcoma <NN>
, <,>
named <VBD>
for <IN>
a <DT>
European <JJ>
doctor <NN>
who <WP>
first <RB>
described <VBD>
it <PRP>
more <JJR>
than <IN>
100 <CD>
years <NNS>
ago <RB>
, <,>
was <VBD>
a <DT>
rare_cancer <NN>
until <IN>
the <DT>
appearance <NN>
early <RB>
in <IN>
this <DT>
decade <NN>
of <IN>
AIDS <NNP>
, <,>
or <CC>
acquired <VBN>
immune <JJ>
deficiency_syndrome <NN>
. <.>
The <DT>
cancer <NN>
causes <NNS>
purple <VBP>
or <CC>
brown <IN>
lesions <NNS>
on <IN>
the <DT>
skin <NN>
and <CC>
can <MD>
attack <VB>
the <DT>
lungs <NNS>
, <,>
brain <NN>
and <CC>
gastrointestinal <JJ>
tract <NN>
. <.>
Kaposi <NNP>
's <POS>
can <MD>
cause <VB>
death <NN>
when <WRB>
it <PRP>
attacks <VBZ>
the <DT>
lungs <NNS>
or <CC>
other_vital <JJ>
organs <NNS>
, <,>
although <IN>
most <JJS>
AIDS_patients <NNS>
die <VB>
of <IN>
other <JJ>
causes <NNS>
. <.>
Alpha <NNP>
interferon_was <VBD>
used <VBN>
experimentally <RB>
to <TO>
treat <VB>
Kaposi <NNP>
's <POS>
in <IN>
a <DT>
number <NN>
of <IN>
studies <NNS>
, <,>
including <VBG>
some <DT>
conducted <JJ>
at <IN>
the <DT>
National_Institute <NNP>
of <IN>
Allergy <NNP>
and <CC>
Infectious_Diseases <NNP>
, <,>
part <NN>
of <IN>
the <DT>
National <NNP>
Institutes <NNPS>
of <IN>
Health <NNP>
. <.>
Anthony_S._Fauci <NNP>
, <,>
the <DT>
NIAID <NNP>
director <NN>
, <,>
said <VBD>
that <IN>
studies <NNS>
by <IN>
H._Clifford_Lane <NNP>
of <IN>
the <DT>
NIAID <NNP>
`` <``>
demonstrated <VBN>
that <DT>
alpha_interferon <NN>
was <VBD>
an <DT>
effective <JJ>
anti-Kaposi <NN>
's <POS>
sarcoma_agent <NN>
'' <''>
in <IN>
patients <NNS>
who <WP>
were <VBD>
in <IN>
the <DT>
early <JJ>
stages <NNS>
of <IN>
the <DT>
AIDS <NNP>
infection <NN>
. <.>
According <VBG>
to <TO>
the <DT>
FDA <NNP>
, <,>
several_human <JJ>
studies <NNS>
showed <VBD>
that <IN>
high <JJ>
doses <NNS>
of <IN>
alpha_inteferon <NN>
would <MD>
reduce <VB>
Kaposi <NNP>
's <POS>
tumors <NNS>
in <IN>
40 <CD>
to <TO>
45 <CD>
percent <NN>
of <IN>
patients <NNS>
who <WP>
were <VBD>
in <IN>
early <JJ>
stages <NNS>
of <IN>
the <DT>
AIDS <NNP>
infection <NN>
. <.>
AIDS_patients <NNS>
who <WP>
were <VBD>
helped <VBN>
most <JJS>
were <VBD>
those <DT>
whose <WP$>
blood <NN>
showed <VBD>
a <DT>
T4-helper <JJ>
cell_count <NN>
of_above <IN>
200 <CD>
per <IN>
square <JJ>
centimeter <NN>
, <,>
and <CC>
who <WP>
have <VBP>
not <RB>
experienced <VBN>
other_opportunistic <JJ>
infections <NNS>
. <.>
T4-helper <JJ>
cells <NNS>
are <VBP>
part <NN>
of <IN>
the <DT>
body <NN>
's <POS>
immune_system <NN>
and <CC>
are <VBP>
attacked <VBN>
by <IN>
the <DT>
AIDS <NNP>
virus <VBZ>
. <.>
Healthy <NNP>
people <NNS>
have <VBP>
a <DT>
T4-helper <JJ>
cell_count <NN>
of <IN>
800 <CD>
to <TO>
1 <CD>
, <,>
000 <CD>
. <.>
Those <DT>
with <IN>
more <JJR>
advanced <JJ>
AIDS <NNS>
tend <VBP>
to <TO>
have <VB>
T4-helper <JJ>
cell <NN>
counts <NNS>
below <IN>
200 <CD>
and <CC>
do <VBP>
not <RB>
benefit <VB>
from <IN>
the <DT>
alpha_interferon_treatment <NN>
. <.>
Alpha <NNP>
interferon_was <VBD>
first <JJ>
identified <VBN>
in <IN>
1957 <CD>
as <IN>
a <DT>
hormone-like <JJ>
protein <NN>
that <WDT>
is <VBZ>
a <DT>
natural <JJ>
disease-fighting_component <NN>
of <IN>
the <DT>
blood <NN>
. <.>
In <IN>
the <DT>
early <JJ>
1980s <CD>
, <,>
researchers <NNS>
were <VBD>
able <JJ>
to <TO>
insert <VB>
the <DT>
gene <NN>
coded <VBD>
for <IN>
alpha_interferon <NN>
into <IN>
a <DT>
bacteria <NN>
which <WDT>
then <RB>
produces <VBZ>
the <DT>
protein <NN>
in <IN>
large <JJ>
quantities <NNS>
. <.>
This <DT>
is <VBZ>
the <DT>
technique <NN>
called <VBD>
gene-splicing <JJ>
. <.>
The <DT>
FDA <NNP>
said <VBD>
that <IN>
alpha_interferon <NN>
is <VBZ>
marketed <VBN>
by <IN>
Schering_Corp. <NNP>
of <IN>
Kenilworth <NNP>
, <,>
N.J. <NNP>
, <,>
under <IN>
the <DT>
brand_name <NN>
Intron-A <NNP>
, <,>
and <CC>
by <IN>
Hoffmann-La_Roche <NNP>
of <IN>
Nutley <NNP>
, <,>
N.J. <NNP>
under <IN>
the <DT>
brand_name <NN>
Roferon <NNP>
. <.>
Both <DT>
products <NNS>
were <VBD>
first <RB>
approved <VBN>
in <IN>
1986 <CD>
for <IN>
the <DT>
treatment <NN>
of <IN>
hairy-cell <NNP>
leukemia <NN>
, <,>
and <CC>
last <JJ>
June <NNP>
for <IN>
the <DT>
treatment <NN>
of <IN>
genital <JJ>
warts <NNS>
. <.>
AIDS <NNS>
is <VBZ>
a <DT>
contagious <JJ>
disease <NN>
that <WDT>
attacks <VBZ>
the <DT>
body <NN>
's <POS>
immune_system <NN>
, <,>
rendering <VBG>
it <PRP>
incapable <JJ>
of <IN>
resisting <NN>
other <JJ>
diseases <NNS>
and <CC>
infections <NNS>
. <.>
The <DT>
virus <NN>
most <JJS>
often <RB>
is <VBZ>
spread <VBN>
through <IN>
contact <NN>
with <IN>
blood <NN>
, <,>
blood <NN>
products <NNS>
or <CC>
semen <NNS>
from <IN>
infected <VBN>
persons <NNS>
. <.>
AIDS <NNS>
is <VBZ>
incurable <JJ>
and <CC>
fatal <JJ>
. <.>
As_of <IN>
Nov. <NNP>
7 <CD>
, <,>
AIDS <NNP>
had <VBD>
been_diagnosed <VBN>
in <IN>
77 <CD>
, <,>
994 <CD>
Americans <NNS>
, <,>
of <IN>
whom <WP>
more <JJR>
than <IN>
half <PDT>
, <,>
or <CC>
43 <CD>
, <,>
888 <CD>
, <,>
have <VBP>
died <VBN>
since <IN>
June <NNP>
1 <CD>
, <,>
1981 <CD>
, <,>
according <VBG>
to <TO>
the <DT>
government <NN>
AP900809-0104 <DOCNO>
. <.>
A <DT>
leukemia_patient <NN>
received <VBD>
her <PRP>
mother <RB>
's <VBZ>
bone_marrow <NN>
Thursday <NNP>
, <,>
after <IN>
doctors <NNS>
failed <VBD>
to <TO>
find <VB>
a <DT>
perfect_match <NN>
among <IN>
50 <CD>
, <,>
000 <CD>
people <NNS>
who <WP>
volunteered <VBN>
as <IN>
donors <NNS>
. <.>
Allison_Atlas <NNP>
, <,>
20 <CD>
, <,>
had <VBD>
the <DT>
transplant <NN>
at <IN>
Fred_Hutchison_Cancer_Research_Center <NNP>
in <IN>
Seattle <NNP>
. <.>
Her <PRP$>
mother <NN>
, <,>
Arline <NNP>
, <,>
54 <CD>
, <,>
was <VBD>
the <DT>
donor <NN>
. <.>
The <DT>
plight <NN>
of <IN>
Miss_Atlas <NNP>
, <,>
a <DT>
New_York_University <NNP>
student <NN>
from <IN>
Bethesda <NNP>
, <,>
Md. <NNP>
, <,>
prompted <VBD>
50 <CD>
, <,>
000 <CD>
people <NNS>
to <TO>
volunteer <NN>
for <IN>
bone_marrow <NN>
tests <NNS>
. <.>
There <EX>
was <VBD>
no <DT>
perfect_match <NN>
for <IN>
Miss_Atlas <NNP>
, <,>
but <CC>
10 <CD>
other <JJ>
leukemia <NN>
patients <NNS>
got <VBD>
donors <NNS>
. <.>
Mrs._Atlas <NNP>
' <POS>
marrow <NN>
matched <VBD>
four <CD>
of <IN>
six <CD>
antigens <NNS>
, <,>
or <CC>
cell <NN>
identifiers <NNS>
, <,>
from <IN>
her <PRP$>
daughter <NN>
's <POS>
marrow <NN>
. <.>
Doctors <NNS>
said <VBD>
Miss_Atlas <NNP>
would <MD>
have <VB>
had <VBD>
a <DT>
60 <CD>
percent_chance <NN>
of <IN>
recovery <NN>
if <IN>
the <DT>
donated <VBN>
marrow <NN>
was <VBD>
a <DT>
perfect_match <NN>
. <.>
Her <PRP$>
chances <NNS>
are <VBP>
reduced <VBN>
`` <``>
somewhat <RB>
'' <''>
but <CC>
other <JJ>
patients <NNS>
with <IN>
the <DT>
same <JJ>
degree <NN>
of <IN>
mismatch <NN>
have <VBP>
recovered <VBN>
, <,>
said <VBD>
hospital <JJ>
spokeswoman <NN>
Alice_Burgess <NNP>
said <VBD>
. <.>
Without <IN>
the <DT>
transplant <NN>
, <,>
she <PRP>
would <MD>
live <VB>
less <RBR>
than <IN>
a <DT>
year <NN>
, <,>
Burgess <NNP>
said <VBD>
. <.>
Leukemia <NNP>
causes <NNS>
white <VBP>
blood <NN>
cells <NNS>
to <TO>
multiply_uncontrollably <RB>
. <.>
Bone_marrow <NN>
produces <NNS>
blood <NN>
, <,>
and <CC>
doctors <NNS>
combat <VBP>
the <DT>
cancer <NN>
by <IN>
replacing <NN>
the <DT>
diseased <VBN>
marrow <NN>
. <.>
The <DT>
Atlas <NNP>
family <NN>
's <POS>
public <JJ>
campaign <NN>
last <JJ>
fall <NN>
raised <VBD>
$ <$>
3_million <CD>
to <TO>
process_blood <NN>
samples <NNS>
from <IN>
the <DT>
50 <CD>
, <,>
000 <CD>
people <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
and <CC>
Israel <NNP>
who <WP>
registered <VBN>
with <IN>
the <DT>
National_Marrow_Donor_Program <NNP>
AP900809-0001 <DOCNO>
. <.>
A <DT>
leukemia_patient <NN>
whose <WP$>
plight <NN>
prompted <VBD>
50 <CD>
, <,>
000 <CD>
people <NNS>
to <TO>
step <VB>
forward <RB>
as <IN>
possible <JJ>
bone-marrow <NN>
donors <NNS>
will <MD>
undergo <VB>
a <DT>
transplant <NN>
of <IN>
bone_marrow <NN>
from <IN>
her <PRP$>
mother <NN>
Thursday <NNP>
, <,>
a <DT>
hospital_spokeswoman <NN>
said <VBD>
Wednesday <NNP>
. <.>
The <DT>
operation <NN>
on <IN>
Allison_Atlas <NNP>
, <,>
20 <CD>
, <,>
is <VBZ>
expected <VBN>
to <TO>
take <VB>
at <IN>
least <JJS>
four <CD>
hours <NNS>
and <CC>
could <MD>
last <VB>
six <CD>
hours <NNS>
or <CC>
more <JJR>
, <,>
said <VBD>
Fred_Hutchinson_Cancer_Research_Center <NNP>
spokeswoman <NN>
Alice_Burgess <NNP>
. <.>
Doctors <NNS>
are <VBP>
scheduled <VBN>
to <TO>
extract <VB>
the <DT>
marrow <NN>
from <IN>
Miss_Atlas' <NNP>
mother <NN>
at <IN>
9 <CD>
a.m. <NNP>
, <,>
the <DT>
spokeswoman <NN>
said <VBD>
. <.>
The <DT>
marrow <NN>
from <IN>
her <PRP$>
mother <NN>
matches <NNS>
only <RB>
four <CD>
of <IN>
six <CD>
antigens <NNS>
, <,>
or <CC>
cell <NN>
identifiers <NNS>
. <.>
But <CC>
the <DT>
New_York_University <NNP>
student <NN>
from <IN>
Bethesda <NNP>
, <,>
Md. <NNP>
, <,>
decided <VBD>
to <TO>
undergo <VB>
the <DT>
operation <NN>
while <IN>
she <PRP>
is <VBZ>
still <RB>
strong <JJ>
enough <RB>
. <.>
She <PRP>
began <VBD>
chemotherapy <NN>
July <NNP>
31 <CD>
, <,>
and <CC>
has <VBZ>
responded <VBN>
well <RB>
, <,>
Burgess <NNP>
said <VBD>
. <.>
Doctors <NNS>
said <VBD>
a <DT>
patient <NN>
with <IN>
Miss_Atlas <NNP>
' <POS>
type <NN>
of <IN>
leukemia <NN>
can <MD>
expect <VB>
a <DT>
60 <CD>
percent_chance <NN>
of <IN>
recovery <NN>
if <IN>
the <DT>
transplant_marrow <NN>
is <VBZ>
perfectly <RB>
matched <VBN>
. <.>
Without <IN>
a <DT>
transplant <NN>
, <,>
they <PRP>
say <VBP>
the <DT>
disease <NN>
is <VBZ>
100 <CD>
percent_fatal <NN>
. <.>
In <IN>
leukemia <NN>
, <,>
a <DT>
form <NN>
of <IN>
cancer <NN>
, <,>
white <JJ>
blood <NN>
cells <NNS>
multiply_uncontrollably <RB>
. <.>
Bone_marrow <NN>
produces <NNS>
blood <NN>
, <,>
and <CC>
doctors <NNS>
can <MD>
combat <VB>
the <DT>
cancer <NN>
by <IN>
replacing <NN>
the <DT>
diseased <VBN>
marrow <NN>
with <IN>
healthy <JJ>
tissue <NN>
. <.>
Miss_Atlas <NNP>
' <POS>
condition <NN>
prompted <VBD>
a <DT>
campaign <NN>
by <IN>
her <PRP$>
family <NN>
last <JJ>
fall <NN>
to <TO>
find <VB>
a <DT>
perfectly <RB>
matched <VBN>
donor <NN>
. <.>
They <PRP>
were <VBD>
unsuccessful <JJ>
, <,>
but <CC>
the <DT>
effort <NN>
raised <VBD>
$ <$>
3_million <CD>
to <TO>
process_blood <NN>
samples <NNS>
from <IN>
the <DT>
50 <CD>
, <,>
000 <CD>
people <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
and <CC>
Israel <NNP>
who <WP>
volunteered <VBN>
. <.>
Ten <CD>
patients <NNS>
found <VBD>
perfect <NN>
donors <NNS>
AP900523-0025 <DOCNO>
. <.>
In <IN>
a <DT>
unique <JJ>
assault <NN>
on <IN>
leukemia <NN>
, <,>
doctors <NNS>
have <VBP>
found <VBN>
that <IN>
a <DT>
form <NN>
of <IN>
vitamin <NN>
A <DT>
will <MD>
turn <VB>
cancer <NN>
cells <NNS>
into <IN>
normal <JJ>
ones <NNS>
. <.>
Medicine <NNP>
's <POS>
usual <JJ>
way <NN>
of <IN>
combating <VBG>
cancer <NN>
is <VBZ>
to <TO>
kill <VB>
it <PRP>
. <.>
Doctors <NNS>
administer <VBP>
powerful_toxic <JJ>
drugs <NNS>
in <IN>
the <DT>
hopes <NNS>
that <IN>
they <PRP>
will <MD>
destroy <VB>
more <RBR>
cancerous <JJ>
cells <NNS>
than <IN>
healthy <JJ>
ones <NNS>
. <.>
The <DT>
new <JJ>
approach <NN>
instead <RB>
tries <VBZ>
to <TO>
reform_cancer <NN>
cells <NNS>
. <.>
It <PRP>
changes <VBZ>
the <DT>
cells <NNS>
' <POS>
genetic <JJ>
program <NN>
, <,>
bypassing <VBG>
the <DT>
genetic <JJ>
mix <NN>
up <IN>
that <DT>
makes <VBZ>
them <PRP>
kill <MD>
. <.>
In <IN>
this <DT>
way <NN>
, <,>
the <DT>
treatment <NN>
induces <NNS>
the <DT>
cancer <NN>
cells <NNS>
to <TO>
live <VB>
, <,>
to <TO>
grow <VB>
and <CC>
eventually <RB>
to <TO>
die <VB>
by <IN>
the <DT>
same <JJ>
rules <NNS>
that <WDT>
govern <NN>
the <DT>
rest <NN>
of <IN>
the <DT>
body <NN>
. <.>
The <DT>
drug <NN>
, <,>
a <DT>
synthetic <JJ>
form <NN>
of <IN>
vitamin <NN>
A <DT>
called <VBN>
all-trans <NNS>
retinoic <JJ>
acid <NN>
, <,>
was <VBD>
developed <VBN>
in <IN>
China <NNP>
and <CC>
tested <VBD>
in <IN>
France <NNP>
. <.>
Though <IN>
it <PRP>
has <VBZ>
drawbacks <NNS>
and <CC>
works <NNS>
in <IN>
just <RB>
one <CD>
rare <JJ>
form <NN>
of <IN>
leukemia <NN>
, <,>
doctors <NNS>
hope <VBP>
it <PRP>
will <MD>
provide <VB>
clues <NNS>
for <IN>
short-circuiting <JJ>
the <DT>
basic <JJ>
errors <NNS>
that <WDT>
underlie <NN>
all <DT>
cancers <NNS>
. <.>
`` <``>
The <DT>
dogma <NN>
has <VBZ>
been <VBN>
to <TO>
try <VB>
to <TO>
kill <VB>
cancer <NN>
cells <NNS>
, <,>
'' <''>
said <VBD>
Dr._Laurent_Degos <NNP>
. <.>
`` <``>
Is <VBZ>
it <PRP>
possible <JJ>
to <TO>
change <VB>
a <DT>
cell <NN>
, <,>
and <CC>
not <RB>
kill <VBP>
it <PRP>
, <,>
so <RB>
it <PRP>
becomes <VBZ>
normal <JJ>
? <.>
'' <''>
Degos <NNP>
, <,>
a <DT>
researcher <NN>
at <IN>
Hopital_Saint-Louis <NNP>
in <IN>
Paris <NNP>
, <,>
presented <VBD>
evidence <NN>
that <IN>
this <DT>
indeed <NN>
is <VBZ>
possible <JJ>
in <IN>
a <DT>
report <NN>
Tuesday <NNP>
at <IN>
the <DT>
annual <JJ>
meeting <NN>
of <IN>
the <DT>
American_Society <NNP>
of <IN>
Clinical_Oncology <NNP>
. <.>
He <PRP>
tested <VBD>
the <DT>
drug <NN>
on <IN>
victims <NNS>
of <IN>
acute_promyelocytic <JJ>
leukemia <NN>
, <,>
a <DT>
rare_blood_cancer <NN>
that <WDT>
strikes <VBZ>
a <DT>
few <JJ>
hundred <VBN>
people <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
each <DT>
year <NN>
. <.>
All <DT>
of <IN>
them <PRP>
had <VBD>
failed <VBN>
earlier <JJR>
standard <JJ>
therapy <NN>
. <.>
He <PRP>
achieved <VBD>
complete <JJ>
, <,>
though <IN>
often <RB>
temporary <JJ>
, <,>
elimination <NN>
of <IN>
all <DT>
signs <NNS>
of <IN>
the <DT>
disease <NN>
in <IN>
16 <CD>
of <IN>
17 <CD>
patients <NNS>
who <WP>
had <VBD>
relapsed <VBN>
for <IN>
the <DT>
first <JJ>
time <NN>
. <.>
There <EX>
was <VBD>
complete <JJ>
remission <NN>
in <IN>
one <CD>
of <IN>
four <CD>
patients <NNS>
who <WP>
had <VBD>
relapsed <VBN>
a <DT>
second <JJ>
time <NN>
. <.>
`` <``>
There <EX>
was <VBD>
no <DT>
killing <NN>
of <IN>
cells <NNS>
, <,>
but <CC>
they <PRP>
change <VBP>
, <,>
'' <''>
said <VBD>
Degos <NNP>
. <.>
`` <``>
We <PRP>
see <VBP>
more <JJR>
mature <NN>
cells <NNS>
. <.>
'' <''>
This <DT>
form <NN>
of <IN>
leukemia <NN>
is <VBZ>
caused <VBN>
by <IN>
a <DT>
specific_genetic <JJ>
defect <NN>
, <,>
the <DT>
mislocation <NN>
of <IN>
a <DT>
piece <NN>
of <IN>
one <CD>
string <VBG>
of <IN>
genes <NNS>
, <,>
or <CC>
chromosome <VB>
, <,>
onto <IN>
another <DT>
chromosome <NN>
. <.>
As <IN>
a <DT>
result <NN>
, <,>
the <DT>
cells <NNS>
get <VBP>
stuck <NN>
in <IN>
their <PRP$>
juvenile <JJ>
stage <NN>
. <.>
They <PRP>
fail <VBP>
to <TO>
mature <VB>
normally <RB>
and <CC>
eventually <RB>
die <VB>
. <.>
Treatment <NNP>
with <IN>
all-trans <NNS>
retinoic <JJ>
acid <NN>
appears <VBZ>
to <TO>
bump <VB>
the <DT>
cells <NNS>
past <VBP>
this <DT>
roadblock <NN>
in <IN>
their <PRP$>
development <NN>
so <IN>
they <PRP>
grow <VBP>
old <JJ>
. <.>
`` <``>
This <DT>
is <VBZ>
a <DT>
smashing_development <NN>
, <,>
'' <''>
commented <VBD>
Dr._Charles_Schiffer <NNP>
of <IN>
the <DT>
University <NNP>
of <IN>
Maryland <NNP>
. <.>
`` <``>
It <PRP>
has <VBZ>
impressed <VBN>
even <RB>
the <DT>
most <RBS>
cynical <JJ>
. <.>
This <DT>
is <VBZ>
a <DT>
different <JJ>
approach <NN>
to <TO>
anything <NN>
we <PRP>
have <VBP>
done <VBN>
in <IN>
this <DT>
disease <NN>
in <IN>
the <DT>
past <JJ>
. <.>
'' <''>
Dr._Bruce_Chesen <NNP>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
said <VBD>
the <DT>
institute <NN>
plans <VBZ>
soon <RB>
to <TO>
sponsor <VB>
four <CD>
small <JJ>
safety <NN>
studies <NNS>
of <IN>
the <DT>
drug <NN>
. <.>
Once <RB>
those <DT>
are <VBP>
done <VBN>
, <,>
it <PRP>
will <MD>
begin <VB>
a <DT>
larger <JJR>
review <NN>
of <IN>
its <PRP$>
effectiveness <NN>
. <.>
Though <IN>
the <DT>
synthetic <JJ>
vitamin <NN>
wiped <VBD>
out <RP>
obvious <JJ>
signs <NNS>
of <IN>
the <DT>
leukemia <NN>
, <,>
the <DT>
disease <NN>
frequently <RB>
came <VBD>
back <RB>
, <,>
apparently <RB>
because <IN>
some <DT>
cancer <NN>
cells <NNS>
were <VBD>
resistant <JJ>
to <TO>
the <DT>
drug <NN>
. <.>
Degas <NNP>
said <VBD>
it <PRP>
may <MD>
be <VB>
necessary <JJ>
to <TO>
combine <NN>
the <DT>
treatment <NN>
with <IN>
standard <JJ>
chemotherapy <NN>
to <TO>
try <VB>
to <TO>
obliterate <VB>
the <DT>
few <JJ>
remaining <VBG>
cancer <NN>
cells <NNS>
. <.>
The <DT>
drug <NN>
was <VBD>
developed <VBN>
in <IN>
China <NNP>
by <IN>
Wang_Zeng_Yi <NNP>
, <,>
dean <JJ>
of <IN>
Shanghai_University_II <NNP>
, <,>
a <DT>
French-speaking_medical <JJ>
school <NN>
. <.>
It <PRP>
is <VBZ>
now <RB>
being <VBG>
produced <VBN>
by <IN>
Hoffman_LaRoche <NNP>
, <,>
the <DT>
pharmaceutical <JJ>
firm <NN>
. <.>
In <IN>
an <DT>
earlier <JJR>
report <NN>
, <,>
doctors <NNS>
said <VBD>
they <PRP>
found <VBD>
that <IN>
the <DT>
acne_medicine <NN>
Accutane <NNP>
, <,>
another <DT>
synthetic <JJ>
form <NN>
of <IN>
vitamin <NN>
A <DT>
, <,>
prevents <VBZ>
new <JJ>
tumors <NNS>
from <IN>
developing <VBG>
in <IN>
people <NNS>
treated <VBN>
for <IN>
smoking-related <JJ>
throat_cancer <NN>
. <.>
Among <IN>
other <JJ>
research <NN>
presented <VBD>
at <IN>
the <DT>
meeting <NN>
: <:>
_Dr <NNP>
. <.>
Steven_A._Rosenberg <NNP>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
outlined <VBD>
the <DT>
first <JJ>
results <NNS>
of <IN>
his <PRP$>
pioneering_attempt <NN>
to <TO>
insert <VB>
foreign <JJ>
genes <NNS>
into <IN>
cancer <NN>
patients <NNS>
. <.>
The <DT>
initial <JJ>
effort <NN>
, <,>
carried <VBD>
out <RP>
on <IN>
seven <CD>
melanoma <NN>
patients <NNS>
, <,>
was <VBD>
intended <VBN>
to <TO>
show <VB>
that <IN>
gene_therapy <NN>
is <VBZ>
possible <JJ>
. <.>
Doctors <NNS>
removed <VBD>
cancer-fighting <JJ>
blood <NN>
cells <NNS>
from <IN>
the <DT>
patients' <NN>
tumors <NNS>
, <,>
inserted <VBD>
a <DT>
bacteria_gene <NN>
into <IN>
them <PRP>
and <CC>
then <RB>
put <VBD>
them <PRP>
back <RB>
into <IN>
the <DT>
patients <NNS>
' <POS>
bodies <NNS>
. <.>
The <DT>
manipulated <VBN>
cells <NNS>
zeroed <VBN>
in_on <IN>
their <PRP$>
tumors <NNS>
. <.>
The <DT>
doctors <NNS>
hope <VBP>
soon <RB>
to <TO>
repeat <VB>
the <DT>
experiment <NN>
, <,>
this <DT>
time <NN>
inserting <VBG>
a <DT>
gene <NN>
that <WDT>
produces <VBZ>
a <DT>
cancer-killing <JJ>
chemical <NN>
called <VBN>
tumer_necrosis_factor <NN>
. <.>
_A <NNP>
survey <NN>
of <IN>
American <JJ>
and <CC>
Caribbean <NNP>
blacks <NNS>
in <IN>
central <JJ>
Brooklyn <NNP>
showed <VBD>
that <IN>
a <DT>
surprising <JJ>
4 <CD>
percent <NN>
were <VBD>
infected <VBN>
with <IN>
cancer-causing <JJ>
human_T-cell_leukemia <NN>
virus <VBZ>
Type <NNP>
1 <CD>
, <,>
or <CC>
HTLV-I <NNP>
. <.>
Dr._Harvey_Dosik <NNP>
of <IN>
Interfaith_Medical_Center <NNP>
in <IN>
Brooklyn <NNP>
said <VBD>
the <DT>
infection_rate <NN>
is <VBZ>
200 <CD>
times <NNS>
higher <JJR>
than <IN>
that <DT>
seen <VBN>
nationwide <NN>
in <IN>
blood <NN>
donors <NNS>
. <.>
_Dr <NNP>
. <.>
Lode_J._Swinnen <NNP>
of <IN>
Loyola_University <NNP>
in <IN>
Chicago <NNP>
said <VBD>
he <PRP>
had <VBD>
found <VBN>
evidence <NN>
that <IN>
OKT3 <NNP>
, <,>
an <DT>
antibody_treatment <NN>
widely <RB>
given <VBN>
to <TO>
recipients <NNS>
of <IN>
organ <JJ>
transplants <NNS>
, <,>
significantly <RB>
increases <VBZ>
their <PRP$>
risk <NN>
of <IN>
non-Hodgkins <NNS>
lymphoma <VBP>
, <,>
a <DT>
blood_cancer <NN>
. <.>
He <PRP>
reviewed <VBD>
154 <CD>
heart_transplant <NN>
patients <NNS>
and <CC>
found <VBN>
that <IN>
11 <CD>
percent <NN>
of <IN>
those <DT>
getting <VBG>
OKT3 <NNP>
since <IN>
1986 <CD>
had <VBD>
developed <VBN>
the <DT>
disease <NN>
AP900111-0061 <DOCNO>
. <.>
A <DT>
form <NN>
of <IN>
blood_cancer <NN>
that <WDT>
strikes <VBZ>
children <NNS>
appears <VBZ>
to <TO>
be <VB>
sometimes <RB>
linked <VBN>
with <IN>
genetic <JJ>
damage <NN>
that <WDT>
hinders <NNS>
the <DT>
body <NN>
's <POS>
ability <NN>
to <TO>
make <VB>
interferon <NN>
, <,>
according <VBG>
to <TO>
a <DT>
study <NN>
published <VBN>
today <NN>
. <.>
The <DT>
researchers <NNS>
speculate <VBP>
that <IN>
genes <NNS>
that <WDT>
oversee <NN>
the <DT>
body's <NNP>
production <NN>
of <IN>
interferon <NN>
, <,>
a <DT>
disease-fighting <JJ>
substance <NN>
, <,>
may <MD>
play <VB>
a <DT>
role <NN>
in <IN>
warding <NN>
off <IN>
the <DT>
development <NN>
of <IN>
cancer <NN>
. <.>
The <DT>
researchers <NNS>
speculate <VBP>
that <IN>
the <DT>
interferon <NN>
genes <NNS>
may <MD>
act <VB>
as <IN>
regulators <NNS>
that <IN>
stop <NN>
the <DT>
body <NN>
's <POS>
cells <NNS>
from <IN>
becoming <VBG>
cancerous <JJ>
. <.>
The <DT>
researchers <NNS>
, <,>
based <VBN>
at <IN>
the <DT>
University <NNP>
of <IN>
Chicago <NNP>
, <,>
found <VBD>
an <DT>
association <NN>
between <IN>
loss <NN>
of <IN>
the <DT>
genes <NNS>
and <CC>
development <NN>
of <IN>
acute <NN>
lymphoblastic <JJ>
leukemia <NN>
, <,>
the <DT>
most <RBS>
common <JJ>
form <NN>
of <IN>
childhood_leukemia <NN>
. <.>
They <PRP>
tested <VBD>
62 <CD>
patients <NNS>
with <IN>
this <DT>
kind <NN>
of <IN>
leukemia <NN>
and <CC>
found <VBD>
that <IN>
29 <CD>
percent <NN>
of <IN>
them <PRP>
were <VBD>
missing <VBG>
the <DT>
interferon <NN>
genes <NNS>
. <.>
Their <PRP$>
work <NN>
, <,>
directed <VBD>
by <IN>
Dr._Manuel_O._Diaz <NNP>
, <,>
was <VBD>
published <VBN>
in <IN>
the <DT>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
. <.>
It <PRP>
adds <VBZ>
to <TO>
the <DT>
growing <VBG>
list <NN>
of <IN>
cancers <NNS>
that <WDT>
have <VBP>
been_associated <VBN>
with <IN>
the <DT>
presence <NN>
or <CC>
absence <NN>
of <IN>
particular <JJ>
genes <NNS>
. <.>
Some <DT>
genes <NNS>
, <,>
known <VBN>
oncogenes <NNS>
, <,>
are <VBP>
though <IN>
to <TO>
trigger <JJR>
cancer <NN>
. <.>
Cancer <NN>
can <MD>
also <RB>
occur <VB>
when <WRB>
other <JJ>
genes <NNS>
, <,>
known <VBN>
as <IN>
anti-oncogenes <NNS>
, <,>
are <VBP>
missing <VBG>
. <.>
Interferon <NNP>
plays <VBZ>
a <DT>
variety <NN>
of <IN>
roles <NNS>
in <IN>
regulating <VBG>
the <DT>
body's <JJ>
immune <NN>
defenses <NNS>
and <CC>
controlling <VBG>
cell_growth <NN>
. <.>
The <DT>
production <NN>
of <IN>
two <CD>
forms <NNS>
of <IN>
interferon <NN>
, <,>
known <VBN>
as <IN>
alpha <NN>
and <CC>
beta-1 <-NONE->
, <,>
are <VBP>
controlled <VBN>
by <IN>
two <CD>
genes <NNS>
that <WDT>
are <VBP>
close_together <RB>
on <IN>
chromosome <NN>
9 <CD>
in <IN>
the <DT>
body <NN>
's <POS>
library <NN>
of <IN>
genes <NNS>
. <.>
In <IN>
the <DT>
latest <JJS>
work <NN>
, <,>
the <DT>
researchers <NNS>
found <VBD>
that <IN>
this <DT>
section <NN>
of <IN>
the <DT>
chromosome <NN>
was <VBD>
frequently <RB>
missing <VBG>
in <IN>
those <DT>
with <IN>
acute_lymphoblastic <JJ>
leukemia <NN>
. <.>
However <RB>
, <,>
they <PRP>
left <VBD>
open <JJ>
the <DT>
possibility <NN>
that <IN>
some <DT>
other <JJ>
gene <NN>
in <IN>
this <DT>
region <NN>
besides <VBZ>
those <DT>
that <WDT>
make <VBP>
interferon <RP>
could <MD>
also <RB>
be <VB>
the <DT>
tumor-suppressing <JJ>
gene <NN>
. <.>
Acute <NNP>
lymphoblastic <JJ>
leukemia <NN>
accounts <NNS>
for_about <IN>
one-quarter <JJ>
of <IN>
all <DT>
childhood <NN>
cancers <NNS>
. <.>
It <PRP>
strikes <VBZ>
one <CD>
in <IN>
every <DT>
30 <CD>
, <,>
000 <CD>
children <NNS>
AP900215-0120 <DOCNO>
. <.>
Researchers <NNS>
, <,>
using <VBG>
an <DT>
intricate <JJ>
manipulation <NN>
of <IN>
genes <NNS>
and <CC>
transplantation <NN>
of <IN>
bone_marrow <NN>
, <,>
have <VBP>
produced <VBN>
a <DT>
mouse <NN>
that <WDT>
suffers <NNS>
from <IN>
a <DT>
vicious <JJ>
form <NN>
of <IN>
human <JJ>
leukemia <NN>
, <,>
giving <VBG>
scientists <NNS>
a <DT>
new <JJ>
way <NN>
to <TO>
test <NN>
therapies <NNS>
against <IN>
the <DT>
killer_disease <NN>
. <.>
In <IN>
a <DT>
report <NN>
to <TO>
be <VB>
published <VBN>
Friday <NNP>
in <IN>
the <DT>
magazine <NN>
Science <NNP>
, <,>
researchers <NNS>
at <IN>
the <DT>
Whitehead_Institute <NNP>
for <IN>
Biomedical_Research <NNP>
said <VBD>
they <PRP>
have <VBP>
discovered <VBN>
a <DT>
way <NN>
to <TO>
give <VB>
chronic_myelogenous <JJ>
leukemia <NN>
, <,>
CML <NNP>
, <,>
to <TO>
laboratory_mice <NN>
. <.>
CML <NNP>
is <VBZ>
a <DT>
form <NN>
of <IN>
leukemia <NN>
that <IN>
usually <RB>
attacks <VBZ>
adults <NNS>
and <CC>
is <VBZ>
only_rarely <RB>
cured <VBN>
. <.>
`` <``>
With <IN>
this <DT>
new <JJ>
animal_model <NN>
, <,>
experimental <JJ>
therapies <NNS>
that <WDT>
might <MD>
otherwise_be <VB>
tried <VBN>
in <IN>
human <JJ>
patients <NNS>
can <MD>
now <RB>
be <VB>
tested <VBN>
in <IN>
these <DT>
mice <NN>
, <,>
'' <''>
said <VBD>
George_Daley <NNP>
, <,>
lead <VBP>
researcher <NN>
in <IN>
the <DT>
study <NN>
at <IN>
Whitehead <NNP>
. <.>
`` <``>
You <PRP>
obviously <RB>
can <MD>
do <VB>
more <RBR>
with <IN>
the <DT>
mice <NN>
than <IN>
you <PRP>
could <MD>
with <IN>
human <JJ>
patients <NNS>
. <.>
'' <''>
Daley <NNP>
said <VBD>
the <DT>
study <NN>
also <RB>
proves <VBZ>
that <IN>
CML <NNP>
is <VBZ>
initiated <VBN>
by <IN>
the <DT>
fusion <NN>
of <IN>
parts <NNS>
from <IN>
two <CD>
broken <VBN>
chromosomes <NNS>
, <,>
a <DT>
finding <NN>
that <WDT>
had <VBD>
been_suggested <VBN>
by <IN>
earlier <JJR>
studies <NNS>
in <IN>
other <JJ>
laboratories <NNS>
. <.>
Those <DT>
parts <NNS>
have <VBP>
been_identified <VBN>
as <IN>
the <DT>
so-called <JJ>
ABL <NNP>
gene <NN>
from <IN>
chromosome <NN>
9 <CD>
and <CC>
a <DT>
gene <NN>
called <VBN>
BCR <NNP>
from <IN>
chromosome <NN>
22 <CD>
. <.>
Cells <NNS>
containing <VBG>
this <DT>
hybrid_gene_produce <NN>
a <DT>
protein <NN>
, <,>
called <VBN>
P210 <NNP>
, <,>
that <IN>
changes <NNS>
healthy <JJ>
cells <NNS>
into <IN>
cancer <NN>
cells <NNS>
. <.>
Daley <NNP>
said <VBD>
his <PRP$>
study <NN>
showed <VBD>
that <IN>
transferring <NN>
the <DT>
BCR_@_ABL <NNP>
gene <NN>
into <IN>
mouse_bone_marrow <NN>
and <CC>
then <RB>
putting <VBG>
these <DT>
infected <JJ>
cells <NNS>
into <IN>
healthy <JJ>
mice <NN>
could <MD>
produce <VB>
CML <NNP>
in <IN>
those <DT>
mice <NN>
. <.>
`` <``>
It <PRP>
answers <VBZ>
a <DT>
question <NN>
of <IN>
basic <JJ>
science <NN>
, <,>
that <IN>
is <VBZ>
, <,>
what <WP>
causes <NNS>
the <DT>
disease <NN>
, <,>
'' <''>
said <VBD>
Daley <NNP>
. <.>
`` <``>
We <PRP>
now <RB>
know <VBP>
that <IN>
the <DT>
BCR_@_ABL <NNP>
gene <NN>
is <VBZ>
sufficient <JJ>
to <TO>
induce <VB>
the <DT>
leukemia <NN>
. <.>
'' <''>
He <PRP>
said <VBD>
it <PRP>
is <VBZ>
still_not <RB>
known <VBN>
precisely <RB>
what <WP>
causes <NNS>
the <DT>
two <CD>
chromosomes <NNS>
to <TO>
break <VB>
and <CC>
create <VB>
the <DT>
hybrid <JJ>
gene <NN>
, <,>
but <CC>
a <DT>
high <JJ>
exposure <NN>
to <TO>
radiation <NN>
is <VBZ>
thought <VBN>
to <TO>
be <VB>
a <DT>
factor <NN>
. <.>
Dr._George_Canellos <NNP>
, <,>
chief <NN>
of <IN>
medical <JJ>
oncology <NN>
at <IN>
the <DT>
Dana-Farber <JJ>
Institute <NNP>
in <IN>
Boston <NNP>
, <,>
described <VBD>
the <DT>
Whitehead <NNP>
finding <NN>
as <IN>
`` <``>
an <DT>
important <JJ>
advance <NN>
in <IN>
understanding <NN>
the <DT>
disease <NN>
. <.>
'' <''>
He <PRP>
said <VBD>
the <DT>
new_animal <JJ>
model <NN>
of <IN>
the <DT>
disease <NN>
possibly <RB>
may <MD>
help <VB>
scientists <NNS>
find <VB>
ways <NNS>
to <TO>
block <VB>
the <DT>
action <NN>
of <IN>
the <DT>
P210 <NNP>
protein <NN>
produced <VBN>
by <IN>
the <DT>
BCR_@_ABL <NNP>
gene <NN>
, <,>
thus <RB>
preventing <VBG>
the <DT>
disease <NN>
. <.>
Daley <NNP>
said <VBD>
that <IN>
the <DT>
mouse <NN>
can <MD>
be <VB>
used <VBN>
to <TO>
test <NN>
`` <``>
biological <JJ>
inhibitors <NNS>
'' <''>
that <IN>
would <MD>
prevent <VB>
the <DT>
P210 <NNP>
protein <NN>
from <IN>
transforming <VBG>
normal <JJ>
cells <NNS>
into <IN>
cancers <NNS>
. <.>
Such <JJ>
inhibitors <NNS>
formally <RB>
could <MD>
only <RB>
be <VB>
tested <VBN>
on <IN>
human <JJ>
patients <NNS>
, <,>
a <DT>
process <NN>
that <WDT>
could <MD>
take <VB>
years <NNS>
. <.>
With <IN>
a <DT>
mouse_model <NN>
of <IN>
the <DT>
disease <NN>
, <,>
experiments <NNS>
can <MD>
be <VB>
speeded <VBN>
up <RP>
and <CC>
can <MD>
be <VB>
more <RBR>
extensive <JJ>
. <.>
To <TO>
create <VB>
the <DT>
mouse_model <NN>
, <,>
Daley <NNP>
said <VBD>
he <PRP>
and <CC>
his <PRP$>
collegues <NNS>
inserted <VBD>
the <DT>
human <JJ>
BCR_@_ABL <NNP>
gene <NN>
into <IN>
a <DT>
virus <JJ>
. <.>
Normal <JJ>
mouse_bone_marrow <NN>
cells <NNS>
were <VBD>
then <RB>
exposed <VBN>
to <TO>
the <DT>
virus <NN>
, <,>
which <WDT>
transferred <VBN>
the <DT>
gene <NN>
into <IN>
the <DT>
marrow <NN>
cells <NNS>
. <.>
Thirty <NNP>
healthy <JJ>
mice <NN>
were <VBD>
then <RB>
irradiated <VBN>
to <TO>
kill <VB>
their <PRP$>
bone_marrow <NN>
cells <NNS>
. <.>
The <DT>
bone_marrow <NN>
carrying <VBG>
the <DT>
BCR_@_ABL <NNP>
gene <NN>
was <VBD>
then <RB>
transplanted <VBN>
into <IN>
the <DT>
30 <CD>
mice <NN>
. <.>
Within <NNP>
five <CD>
months <NNS>
, <,>
13 <CD>
of <IN>
the <DT>
30 <CD>
mice <NN>
developed <VBD>
a <DT>
blood_disease <NN>
that <WDT>
mimicked <VBD>
human_chronic <NN>
myelogenous <JJ>
leukemia <NN>
. <.>
CML <NNP>
in <IN>
humans <NNS>
can <MD>
be <VB>
controlled <VBN>
by <IN>
chemotherpy <NN>
for <IN>
3 <CD>
to <TO>
5 <CD>
years <NNS>
. <.>
This <DT>
remission_period <NN>
usually <RB>
ends <VBZ>
with <IN>
the <DT>
sudden <JJ>
increase <NN>
in <IN>
abnormal <JJ>
cells <NNS>
, <,>
a <DT>
disease_phase <NN>
called <VBN>
`` <``>
blast <JJ>
crisis <NN>
'' <''>
that <WDT>
usually <RB>
results <VBZ>
in <IN>
death <NN>
. <.>
The <DT>
only_successful <JJ>
therapy <NN>
now <RB>
is <VBZ>
to <TO>
kill <VB>
the <DT>
diseased <VBN>
bone_marrow <NN>
in <IN>
the <DT>
patient <NN>
and <CC>
replace <NN>
it <PRP>
with <IN>
healthy <JJ>
bone_marrow <NN>
from <IN>
a <DT>
compatible <JJ>
donor <NN>
, <,>
but <CC>
even <RB>
this <DT>
treatment <NN>
often <RB>
fails <VBZ>
. <.>
Daley <NNP>
said <VBD>
that <IN>
continued <VBN>
studies <NNS>
of <IN>
the <DT>
CML <NNP>
mice <NN>
shows <VBZ>
that <IN>
many <JJ>
of <IN>
the <DT>
laboratory <NN>
animals <NNS>
develop <VB>
the <DT>
`` <``>
blast <JJ>
crisis <NN>
'' <''>
phase <NN>
of <IN>
the <DT>
disease <NN>
. <.>
This <DT>
, <,>
he <PRP>
said <VBD>
, <,>
is <VBZ>
further <JJ>
verification <NN>
that <WDT>
the <DT>
course <NN>
of <IN>
the <DT>
disease <NN>
in <IN>
the <DT>
mice <NN>
is <VBZ>
similar <JJ>
to <TO>
CML <NNP>
in <IN>
humans <NNS>
. <.>
Co-authors <NNS>
of <IN>
the <DT>
study <NN>
with <IN>
Daley <NNP>
were <VBD>
Richard <NNP>
A <DT>
. <.>
Van_Etten <NNP>
and <CC>
David_Baltimore <NNP>
, <,>
both <DT>
of <IN>
the <DT>
Whitehead_Institute <NNP>
. <.>
Science <NN>
, <,>
which <WDT>
published <VBD>
the <DT>
study <NN>
, <,>
is <VBZ>
the <DT>
journal <NN>
of <IN>
the <DT>
American_Association <NNP>
for <IN>
the <DT>
Advancement <NNP>
of <IN>
Science <NNP>
SJMN91-06040145 <DOCNO>
. <.>
Frequent <NNP>
use <VBP>
of <IN>
hair <NN>
dryers <NNS>
and <CC>
black-and-white <JJ>
televisions <NNS>
also_slightly <RB>
increased <VBN>
the <DT>
risk <NN>
of <IN>
leukemia <NN>
, <,>
although <IN>
the <DT>
exact <JJ>
increase <NN>
was <VBD>
not <RB>
released <VBN>
. <.>
; <:>
Dr._John_Peters <NNP>
, <,>
director <NN>
of <IN>
USC <NNP>
's <POS>
occupational <JJ>
health_division <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
Southern_California <NNP>
, <,>
presented <VBD>
his <PRP$>
findings <NNS>
Thursday <NNP>
at <IN>
a <DT>
closed <VBN>
scientific <JJ>
meeting <NN>
in <IN>
Carmel <NNP>
. <.>
; <:>
Peters <NNP>
said <VBD>
, <,>
through <IN>
a <DT>
spokesman <NN>
, <,>
that <IN>
he <PRP>
would <MD>
not <RB>
release <VB>
his <PRP$>
data <NNS>
or <CC>
discuss <NNS>
his <PRP$>
findings <NNS>
in <IN>
public <JJ>
until <IN>
they <PRP>
have <VBP>
been_reviewed <VBN>
and <CC>
accepted <VBN>
for <IN>
publication <NN>
in <IN>
a <DT>
scientific_journal <JJ>
. <.>
But <CC>
in <IN>
a <DT>
departure <NN>
from <IN>
usual_scientific <JJ>
procedure <NN>
, <,>
summaries <NNS>
of <IN>
his <PRP$>
findings <NNS>
were <VBD>
distributed <VBN>
by <IN>
the <DT>
Electric_Power_Research_Institute <NNP>
, <,>
the <DT>
Palo <NNP>
Alto-based <JJ>
industry_group <NN>
that <WDT>
financed <VBN>
his <PRP$>
study <NN>
and <CC>
sponsored <VBD>
the <DT>
Carmel <NNP>
meeting <NN>
. <.>
; <:>
The <DT>
institute <NN>
acted <VBD>
on <IN>
its <PRP$>
own <JJ>
because <IN>
it <PRP>
assumed <VBD>
that <IN>
word <NN>
of <IN>
the <DT>
results <NNS>
would <MD>
leak <VB>
out <RP>
anyway <RB>
, <,>
and <CC>
it <PRP>
wanted <VBD>
to <TO>
provide <VB>
as <IN>
thorough <JJ>
a <DT>
report <NN>
as <IN>
possible <JJ>
, <,>
a <DT>
spokeswoman <NN>
said <VBD>
. <.>
; <:>
Electromagnetic <JJ>
fields <NNS>
are <VBP>
routinely <RB>
produced <VBN>
when <WRB>
electrical_current <JJ>
passes <NNS>
through <IN>
a <DT>
wire <NN>
or <CC>
household_appliance <NN>
. <.>
; <:>
In <IN>
the <DT>
past <JJ>
decade <NN>
, <,>
several_inconclusive <JJ>
studies <NNS>
have <VBP>
suggested <VBN>
that <IN>
children <NNS>
living <VBG>
near <IN>
high-voltage <JJ>
lines <NNS>
have <VBP>
a <DT>
higher-than-normal <JJ>
chance <NN>
of <IN>
developing <VBG>
leukemia <NN>
. <.>
; <:>
No <DT>
one <NN>
has <VBZ>
proved <VBN>
that <IN>
the <DT>
power <NN>
lines <NNS>
are <VBP>
causing <VBG>
cancer <NN>
, <,>
or <CC>
even <RB>
how <WRB>
they <PRP>
might <MD>
. <.>
But <CC>
the <DT>
Environmental_Protection_Agency <NNP>
, <,>
in <IN>
a <DT>
recent <JJ>
draft_report <NN>
, <,>
concluded <VBD>
that <IN>
there <EX>
was <VBD>
enough <RB>
evidence <NN>
of <IN>
a <DT>
possible <JJ>
link <NN>
to <TO>
warrant <VB>
new <JJ>
research <NN>
. <.>
; <:>
In <IN>
the <DT>
USC <NNP>
study <NN>
, <,>
which <WDT>
began <VBD>
in <IN>
1986 <CD>
, <,>
Peters <NNP>
examined <VBD>
the <DT>
lives <NNS>
of <IN>
464 <CD>
children <NNS>
under <IN>
the <DT>
age <NN>
of <IN>
10 <CD>
. <.>
Half <NNP>
had <VBD>
leukemia <NNS>
and <CC>
half <DT>
did <VBD>
not <RB>
. <.>
Each <DT>
leukemia_patient <NN>
was <VBD>
compared <VBN>
to <TO>
a <DT>
healthy <JJ>
child <NN>
of <IN>
the <DT>
same <JJ>
age <NN>
, <,>
sex <NN>
, <,>
race <NN>
and <CC>
geographic <JJ>
area <NN>
. <.>
; <:>
Parents <NNS>
were <VBD>
interviewed <VBN>
by <IN>
telephone <NN>
about <IN>
occupation <NN>
, <,>
household_use <NN>
of <IN>
chemicals <NNS>
, <,>
smoking <VBG>
, <,>
drug_use <NN>
and <CC>
daily <JJ>
activities <NNS>
, <,>
including <VBG>
exposure <NN>
to <TO>
electrical <JJ>
appliances <NNS>
. <.>
; <:>
Unlike <NNP>
those <DT>
who <WP>
conducted <VBN>
earlier <JJR>
studies <NNS>
, <,>
Peters <NNP>
' <POS>
group <NN>
entered <VBD>
homes <NNS>
and <CC>
took <VBD>
direct <JJ>
measurements <NNS>
of <IN>
the <DT>
electric <JJ>
and <CC>
magnetic <JJ>
fields <NNS>
. <.>
A <DT>
recording_device <NN>
was <VBD>
placed <VBN>
in <IN>
each <DT>
child <NN>
's <POS>
bedroom <NN>
to <TO>
measure <VB>
such <JJ>
fields <NNS>
every <DT>
minute <NN>
for <IN>
24 <CD>
hours <NNS>
. <.>
; <:>
Power <NNP>
lines <NNS>
in <IN>
the <DT>
neighborhood <NN>
were <VBD>
examined <VBN>
, <,>
as <IN>
well <RB>
as <IN>
the <DT>
thickness <NN>
of <IN>
the <DT>
wires <NNS>
and <CC>
their <PRP$>
distance <NN>
from <IN>
the <DT>
houses <NNS>
. <.>
; <:>
Like <IN>
previous <JJ>
researchers <NNS>
, <,>
Peters <NNP>
found <VBD>
an <DT>
association <NN>
between <IN>
neighborhood_power <NN>
lines <NNS>
and <CC>
the <DT>
risk <NN>
for <IN>
childhood_leukemia <NN>
. <.>
The <DT>
normal <JJ>
risk <NN>
of <IN>
childhood_leukemia <NN>
is <VBZ>
1 <CD>
in <IN>
20 <CD>
, <,>
000 <CD>
a <DT>
year <NN>
, <,>
the <DT>
institute <NN>
said <VBD>
, <,>
and <CC>
the <DT>
children <NNS>
with <IN>
the <DT>
greatest <JJS>
exposure <NN>
to <TO>
the <DT>
most <JJS>
powerful <JJ>
transmission <NN>
lines <NNS>
had <VBD>
a <DT>
risk <NN>
of <IN>
2.5 <CD>
in <IN>
20 <CD>
, <,>
000. <CD>
; <:>
But <CC>
oddly <RB>
, <,>
there <EX>
was <VBD>
little <JJ>
or <CC>
no <DT>
association <NN>
between <IN>
leukemia <NN>
and <CC>
measures <VBZ>
of <IN>
exposure <NN>
to <TO>
electric <JJ>
or <CC>
magnetic <JJ>
fields <NNS>
. <.>
; <:>
In <IN>
fact <NN>
, <,>
children <NNS>
in <IN>
homes <NNS>
with <IN>
moderate_magnetic <JJ>
field <NN>
exposures <NNS>
had <VBD>
a <DT>
lower <JJR>
cancer_risk <NN>
than <IN>
children <NNS>
in <IN>
homes <NNS>
with <IN>
the <DT>
least <JJS>
exposures <NNS>
. <.>
; <:>
The <DT>
study <NN>
also <RB>
found <VBD>
other <JJ>
factors <NNS>
associated <VBN>
with <IN>
leukemia_risk <NN>
: <:>
parents <NNS>
' <POS>
use <NN>
of <IN>
incense <NN>
, <,>
pesticides <VBZ>
inside <NN>
the <DT>
house <NN>
and <CC>
men <NNS>
's <POS>
use <NN>
of <IN>
spray_paint <NN>
at <IN>
work <NN>
during <IN>
their <PRP$>
wives <NNS>
' <POS>
pregnancies <NNS>
AP880524-0168 <DOCNO>
. <.>
The <DT>
natural <JJ>
protein_interferon <NN>
, <,>
combined <VBN>
with <IN>
standard <JJ>
chemotherapy <NN>
drugs <NNS>
, <,>
shows <VBZ>
promise <NN>
in <IN>
controlling_multiple_myeloma <NN>
, <,>
a <DT>
lethal <JJ>
form <NN>
of <IN>
bone_cancer <NN>
, <,>
researchers <NNS>
said <VBD>
Tuesday <NNP>
. <.>
`` <``>
We <PRP>
finally <RB>
have <VBP>
a <DT>
leg <NN>
up <RP>
on <IN>
arresting <NN>
the <DT>
natural <JJ>
progression <NN>
of <IN>
the <DT>
disease <NN>
and <CC>
producing <VBG>
patients <NNS>
who <WP>
are <VBP>
alive <JJ>
at <IN>
five <CD>
years <NNS>
, <,>
which <WDT>
has <VBZ>
been <VBN>
a <DT>
rarity <NN>
, <,>
'' <''>
said <VBD>
Dr._Martin_M._Oken <NNP>
of <IN>
the <DT>
University <NNP>
of <IN>
Minnesota <NNP>
. <.>
His <PRP$>
research <NN>
is <VBZ>
part <NN>
of <IN>
a <DT>
new <JJ>
effort <NN>
by <IN>
scientists <NNS>
to <TO>
find <VB>
a <DT>
role <NN>
for <IN>
interferon <NN>
by <IN>
combining <NN>
it <PRP>
with <IN>
the <DT>
drugs <NNS>
that <WDT>
have <VBP>
long <RB>
been_used <VBN>
to <TO>
attack <VB>
cancer <NN>
. <.>
Oken <NNP>
said <VBD>
interferon <NN>
might <MD>
provide <VB>
a <DT>
knockout_punch <NN>
after <IN>
cancer <NN>
has <VBZ>
been_weakened <VBN>
, <,>
but <CC>
not <RB>
destroyed <VBN>
, <,>
by <IN>
medicines <NNS>
. <.>
The <DT>
work <NN>
may <MD>
also <RB>
represent <VB>
a <DT>
revival <NN>
of <IN>
the <DT>
fortunes <NNS>
of <IN>
interferon <NN>
, <,>
which <WDT>
has <VBZ>
been <VBN>
on <IN>
a <DT>
roller_coaster <NN>
of <IN>
public <JJ>
acclaim <NN>
and <CC>
disdain <NN>
for <IN>
a <DT>
decade <NN>
. <.>
Interferon <NNP>
is <VBZ>
a <DT>
natural <JJ>
, <,>
hormone-like <JJ>
substance <NN>
that <WDT>
, <,>
among <IN>
other <JJ>
things <NNS>
, <,>
helps <NNS>
regulate <VBP>
the <DT>
body <NN>
's <POS>
immune_system <NN>
. <.>
When <WRB>
the <DT>
human <JJ>
gene <NN>
that <WDT>
makes <VBZ>
this <DT>
chemical <JJ>
was <VBD>
isolated <VBN>
, <,>
some <DT>
experts <NNS>
predicted <VBD>
many <JJ>
uses <NNS>
for <IN>
interferon <NN>
in <IN>
eliminating_cancer <NN>
and <CC>
infections <NNS>
. <.>
However <RB>
, <,>
studies <NNS>
showed <VBD>
that <IN>
when <WRB>
used <VBN>
alone <NN>
, <,>
interferon <NN>
had <VBD>
little_major <JJ>
impact <NN>
on <IN>
any <DT>
cancer <NN>
except <IN>
an <DT>
exceedingly <RB>
rare <JJ>
malignancy <NN>
called <VBN>
hairy_cell_leukemia <NN>
, <,>
for <IN>
which <WDT>
it <PRP>
has <VBZ>
become <VBN>
standard <JJ>
therapy <NN>
. <.>
In <IN>
the <DT>
latest <JJS>
research <NN>
, <,>
presented <VBD>
at <IN>
the <DT>
annual <JJ>
meeting <NN>
of <IN>
the <DT>
American_Association <NNP>
of <IN>
Clinical_Oncology <NNP>
, <,>
doctors <NNS>
found <VBD>
that <IN>
interferon <NN>
plus <CC>
chemotherapy <NN>
produced <VBN>
complete <JJ>
remissions <NNS>
in <IN>
30 <CD>
percent <NN>
of <IN>
the <DT>
54 <CD>
patients <NNS>
studied <VBD>
. <.>
Such <JJ>
remissions <NNS>
, <,>
in <IN>
which <WDT>
all <DT>
signs <NNS>
of <IN>
the <DT>
disease <NN>
are <VBP>
gone <VBN>
, <,>
are <VBP>
rare <JJ>
in <IN>
multiple_myeloma <NN>
, <,>
and <CC>
they <PRP>
are <VBP>
the <DT>
first <JJ>
step <NN>
toward <IN>
curing <VBG>
the <DT>
disease <NN>
. <.>
In <IN>
all <DT>
, <,>
41 <CD>
percent <NN>
of <IN>
the <DT>
patients <NNS>
had <VBD>
remissions <NNS>
that <IN>
were <VBD>
complete <JJ>
or <CC>
nearly <RB>
complete <JJ>
. <.>
In <IN>
an <DT>
earlier <JJR>
study <NN>
, <,>
only <RB>
11 <CD>
percent <NN>
of <IN>
the <DT>
patients <NNS>
reached <VBD>
this <DT>
level <NN>
after <IN>
receiving <VBG>
chemotherapy <NN>
alone <RB>
. <.>
In <IN>
another <DT>
study <NN>
presented <VBD>
at <IN>
the <DT>
meeting <NN>
, <,>
doctors <NNS>
from <IN>
the <DT>
University <NNP>
of <IN>
North_Carolina <NNP>
showed <VBD>
promising <VBG>
early <JJ>
results <NNS>
of <IN>
testing_interferon <NN>
against <IN>
chronic_myelogenous <JJ>
leukemia <NN>
. <.>
`` <``>
These <DT>
are <VBP>
interesting <VBG>
results <NNS>
, <,>
'' <''>
said <VBD>
Dr._James_Griffin <NNP>
of <IN>
the <DT>
Dana-Farber <JJ>
Cancer_Institute <NNP>
in <IN>
Boston <NNP>
. <.>
`` <``>
Response <NN>
rates <NNS>
can <MD>
be <VB>
improved <VBN>
and <CC>
toxicity <NN>
minimized <VBD>
by <IN>
these <DT>
recombinant <JJ>
proteins <NNS>
. <.>
'' <''>
About <IN>
11 <CD>
, <,>
000 <CD>
new <JJ>
cases <NNS>
of <IN>
multiple_myeloma <NN>
and <CC>
5 <CD>
, <,>
000 <CD>
cases <NNS>
of <IN>
chronic_myelogenous <JJ>
leukemia <NN>
are <VBP>
found <VBN>
each <DT>
year <NN>
. <.>
This <DT>
form <NN>
of <IN>
leukemia <NN>
can <MD>
be <VB>
effectively <RB>
treated <VBN>
with <IN>
bone_marrow <NN>
transplants <NNS>
. <.>
However <RB>
, <,>
many <JJ>
victims <NNS>
do <VBP>
not <RB>
receive <VB>
transplants <NNS>
because <IN>
no <DT>
suitable <JJ>
narrow <NN>
donors <NNS>
are <VBP>
available <JJ>
. <.>
Dr._Howard_Ozer <NNP>
and <CC>
his <PRP$>
colleagues <NNS>
at <IN>
the <DT>
University <NNP>
of <IN>
North_Carolina <NNP>
found <VBD>
they <PRP>
could <MD>
reduce <VB>
the <DT>
outward <NN>
signs <NNS>
of <IN>
myelogenous <JJ>
leukemia <NN>
and <CC>
help <VB>
the <DT>
body_replace_defective <NN>
cells <NNS>
with <IN>
normal <JJ>
ones <NNS>
. <.>
`` <``>
For <IN>
the <DT>
first <JJ>
time <NN>
, <,>
there <EX>
is <VBZ>
a <DT>
drug <NN>
available <JJ>
that <IN>
potentially <RB>
keeps <VBZ>
the <DT>
abnormal <JJ>
(_cell <NN>
) <:>
clone <NN>
under <IN>
control <NN>
and <CC>
allows <VBZ>
the <DT>
normal <JJ>
clone <NN>
to <TO>
come <VB>
back <RB>
, <,>
'' <''>
Ozer <NNP>
said <VBD>
. <.>
His <PRP$>
team <NN>
tested <VBD>
interferon <NN>
on <IN>
112 <CD>
people <NNS>
with <IN>
this <DT>
form <NN>
of <IN>
cancer <NN>
. <.>
They <PRP>
found <VBD>
that <IN>
70 <CD>
percent <NN>
of <IN>
them <PRP>
improved <VBN>
, <,>
although <IN>
it <PRP>
is <VBZ>
still_too_soon <RB>
to <TO>
know <VB>
how <WRB>
the <DT>
treatment <NN>
affects <VBZ>
long-term <JJ>
survival <NN>
. <.>
He <PRP>
said <VBD>
that <IN>
interferon <NN>
may <MD>
have <VB>
to <TO>
be <VB>
given <VBN>
for <IN>
several <JJ>
years <NNS>
to <TO>
keep <VB>
the <DT>
disease <NN>
under <IN>
control <NN>
. <.>
Oken <NNP>
said <VBD>
more <JJR>
study <NN>
will <MD>
be <VB>
needed <VBN>
as <IN>
well <RB>
to <TO>
see <VB>
how <WRB>
interferon <NN>
affects <NNS>
multiple <VBP>
myeloma <NN>
over <IN>
time <NN>
. <.>
However <RB>
, <,>
he <PRP>
added <VBD>
, <,>
`` <``>
I <PRP>
think <VBP>
it <PRP>
's <VBZ>
a <DT>
real <JJ>
advance <NN>
. <.>
'' <''>
Typically <NNP>
, <,>
about <IN>
30 <CD>
percent <NN>
of <IN>
multiple_myeloma <NN>
patients <NNS>
survive <VBP>
for <IN>
five <CD>
years <NNS>
. <.>
Just <RB>
how <WRB>
interferon <JJ>
works <NNS>
against <IN>
cancer <NN>
is <VBZ>
unclear <JJ>
. <.>
Ozer <NNP>
speculates <VBZ>
that <IN>
it <PRP>
acts <VBZ>
as <IN>
a <DT>
sort <NN>
of <IN>
negative <JJ>
growth_regulator <NN>
, <,>
shutting <VBG>
down <IN>
bone_marrow <NN>
cells <NNS>
that <WDT>
produce <NN>
cancerous <VBZ>
blood <NN>
cells <NNS>
. <.>
Interferon <NNP>
is <VBZ>
produced <VBN>
by <IN>
inserting <NN>
a <DT>
human_gene <NN>
into <IN>
bacteria <NN>
or <CC>
yeast <JJ>
, <,>
which <WDT>
can <MD>
churn <VB>
out <RP>
the <DT>
substance <NN>
in <IN>
limitless <NN>
quantities <NNS>
. <.>
It <PRP>
is <VBZ>
just <RB>
one <CD>
of <IN>
several <JJ>
otherwise_rare <NN>
natural <JJ>
chemicals <NNS>
to <TO>
be <VB>
made <VBN>
through <IN>
genetic <JJ>
engineering <NN>
AP900216-0033 <DOCNO>
. <.>
Researchers <NNS>
report <VBP>
today <NN>
they <PRP>
have <VBP>
succeeded <VBN>
in <IN>
giving <NN>
a <DT>
form <NN>
of <IN>
human <JJ>
leukemia <NN>
to <TO>
laboratory_mice <NN>
, <,>
producing <VBG>
an <DT>
animal <JJ>
that <IN>
now <RB>
can <MD>
be <VB>
used <VBN>
to <TO>
test <NN>
therapies <NNS>
against <IN>
the <DT>
disease <NN>
. <.>
`` <``>
With <IN>
this <DT>
new <JJ>
animal_model <NN>
, <,>
experimental <JJ>
therapies <NNS>
that <WDT>
might <MD>
otherwise_be <VB>
tried <VBN>
in <IN>
human <JJ>
patients <NNS>
can <MD>
now <RB>
be <VB>
tested <VBN>
in <IN>
these <DT>
mice <NN>
, <,>
'' <''>
said <VBD>
George_Daley <NNP>
, <,>
lead <VBP>
researcher <NN>
in <IN>
the <DT>
study <NN>
conducted <VBD>
at <IN>
the <DT>
Whitehead_Institute <NNP>
for <IN>
Biomedical_Research <NNP>
in <IN>
Cambridge <NNP>
, <,>
Mass <NNP>
. <.>
`` <``>
You <PRP>
obviously <RB>
can <MD>
do <VB>
more <RBR>
with <IN>
the <DT>
mice <NN>
than <IN>
you <PRP>
could <MD>
with <IN>
human <JJ>
patients <NNS>
, <,>
'' <''>
he <PRP>
said <VBD>
. <.>
The <DT>
study <NN>
, <,>
published <VBD>
today <NN>
in <IN>
Science <NNP>
, <,>
says <VBZ>
the <DT>
Whitehead <NNP>
researchers <NNS>
used <VBN>
intricate_genetic <JJ>
engineering <NN>
to <TO>
inject <VB>
into <IN>
the <DT>
bone_marrow <NN>
of <IN>
laboratory_mice <NN>
the <DT>
human_gene <NN>
linked <VBD>
to <TO>
chronic_myelogenous <JJ>
leukemia <NN>
( <:>
CML <NNP>
) <:>
, <,>
a <DT>
form <NN>
of <IN>
a <DT>
blood_cancer <NN>
that <WDT>
usually <RB>
attacks <VBZ>
adults <NNS>
and <CC>
is <VBZ>
only_rarely <RB>
cured <VBN>
. <.>
Daley <NNP>
said <VBD>
the <DT>
study <NN>
also <RB>
proves <VBZ>
CML <NNP>
is <VBZ>
initiated <VBN>
by <IN>
the <DT>
fusion <NN>
of <IN>
parts <NNS>
from <IN>
two <CD>
broken <VBN>
chromosomes <NNS>
, <,>
a <DT>
finding <NN>
that <WDT>
was <VBD>
suggested <VBN>
by <IN>
earlier <JJR>
studies <NNS>
in <IN>
other <JJ>
laboratories <NNS>
. <.>
Those <DT>
parts <NNS>
have <VBP>
been_identified <VBN>
as <IN>
the <DT>
so-called <JJ>
ABL <NNP>
gene <NN>
from <IN>
chromosome <NN>
9 <CD>
and <CC>
a <DT>
gene <NN>
called <VBN>
BCR <NNP>
from <IN>
chromosome <NN>
22 <CD>
. <.>
Cells <NNS>
containing <VBG>
this <DT>
hybrid_gene_produce <NN>
a <DT>
protein <NN>
, <,>
called <VBN>
P210 <NNP>
, <,>
that <IN>
changes <NNS>
healthy <JJ>
cells <NNS>
into <IN>
cancer <NN>
cells <NNS>
. <.>
Daley <NNP>
said <VBD>
his <PRP$>
study <NN>
showed <VBD>
that <IN>
transferring <NN>
the <DT>
BCR_@_ABL <NNP>
gene <NN>
into <IN>
mouse_bone_marrow <NN>
and <CC>
then <RB>
putting <VBG>
these <DT>
infected <JJ>
cells <NNS>
into <IN>
healthy <JJ>
mice <NN>
could <MD>
produce <VB>
CML <NNP>
in <IN>
those <DT>
mice <NN>
. <.>
`` <``>
It <PRP>
answers <VBZ>
a <DT>
question <NN>
of <IN>
basic <JJ>
science <NN>
, <,>
that <IN>
is <VBZ>
, <,>
what <WP>
causes <NNS>
the <DT>
disease <NN>
, <,>
'' <''>
said <VBD>
Daley <NNP>
. <.>
`` <``>
We <PRP>
now <RB>
know <VBP>
that <IN>
the <DT>
BCR_@_ABL <NNP>
gene <NN>
is <VBZ>
sufficient <JJ>
to <TO>
induce <VB>
the <DT>
leukemia <NN>
. <.>
'' <''>
He <PRP>
said <VBD>
it <PRP>
is <VBZ>
still_not <RB>
known <VBN>
precisely <RB>
what <WP>
causes <NNS>
the <DT>
two <CD>
chromosomes <NNS>
to <TO>
break <VB>
and <CC>
create <VB>
the <DT>
hybrid <JJ>
gene <NN>
, <,>
but <CC>
a <DT>
high <JJ>
exposure <NN>
to <TO>
radiation <NN>
is <VBZ>
thought <VBN>
to <TO>
be <VB>
a <DT>
factor <NN>
. <.>
Dr._George_Canellos <NNP>
, <,>
chief <NN>
of <IN>
medical <JJ>
oncology <NN>
at <IN>
the <DT>
Dana-Farber <JJ>
Institute <NNP>
in <IN>
Boston <NNP>
, <,>
said <VBD>
the <DT>
Whitehead <NNP>
finding <NN>
is <VBZ>
`` <``>
an <DT>
important <JJ>
advance <NN>
in <IN>
understanding <NN>
the <DT>
disease <NN>
. <.>
'' <''>
He <PRP>
said <VBD>
the <DT>
new_animal <JJ>
model <NN>
of <IN>
the <DT>
disease <NN>
may <MD>
help <VB>
scientists <NNS>
find <VB>
ways <NNS>
to <TO>
block <VB>
the <DT>
action <NN>
of <IN>
the <DT>
P210 <NNP>
protein <NN>
produced <VBN>
by <IN>
the <DT>
BCR_@_ABL <NNP>
gene <NN>
, <,>
thus <RB>
preventing <VBG>
the <DT>
disease <NN>
. <.>
`` <``>
In <IN>
screening <NN>
biological <JJ>
substances <NNS>
, <,>
it <PRP>
will <MD>
make <VB>
a <DT>
very <RB>
nice <JJ>
model <NN>
, <,>
'' <''>
said <VBD>
Canellos <NNP>
. <.>
Daley <NNP>
said <VBD>
the <DT>
mouse <NN>
can <MD>
be <VB>
used <VBN>
to <TO>
test <NN>
`` <``>
biological <JJ>
inhibitors <NNS>
'' <''>
that <IN>
would <MD>
prevent <VB>
the <DT>
P210 <NNP>
protein <NN>
from <IN>
transforming <VBG>
normal <JJ>
cells <NNS>
into <IN>
cancers <NNS>
. <.>
Such <JJ>
inhibitors <NNS>
formally <RB>
could <MD>
only <RB>
be <VB>
tested <VBN>
on <IN>
human <JJ>
patients <NNS>
, <,>
a <DT>
process <NN>
that <WDT>
could <MD>
take <VB>
years <NNS>
. <.>
With <IN>
a <DT>
mouse_model <NN>
of <IN>
the <DT>
disease <NN>
, <,>
experiments <NNS>
can <MD>
be <VB>
sped <VBN>
up <RP>
and <CC>
can <MD>
be <VB>
more <RBR>
extensive <JJ>
. <.>
To <TO>
create <VB>
the <DT>
mouse_model <NN>
, <,>
Daley <NNP>
said <VBD>
he <PRP>
and <CC>
his <PRP$>
colleagues <NNS>
inserted <VBD>
the <DT>
human <JJ>
BCR_@_ABL <NNP>
gene <NN>
into <IN>
a <DT>
virus <JJ>
. <.>
Normal <JJ>
mouse_bone_marrow <NN>
cells <NNS>
were <VBD>
then <RB>
exposed <VBN>
to <TO>
the <DT>
virus <NN>
, <,>
which <WDT>
transferred <VBN>
the <DT>
gene <NN>
into <IN>
the <DT>
marrow <NN>
cells <NNS>
. <.>
Thirty <NNP>
healthy <JJ>
mice <NN>
were <VBD>
then <RB>
irradiated <VBN>
to <TO>
kill <VB>
their <PRP$>
bone_marrow <NN>
cells <NNS>
. <.>
Next <JJ>
, <,>
the <DT>
bone_marrow <NN>
carrying <VBG>
the <DT>
BCR_@_ABL <NNP>
gene <NN>
was <VBD>
transplanted <VBN>
into <IN>
the <DT>
30 <CD>
mice <NN>
. <.>
Within <NNP>
five <CD>
months <NNS>
, <,>
13 <CD>
of <IN>
the <DT>
30 <CD>
mice <NN>
developed <VBD>
a <DT>
blood_disease <NN>
that <WDT>
mimicked <VBD>
human_chronic <NN>
myelogenous <JJ>
leukemia <NN>
. <.>
CML <NNP>
in <IN>
humans <NNS>
can <MD>
be <VB>
controlled <VBN>
by <IN>
chemotherapy <NN>
for <IN>
3 <CD>
to <TO>
5 <CD>
years <NNS>
. <.>
This <DT>
remission_period <NN>
usually <RB>
ends <VBZ>
with <IN>
the <DT>
sudden <JJ>
increase <NN>
in <IN>
abnormal <JJ>
cells <NNS>
, <,>
a <DT>
disease_phase <NN>
called <VBN>
`` <``>
blast <JJ>
crisis <NN>
'' <''>
that <WDT>
usually <RB>
results <VBZ>
in <IN>
death <NN>
. <.>
The <DT>
only_successful <JJ>
therapy <NN>
used <VBN>
now <RB>
is <VBZ>
to <TO>
kill <VB>
the <DT>
diseased <VBN>
bone_marrow <NN>
in <IN>
the <DT>
patient <NN>
and <CC>
replace <NN>
it <PRP>
with <IN>
healthy <JJ>
bone_marrow <NN>
from <IN>
a <DT>
compatible <JJ>
donor <NN>
, <,>
but <CC>
even <RB>
this <DT>
treatment <NN>
often <RB>
fails <VBZ>
. <.>
Daley <NNP>
said <VBD>
that <IN>
continued <VBN>
studies <NNS>
of <IN>
the <DT>
CML <NNP>
mice_show <NN>
that <IN>
many <JJ>
of <IN>
the <DT>
laboratory <NN>
animals <NNS>
develop <VB>
the <DT>
`` <``>
blast <JJ>
crisis <NN>
'' <''>
phase <NN>
of <IN>
the <DT>
disease <NN>
. <.>
This <DT>
, <,>
he <PRP>
said <VBD>
, <,>
is <VBZ>
further <JJ>
verification <NN>
that <WDT>
the <DT>
course <NN>
of <IN>
the <DT>
disease <NN>
in <IN>
the <DT>
mice <NN>
mimics <NNS>
CML <NNP>
in <IN>
humans <NNS>
. <.>
Richard <NNP>
A <DT>
. <.>
Van_Etten <NNP>
and <CC>
David_Baltimore <NNP>
, <,>
both <DT>
of <IN>
the <DT>
Whitehead_Institute <NNP>
, <,>
were <VBD>
coauthors <NNS>
of <IN>
the <DT>
study <NN>
with <IN>
Daley <NNP>
. <.>
Science <NN>
, <,>
which <WDT>
published <VBD>
the <DT>
study <NN>
, <,>
is <VBZ>
the <DT>
journal <NN>
of <IN>
the <DT>
American_Association <NNP>
for <IN>
the <DT>
Advancement <NNP>
of <IN>
Science <NNP>
WSJ910208-0083 <DOCNO>
. <.>
The <DT>
study <NN>
, <,>
though <IN>
still <RB>
subject <JJ>
to <TO>
scientific <JJ>
peer_review <NN>
, <,>
appears <VBZ>
to <TO>
support <VB>
growing <VBG>
evidence <NN>
of <IN>
ties <NNS>
between <IN>
electrical <JJ>
equipment <NN>
and <CC>
cancer <NN>
risks <NNS>
. <.>
A <DT>
recent <JJ>
Environmental_Protection_Agency <NNP>
report <NN>
said <VBD>
that <IN>
electro-magnetic <JJ>
fields <NNS>
from <IN>
electric <JJ>
power <NN>
lines <NNS>
are <VBP>
a <DT>
possible <JJ>
-- <:>
if <IN>
not <RB>
proven <VBN>
-- <:>
cause <NN>
of <IN>
cancer <NN>
. <.>
There <EX>
have <VBP>
been <VBN>
reports <NNS>
that <IN>
electrical <JJ>
workers <NNS>
may <MD>
be <VB>
more <RBR>
at <IN>
risk <NN>
of <IN>
brain <NN>
tumors <NNS>
and <CC>
leukemia <NN>
. <.>
And <CC>
frequently-cited <JJ>
studies <NNS>
of <IN>
Denver <NNP>
residents <NNS>
found <VBD>
correlations <NNS>
between <IN>
childhood_cancer <NN>
and <CC>
neighboring <VBG>
power <NN>
lines <NNS>
. <.>
Dr._Peters <NNP>
's <POS>
work <NN>
`` <``>
adds <VBZ>
to <TO>
the <DT>
body <NN>
of <IN>
evidence <NN>
'' <''>
that <WDT>
some <DT>
still-unexplained <JJ>
process <NN>
may <MD>
be <VB>
increasing <VBG>
the <DT>
risk <NN>
of <IN>
cancer <NN>
, <,>
said <VBD>
George_Hidy <NNP>
, <,>
who <WP>
heads <NNS>
the <DT>
environment_division <NN>
of <IN>
the <DT>
Electric_Power_Research_Institute <NNP>
, <,>
an <DT>
industry-financed <JJ>
group <NN>
that <WDT>
paid <VBN>
for <IN>
the <DT>
study <NN>
. <.>
The <DT>
results <NNS>
of <IN>
the <DT>
University <NNP>
of <IN>
Southern_California <NNP>
study <NN>
had <VBD>
been <VBN>
widely <RB>
awaited <VBN>
because_of <IN>
a <DT>
large <JJ>
sample_size <NN>
-- <:>
some <DT>
232 <CD>
children <NNS>
with <IN>
leukemia <NN>
and <CC>
an <DT>
equal <JJ>
number <NN>
of <IN>
healthy <JJ>
children <NNS>
-- <:>
as <IN>
well <RB>
as <IN>
detailed <JJ>
readings <NNS>
of <IN>
electrical <JJ>
and <CC>
magnetic <JJ>
fields <NNS>
that <WDT>
were <VBD>
a <DT>
part <NN>
of <IN>
the <DT>
research <NN>
's <POS>
design <NN>
. <.>
But <CC>
while <IN>
the <DT>
research <NN>
appeared <VBD>
to <TO>
offer <VB>
important <JJ>
affirmation <NN>
that <WDT>
physical <JJ>
proximity <NN>
to <TO>
electrical-transmission_equipment <NN>
may <MD>
increase <VB>
the <DT>
risk <NN>
of <IN>
leukemia <NN>
, <,>
it <PRP>
did <VBD>
n't <RB>
answer <VB>
why <WRB>
. <.>
Its <PRP$>
careful <JJ>
readings <NNS>
of <IN>
magnetic <JJ>
and <CC>
electrical <JJ>
fields <NNS>
in <IN>
houses <NNS>
where <WRB>
the <DT>
children <NNS>
lived_did <VBD>
n't <RB>
find <VB>
that <IN>
the <DT>
more <RBR>
intense <JJ>
fields <NNS>
of <IN>
bigger <JJR>
power <NN>
lines <NNS>
can <MD>
be <VB>
directly <RB>
identified <VBN>
with <IN>
increased <VBN>
likelihood <NN>
of <IN>
cancer <NN>
. <.>
This <DT>
initial <JJ>
failure <NN>
to <TO>
tie <VB>
magnetic <JJ>
fields <NNS>
to <TO>
cancer <NN>
is <VBZ>
perplexing <VBG>
. <.>
`` <``>
We <PRP>
are <VBP>
obviously <RB>
missing <VBG>
something <NN>
in <IN>
this <DT>
work <NN>
, <,>
'' <''>
said <VBD>
Mr._Hidy <NNP>
. <.>
And <CC>
, <,>
in <IN>
that <DT>
sense <NN>
, <,>
the <DT>
findings <NNS>
of <IN>
the <DT>
latest <JJS>
study <NN>
may <MD>
focus <VB>
future <JJ>
research <NN>
, <,>
he <PRP>
said <VBD>
. <.>
The <DT>
cancer <NN>
risks <NNS>
uncovered_were <VBD>
relatively <RB>
low <JJ>
. <.>
The <DT>
overall <JJ>
frequency <NN>
of <IN>
childhood_leukemia <NN>
is <VBZ>
about <IN>
one <CD>
case <NN>
for <IN>
each <DT>
20 <CD>
, <,>
000 <CD>
children <NNS>
, <,>
and <CC>
an <DT>
increase <NN>
of <IN>
2.5 <CD>
times <NNS>
in <IN>
this <DT>
frequency <NN>
implies <VBZ>
2.5 <CD>
cases <NNS>
for <IN>
each <DT>
20 <CD>
, <,>
000 <CD>
youngsters <NNS>
. <.>
Results <NNS>
of <IN>
the <DT>
research <NN>
were <VBD>
discussed <VBN>
yesterday <NN>
at <IN>
a <DT>
scientific <JJ>
conference <NN>
in <IN>
Carmel <NNP>
, <,>
Calif._Sketchy <NNP>
conclusions <NNS>
were <VBD>
disclosed <VBN>
in <IN>
both_an <DT>
`` <``>
executive <JJ>
summary <NN>
'' <''>
written <VBN>
by <IN>
Dr._Peters <NNP>
and <CC>
in <IN>
material <NN>
prepared <VBN>
by <IN>
the <DT>
Electric_Power_Research_Institute <NNP>
. <.>
However <RB>
, <,>
Dr._Peters <NNP>
could <MD>
n't <RB>
be <VB>
reached <VBN>
for <IN>
comment <NN>
and <CC>
has <VBZ>
indicated <VBN>
that <IN>
he <PRP>
wo <MD>
n't <RB>
discuss <VB>
results <NNS>
of <IN>
the <DT>
study <NN>
outside <IN>
scientific <JJ>
circles <NNS>
until <IN>
they <PRP>
have <VBP>
received <VBN>
`` <``>
peer_review <NN>
'' <''>
by <IN>
fellow <JJ>
scientists <NNS>
and <CC>
been_published <VBN>
. <.>
In <IN>
his <PRP$>
executive_summary <NN>
, <,>
Dr._Peters <NNP>
noted <VBD>
`` <``>
considerable <JJ>
'' <''>
evidence <NN>
of <IN>
a <DT>
relationship <NN>
between <IN>
childrens <NNS>
' <POS>
use <NN>
of <IN>
electric <JJ>
appliances <NNS>
and <CC>
the <DT>
risk <NN>
of <IN>
leukemia <NN>
. <.>
According <VBG>
to <TO>
the <DT>
Electric_Power_Research_Institute <NNP>
, <,>
the <DT>
appliances <NNS>
found <VBD>
to <TO>
have <VB>
strong <JJ>
correlations <NNS>
were <VBD>
hair-dryers <NNS>
and <CC>
black-and-white <JJ>
television <NN>
sets <NNS>
. <.>
The <DT>
industry_research_group <NN>
questioned <VBD>
these <DT>
particular <JJ>
findings <NNS>
, <,>
saying <VBG>
that <IN>
they <PRP>
depended <VBD>
on <IN>
parents <NNS>
' <POS>
memories <NNS>
of <IN>
appliance_use <NN>
and <CC>
thus <RB>
were <VBD>
less <JJR>
objective <JJ>
than <IN>
other <JJ>
elements <NNS>
of <IN>
Dr._Peters <NNP>
's <POS>
findings <NNS>
. <.>
The <DT>
apparent <JJ>
lack <NN>
of <IN>
correlation <NN>
between <IN>
careful <JJ>
measurements <NNS>
of <IN>
magnetic-field <JJ>
strength <NN>
and <CC>
cancer <NN>
could <MD>
be <VB>
reversed <VBN>
with <IN>
more <JJR>
statistical <JJ>
analysis <NN>
. <.>
The <DT>
study <NN>
, <,>
begun <NN>
in <IN>
1986 <CD>
as <IN>
an <DT>
expansion <NN>
of <IN>
an <DT>
existing <VBG>
work <NN>
on <IN>
various <JJ>
potentially <RB>
leukemia-related_environmental <JJ>
factors <NNS>
, <,>
included <VBD>
a <DT>
wide <JJ>
range <NN>
of <IN>
factors <NNS>
such <JJ>
as <IN>
household <NN>
chemicals <NNS>
, <,>
cigarette_smoke <NN>
and <CC>
parent <NN>
's <POS>
occupations <NNS>
. <.>
But <CC>
beyond <IN>
more <JJR>
statistical <JJ>
analysis <NN>
, <,>
the <DT>
lack <NN>
of <IN>
a <DT>
link <NN>
between <IN>
magnetic-field <JJ>
strength <NN>
and <CC>
leukemia_risk <NN>
may <MD>
stem <VB>
from <IN>
a <DT>
24-hour <CD>
, <,>
concentrated <VBN>
period <NN>
in <IN>
which <WDT>
magnetic <JJ>
readings <NNS>
were <VBD>
made <VBN>
in <IN>
houses <NNS>
. <.>
`` <``>
Over <IN>
a <DT>
much <JJ>
longer_term <NN>
, <,>
it <PRP>
may <MD>
be <VB>
that <IN>
we <PRP>
will <MD>
find <VB>
the <DT>
relationship <NN>
, <,>
'' <''>
said <VBD>
Mr._Hidy <NNP>
. <.>
Less <RBR>
plausibly_perhaps <RB>
, <,>
the <DT>
relationship <NN>
between <IN>
wires <NNS>
and <CC>
cancer <NN>
could <MD>
stem <VB>
not <RB>
from <IN>
magnetic <JJ>
fields <NNS>
but <CC>
some <DT>
other_nonelectrical_environmental <JJ>
threat <NN>
WSJ870320-0168 <DOCNO>
. <.>
THE <DT>
EPISODE_WAS <NNP>
the <DT>
kind <NN>
that <IN>
makes <VBZ>
grist <NN>
for <IN>
novels <NNS>
and <CC>
movies <NNS>
. <.>
A <DT>
40-year-old <JJ>
man_suffering <NN>
a <DT>
severe <JJ>
liver_disease <NN>
had <VBD>
suddenly <RB>
developed <VBN>
a <DT>
life-threatening <JJ>
skin_condition <NN>
. <.>
`` <``>
His <PRP$>
skin <NN>
was <VBD>
sloughing <VBG>
off <RP>
all <DT>
over <IN>
his <PRP$>
body <NN>
, <,>
'' <''>
recalls <VBZ>
Marshall_M._Kaplan <NNP>
, <,>
the <DT>
Tufts <NNPS>
University <NNP>
gastroenterologist <NN>
who <WP>
had <VBD>
been <VBN>
tending <VBG>
the <DT>
patient <NN>
's <POS>
liver <NN>
problems <NNS>
. <.>
Cortisone <NNP>
was <VBD>
n't <RB>
helping <VBG>
, <,>
`` <``>
so <IN>
the <DT>
question <NN>
came <VBD>
up <RP>
whether <IN>
methotrexate <JJ>
would <MD>
help <VB>
, <,>
'' <''>
Dr._Kaplan <NNP>
says <VBZ>
. <.>
Methotrexate <NNP>
is <VBZ>
an <DT>
old <JJ>
anti-cancer_drug <NN>
that <WDT>
had <VBD>
been_found <VBN>
to <TO>
aid <NN>
certain_other <JJ>
skin <NN>
conditions <NNS>
, <,>
but <CC>
it <PRP>
also <RB>
has <VBZ>
a <DT>
dangerous <JJ>
side_effect <NN>
-- <:>
liver_damage <NN>
. <.>
The <DT>
idea <NN>
of <IN>
using <VBG>
this <DT>
drug <NN>
in <IN>
a <DT>
man <NN>
with <IN>
a <DT>
diseased <VBN>
liver <NN>
was <VBD>
`` <``>
frightening <NN>
, <,>
'' <''>
Dr._Kaplan <NNP>
says <VBZ>
. <.>
`` <``>
But <CC>
if <IN>
we <PRP>
did <VBD>
n't <RB>
use <VB>
it <PRP>
, <,>
there <EX>
was <VBD>
a <DT>
good <JJ>
chance <NN>
he <PRP>
would <MD>
die <VB>
from <IN>
the <DT>
skin_condition <NN>
. <.>
`` <``>
Balancing <JJ>
the <DT>
risks <NNS>
, <,>
doctors <NNS>
began <VBD>
giving <VBG>
the <DT>
man_methotrexate <NN>
. <.>
`` <``>
We <PRP>
watched <VBD>
his <PRP$>
blood <NN>
tests <NNS>
( <:>
for <IN>
signs <NNS>
of <IN>
liver_damage <NN>
) <:>
, <,>
fully <RB>
expecting <VBG>
them <PRP>
to <TO>
get <VB>
worse <NN>
, <,>
'' <''>
Dr._Kaplan <NNP>
says <VBZ>
. <.>
Instead <RB>
, <,>
not_only <RB>
did <VBD>
his <PRP$>
skin_condition_clear <NN>
up <IN>
, <,>
but <CC>
to <TO>
the <DT>
doctors <NNS>
' <POS>
astonishment <NN>
, <,>
his <PRP$>
liver <NN>
began <VBD>
to <TO>
improve <VB>
. <.>
Now <RB>
, <,>
eight <CD>
years <NNS>
later <RBR>
, <,>
he <PRP>
takes <VBZ>
maintenance <NN>
doses <NNS>
of <IN>
methotrexate <JJ>
, <,>
and <CC>
both <DT>
his <PRP$>
skin <NN>
and <CC>
liver <NN>
are <VBP>
normal <JJ>
. <.>
THIS <DT>
EPISODE <NNP>
, <,>
recently <RB>
published <VBD>
in <IN>
Annals <NNP>
of <IN>
Internal_Medicine <NNP>
, <,>
marks <VBZ>
another <DT>
serendipitous <JJ>
incident <NN>
in <IN>
the <DT>
strange_history <NN>
of <IN>
methotrexate <NN>
. <.>
In <IN>
these <DT>
days <NNS>
when <WRB>
genetic <JJ>
engineering <NN>
and <CC>
molecular <JJ>
manipulation_turn <NN>
up <IN>
new <JJ>
wonder <NN>
drugs <NNS>
almost <RB>
weekly <JJ>
, <,>
methotrexate <JJ>
stands <NNS>
out <IN>
as <RB>
a <DT>
baffling <NN>
technological <JJ>
anomaly <RB>
. <.>
In <IN>
the <DT>
40 <CD>
years <NNS>
since <IN>
the <DT>
drug <NN>
was <VBD>
first <JJ>
synthesized <VBN>
, <,>
it <PRP>
has <VBZ>
been <VBN>
alternately <RB>
lauded <VBN>
as <IN>
a <DT>
treatment <NN>
for <IN>
a <DT>
variety <NN>
of <IN>
human <NN>
scourges <NNS>
and <CC>
castigated <VBD>
as <IN>
a <DT>
poison <NN>
whose <WP$>
risks <NNS>
are <VBP>
greater <JJR>
than <IN>
the <DT>
diseases <NNS>
it <PRP>
's <VBZ>
being <VBG>
used <VBN>
to <TO>
treat <VB>
. <.>
Yet <CC>
no <DT>
one <NN>
is <VBZ>
quite <RB>
sure <JJ>
how <WRB>
or <CC>
why <WRB>
it <PRP>
does <VBZ>
what <WP>
it <PRP>
does <VBZ>
. <.>
The <DT>
methotrexate_story <NN>
begins <VBZ>
in <IN>
the <DT>
mid-1940s <JJ>
when <WRB>
the <DT>
late <JJ>
Sidney_Farber <NNP>
and <CC>
his <PRP$>
colleagues <NNS>
at <IN>
Children <NNP>
's <POS>
Hospital <NNP>
in <IN>
Boston <NNP>
were <VBD>
attempting <VBG>
the <DT>
first <JJ>
use <NN>
of <IN>
chemicals <NNS>
in <IN>
the <DT>
treatment <NN>
of <IN>
acute_childhood_leukemia <NN>
, <,>
then <RB>
an <DT>
invariably <RB>
fatal <JJ>
blood_cancer <NN>
. <.>
The <DT>
cancer <NN>
researchers <NNS>
, <,>
according <VBG>
to <TO>
an <DT>
oft-told <JJ>
story <NN>
, <,>
had <VBD>
noticed <VBN>
a <DT>
similarity <NN>
between <IN>
the <DT>
leukemia <NN>
and <CC>
a <DT>
certain <JJ>
anemia <NN>
which <WDT>
was <VBD>
due <JJ>
to <TO>
a <DT>
deficiency <NN>
of <IN>
the <DT>
vitamin <NN>
folic <JJ>
acid <NN>
. <.>
This <DT>
led <VBN>
them <PRP>
to <TO>
treat <VB>
the <DT>
leukemia <NN>
with <IN>
folic <JJ>
acid <NN>
. <.>
To <TO>
their <PRP$>
horror <NN>
, <,>
the <DT>
folic <JJ>
acid <NN>
accelerated <VBD>
the <DT>
leukemia <NN>
instead <RB>
of <IN>
retarding <VBG>
it <PRP>
. <.>
This <DT>
near-disaster <JJ>
, <,>
however <RB>
, <,>
led <VBN>
them <PRP>
to <TO>
try <VB>
a <DT>
second <JJ>
chemical <NN>
, <,>
called <VBN>
aminopterin <NN>
, <,>
that <IN>
blocked <VBN>
the <DT>
cancer <NN>
cells <NNS>
' <POS>
use <NN>
of <IN>
folic <JJ>
acid <NN>
. <.>
In <IN>
1948 <CD>
, <,>
in <IN>
an <DT>
historic <JJ>
research_paper <NN>
, <,>
the <DT>
Boston <NNP>
researchers <NNS>
reported <VBD>
the <DT>
first <JJ>
remissions <NNS>
of <IN>
acute <JJ>
leukemia <NN>
through <IN>
chemotherapy <NN>
. <.>
Unfortunately <RB>
, <,>
the <DT>
remissions <NNS>
lasted <VBD>
only <RB>
a <DT>
few <JJ>
weeks <NNS>
or <CC>
months <NNS>
. <.>
The <DT>
Boston <NNP>
discovery <NN>
led <VBD>
chemists <NNS>
at <IN>
Lederle <NNP>
Laboratories <NNPS>
, <,>
the <DT>
pharmaceutical <JJ>
subsidiary <NN>
of <IN>
American_Cyanamid_Co. <NNP>
, <,>
to <TO>
synthesize <VB>
an <DT>
improved <VBN>
version <NN>
of <IN>
aminopterin <NN>
they <PRP>
called <VBD>
a-methopterin <JJ>
, <,>
to <TO>
which <WDT>
Lederle <NNP>
's <POS>
marketing <NN>
people <NNS>
affixed <VBN>
the <DT>
brand_name <NN>
, <,>
Methotrexate_( <NNP>
the <DT>
brand_name <NN>
has <VBZ>
since <IN>
slid <JJ>
into <IN>
generic <JJ>
use <NN>
) <:>
. <.>
METHOTREXATE <NNP>
PROVED <VBD>
even <RB>
better <JJR>
at <IN>
bringing <VBG>
about <IN>
remissions <NNS>
of <IN>
acute_lymphoblastic <JJ>
leukemia <NN>
, <,>
and <CC>
today <NN>
it <PRP>
is <VBZ>
one <CD>
of <IN>
the <DT>
drugs <NNS>
achieving <VBG>
cures <NNS>
of <IN>
leukemia <NN>
in_about <IN>
50 <CD>
% <NN>
of <IN>
afflicted <VBN>
children <NNS>
. <.>
By <IN>
1956 <CD>
, <,>
cancer <NN>
researchers <NNS>
reported <VBD>
another <DT>
first <JJ>
: <:>
Women <NNS>
developing <VBG>
an <DT>
unusual <JJ>
cancer <NN>
of <IN>
the <DT>
placenta <NN>
during <IN>
pregnancy <NN>
had <VBD>
been <VBN>
permanently <RB>
cured <VBN>
by <IN>
methotrexate <NN>
, <,>
the <DT>
first <JJ>
cancer <NN>
ever <RB>
cured <VBN>
by <IN>
chemotherapy <NN>
. <.>
In <IN>
the <DT>
early <JJ>
1960s <CD>
, <,>
serendipity_struck <NN>
again <RB>
. <.>
A <DT>
New_York <NNP>
dermatologist <NN>
reported <VBD>
instances <NNS>
of <IN>
some <DT>
patients <NNS>
being <VBG>
relieved <VBN>
of <IN>
psoriasis <NN>
, <,>
a <DT>
chronic <JJ>
and <CC>
severely <RB>
disturbing <VBG>
skin_disease <NN>
, <,>
when <WRB>
treated <VBN>
with <IN>
methotrexate <JJ>
. <.>
This <DT>
led <VBN>
William_O'Brien <NNP>
and <CC>
Roger_Black <NNP>
at <IN>
the <DT>
National <NNP>
Institutes <NNPS>
of <IN>
Health <NNP>
to <TO>
run <VB>
a <DT>
controlled <JJ>
trial <NN>
on <IN>
21 <CD>
psoriasis <NN>
patients <NNS>
. <.>
Not_only <RB>
did <VBD>
the <DT>
skin_disorder_clear <NN>
up_in <IN>
several <JJ>
patients <NNS>
but <CC>
so <RB>
did <VBD>
a <DT>
type <NN>
of <IN>
arthritis <NNS>
that <WDT>
often <RB>
accompanies <VBZ>
psoriasis <NN>
. <.>
The <DT>
scientists <NNS>
then <RB>
reported <VBD>
a <DT>
second <JJ>
trial <NN>
showing <VBG>
that <IN>
methotrexate <JJ>
produced <VBN>
remissions <NNS>
in <IN>
some <DT>
patients <NNS>
with <IN>
rheumatoid <JJ>
arthritis <NNS>
, <,>
the <DT>
most <RBS>
common <JJ>
form <NN>
of <IN>
the <DT>
crippling_disorder <NN>
. <.>
But <CC>
, <,>
in <IN>
treating_psoriasis <NN>
patients <NNS>
, <,>
the <DT>
dangers <NNS>
of <IN>
methotrexate <JJ>
became_apparent <NN>
. <.>
In <IN>
high <JJ>
doses <NNS>
and <CC>
daily <JJ>
use <NN>
, <,>
the <DT>
drug <NN>
can <MD>
cause <VB>
severe <JJ>
liver_damage <NN>
and <CC>
sometimes <RB>
a <DT>
lung_disorder <NN>
. <.>
IN <IN>
SOME <DT>
CANCER <NN>
PATIENTS <NNS>
, <,>
doctors <NNS>
have <VBP>
worked <VBN>
out <RP>
a <DT>
unique <JJ>
`` <``>
rescue <NN>
'' <''>
concept <NN>
, <,>
giving <VBG>
a <DT>
patient <NN>
dangerously <RB>
high <JJ>
doses <NNS>
of <IN>
methotrexate <JJ>
to <TO>
kill <VB>
cancer <NN>
cells <NNS>
and <CC>
then_shortly_afterward <RB>
administering <VBG>
an <DT>
antidote <NN>
to <TO>
save <VB>
normal <JJ>
tissues <NNS>
from <IN>
its <PRP$>
poisonous <JJ>
effects <NNS>
. <.>
Methotrexate <NNP>
's <POS>
use <NN>
in <IN>
arthritis <NN>
, <,>
at <IN>
least <JJS>
for <IN>
patients <NNS>
whose <WP$>
disease <NN>
is <VBZ>
n't <RB>
helped <VBN>
by <IN>
any <DT>
other <JJ>
drug <NN>
, <,>
is <VBZ>
now <RB>
being <VBG>
revived <VBN>
. <.>
Researchers <NNS>
have <VBP>
treated <VBN>
several <JJ>
hundred <CD>
arthritis_patients <NNS>
with <IN>
low <JJ>
doses <NNS>
of <IN>
methotrexate <JJ>
given <VBN>
only_once <RB>
a <DT>
week <NN>
. <.>
Anywhere <RB>
from <IN>
half <DT>
to <TO>
two-thirds <NNS>
of <IN>
these <DT>
patients <NNS>
improve <VBP>
; <:>
some <DT>
have <VBP>
remissions <NNS>
of <IN>
their <PRP$>
arthritis <NNS>
. <.>
But <CC>
while <IN>
many <JJ>
arthritis_specialists <NNS>
are <VBP>
using <VBG>
methotrexate <NN>
in <IN>
`` <``>
refractory <NN>
'' <''>
patients <NNS>
, <,>
others <NNS>
shun <VBP>
it <PRP>
. <.>
One <CD>
is <VBZ>
Dr._O'Brien <NNP>
, <,>
who <WP>
did <VBD>
the <DT>
first <JJ>
trial <NN>
of <IN>
methotrexate <NN>
in <IN>
arthritis <NN>
and <CC>
who <WP>
is <VBZ>
now <RB>
a <DT>
professor <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
Virginia <NNP>
. <.>
Because_of <IN>
its <PRP$>
toxicity <NN>
, <,>
he <PRP>
says <VBZ>
, <,>
`` <``>
we <PRP>
do <VBP>
n't <RB>
use <VB>
it <PRP>
anymore <JJR>
here <RB>
in <IN>
Charlottesville <NNP>
. <.>
`` <``>
Meanwhile <RB>
, <,>
in <IN>
Boston <NNP>
, <,>
Dr._Kaplan <NNP>
and <CC>
his <PRP$>
colleagues <NNS>
say <VBP>
they <PRP>
had <VBD>
a <DT>
second <JJ>
patient <NN>
with <IN>
the <DT>
same <JJ>
severe_liver_disease <NN>
as <IN>
the <DT>
first <JJ>
but <CC>
without <IN>
the <DT>
skin_problem <NN>
. <.>
`` <``>
He <PRP>
was <VBD>
at <IN>
his <PRP$>
wits <NNS>
' <POS>
end <NN>
, <,>
'' <''>
Dr._Kaplan <NNP>
says <VBZ>
. <.>
`` <``>
I <PRP>
thought <VBD>
of <IN>
that <DT>
first <JJ>
patient <NN>
and <CC>
said <VBD>
, <,>
'If <JJ>
you <PRP>
're <VBP>
a <DT>
gambler <NN>
and <CC>
you <PRP>
want <VBP>
to <TO>
try_methotrexate <NN>
, <,>
we <PRP>
'll <MD>
do <VB>
it <PRP>
. <.>
' <POS>
'' <''>
The <DT>
patient <NN>
's <POS>
liver <NN>
is <VBZ>
now <RB>
normal <JJ>
. <.>
A <DT>
clinical <JJ>
trial <NN>
of <IN>
methotrexate <NN>
in <IN>
the <DT>
liver_disease <NN>
, <,>
called <VBN>
primary <JJ>
sclerosis <NN>
cholangitis <NNS>
, <,>
is <VBZ>
now <RB>
under <IN>
way <NN>
SJMN91-06080197 <DOCNO>
. <.>
`` <``>
I <PRP>
think <VBP>
it <PRP>
's <VBZ>
disturbing <VBG>
, <,>
'' <''>
said <VBD>
Steve_Wing <NNP>
, <,>
a <DT>
University <NNP>
of <IN>
North_Carolina <NNP>
epidemiologist <NN>
who <WP>
was <VBD>
the <DT>
principal <JJ>
author <NN>
of <IN>
the <DT>
study <NN>
. <.>
`` <``>
We <PRP>
have <VBP>
seen <VBN>
an <DT>
association <NN>
between <IN>
cancer_mortality <NN>
and <CC>
radiation <NN>
doses <NNS>
at <IN>
a <DT>
very <RB>
low <JJ>
level <NN>
._._._. <.>
Many <JJ>
people <NNS>
have <VBP>
assumed <VBN>
that <IN>
there <EX>
is <VBZ>
no <DT>
safe_level <NN>
of <IN>
exposure <NN>
, <,>
but <CC>
it <PRP>
has <VBZ>
been_assumed <VBN>
that <IN>
the <DT>
chances <NNS>
of <IN>
finding <VBG>
an <DT>
effect <NN>
of <IN>
exposures <NNS>
at <IN>
this <DT>
level <NN>
would <MD>
be <VB>
like <IN>
a <DT>
few <JJ>
drops <NNS>
of <IN>
water <NN>
in <IN>
a <DT>
swimming_pool <NN>
, <,>
not_enough <RB>
to <TO>
be <VB>
measurable <JJ>
. <.>
Now <RB>
we <PRP>
see <VBP>
it <PRP>
looks <VBZ>
like <IN>
it <PRP>
's <VBZ>
not_just <RB>
a <DT>
few <JJ>
drops <NNS>
, <,>
and <CC>
that's <NNP>
disturbing <NN>
. <.>
`` <``>
; <:>
The <DT>
report <NN>
does <VBZ>
not <RB>
say <VB>
there <EX>
is <VBZ>
a <DT>
cause-and-effect <JJ>
relationship <NN>
between <IN>
the <DT>
low-exposure <JJ>
levels <NNS>
and <CC>
the <DT>
increased <VBN>
leukemia_rate <NN>
. <.>
Nor <NNP>
does <VBZ>
it <PRP>
suggest <VBP>
that <IN>
there <EX>
is <VBZ>
any <DT>
danger <NN>
to <TO>
residents <NNS>
of <IN>
communities <NNS>
surrounding <VBG>
nuclear <JJ>
facilities <NNS>
. <.>
On <IN>
the <DT>
contrary <NN>
, <,>
a <DT>
previously <RB>
publicized <VBN>
study <NN>
, <,>
published <VBD>
in <IN>
the <DT>
same <JJ>
issue <NN>
, <,>
says <VBZ>
`` <``>
deaths <NNS>
due <JJ>
to <TO>
leukemia <VB>
or <CC>
other <JJ>
cancers <NNS>
'' <''>
in <IN>
107 <CD>
counties <NNS>
where <WRB>
such <JJ>
facilities <NNS>
are <VBP>
located <VBN>
were <VBD>
not <RB>
more <RBR>
frequent <JJ>
than <IN>
elsewhere <RB>
. <.>
; <:>
Wing <NNP>
and <CC>
his <PRP$>
colleagues <NNS>
examined <VBD>
the <DT>
records <NNS>
of <IN>
8 <CD>
, <,>
318 <CD>
white <JJ>
men <NNS>
who <WP>
worked <VBD>
at <IN>
Oak_Ridge <NNP>
from <IN>
1943 <CD>
to <TO>
1972 <CD>
. <.>
Because <IN>
they <PRP>
came <VBD>
from <IN>
a <DT>
generally <RB>
well-educated <JJ>
and <CC>
prosperous <JJ>
segment <NN>
of <IN>
the <DT>
population <NN>
, <,>
the <DT>
researchers <NNS>
said <VBD>
, <,>
the <DT>
workers <NNS>
had <VBD>
lower-than-expected <JJ>
death <NN>
rates <NNS>
from <IN>
all <DT>
causes <NNS>
, <,>
including <VBG>
cancers <NNS>
other <JJ>
than <IN>
leukemia <NN>
. <.>
; <:>
But <CC>
of <IN>
the <DT>
1 <CD>
, <,>
524 <CD>
who <WP>
are <VBP>
known <VBN>
to <TO>
have <VB>
died <VBN>
, <,>
28 <CD>
died <VBD>
of <IN>
leukemia <NN>
, <,>
and <CC>
two <CD>
others <NNS>
had <VBD>
leukemia <NNS>
among <IN>
other <JJ>
illnesses <NNS>
, <,>
a <DT>
rate <NN>
`` <``>
63 <CD>
percent <NN>
higher <JJR>
than <IN>
expected <VBN>
, <,>
'' <''>
the <DT>
researchers <NNS>
found <VBD>
. <.>
; <:>
Wing <NNP>
's <POS>
study <NN>
was <VBD>
financed <VBN>
by <IN>
the <DT>
Energy_Department <NNP>
, <,>
which <WDT>
operates <VBZ>
Oak_Ridge <NNP>
, <,>
as <IN>
part <NN>
of <IN>
a <DT>
long-term <JJ>
study_begun <NN>
in <IN>
1943 <CD>
of <IN>
the <DT>
effects <NNS>
on <IN>
workers <NNS>
and <CC>
nearby <JJ>
residents <NNS>
of <IN>
the <DT>
nuclear <JJ>
weapons <NNS>
manufacturing <VBG>
operations <NNS>
. <.>
; <:>
Assistant_Energy_Secretary_Paul_Ziemer <NNP>
, <,>
a <DT>
former <JJ>
health_physicist <NN>
at <IN>
Oak_Ridge <NNP>
, <,>
said <VBD>
Wing <NNP>
's <POS>
report <NN>
was <VBD>
`` <``>
clearly <RB>
a <DT>
real <JJ>
finding <NN>
, <,>
'' <''>
but <CC>
he <PRP>
said <VBD>
it <PRP>
would <MD>
be <VB>
premature <NN>
to <TO>
decrease <VB>
the <DT>
permissible-exposure_standard <JJ>
on <IN>
that <DT>
basis_alone <NN>
. <.>
; <:>
International <NNP>
agencies <NNS>
that <WDT>
set <VBN>
exposure <NN>
limits <NNS>
are <VBP>
constantly <RB>
re-evaluating_available <JJ>
data <NNS>
and <CC>
will <MD>
consider <VB>
Wing <NNP>
's <POS>
findings <NNS>
among <IN>
others <NNS>
in <IN>
deciding <NN>
whether <IN>
to <TO>
recommend <VB>
that <IN>
limits <NNS>
be <VB>
tightened <VBN>
, <,>
Ziemer <NNP>
said <VBD>
AP880609-0061 <DOCNO>
. <.>
The <DT>
rate <NN>
of <IN>
leukemia <NN>
among <IN>
young <JJ>
people <NNS>
living <VBG>
near <IN>
a <DT>
nuclear <JJ>
complex <NN>
in <IN>
a <DT>
barren_area <NN>
of <IN>
northern <JJ>
Scotland <NNP>
is <VBZ>
nearly <RB>
twice <NN>
Britain <NNP>
's <POS>
national <JJ>
rate <NN>
, <,>
a <DT>
report <NN>
published <VBD>
today <NN>
says <VBZ>
. <.>
The <DT>
report <NN>
by <IN>
the <DT>
government-sponsored <JJ>
Committee <NNP>
on <IN>
Medical_Aspects <NNP>
of <IN>
Radiation <NNP>
in <IN>
the <DT>
Environment <NNP>
says <VBZ>
six <CD>
known <VBN>
cases <NNS>
of <IN>
leukemia <NN>
were <VBD>
diagnosed <VBN>
among <IN>
young <JJ>
people <NNS>
under <IN>
24 <CD>
who <WP>
lived <VBN>
within <IN>
15 <CD>
miles <NNS>
of <IN>
the <DT>
plant <NN>
in <IN>
Dounreay <NNP>
between <IN>
1968 <CD>
and <CC>
1984 <CD>
. <.>
`` <``>
This <DT>
is <VBZ>
twice <NN>
the <DT>
number <NN>
expected <VBN>
on <IN>
the <DT>
basis <NN>
of <IN>
the <DT>
national <JJ>
rate <NN>
, <,>
'' <''>
the <DT>
report <NN>
says <VBZ>
, <,>
adding <VBG>
that <IN>
the <DT>
likelihood <NN>
of <IN>
such <JJ>
a <DT>
high <JJ>
rate <NN>
occurring <VBG>
by <IN>
chance <NN>
is <VBZ>
about <IN>
one <CD>
in <IN>
12 <CD>
. <.>
Five <CD>
of <IN>
the <DT>
victims <NNS>
lived <VBD>
within <IN>
7.8 <CD>
miles <NNS>
of <IN>
the <DT>
nuclear <JJ>
complex <NN>
, <,>
the <DT>
center <NN>
for <IN>
Britain <NNP>
's <POS>
fast-breeder <JJ>
reactor_research_program <NN>
, <,>
the <DT>
study <NN>
says <VBZ>
. <.>
The <DT>
report <NN>
says <VBZ>
the <DT>
reason <NN>
for <IN>
the <DT>
number <NN>
of <IN>
leukemia <NN>
cases <NNS>
is <VBZ>
not <RB>
known <VBN>
, <,>
though <IN>
the <DT>
findings <NNS>
echo <VBP>
a <DT>
1986 <CD>
government_investigation <NN>
showing <VBG>
the <DT>
childhood_leukemia_rate <NN>
near <IN>
the <DT>
Sellafield <NNP>
nuclear <JJ>
reprocessing_plant <NN>
in <IN>
Cumbria <NNP>
, <,>
northwest <JJS>
England <NNP>
, <,>
to <TO>
be <VB>
four <CD>
times <NNS>
the <DT>
national <JJ>
average <NN>
. <.>
`` <``>
It <PRP>
is <VBZ>
hard <RB>
to <TO>
imagine <VB>
that <IN>
you <PRP>
could <MD>
see <VB>
an <DT>
excess <NN>
around <IN>
Dounreay <NNP>
and <CC>
an <DT>
excess <NN>
around <IN>
Sellafield <NNP>
, <,>
and <CC>
it <PRP>
is <VBZ>
just <RB>
bad <JJ>
luck <NN>
, <,>
'' <''>
said <VBD>
commission_chairman <NN>
Martin_Bobrow <NNP>
. <.>
The <DT>
committee <NN>
said <VBD>
it <PRP>
was <VBD>
`` <``>
conceivable <JJ>
that <DT>
minute <NN>
amounts <VBZ>
of <IN>
radioactive <JJ>
material <NN>
carried <VBD>
home <NN>
may <MD>
accumulate <VB>
and <CC>
lead <VB>
to <TO>
exposure <VB>
of <IN>
infants <NNS>
in <IN>
some <DT>
unforeseen_way <NN>
. <.>
'' <''>
But <CC>
it <PRP>
said <VBD>
the <DT>
level <NN>
of <IN>
leukemia <NN>
might <MD>
also <RB>
be <VB>
due <JJ>
to <TO>
exposure <VB>
to <TO>
chemicals <NNS>
, <,>
viruses <NNS>
or <CC>
even <RB>
chance <NN>
. <.>
Scottish <JJ>
Health_Minister_Michael_Forsyth <NNP>
said <VBD>
the <DT>
government <NN>
had <VBD>
accepted <VBN>
the <DT>
committee <NN>
's <POS>
recommendation <NN>
to <TO>
hold <VB>
an <DT>
investigation <NN>
into <IN>
the <DT>
high <JJ>
rates <NNS>
, <,>
despite <IN>
the <DT>
`` <``>
small <JJ>
number <NN>
of <IN>
cases <NNS>
involved <VBN>
. <.>
'' <''>
However <NNP>
, <,>
union_spokesman <NN>
Bryan_Durrans <NNP>
of <IN>
the <DT>
Institute <NNP>
of <IN>
Professional_Civil_Servants <NNP>
called <VBD>
the <DT>
report <NN>
`` <``>
inconclusive <JJ>
. <.>
'' <''>
`` <``>
If <IN>
most <JJS>
of <IN>
us <PRP>
thought <VBD>
anything <NN>
was <VBD>
likely <JJ>
to <TO>
happen <VB>
to <TO>
our <PRP$>
children <NNS>
or <CC>
families <NNS>
, <,>
we <PRP>
would <MD>
not <RB>
be <VB>
here <RB>
. <.>
'' <''>
he <PRP>
said <VBD>
. <.>
The <DT>
Dounreay <NNP>
complex <NN>
employs <VBZ>
2 <CD>
, <,>
100 <CD>
workers <NNS>
in <IN>
a <DT>
barren_area <NN>
of <IN>
Northern_Scotland <NNP>
that <IN>
offers <NNS>
little <RB>
alternative <JJ>
employment <NN>
. <.>
The <DT>
environmental <JJ>
group <NN>
Friends <NNPS>
of <IN>
the <DT>
Earth <NNP>
lauded <VBD>
the <DT>
report <NN>
as <IN>
the <DT>
first <JJ>
government_admission <NN>
of <IN>
a <DT>
link <NN>
between <IN>
leukemia <NN>
and <CC>
nuclear <JJ>
emissions <NNS>
, <,>
and <CC>
called <VBN>
for <IN>
an <DT>
immediate <JJ>
closure <NN>
of <IN>
both_the <DT>
Dounreay <NNP>
and <CC>
Sellafield <NNP>
plants <NNS>
. <.>
`` <``>
The <DT>
nuclear <JJ>
industry <NN>
has <VBZ>
finally <RB>
been_implicated <VBN>
in <IN>
causing <NN>
cancers <NNS>
_ <NNP>
something <NN>
it <PRP>
has <VBZ>
denied <VBN>
for <IN>
years <NNS>
, <,>
'' <''>
said <VBD>
spokesman <NN>
Stewart_Boyle <NNP>
. <.>
Leukemia <NNP>
clusters <NNS>
_ <NNP>
occurrences <NNS>
of <IN>
the <DT>
disease <NN>
statistically <RB>
higher <JJR>
than <IN>
normal <JJ>
_ <NNP>
have <VBP>
also <RB>
been_found <VBN>
in <IN>
southern <NN>
England <NNP>
near <IN>
the <DT>
Atomic_Weapons_Research_Establishment <NNP>
, <,>
the <DT>
Royal_Ordnance_Factory <NNP>
and <CC>
the <DT>
U.K._Atomic_Energy_Authority <NNP>
. <.>
In <IN>
each <DT>
case <NN>
, <,>
scientists <NNS>
in <IN>
the <DT>
nuclear <JJ>
industry <NN>
argued <VBD>
that <IN>
recorded <VBN>
emissions <NNS>
of <IN>
radiation <NN>
were <VBD>
not <RB>
high <JJ>
enough <RB>
to <TO>
account <VB>
for <IN>
higher <JJR>
rates <NNS>
of <IN>
the <DT>
radiation-linked <JJ>
disease <NN>
. <.>
The <DT>
national <JJ>
leukemia_rate <NN>
is <VBZ>
eight <CD>
cases <NNS>
per <IN>
100 <CD>
, <,>
000 <CD>
people <NNS>
AP880909-0135 <DOCNO>
. <.>
The <DT>
death_rate <NN>
from <IN>
leukemia <NN>
was <VBD>
nearly <RB>
60 <CD>
percent <NN>
higher <JJR>
among <IN>
smokers <NNS>
of <IN>
more <JJR>
than <IN>
10 <CD>
cigarettes <NNS>
a <DT>
day <NN>
than_among <IN>
non-smokers <NNS>
, <,>
according <VBG>
to <TO>
a <DT>
study <NN>
published <VBN>
Friday <NNP>
. <.>
While <IN>
no <DT>
direct <JJ>
link <NN>
has <VBZ>
been_established <VBN>
between <IN>
smoking <NN>
and <CC>
leukemia <NN>
, <,>
research <NN>
published <VBD>
in <IN>
the <DT>
British_Medical <JJ>
Journal <NNP>
showed <VBD>
that <IN>
the <DT>
leukemia_death_rate <NN>
among <IN>
people <NNS>
who <WP>
smoked <VBN>
fewer <JJR>
than <IN>
10 <CD>
cigarettes <NNS>
a <DT>
day <NN>
was <VBD>
34 <CD>
percent <NN>
higher <JJR>
than_among <IN>
non-smokers <NNS>
. <.>
For <IN>
smokers <NNS>
of <IN>
10 <CD>
to <TO>
20 <CD>
cigarettes <NNS>
a <DT>
day <NN>
it <PRP>
was <VBD>
57 <CD>
percent <NN>
, <,>
and <CC>
for <IN>
smokers <NNS>
of <IN>
21 <CD>
or <CC>
more <JJR>
cigarettes <NNS>
63 <CD>
percent <NN>
, <,>
the <DT>
study <NN>
showed <VBD>
. <.>
`` <``>
If <IN>
the <DT>
findings <NNS>
in <IN>
our <PRP$>
study <NN>
represented <VBD>
a <DT>
direct <JJ>
relationship <NN>
between <IN>
smoking <NN>
and <CC>
leukemia <NN>
, <,>
then <RB>
it <PRP>
must <MD>
follow <VB>
that <IN>
smoking <NN>
is <VBZ>
responsible <JJ>
for <IN>
more <RBR>
cases <NNS>
of <IN>
leukemia <NN>
than <IN>
all_the <DT>
hitherto <NN>
established <VBD>
causes <NNS>
combined <VBN>
, <,>
'' <''>
said <VBD>
Dr._Leo_Kinlen <NNP>
, <,>
director <NN>
of <IN>
the <DT>
Cancer_Epidemiology_Unit <NNP>
at <IN>
the <DT>
University <NNP>
of <IN>
Edinburgh <NNP>
. <.>
Kinlen <NNP>
conducted <VBD>
the <DT>
study <NN>
of <IN>
248 <CD>
, <,>
000 <CD>
U.S. <NNP>
military <JJ>
veterans <NNS>
with <IN>
E._Rogot <NNP>
, <,>
a <DT>
statistician <JJ>
at <IN>
the <DT>
National_Heart <NNP>
, <,>
Lung <NNP>
and <CC>
Blood_Institute <NNP>
of <IN>
the <DT>
National <NNP>
Institutes <NNPS>
of <IN>
Health <NNP>
in <IN>
Bethesda <NNP>
, <,>
Maryland <NNP>
. <.>
They <PRP>
wrote <VBD>
that <IN>
it <PRP>
was <VBD>
`` <``>
the <DT>
largest <JJS>
study <NN>
of <IN>
leukemia <NN>
and <CC>
smoking <NN>
habits <NNS>
to <TO>
date <NN>
( <:>
and <CC>
) <:>
represents <NNS>
additional <JJ>
evidence <NN>
that <IN>
leukemia <NN>
is <VBZ>
a <DT>
smoking-related <JJ>
disease <NN>
. <.>
'' <''>
In <IN>
an <DT>
editorial <NN>
in <IN>
the <DT>
prestigious_weekly <JJ>
, <,>
Professor_Nicholas_Wald <NNP>
of <IN>
St._Bartholemew <NNP>
's <POS>
Hospital <NNP>
in <IN>
London <NNP>
cautioned <VBD>
that <IN>
no <DT>
cause-and-effect <JJ>
relationship <NN>
had <VBD>
been_established <VBN>
. <.>
But <CC>
he <PRP>
added <VBD>
: <:>
`` <``>
Whatever <RB>
the <DT>
mechanism <NN>
, <,>
the <DT>
balance <NN>
of <IN>
evidence <NN>
suggests <VBZ>
that <IN>
smoking <NN>
may <MD>
cause <VB>
leukemia <NN>
. <.>
'' <''>
It <PRP>
should <MD>
therefore_be <VB>
added <VBN>
to <TO>
the <DT>
World_Heath_Organization's <NNP>
list <NN>
of <IN>
tobacco-related <JJ>
causes <NNS>
of <IN>
death <NN>
, <,>
he <PRP>
wrote <VBD>
. <.>
The <DT>
study <NN>
was <VBD>
conducted <VBN>
on <IN>
data <NNS>
collected <VBN>
from <IN>
248 <CD>
, <,>
000 <CD>
veterans <NNS>
between <IN>
1954 <CD>
and <CC>
1969 <CD>
, <,>
the <DT>
researchers <NNS>
wrote <VBD>
. <.>
During <IN>
that <DT>
period <NN>
723 <CD>
died <VBD>
of <IN>
leukemia <NN>
. <.>
Of <IN>
these <DT>
330 <CD>
were <VBD>
cigarette <JJ>
smokers <NNS>
, <,>
185 <CD>
were <VBD>
ex-smokers <NNS>
, <,>
46 <CD>
smoked <VBD>
cigars <NNS>
or_and <CC>
162 <CD>
were <VBD>
non-smokers <NNS>
. <.>
The <DT>
study <NN>
found <VBD>
that_in <IN>
some <DT>
types <NNS>
of <IN>
leukemia <NN>
, <,>
the <DT>
death_rate <NN>
among <IN>
smokers <NNS>
was <VBD>
sharply <RB>
higher <JJR>
than <IN>
the <DT>
average <NN>
. <.>
Thus <RB>
for <IN>
monocytic <JJ>
and <CC>
myeloid <JJ>
leukemias <NNS>
, <,>
the <DT>
rate <NN>
among <IN>
smokers <NNS>
of <IN>
more <JJR>
than <IN>
20 <CD>
cigarettes <NNS>
a <DT>
day <NN>
was <VBD>
93 <CD>
percent <NN>
higher <JJR>
, <,>
compared <VBN>
with <IN>
48 <CD>
percent <NN>
for <IN>
lymphatic <JJ>
leukemias <NNS>
. <.>
For <IN>
smokers <NNS>
of <IN>
10 <CD>
to <TO>
20 <CD>
cigarettes <NNS>
a <DT>
day <NN>
the <DT>
rate <NN>
of <IN>
death <NN>
from <IN>
lymphatic <JJ>
leukemia <NN>
was <VBD>
76 <CD>
percent <NN>
higher <JJR>
, <,>
and <CC>
for <IN>
one <CD>
to <TO>
10 <CD>
cigarettes <NNS>
, <,>
40 <CD>
percent <NN>
higher <JJR>
. <.>
When <WRB>
the <DT>
data <NNS>
was <VBD>
broken <VBN>
down <RP>
into <IN>
smokers <NNS>
and <CC>
ex-smokers <NNS>
, <,>
it <PRP>
suggested <VBD>
that <IN>
ex-smokers <NNS>
also <RB>
are <VBP>
significantly <RB>
more <RBR>
at <IN>
risk <NN>
. <.>
The <DT>
death_rate <NN>
among <IN>
smokers <NNS>
was <VBD>
53 <CD>
percent <NN>
higher <JJR>
, <,>
and <CC>
among <IN>
ex-smokers <NNS>
39 <CD>
percent <NN>
WSJ910516-0166 <DOCNO>
. <.>
Because_of <IN>
the <DT>
way <NN>
the <DT>
acne_drug <NN>
is <VBZ>
thought <VBN>
to <TO>
work <VB>
, <,>
the <DT>
results <NNS>
support <NN>
a <DT>
new <JJ>
concept <NN>
of <IN>
cancer_chemotherapy <NN>
. <.>
In <IN>
the <DT>
type <NN>
of <IN>
leukemia <NN>
suffered <VBD>
by <IN>
the <DT>
patients <NNS>
, <,>
white <JJ>
blood <NN>
cells <NNS>
have <VBP>
turned <VBN>
malignant <JJ>
at <IN>
an <DT>
immature_stage <NN>
of <IN>
cell_development <NN>
. <.>
Their <PRP$>
arrested <VBN>
development <NN>
is <VBZ>
what <WP>
renders <NNS>
them <PRP>
practically <RB>
immortal <JJ>
and <CC>
dangerous <JJ>
. <.>
The <DT>
acne_drug <NN>
is <VBZ>
believed <VBN>
to <TO>
trigger <JJR>
these <DT>
immature <NN>
but <CC>
malignant <JJ>
cells <NNS>
to <TO>
divide <VB>
and <CC>
mature <VB>
and <CC>
then <RB>
die <VB>
essentially <RB>
a <DT>
natural <JJ>
death <NN>
. <.>
This <DT>
new <JJ>
concept <NN>
of <IN>
triggering <VBG>
cancer <NN>
cells <NNS>
to <TO>
mature <VB>
and <CC>
die <VB>
contrasts <NNS>
with <IN>
the <DT>
conventional <JJ>
concept <NN>
of <IN>
chemotherapy <NN>
, <,>
in <IN>
which <WDT>
drugs <NNS>
simply <RB>
poison_malignant <NN>
cells <NNS>
. <.>
The <DT>
drug <NN>
used <VBD>
in <IN>
the <DT>
experimental <JJ>
treatment <NN>
is <VBZ>
known <VBN>
as <IN>
tretinoin <NN>
, <,>
which <WDT>
belongs <NNS>
to <TO>
a <DT>
class <NN>
of <IN>
chemicals <NNS>
called <VBN>
retinoic <JJ>
acids <NNS>
that <WDT>
are <VBP>
related <VBN>
to <TO>
vitamin <VB>
A._Tretinoin <NNP>
is <VBZ>
sold <VBN>
in <IN>
ointment_form <NN>
as <IN>
Retin-A <NNP>
, <,>
the <DT>
acne_medication <NN>
produced <VBN>
by <IN>
Johnson <NNP>
& <CC>
amp <VB>
; <:>
Johnson <NNP>
's <POS>
Ortho_Pharmaceutical <NNP>
division <NN>
. <.>
The <DT>
tretinoin <NN>
used <VBD>
in <IN>
the <DT>
leukemia <NN>
patients <NNS>
, <,>
however <RB>
, <,>
is <VBZ>
a <DT>
pill <NN>
that <WDT>
was <VBD>
prepared <VBN>
for <IN>
the <DT>
experiment <NN>
by <IN>
chemists <NNS>
at <IN>
Hoffmann-La_Roche_Inc. <NNP>
, <,>
the <DT>
U.S. <NNP>
arm <NN>
of <IN>
Roche_Holding_Ltd. <NNP>
of <IN>
Switzerland <NNP>
. <.>
Roche <NNP>
, <,>
which <WDT>
has <VBZ>
a <DT>
long <JJ>
history <NN>
of <IN>
making <VBG>
retinoic <JJ>
acids <NNS>
, <,>
sells <NNS>
one <CD>
of <IN>
its <PRP$>
acids <NNS>
as <IN>
Accutane <NNP>
, <,>
a <DT>
pill <NN>
for <IN>
treating <NN>
severe <RB>
acne <NN>
. <.>
The <DT>
particular <JJ>
form <NN>
of <IN>
leukemia <NN>
that <IN>
appears <NNS>
to <TO>
respond <VB>
readily <RB>
to <TO>
the <DT>
acne-drug_type <NN>
of <IN>
treatment <NN>
is <VBZ>
called <VBN>
acute_promyelocytic <JJ>
leukemia <NN>
. <.>
It <PRP>
is <VBZ>
an <DT>
uncommon_cancer <NN>
, <,>
afflicting <VBG>
about <IN>
1 <CD>
, <,>
000 <CD>
Americans <NNS>
a <DT>
year <NN>
, <,>
in <IN>
which <WDT>
certain <JJ>
cells <NNS>
in <IN>
the <DT>
bone_marrow_become_malignant <NN>
before <IN>
they <PRP>
have <VBP>
matured <VBN>
into <IN>
fully <RB>
functioning <VBG>
white <JJ>
blood <NN>
cells <NNS>
. <.>
The <DT>
malignant <NN>
, <,>
immature_white <NN>
cells <NNS>
( <:>
known <VBN>
as <IN>
myelocytes <NNS>
) <:>
flood <NN>
the <DT>
blood_stream <NN>
, <,>
producing <VBG>
fatigue <NN>
, <,>
fever <RB>
, <,>
weight <RB>
loss <NN>
and <CC>
bleeding <VBG>
. <.>
Until <IN>
now <RB>
, <,>
chemotherapy <NN>
with <IN>
standard <JJ>
anti-cancer <NN>
drugs <NNS>
has <VBZ>
been <VBN>
the <DT>
only_effective <JJ>
treatment <NN>
for <IN>
acute <NN>
promyelocyltic <JJ>
leukemia <NN>
, <,>
but <CC>
it <PRP>
produces <VBZ>
cures <NNS>
in <IN>
only <RB>
about <IN>
a <DT>
third <JJ>
of <IN>
patients <NNS>
. <.>
The <DT>
tip-off <JJ>
that <IN>
an <DT>
tretinoin-like <JJ>
drug <NN>
might <MD>
be <VB>
effective <JJ>
in <IN>
treating <NN>
the <DT>
leukemia <NN>
came <VBD>
from <IN>
a <DT>
genetic <JJ>
finding <NN>
, <,>
Dr._Raymond_P._Warrell_Jr. <NNP>
of <IN>
Memorial <NNP>
Sloan-Kettering <JJ>
and <CC>
his <PRP$>
colleagues <NNS>
in <IN>
New_York <NNP>
and <CC>
at <IN>
M.D <JJ>
. <.>
Anderson_Cancer_Center <NNP>
in <IN>
Houston <NNP>
reported <VBD>
in <IN>
this <DT>
week <NN>
's <POS>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
. <.>
Most <JJS>
patients <NNS>
with <IN>
promyleocytic <JJ>
leukemia <NNS>
apparently <RB>
have <VBP>
the <DT>
same <JJ>
defect <NN>
in <IN>
two <CD>
of <IN>
their <PRP$>
23 <CD>
chromosomes <NNS>
, <,>
the <DT>
structures <NNS>
in <IN>
the <DT>
cell <NN>
that <IN>
contain <NN>
all_the <DT>
genes <NNS>
. <.>
A <DT>
piece <NN>
of <IN>
chromosome_number <NN>
17 <CD>
appears <NNS>
to <TO>
have <VB>
broken <VBN>
loose <JJ>
and <CC>
become <VB>
a <DT>
part <NN>
of <IN>
chromosome_number <NN>
15 <CD>
. <.>
Last <JJ>
year <NN>
, <,>
molecular <JJ>
geneticists <NNS>
identified <VBD>
one <CD>
of <IN>
the <DT>
genes <NNS>
in <IN>
chromosome <NN>
17 <CD>
that <WDT>
was <VBD>
damaged <VBN>
when <WRB>
the <DT>
chunk <NN>
of <IN>
the <DT>
chromosome_broke_loose <NN>
. <.>
The <DT>
damaged <VBN>
gene <NN>
, <,>
it <PRP>
turned <VBD>
out <RP>
, <,>
ordinarily <RB>
made <VBD>
a <DT>
protein <NN>
-- <:>
a <DT>
receptor <NN>
-- <:>
that <IN>
grabbed <JJ>
hold <NN>
of <IN>
retinoic <JJ>
acid <NN>
. <.>
This <DT>
and <CC>
other <JJ>
laboratory <NN>
findings <NNS>
suggested <VBD>
that <IN>
the <DT>
immaturity <NN>
of <IN>
the <DT>
leukemic_white <JJ>
blood <NN>
cells <NNS>
might <MD>
somehow_be <VB>
related <VBN>
to <TO>
a <DT>
foul-up <JJ>
in <IN>
the <DT>
way <NN>
the <DT>
cells <NNS>
handled <VBD>
or <CC>
failed <VBN>
to <TO>
handle <VB>
retinoic <JJ>
acid <NN>
. <.>
The <DT>
nature <NN>
of <IN>
the <DT>
genetic <JJ>
damage <NN>
also <RB>
hinted <VBD>
that <IN>
doses <NNS>
of <IN>
retinoic <JJ>
acids <NNS>
might <MD>
prod <VB>
the <DT>
immature_malignant <NN>
cells <NNS>
to <TO>
proceed <VB>
to <TO>
maturity <NN>
and <CC>
then <RB>
die <VB>
as <IN>
normal_white <JJ>
blood <NN>
cells <NNS>
do <VBP>
. <.>
`` <``>
We <PRP>
're <VBP>
now <RB>
the <DT>
third <JJ>
group <NN>
to <TO>
show <VB>
remissions <NNS>
{ <:>
with <IN>
tretinoin <NN>
} <:>
in <IN>
this <DT>
leukemia <NN>
, <,>
'' <''>
following <VBG>
Chinese <NNP>
and <CC>
French <NNP>
researchers <NNS>
, <,>
Dr._Warrell <NNP>
said <VBD>
. <.>
But <CC>
, <,>
he <PRP>
added <VBD>
, <,>
the <DT>
U.S. <NNP>
group <NN>
is <VBZ>
the <DT>
first <JJ>
to <TO>
show <VB>
that <IN>
the <DT>
drug <NN>
works <VBZ>
by <IN>
triggering <NN>
the <DT>
immature_cancer <NN>
cells <NNS>
to <TO>
mature <VB>
, <,>
or <CC>
to <TO>
`` <``>
differentiate <VB>
, <,>
'' <''>
in <IN>
the <DT>
biologists <NNS>
jargon <VBP>
. <.>
`` <``>
We <PRP>
've <VBP>
documented <VBN>
conclusively <RB>
that <IN>
differentiation <NN>
as <IN>
a <DT>
method <NN>
of <IN>
cancer_therapy <NN>
in <IN>
humans <NNS>
is <VBZ>
a <DT>
reality <NN>
, <,>
'' <''>
he <PRP>
said <VBD>
WSJ870120-0009 <DOCNO>
. <.>
Researchers <NNS>
are <VBP>
quietly <RB>
conducting <VBG>
a <DT>
large-scale <JJ>
sampling <NN>
of <IN>
the <DT>
nation <NN>
's <POS>
blood_supply <NN>
to <TO>
see <VB>
if <IN>
a <DT>
rare_virus <NN>
capable <JJ>
of <IN>
causing <VBG>
cancer <NN>
and <CC>
, <,>
possibly <RB>
, <,>
a <DT>
mysterious <JJ>
nerve_disease <NN>
is <VBZ>
being <VBG>
spread <VBN>
among <IN>
Americans <NNPS>
. <.>
The <DT>
virus <NN>
, <,>
until <IN>
now <RB>
, <,>
has <VBZ>
been_confined <VBN>
to <TO>
small <JJ>
areas <NNS>
of <IN>
Japan <NNP>
, <,>
the <DT>
Caribbean <NNP>
and <CC>
the <DT>
Mediterranean <NNP>
. <.>
It <PRP>
is <VBZ>
, <,>
however <RB>
, <,>
similar <JJ>
to <TO>
the <DT>
virus <NN>
that <IN>
causes <NNS>
acquired <VBD>
immune <JJ>
deficiency_syndrome <NN>
, <,>
or <CC>
AIDS <NNP>
. <.>
Now <RB>
, <,>
scientists <NNS>
are <VBP>
increasingly <RB>
concerned <VBN>
that <IN>
the <DT>
virus <NN>
, <,>
which <WDT>
can <MD>
cause <VB>
a <DT>
form <NN>
of <IN>
adult_leukemia <NN>
, <,>
is <VBZ>
being <VBG>
transmitted <VBN>
like <IN>
AIDS <NNP>
: <:>
through <IN>
an <DT>
exchange <NN>
of <IN>
blood <NN>
by <IN>
hypodermic <JJ>
syringes <NNS>
, <,>
sexual <JJ>
practices <NNS>
or <CC>
transfusions <NNS>
. <.>
Although <IN>
it <PRP>
is <VBZ>
far_too_early <RB>
to <TO>
tell <VB>
how <WRB>
many <JJ>
people <NNS>
have <VBP>
been_infected <VBN>
and <CC>
how <WRB>
many <JJ>
will <MD>
actually <RB>
develop <VB>
cancer <NN>
or <CC>
the <DT>
nerve_disease <NN>
, <,>
evidence <NN>
already <RB>
suggests <VBZ>
that <IN>
many <JJ>
drug <NN>
addicts <NNS>
in <IN>
the <DT>
U.S. <NNP>
have <VBP>
been_exposed <VBN>
to <TO>
the <DT>
virus <NN>
. <.>
And <CC>
there <EX>
is <VBZ>
at <IN>
least <JJS>
one <CD>
cluster <NN>
of <IN>
cases <NNS>
of <IN>
the <DT>
rare_leukemia <NN>
in <IN>
New_York <NNP>
's <POS>
Bedford-Stuyvesant <JJ>
neighborhood <NN>
, <,>
although <IN>
doctors <NNS>
do <VBP>
n't <RB>
know <VB>
how <WRB>
the <DT>
victims <NNS>
acquired <VBD>
the <DT>
virus <NN>
. <.>
In <IN>
an <DT>
unannounced <VBN>
move <NN>
, <,>
the <DT>
American_Red_Cross <NNP>
late <RB>
last <JJ>
week <NN>
began <VBD>
testing <NN>
for <IN>
evidence <NN>
of <IN>
the <DT>
virus <NN>
in <IN>
blood <NN>
donated <VBN>
by <IN>
30 <CD>
, <,>
000 <CD>
people <NNS>
in <IN>
six <CD>
unidentified <VBN>
cities <NNS>
around <IN>
the <DT>
country <NN>
. <.>
The <DT>
effort <NN>
follows <VBZ>
the <DT>
federal <JJ>
government <NN>
's <POS>
approval <NN>
of <IN>
an <DT>
experimental <JJ>
test_kit <NN>
to <TO>
detect <VB>
antibodies <NNS>
to <TO>
the <DT>
virus <NN>
. <.>
The <DT>
sampling <NN>
, <,>
while <IN>
technically <RB>
a <DT>
trial <NN>
of <IN>
the <DT>
accuracy <NN>
of <IN>
the <DT>
new <JJ>
blood_test <NN>
, <,>
should <MD>
also <RB>
indicate <VB>
whether <IN>
the <DT>
cancer <NN>
virus_is <VBZ>
enough <RB>
of <IN>
a <DT>
threat <NN>
for <IN>
blood <NN>
banks <NNS>
to <TO>
begin <VB>
routine <JJ>
screening <NN>
of <IN>
donated <VBN>
blood <NN>
as <IN>
is <VBZ>
now <RB>
done <VBN>
for <IN>
AIDS <NNP>
and <CC>
hepatitis <VBZ>
. <.>
`` <``>
We <PRP>
have <VBP>
evidence <NN>
now <RB>
that <IN>
a <DT>
virus_spread <NN>
by <IN>
blood <NN>
and <CC>
associated <VBN>
with <IN>
a <DT>
very <RB>
serious <JJ>
disease <NN>
has <VBZ>
been_detected <VBN>
in <IN>
the <DT>
U.S. <NNP>
, <,>
'' <''>
says <VBZ>
S._Gerald_Sandler <NNP>
, <,>
medical <JJ>
director <NN>
of <IN>
the <DT>
Red_Cross <NNP>
. <.>
`` <``>
Since <IN>
this <DT>
is <VBZ>
happening <VBG>
, <,>
it <PRP>
is <VBZ>
the <DT>
responsibility <NN>
of <IN>
the <DT>
American_Red_Cross <NNP>
to <TO>
be <VB>
at <IN>
the <DT>
head <NN>
of <IN>
a <DT>
scientific <JJ>
investigation <NN>
to <TO>
quantify <VB>
the <DT>
incidence <NN>
of <IN>
the <DT>
virus <NN>
's <POS>
presence <NN>
and <CC>
spread <NN>
. <.>
`` <``>
Adds <VBZ>
Bernard_Poiesz <NNP>
, <,>
head <NN>
of <IN>
the <DT>
division <NN>
of <IN>
hematology-oncology <NN>
at <IN>
the <DT>
State_University <NNP>
of <IN>
New_York <NNP>
in <IN>
Syracuse <NNP>
: <:>
`` <``>
Incidence <NN>
of <IN>
the <DT>
virus <NN>
in <IN>
the <DT>
U.S. <NNP>
has <VBZ>
been <VBN>
sporadic <JJ>
, <,>
but <CC>
it <PRP>
is <VBZ>
increasing <VBG>
now <RB>
. <.>
We <PRP>
are <VBP>
now <RB>
beginning <VBG>
to <TO>
realize <VB>
that <IN>
the <DT>
virus <NN>
is <VBZ>
causing <VBG>
a <DT>
real <JJ>
health_problem <NN>
in <IN>
this <DT>
country <NN>
. <.>
`` <``>
The <DT>
virus <NN>
poses <VBZ>
an <DT>
unusual <JJ>
threat <NN>
because_of <IN>
its <PRP$>
long <JJ>
latency_period <NN>
. <.>
People <NNS>
infected <VBD>
with <IN>
the <DT>
virus <NNS>
may <MD>
not <RB>
develop <VB>
leukemia <NN>
for <IN>
several <JJ>
years <NNS>
. <.>
Thus <RB>
, <,>
if <IN>
the <DT>
virus <NN>
is <VBZ>
spreading <VBG>
now <RB>
, <,>
it <PRP>
may <MD>
be <VB>
a <DT>
decade <NN>
before <IN>
enough <JJ>
leukemia <NN>
cases <NNS>
develop <VB>
to <TO>
trigger <VB>
the <DT>
nation <NN>
's <POS>
epidemic <JJ>
alarm_system <NN>
. <.>
No <DT>
one <NN>
knows <VBZ>
what <WP>
percentage <NN>
of <IN>
infected <VBN>
individuals <NNS>
will <MD>
develop <VB>
leukemia <NN>
or <CC>
the <DT>
nerve_disease <NN>
. <.>
Although <IN>
the <DT>
cancer_threat_alone <NN>
has <VBZ>
worried <VBN>
health <NN>
officials <NNS>
for <IN>
several <JJ>
months <NNS>
, <,>
those <DT>
concerns <NNS>
have <VBP>
increased <VBN>
following <VBG>
reports <NNS>
that <IN>
link <NN>
the <DT>
virus <NN>
with <IN>
a <DT>
nerve_condition <NN>
known <VBN>
as <IN>
tropical_spastic <JJ>
paraparesis <NN>
or <CC>
TSP <NNP>
, <,>
explains <VBZ>
William_A._Blattner <NNP>
of <IN>
the <DT>
environmental <JJ>
epidemiology_branch <NN>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
. <.>
The <DT>
nerve_disease <NN>
is <VBZ>
similar <JJ>
to <TO>
multiple <VB>
sclerosis <NN>
and <CC>
afflicts <NNS>
muscle_function <NN>
. <.>
It <PRP>
was <VBD>
first <JJ>
identified <VBN>
in <IN>
the <DT>
1960s <CD>
in <IN>
Jamaica <NNP>
. <.>
Last <JJ>
fall <NN>
, <,>
however <RB>
, <,>
French <JJ>
researchers <NNS>
in <IN>
Martinique <NNP>
linked <VBD>
the <DT>
nerve_disease <NN>
to <TO>
the <DT>
virus <NN>
after <IN>
finding <NN>
that <IN>
many <JJ>
TSP <NNP>
victims <NNS>
had <VBD>
been_infected <VBN>
with <IN>
the <DT>
leukemia <NN>
virus <VBZ>
. <.>
Subsequently <RB>
, <,>
Japanese <JJ>
researchers <NNS>
found <VBD>
that <IN>
many <JJ>
TSP <NNP>
victims <NNS>
in <IN>
Japan <NNP>
had <VBD>
previously <RB>
had <VBD>
blood <VBN>
transfusions <NNS>
. <.>
Although <IN>
the <DT>
incidence <NN>
of <IN>
TSP <NNP>
in <IN>
the <DT>
U.S. <NNP>
is <VBZ>
n't <RB>
known <VBN>
, <,>
the <DT>
links <NNS>
between <IN>
the <DT>
leukemia <NN>
virus <VBZ>
, <,>
the <DT>
nerve_disease <NN>
and <CC>
blood <NN>
transfusions <NNS>
have <VBP>
apparently <RB>
spurred <VBN>
the <DT>
preliminary <JJ>
screening <NN>
of <IN>
blood <NN>
supplies <NNS>
by <IN>
the <DT>
Red_Cross <NNP>
. <.>
The <DT>
virus <NN>
is <VBZ>
known <VBN>
as <IN>
human <JJ>
T-cell_leukemia <NN>
virus <VBZ>
one <CD>
, <,>
or <CC>
HTLV-I <NNP>
. <.>
The <DT>
T <NNP>
cell <NN>
is <VBZ>
a <DT>
particular <JJ>
type <NN>
of <IN>
white <JJ>
blood_cell <NN>
that <WDT>
is <VBZ>
infected <VBN>
and <CC>
turned <VBD>
malignant <JJ>
by <IN>
the <DT>
virus <NN>
. <.>
Less <RBR>
than <IN>
a <DT>
decade <NN>
ago <IN>
, <,>
U.S. <NNP>
and <CC>
Japanese <JJ>
scientists <NNS>
proved <VBD>
that <IN>
HTLV-I <JJ>
was <VBD>
responsible <JJ>
for <IN>
a <DT>
type <NN>
of <IN>
leukemia <NN>
seen <VBN>
in <IN>
southern <NN>
Japan <NNP>
. <.>
The <DT>
virus <NN>
thus <RB>
became <VBD>
the <DT>
first <JJ>
virus <NN>
proved <VBD>
to <TO>
cause <VB>
a <DT>
human <JJ>
cancer <NN>
. <.>
So <IN>
far <RB>
, <,>
it <PRP>
is <VBZ>
the <DT>
only <JJ>
proven <CD>
human_cancer <NN>
virus <VBZ>
, <,>
although <IN>
many <JJ>
patients <NNS>
infected <VBN>
with <IN>
the <DT>
AIDS <NNP>
virus <VBZ>
develop <VB>
a <DT>
previously <RB>
rare <JJ>
type <NN>
of <IN>
skin_cancer <NN>
. <.>
The <DT>
rare_leukemia <NN>
, <,>
once <RB>
it <PRP>
develops <VBZ>
, <,>
is <VBZ>
devastating <VBG>
. <.>
`` <``>
The <DT>
median <JJ>
survival <NN>
is <VBZ>
three <CD>
months <NNS>
, <,>
'' <''>
says <VBZ>
Harvey_Dosik <NNP>
, <,>
director <NN>
of <IN>
medicine <NN>
at <IN>
the <DT>
Interfaith_Medical_Center <NNP>
in <IN>
Brooklyn <NNP>
, <,>
N.Y._Dr._Dosik <NNP>
and <CC>
his <PRP$>
colleagues <NNS>
have <VBP>
seen <VBN>
15 <CD>
cases <NNS>
of <IN>
the <DT>
leukemia <NN>
in <IN>
the <DT>
past <JJ>
two <CD>
years <NNS>
. <.>
`` <``>
Only <RB>
one <CD>
of <IN>
the <DT>
15 <CD>
is <VBZ>
still <RB>
alive <JJ>
, <,>
'' <''>
he <PRP>
says <VBZ>
. <.>
The <DT>
15 <CD>
cases <NNS>
constitute <VBP>
the <DT>
largest <JJS>
cluster <NN>
of <IN>
the <DT>
leukemia <NN>
in <IN>
the <DT>
U.S <JJ>
. <.>
The <DT>
victims <NNS>
were <VBD>
all <DT>
blacks <NNS>
who <WP>
moved <VBN>
into <IN>
the <DT>
Bedford-Stuyvesant <JJ>
ghetto <NN>
in <IN>
Brooklyn <NNP>
from <IN>
the <DT>
Carribbean <NNP>
and <CC>
the <DT>
southern <NN>
U.S. <NNP>
, <,>
areas <NNS>
where <WRB>
the <DT>
presence <NN>
of <IN>
the <DT>
virus <NN>
has <VBZ>
been_known <VBN>
for <IN>
some <DT>
time <NN>
. <.>
None <NN>
of <IN>
the <DT>
15 <CD>
victims <NNS>
was <VBD>
known <VBN>
to <TO>
be <VB>
an <DT>
intravenous <JJ>
drug_user <NN>
, <,>
Dr._Dosik <NNP>
says <VBZ>
. <.>
Mainly <RB>
because_of <IN>
the <DT>
lack <NN>
of <IN>
funds <NNS>
, <,>
researchers <NNS>
have <VBP>
been <VBN>
unable <JJ>
to <TO>
explore <VB>
the <DT>
victims <NNS>
' <POS>
backgrounds <NNS>
to <TO>
discover <VB>
what <WP>
they <PRP>
might <MD>
have <VB>
in <IN>
common <JJ>
that <IN>
would <MD>
account <VB>
for <IN>
the <DT>
disease <NN>
, <,>
Dr._Dosik <NNP>
says <VBZ>
. <.>
Evidence <NN>
of <IN>
the <DT>
virus <NN>
's <POS>
spread <NN>
among <IN>
Americans <NNPS>
comes <VBZ>
largely <RB>
from <IN>
tests <NNS>
of <IN>
drug <NN>
addicts <NNS>
. <.>
In <IN>
1984 <CD>
, <,>
British <NNP>
health <NN>
officials <NNS>
, <,>
while <IN>
screening <NN>
for <IN>
AIDS <NNP>
, <,>
first <JJ>
noted <VBD>
that_about <IN>
4 <CD>
% <NN>
of <IN>
addicts <NNS>
there <EX>
had <VBD>
developed <VBN>
antibodies <NNS>
to <TO>
HTLV-I <NNP>
, <,>
evidence <NN>
that <IN>
they <PRP>
had <VBD>
been_exposed <VBN>
to <TO>
the <DT>
virus <NN>
. <.>
Earlier <JJR>
this <DT>
year <NN>
, <,>
a <DT>
team <NN>
from <IN>
the <DT>
U.S._National <NNP>
Institutes <NNPS>
of <IN>
Health <NNP>
checked <VBD>
blood <NN>
samples <NNS>
taken <VBN>
five <CD>
years <NNS>
ago <RB>
from <IN>
56 <CD>
drug <NN>
addicts <NNS>
in <IN>
the <DT>
Queens <NNP>
section <NN>
of <IN>
New_York <NNP>
. <.>
The <DT>
results <NNS>
indicated <VBD>
that_as <IN>
early <JJ>
as <IN>
1981 <CD>
as <IN>
many <JJ>
as <IN>
9 <CD>
% <NN>
of <IN>
the <DT>
intravenous <JJ>
drug <NN>
addicts <NNS>
had <VBD>
been_exposed <VBN>
to <TO>
HTLV-I <NNP>
. <.>
If <IN>
the <DT>
spread <NN>
of <IN>
the <DT>
AIDS <NNP>
virus <VBZ>
since <IN>
then <RB>
is <VBZ>
any <DT>
kind <NN>
of <IN>
index <NN>
for <IN>
the <DT>
growth <NN>
of <IN>
HTLV-I <NNP>
, <,>
the <DT>
virus <NN>
is <VBZ>
presumably_even <RB>
more <RBR>
widespread <JJ>
now <RB>
. <.>
Some <DT>
researchers <NNS>
are <VBP>
also <RB>
worried <VBN>
that <IN>
blood <NN>
screening <VBG>
such <JJ>
as <IN>
that <DT>
being <VBG>
done <NN>
by <IN>
the <DT>
Red_Cross <NNP>
may <MD>
not <RB>
give <VB>
a <DT>
broad <JJ>
enough <RB>
picture <NN>
of <IN>
the <DT>
prevalence <NN>
of <IN>
HTLV-I <NNP>
. <.>
Blood <NNP>
banks <NNS>
have <VBP>
been <VBN>
carefully <RB>
excluding <VBG>
donors <NNS>
who <WP>
are <VBP>
at <IN>
risk <NN>
of <IN>
developing <VBG>
AIDS <NNP>
-- <:>
but <CC>
those <DT>
are <VBP>
the <DT>
people <NNS>
who <WP>
are <VBP>
also <RB>
most <JJS>
likely <JJ>
to <TO>
have <VB>
been_exposed <VBN>
to <TO>
HTLV-I <NNP>
. <.>
Thus <RB>
, <,>
sampling <VBG>
only <RB>
donated <VBN>
blood <NN>
might <MD>
result <VB>
in <IN>
underestimating <NN>
the <DT>
true <JJ>
extent <NN>
of <IN>
the <DT>
virus <NN>
. <.>
The <DT>
Red_Cross <NNP>
screening_program <NN>
was <VBD>
made <VBN>
possible <JJ>
by <IN>
the <DT>
development <NN>
of <IN>
test <NN>
kits <NNS>
by <IN>
Cellular <NNP>
Products <NNPS>
Co. <NNP>
, <,>
a <DT>
Buffalo <NNP>
, <,>
N.Y. <NNP>
, <,>
biotechnology_company <NN>
, <,>
and <CC>
by <IN>
Du_Pont_Co. <NNP>
in <IN>
Wilmington <NNP>
, <,>
Del <NNP>
. <.>
Both <DT>
companies <NNS>
already <RB>
produce <VB>
tests <NNS>
to <TO>
detect <VB>
the <DT>
AIDS <NNP>
virus <VBZ>
, <,>
and <CC>
the <DT>
new <JJ>
tests <NNS>
use <VBP>
the <DT>
same <JJ>
technology <NN>
. <.>
Cellular <JJ>
Products <NNS>
began <VBD>
working <VBG>
on <IN>
a <DT>
test <NN>
at <IN>
the <DT>
`` <``>
insistence <NN>
of <IN>
Dr._Poiesz <NNP>
'' <''>
in <IN>
Syracuse <NNP>
, <,>
`` <``>
who <WP>
told <VBD>
us_he <PRP>
was <VBD>
seeing <VBG>
enough <RB>
instances <NNS>
in <IN>
his <PRP$>
lab <NN>
to <TO>
warrant <VB>
nationwide <JJ>
screening <NN>
soon <RB>
, <,>
'' <''>
says <VBZ>
Richard_Montagna <NNP>
, <,>
Cellular <NNP>
's <POS>
president <NN>
. <.>
Dr._Poiesz <NNP>
, <,>
a <DT>
scientific <JJ>
adviser <NN>
to <TO>
Cellular <NNP>
, <,>
is <VBZ>
an <DT>
expert <NN>
on <IN>
the <DT>
HTLV-I <NNP>
virus <VBZ>
; <:>
he <PRP>
helped <VBD>
identify <VB>
the <DT>
virus <NN>
in <IN>
the <DT>
laboratory <NN>
of <IN>
Dr._Robert_Gallo <NNP>
at <IN>
the <DT>
National_Cancer_Institute <NNP>
in <IN>
1978 <CD>
. <.>
Dr._Poiesz <NNP>
's <POS>
lab <NN>
has <VBZ>
been <VBN>
testing <VBG>
blood <NN>
samples <NNS>
from_around <IN>
the <DT>
world <NN>
, <,>
but <CC>
the <DT>
lab <NN>
's <POS>
test <NN>
is <VBZ>
n't <RB>
simple <JJ>
enough <RB>
for <IN>
use <NN>
by <IN>
blood <NN>
banks <NNS>
. <.>
A <DT>
Du_Pont <NNP>
spokesman <NN>
says <VBZ>
the <DT>
company <NN>
is <VBZ>
gearing <VBG>
up <RP>
to <TO>
produce <VB>
six_million <CD>
test <NN>
kits <NNS>
a <DT>
year <NN>
, <,>
based <VBN>
on <IN>
Du_Pont <NNP>
's <POS>
own <JJ>
studies <NNS>
of <IN>
the <DT>
spread <NN>
of <IN>
the <DT>
virus <NN>
. <.>
Based <VBN>
on <IN>
these <DT>
studies <NNS>
, <,>
he <PRP>
adds <VBZ>
, <,>
the <DT>
company <NN>
believes <VBZ>
there <EX>
will <MD>
be <VB>
a <DT>
need <NN>
within <IN>
a <DT>
few <JJ>
years <NNS>
for_about <IN>
50_million <CD>
to <TO>
75_million <CD>
test <NN>
kits <NNS>
, <,>
about <IN>
the <DT>
same <JJ>
number <NN>
currently <RB>
used <VBN>
to <TO>
screen <VB>
for <IN>
the <DT>
AIDS <NNP>
virus <VBZ>
LA121190-0080 <DOCNO>
. <.>
Cigarette <NNP>
smoking <NN>
appears <VBZ>
to <TO>
be <VB>
a <DT>
major <JJ>
risk_factor <NN>
for <IN>
the <DT>
development <NN>
of <IN>
leukemia <NN>
and <CC>
may <MD>
be <VB>
responsible <JJ>
for <IN>
more <RBR>
than <IN>
1 <CD>
in <IN>
5 <CD>
cases <NNS>
of <IN>
the <DT>
feared <VBN>
blood_cancer <NN>
, <,>
according <VBG>
to <TO>
a <DT>
study <NN>
by <IN>
Loma_Linda_University <NNP>
researchers <NNS>
. <.>
The <DT>
researchers <NNS>
consider <VBP>
the <DT>
findings <NNS>
particularly <RB>
significant <JJ>
because <IN>
almost <RB>
all <DT>
of <IN>
the <DT>
34 <CD>
, <,>
000 <CD>
Seventh-day <JJ>
Adventists <NNS>
studied <VBD>
who <WP>
had <VBD>
smoked_had_stopped <VBN>
years <NNS>
earlier <JJR>
, <,>
suggesting <VBG>
that <IN>
some <DT>
of <IN>
the <DT>
adverse <NN>
effects <NNS>
may <MD>
not <RB>
be <VB>
reversible <JJ>
. <.>
The <DT>
report <NN>
increases <NNS>
the <DT>
credence <NN>
of <IN>
other_recent <JJ>
studies <NNS>
that <WDT>
have <VBP>
suggested <VBN>
a <DT>
link <NN>
between <IN>
smoking <NN>
and <CC>
leukemia <NN>
. <.>
The <DT>
results <NNS>
, <,>
being <VBG>
published <VBN>
this <DT>
month <NN>
in <IN>
the <DT>
Journal <NNP>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
, <,>
add <VBD>
to <TO>
a <DT>
growing <VBG>
list <NN>
of <IN>
cancers <NNS>
that <WDT>
have <VBP>
been_linked <VBN>
to <TO>
cigarette <VB>
smoking <NN>
. <.>
The <DT>
list <NN>
includes <VBZ>
cancers <NNS>
of <IN>
the <DT>
lung <NN>
, <,>
bladder <NN>
, <,>
pancreas <VBZ>
, <,>
esophagus <VBZ>
, <,>
throat <JJ>
and <CC>
perhaps <RB>
the <DT>
cervix <NN>
. <.>
The <DT>
study <NN>
is <VBZ>
part <NN>
of <IN>
the <DT>
ongoing <JJ>
Adventist_Health_Study <NNP>
, <,>
a <DT>
major_epidemiological <JJ>
investigation <NN>
of <IN>
the <DT>
causes <NNS>
of <IN>
various <JJ>
cancers <NNS>
among <IN>
California <NNP>
residents <NNS>
. <.>
Although <IN>
the <DT>
vast <JJ>
majority <NN>
of <IN>
Adventists <NNPS>
do <VBP>
not <RB>
smoke <VB>
by <IN>
church_proscription <NN>
, <,>
many <JJ>
are <VBP>
adult <VBN>
converts <NNS>
to <TO>
the <DT>
religion <NN>
who <WP>
smoked <VBN>
cigarettes <VBZ>
prior <RB>
to <TO>
their <PRP$>
baptism <NN>
into <IN>
the <DT>
church <NN>
. <.>
The <DT>
researchers <NNS>
found <VBD>
that <IN>
the <DT>
Adventist_ex-smokers <NNP>
had <VBD>
twice <NN>
the <DT>
risk <NN>
of <IN>
developing <VBG>
leukemia <NN>
than <IN>
similar <JJ>
individuals <NNS>
who <WP>
never <RB>
had <VBD>
smoked <VBN>
. <.>
The <DT>
results <NNS>
are <VBP>
`` <``>
very <RB>
discouraging <VBG>
, <,>
'' <''>
said <VBD>
Paul_K._Mills <NNP>
, <,>
an <DT>
assistant <JJ>
professor <NN>
of <IN>
preventive <JJ>
medicine <NN>
at <IN>
Loma_Linda <NNP>
and <CC>
principal <JJ>
author <NN>
of <IN>
the <DT>
study <NN>
. <.>
`` <``>
We <PRP>
saw <VBD>
a <DT>
strong <JJ>
association <NN>
between <IN>
prior <RB>
cigarette <JJ>
smoking <NN>
and <CC>
the <DT>
risk <NN>
of <IN>
developing <VBG>
leukemia <NN>
. <.>
`` <``>
The <DT>
findings <NNS>
`` <``>
obviously_strengthen <RB>
the <DT>
gathering_impression <NN>
that <IN>
cigarette_smoking <NN>
is <VBZ>
related <VBN>
to <TO>
leukemia <VB>
risk <NN>
and <CC>
that <IN>
the <DT>
association <NN>
is <VBZ>
likely <JJ>
to <TO>
be <VB>
causal <JJ>
, <,>
'' <''>
Dr._Clark_W._Heath_Jr. <NNP>
, <,>
a <DT>
vice_president <NN>
of <IN>
the <DT>
American_Cancer_Society <NNP>
, <,>
wrote <VBD>
in <IN>
an <DT>
editorial <NN>
published <VBD>
in <IN>
the <DT>
medical_journal <JJ>
along_with <IN>
the <DT>
study <NN>
. <.>
The <DT>
risk <NN>
of <IN>
developing <VBG>
leukemia <NN>
was <VBD>
also <RB>
increased <VBN>
by <IN>
a <DT>
greater <JJR>
number <NN>
of <IN>
cigarettes <NNS>
smoked <VBN>
daily <JJ>
and <CC>
a <DT>
longer_duration <NN>
of <IN>
smoking <NN>
, <,>
which <WDT>
Mills <NNP>
said_was <VBD>
'' <''>
important <JJ>
evidence <NN>
of <IN>
a <DT>
causal_relationship <NN>
. <.>
`` <``>
Individuals <NNS>
who <WP>
regularly <RB>
smoked <VBD>
more <JJR>
than <IN>
25 <CD>
cigarettes <NNS>
a <DT>
day <NN>
had <VBD>
a <DT>
threefold <NN>
increased <VBN>
risk <NN>
of <IN>
developing <VBG>
leukemia <NN>
. <.>
The <DT>
Adventists <NNPS>
who <WP>
had <VBD>
smoked <VBN>
for <IN>
more <JJR>
than <IN>
15 <CD>
years <NNS>
had <VBD>
a <DT>
2 <CD>
1/2-fold <JJ>
increased <VBN>
leukemia_risk <NN>
. <.>
Leukemia <NNP>
is <VBZ>
a <DT>
bone-marrow <JJ>
cancer <NN>
in <IN>
which <WDT>
the <DT>
marrow <NN>
is <VBZ>
replaced <VBN>
by <IN>
immature <NN>
, <,>
abnormal_white <JJ>
blood <NN>
cells <NNS>
. <.>
Leukemia <NNP>
is <VBZ>
a <DT>
relatively <RB>
uncommon <JJ>
tumor <NN>
compared <VBN>
to <TO>
breast <VB>
, <,>
colon <NN>
or <CC>
lung <JJ>
cancer <NN>
. <.>
Each <DT>
year <NN>
, <,>
there <EX>
are <VBP>
about <IN>
27 <CD>
, <,>
000 <CD>
newly <RB>
diagnosed <VBN>
cases <NNS>
and <CC>
18 <CD>
, <,>
000 <CD>
deaths <NNS>
attributed <VBD>
to <TO>
leukemia <VB>
in <IN>
the <DT>
United <NNP>
States <NNPS>
. <.>
According <VBG>
to <TO>
Heath <NNP>
, <,>
until <IN>
1986 <CD>
it <PRP>
was <VBD>
generally <RB>
accepted <VBN>
that <IN>
tobacco_use <NN>
was <VBD>
not <RB>
a <DT>
significant <JJ>
cause <NN>
of <IN>
leukemia <NN>
. <.>
Since <IN>
1988 <CD>
, <,>
several <JJ>
studies <NNS>
, <,>
including <VBG>
a <DT>
large <JJ>
study <NN>
of <IN>
U.S. <NNP>
military <JJ>
veterans <NNS>
and <CC>
two <CD>
American <JJ>
Cancer_Society <NNP>
studies <NNS>
, <,>
had <VBD>
provided <VBN>
preliminary <JJ>
evidence <NN>
of <IN>
a <DT>
link <NN>
. <.>
The <DT>
causes <NNS>
of <IN>
leukemia <NN>
are <VBP>
largely <RB>
unknown <VBN>
. <.>
Those_that <DT>
have <VBP>
been_identified <VBN>
, <,>
such <JJ>
as <IN>
the <DT>
chemical <JJ>
benzene <NN>
and <CC>
ionizing <VBG>
radiation <NN>
, <,>
appear <VBP>
to <TO>
account <NN>
for <IN>
only <RB>
a <DT>
small <JJ>
percentage <NN>
of <IN>
cases <NNS>
, <,>
according <VBG>
to <TO>
Heath <NNP>
. <.>
The <DT>
Loma_Linda <NNP>
study <NN>
calculated <VBD>
that_about <IN>
20 <CD>
% <NN>
of <IN>
leukemia <NN>
cases <NNS>
were <VBD>
associated <VBN>
with <IN>
prior <RB>
smoking <VBG>
. <.>
In <IN>
all <DT>
, <,>
there <EX>
were <VBD>
46 <CD>
new <JJ>
cases <NNS>
of <IN>
leukemia <NN>
diagnosed <VBN>
during <IN>
the <DT>
six-year <JJ>
study_period <NN>
. <.>
On <IN>
the <DT>
basis <NN>
of <IN>
this <DT>
and <CC>
earlier <JJR>
preliminary <JJ>
studies <NNS>
, <,>
Heath <NNP>
estimated <VBD>
that_from <IN>
20 <CD>
% <NN>
to <TO>
30 <CD>
% <NN>
of <IN>
leukemia <NN>
cases <NNS>
may <MD>
be <VB>
linked <VBN>
to <TO>
smoking <NN>
. <.>
Because <IN>
cigarette <NN>
smoking <VBG>
is <VBZ>
very <RB>
common <JJ>
in <IN>
the <DT>
general <JJ>
population <NN>
-- <:>
more <RBR>
than <IN>
25 <CD>
% <NN>
of <IN>
adults <NNS>
smoke <VBP>
-- <:>
the <DT>
proportion <NN>
of <IN>
total <JJ>
leukemia_risk <NN>
that <WDT>
may <MD>
be <VB>
attributed <VBN>
to <TO>
cigarette <VB>
smoking <NN>
is <VBZ>
significant <JJ>
, <,>
according <VBG>
to <TO>
the <DT>
researchers <NNS>
. <.>
In <IN>
a <DT>
related <JJ>
finding <NN>
, <,>
the <DT>
Loma_Linda <NNP>
researchers <NNS>
found <VBD>
that <IN>
ex-smokers <NNS>
among <IN>
the <DT>
Adventists <NNPS>
had <VBD>
a <DT>
threefold <NN>
increased <VBN>
risk <NN>
of <IN>
developing <VBG>
myeloma <NN>
, <,>
another <DT>
bone-marrow_tumor <NN>
, <,>
as <IN>
compared <VBN>
to <TO>
individuals <NNS>
who <WP>
had <VBD>
never <RB>
smoked <VBN>
. <.>
Mills <NNS>
cautioned <VBD>
that <IN>
this <DT>
result <NN>
should <MD>
be <VB>
considered <VBN>
`` <``>
preliminary <JJ>
'' <''>
because <IN>
it <PRP>
was <VBD>
based <VBN>
on <IN>
23 <CD>
cases <NNS>
. <.>
Previously <RB>
, <,>
this <DT>
association <NN>
has <VBZ>
not <RB>
been <VBN>
closely <RB>
examined <VBN>
. <.>
The <DT>
Adventist_Health_Study <NNP>
began <VBD>
in <IN>
1974 <CD>
. <.>
Participants <NNS>
in <IN>
the <DT>
current <JJ>
study <NN>
completed <VBN>
a <DT>
questionnaire <NN>
about <IN>
their <PRP$>
lifestyle <NN>
in <IN>
1976 <CD>
and <CC>
were <VBD>
followed <VBN>
for <IN>
the <DT>
development <NN>
of <IN>
new <JJ>
cancers <NNS>
through <IN>
the <DT>
end <NN>
of <IN>
1982 <CD>
SJMN91-06024248 <DOCNO>
. <.>
Because <IN>
no <DT>
one <NN>
knows <VBZ>
how <WRB>
dioxin <NN>
causes <NNS>
cancer <NN>
, <,>
`` <``>
one <CD>
can <MD>
never <RB>
say <VB>
there <EX>
is <VBZ>
no <DT>
risk <NN>
. <.>
It <PRP>
would <MD>
appear <VB>
that_for <IN>
groups <NNS>
with <IN>
lower <JJR>
exposure <NN>
, <,>
the <DT>
risk <NN>
is <VBZ>
lower <JJR>
, <,>
but <CC>
it <PRP>
does <VBZ>
n't <RB>
say <VB>
there <EX>
is <VBZ>
no <DT>
risk <NN>
, <,>
'' <''>
said <VBD>
Dr._Marilyn_A._Fingerhut <NNP>
, <,>
an <DT>
epidemiologist <NN>
who <WP>
led <VBN>
the <DT>
study <NN>
. <.>
; <:>
The <DT>
cancer-causing <JJ>
potential <NN>
of <IN>
dioxin <NN>
is <VBZ>
of <IN>
concern <NN>
, <,>
in <IN>
part <NN>
, <,>
because <IN>
it <PRP>
was <VBD>
a <DT>
contaminant <JJ>
of <IN>
Agent_Orange <NNP>
, <,>
a <DT>
tree-killing <JJ>
chemical <NN>
used <VBN>
widely <RB>
during <IN>
the <DT>
Vietnam_War <NNP>
. <.>
Soldiers <NNS>
who <WP>
were <VBD>
sprayed <VBN>
with <IN>
it <PRP>
regularly <RB>
had <VBD>
far <RB>
less <JJR>
exposure <NN>
than <IN>
most <JJS>
of <IN>
the <DT>
chemical <JJ>
workers <NNS>
studied <VBD>
. <.>
; <:>
PARENTS <NNS>
' <POS>
SMOKING <NN>
LINKED <NNP>
TO <TO>
CHILDREN <NNP>
'S <POS>
HEALTH_RISK <NNP>
; <:>
Fathers <NNP>
who <WP>
smoke <NN>
have <VBP>
an <DT>
increased <VBN>
risk <NN>
of <IN>
having <VBG>
children <NNS>
with <IN>
brain_cancer <NN>
and <CC>
leukemia <NN>
, <,>
suggesting <VBG>
that <IN>
smoking <NN>
might <MD>
have <VB>
damaged <VBN>
the <DT>
fathers <NNS>
' <POS>
sperm <NN>
, <,>
researchers <NNS>
said <VBD>
Wednesday <NNP>
. <.>
; <:>
That <DT>
conclusion <NN>
is <VBZ>
speculative <JJ>
, <,>
said <VBD>
one <CD>
of <IN>
the <DT>
study <NN>
's <POS>
authors <NNS>
, <,>
Dale_P._Sandler <NNP>
of <IN>
the <DT>
National_Institute <NNP>
of <IN>
Environmental_Health <NNP>
Sciences <NNPS>
in <IN>
Research_Triangle_Park <NNP>
, <,>
N.C <NNP>
. <.>
But <CC>
the <DT>
study <NN>
points <NNS>
to <TO>
the <DT>
possibility <NN>
of <IN>
an <DT>
effect <NN>
on <IN>
sperm <NN>
, <,>
`` <``>
and <CC>
another <DT>
study <NN>
with <IN>
bigger <JJR>
numbers <NNS>
ought <MD>
to <TO>
look <VB>
at <IN>
it <PRP>
carefully <RB>
, <,>
'' <''>
she <PRP>
said <VBD>
. <.>
; <:>
In <IN>
a <DT>
separate <JJ>
study <NN>
, <,>
doctors <NNS>
found <VBD>
that <IN>
children <NNS>
whose <WP$>
parents <NNS>
smoke_are <VBP>
three <CD>
to <TO>
four <CD>
times <NNS>
as <RB>
likely <JJ>
as <IN>
other <JJ>
children <NNS>
to <TO>
develop <VB>
serious_infectious <JJ>
diseases <NNS>
requiring <VBG>
hospitalization <NN>
. <.>
; <:>
`` <``>
I <PRP>
do <VBP>
n't <RB>
think <VB>
anyone <NN>
before <IN>
has <VBZ>
demonstrated <VBN>
that <IN>
the <DT>
association <NN>
is <VBZ>
not_just <RB>
for <IN>
mild <NN>
illnesses <NNS>
but <CC>
for <IN>
really <RB>
serious <JJ>
infections <NNS>
as <IN>
well <RB>
, <,>
'' <''>
said <VBD>
Anne_T._Berg <NNP>
of <IN>
the <DT>
Yale_University_School <NNP>
of <IN>
Medicine <NNP>
, <,>
the <DT>
principal <JJ>
author <NN>
of <IN>
the <DT>
study <NN>
. <.>
; <:>
SYNTHETIC_GENE_MAY_AID_MUSCULAR_DYSTROPHY_WAR <NNP>
; <:>
Scientists <NNP>
have <VBP>
made <VBN>
a <DT>
synthetic <JJ>
form <NN>
of <IN>
the <DT>
gene <NN>
linked <VBD>
to <TO>
the <DT>
most <JJS>
severe <JJ>
kind <NN>
of <IN>
muscular <JJ>
dystrophy <NN>
, <,>
a <DT>
`` <``>
milestone <NN>
'' <''>
step <VB>
toward <IN>
gene_therapy <NN>
for <IN>
the <DT>
disease <NN>
. <.>
; <:>
The <DT>
gene <NN>
, <,>
made <VBN>
from <IN>
mouse <NN>
genetic <JJ>
material <NN>
, <,>
was <VBD>
shown <VBN>
to <TO>
work <VB>
in <IN>
experimental <JJ>
cells <NNS>
. <.>
; <:>
Scientists <NNS>
said <VBD>
the <DT>
accomplishment <NN>
boosts <VBZ>
prospects <NNS>
for <IN>
treating <VBG>
Duchenne <NNP>
dystrophy <NN>
, <,>
the <DT>
most <RBS>
devastating <JJ>
and <CC>
common <JJ>
form <NN>
, <,>
by <IN>
supplying_muscle <NN>
cells <NNS>
with <IN>
a <DT>
functioning <VBG>
version <NN>
of <IN>
the <DT>
gene <NN>
. <.>
Duchenne <NNP>
appears <VBZ>
when <WRB>
people <NNS>
lack <VBP>
a <DT>
functioning_version <NN>
. <.>
; <:>
But <CC>
creating <VBG>
the <DT>
gene <NN>
is <VBZ>
still <RB>
`` <``>
a <DT>
long <JJ>
way <NN>
from <IN>
putting <VBG>
it <PRP>
into <IN>
a <DT>
patient <NN>
, <,>
'' <''>
cautioned <VBD>
Louis_Kunkel <NNP>
of <IN>
Children <NNP>
's <POS>
Hospital <NNP>
in <IN>
Boston <NNP>
, <,>
Harvard_Medical_School <NNP>
and <CC>
the <DT>
Hughes <NNPS>
institute <NN>
there <RB>
. <.>
; <:>
AIDS-TYPE <JJ>
FUNGUS_HITS_PEOPLE_WITHOUT_DISEASE <NNP>
; <:>
A <DT>
fungus <NN>
that <WDT>
is <VBZ>
the <DT>
leading <VBG>
cause <NN>
of <IN>
fatal <JJ>
infections <NNS>
among <IN>
AIDS <NNP>
patients <NNS>
has <VBZ>
afflicted <VBN>
a <DT>
small <JJ>
number <NN>
of <IN>
elderly <RB>
New <NNP>
Yorkers <NNPS>
without <IN>
AIDS <NNP>
, <,>
and <CC>
experts <NNS>
do <VBP>
not <RB>
know <VB>
why <WRB>
, <,>
according <VBG>
to <TO>
a <DT>
report <NN>
published <VBD>
today <NN>
. <.>
; <:>
The <DT>
fungus <NN>
, <,>
pneumocystis <VBZ>
carinii <NN>
, <,>
causes <NNS>
pneumocystis <VBZ>
pneumonia <NN>
, <,>
or <CC>
PCP <NNP>
, <,>
which <WDT>
rarely <RB>
has <VBZ>
struck <NN>
people <NNS>
with <IN>
a <DT>
healthy <JJ>
immune_system <NN>
. <.>
Yet <CC>
none <NN>
of <IN>
the <DT>
five <CD>
elderly <RB>
patients <NNS>
reported <VBD>
with <IN>
PCP <NNP>
had <VBD>
a <DT>
faulty_immune_system <NN>
AP880519-0175 <DOCNO>
. <.>
People <NNS>
infected <VBD>
by <IN>
the <DT>
AIDS <NNP>
virus <VBZ>
may <MD>
be <VB>
more <RBR>
likely <JJ>
to <TO>
go <VB>
on <IN>
to <TO>
develop <VB>
the <DT>
deadly <RB>
disease <NN>
if <IN>
they <PRP>
also <RB>
are <VBP>
infected <VBN>
by <IN>
a <DT>
related <JJ>
virus <NN>
that <WDT>
can <MD>
cause <VB>
a <DT>
particularly <RB>
fatal <JJ>
form <NN>
of <IN>
leukemia <NN>
, <,>
a <DT>
study <NN>
says <VBZ>
. <.>
`` <``>
These <DT>
laboratory <NN>
results <NNS>
suggest <VBP>
that <IN>
doubly <RB>
infected <VBN>
individuals <NNS>
have <VBP>
a <DT>
worse_prognosis <NN>
for <IN>
developing <VBG>
AIDS <NNP>
'' <''>
than <IN>
those <DT>
who <WP>
are <VBP>
infected <VBN>
only <RB>
by <IN>
the <DT>
AIDS <NNP>
virus <VBZ>
, <,>
said <VBD>
molecular <JJ>
virologist <NN>
Irvin_S.Y <NNP>
. <.>
Chen <NNP>
, <,>
who <WP>
published <VBD>
his <PRP$>
study <NN>
in <IN>
Friday <NNP>
's <POS>
issue <NN>
of <IN>
the <DT>
journal <NN>
Science <NNP>
. <.>
`` <``>
The <DT>
chances <NNS>
of <IN>
any <DT>
individual <JJ>
being <VBG>
infected <VBN>
by <IN>
both <DT>
viruses <NNS>
are <VBP>
very <RB>
slim <JJ>
, <,>
but <CC>
among <IN>
selected <VBN>
populations <NNS>
, <,>
such <JJ>
as <IN>
intravenous <JJ>
drug <NN>
abusers <NNS>
, <,>
the <DT>
chances <NNS>
are <VBP>
quite <RB>
high <JJ>
, <,>
'' <''>
said <VBD>
Chen <NNP>
, <,>
of <IN>
the <DT>
University <NNP>
of <IN>
California <NNP>
, <,>
Los_Angeles <NNP>
. <.>
Except_among <IN>
IV <NNP>
drug <NN>
abusers <NNS>
, <,>
the <DT>
leukemia <NN>
virus_is <VBZ>
quite <RB>
rare <JJ>
in <IN>
the <DT>
United <NNP>
States <NNPS>
. <.>
It <PRP>
is <VBZ>
fairly <RB>
common <JJ>
in <IN>
southern <NN>
Japan <NNP>
, <,>
the <DT>
Caribbean <NNP>
and <CC>
parts <NNS>
of <IN>
Africa <NNP>
, <,>
Chen <NNP>
said <VBD>
. <.>
So <IN>
the <DT>
study <NN>
suggests <VBZ>
that <IN>
people <NNS>
in <IN>
those <DT>
areas <NNS>
may <MD>
be <VB>
more <RBR>
likely <JJ>
to <TO>
develop <VB>
full-fledged <JJ>
AIDS <NNS>
if <IN>
they <PRP>
are <VBP>
exposed <VBN>
to <TO>
the <DT>
AIDS <NNP>
virus <VBZ>
. <.>
But <CC>
more <RBR>
study <JJ>
of <IN>
people <NNS>
infected <VBN>
by <IN>
both <DT>
viruses <NNS>
must <MD>
be <VB>
done <VBN>
to <TO>
confirm <VB>
the <DT>
suspicion <NN>
raised <VBD>
by <IN>
laboratory <NN>
studies <NNS>
, <,>
said <VBD>
Dr._Stanley_H._Weiss <NNP>
, <,>
chief <NN>
of <IN>
AIDS <NNP>
epidemiology <NN>
at <IN>
New_Jersey_Medical_School <NNP>
in <IN>
Newark <NNP>
. <.>
Weiss <NNP>
is <VBZ>
already <RB>
undertaking <VBG>
such <JJ>
research <NN>
in <IN>
the <DT>
Newark <NNP>
and <CC>
New_York <NNP>
area <NN>
. <.>
Acquired <NNP>
immune_deficiency_syndrome <NN>
is <VBZ>
caused <VBN>
by <IN>
the <DT>
human <JJ>
immunodeficiency <NN>
virus <VBZ>
, <,>
or <CC>
HIV <NNP>
, <,>
which <WDT>
usually <RB>
remains <VBZ>
dormant <JJ>
in <IN>
infected <JJ>
people <NNS>
for <IN>
years <NNS>
before <IN>
it <PRP>
may <MD>
be <VB>
activated <VBN>
to <TO>
cause <VB>
full-fledged <JJ>
AIDS <NNS>
, <,>
which <WDT>
cripples <NNS>
the <DT>
disease-fighting <JJ>
immune_system <NN>
. <.>
Previous <JJ>
studies <NNS>
suggested <VBD>
almost <RB>
any <DT>
infection <NN>
may <MD>
help <VB>
trigger <JJR>
the <DT>
dormant <JJ>
AIDS <NNP>
virus <NN>
into <IN>
an <DT>
active <JJ>
killer <NN>
. <.>
Chen <NNP>
and <CC>
his <PRP$>
colleagues <NNS>
performed <VBD>
experiments <NNS>
in <IN>
laboratory_culture <NN>
dishes <NNS>
showing <VBG>
that <IN>
AIDS-infected_white <JJ>
blood <NN>
cells <NNS>
called <VBN>
T <NNP>
cells <NNS>
produce <VBP>
large <JJ>
amounts <NNS>
of <IN>
active <JJ>
AIDS <NNS>
virus <VBZ>
if <IN>
the <DT>
cells <NNS>
also <RB>
are <VBP>
exposed <VBN>
to <TO>
the <DT>
human <JJ>
T-cell_leukemia <NN>
virus <VBZ>
type <NN>
I <PRP>
, <,>
or <CC>
HTLV-I <NNP>
. <.>
People <NNS>
infected <VBD>
by <IN>
HTLV-I <NNP>
have <VBP>
a <DT>
1 <CD>
percent_lifetime_chance <NN>
of <IN>
developing <VBG>
a <DT>
blood_cancer <NN>
called <VBN>
adult <NN>
T-cell <NNP>
leukemia <NN>
, <,>
which <WDT>
often <RB>
kills <VBZ>
quickly <RB>
. <.>
It <PRP>
is <VBZ>
an <DT>
important <JJ>
cause <NN>
of <IN>
leukemia <NN>
in <IN>
southern <NN>
Japan <NNP>
and <CC>
the <DT>
Caribbean <NNP>
. <.>
HTLV-I <NN>
also <RB>
is <VBZ>
linked <VBN>
to <TO>
a <DT>
potentially <RB>
fatal <JJ>
, <,>
degenerative <JJ>
nerve_disease <NN>
that <WDT>
causes <VBZ>
spasticity <NN>
and <CC>
paralysis <NN>
of <IN>
the <DT>
legs <NNS>
. <.>
Last <JJ>
month <NN>
, <,>
the <DT>
American_Red_Cross <NNP>
recommended <VBD>
that <IN>
all <DT>
donated <VBN>
blood <NN>
be <VB>
tested <VBN>
for <IN>
HTLV-I <NNP>
as <IN>
soon <RB>
as <IN>
scientists <NNS>
develop <VB>
a <DT>
practical <JJ>
test <NN>
. <.>
A <DT>
Red_Cross <NNP>
study <NN>
found <VBD>
about <IN>
one <CD>
out_of <IN>
every <DT>
4 <CD>
, <,>
286 <CD>
units <NNS>
of <IN>
donated <VBN>
blood <NN>
carries <NNS>
HTLV-I <-NONE->
. <.>
The <DT>
risk <NN>
of <IN>
AIDS <NNP>
virus <NN>
in <IN>
blood <NN>
has <VBZ>
been_reduced <VBN>
to <TO>
about <IN>
one <CD>
in <IN>
40 <CD>
, <,>
000 <CD>
units <NNS>
because <IN>
donors <NNS>
are <VBP>
tested <VBN>
for <IN>
signs <NNS>
of <IN>
AIDS <NNP>
infection <NN>
. <.>
A <DT>
study <NN>
performed <VBN>
by <IN>
Weiss <NNP>
when <WRB>
he <PRP>
worked <VBD>
for <IN>
the <DT>
National_Cancer_Institute <NNP>
showed <VBD>
HTLV-I <NNP>
is <VBZ>
spreading <VBG>
among <IN>
intravenous <JJ>
drug <NN>
abusers <NNS>
, <,>
with <IN>
infection <NN>
rates <NNS>
of <IN>
12 <CD>
percent <NN>
among <IN>
New_Jersey <NNP>
addicts <NNS>
, <,>
33 <CD>
percent <NN>
among <IN>
New_Orleans <NNP>
addicts <NNS>
overall <VBP>
, <,>
and <CC>
49 <CD>
percent <NN>
among <IN>
black <JJ>
addicts <NNS>
in <IN>
New_Orleans <NNP>
. <.>
Intravenous <JJ>
drug <NN>
addicts <NNS>
also <RB>
are <VBP>
high <JJ>
risk <NN>
for <IN>
infection <NN>
by <IN>
the <DT>
AIDS <NNP>
virus <VBZ>
, <,>
which <WDT>
also <RB>
is <VBZ>
spread <VBN>
in <IN>
blood <NN>
on <IN>
shared <VBN>
needles <NNS>
and <CC>
by <IN>
sexual <JJ>
contact <NN>
. <.>
Infection <NN>
by <IN>
HTLV-I <NNP>
apparently <RB>
activates <VBZ>
the <DT>
AIDS <NNP>
virus <VBZ>
by <IN>
stimulating <NN>
AIDS-infected <JJ>
white_blood <NN>
cells <NNS>
to <TO>
divide <VB>
, <,>
according <VBG>
to <TO>
the <DT>
study <NN>
Chen <NNP>
performed <VBD>
with <IN>
molecular <JJ>
virologists <NNS>
Jerome_Zack <NNP>
, <,>
Alan_Cann <NNP>
and <CC>
James_Lugo <NNP>
. <.>
While <IN>
the <DT>
study <NN>
in <IN>
Science <NNP>
deals <NNS>
only <RB>
with <IN>
HTLV-I <JJ>
, <,>
unpublished <JJ>
laboratory <NN>
results <NNS>
suggest <VBP>
full-fledged <JJ>
AIDS <NNS>
also <RB>
may <MD>
be <VB>
triggered <VBN>
in <IN>
AIDS-infected <JJ>
people <NNS>
who <WP>
also <RB>
are <VBP>
infected <VBN>
by <IN>
HTLV-II <NNP>
, <,>
an <DT>
extremely <RB>
rare <JJ>
virus <NN>
that <WDT>
can <MD>
cause <VB>
another <DT>
type <NN>
of <IN>
leukemia <NN>
. <.>
The <DT>
AIDS <NNP>
virus_is <VBZ>
distantly <RB>
related <VBN>
to <TO>
the <DT>
leukemia <NN>
viruses <VBZ>
. <.>
Dr._Edward_L._Murphy_Jr. <NNP>
, <,>
a <DT>
National_Cancer_Institute <NNP>
expert <NN>
on <IN>
HTLV-I <NNP>
, <,>
agreed <VBD>
with <IN>
Chen <NNP>
that <IN>
the <DT>
problem <NN>
of <IN>
dual <JJ>
infection <NN>
by <IN>
the <DT>
AIDS <NNP>
and <CC>
leukemia <NN>
viruses <NNS>
is <VBZ>
mainly <RB>
a <DT>
problem <NN>
for <IN>
U.S. <NNP>
drug <NN>
addicts <NNS>
and <CC>
for <IN>
people <NNS>
in <IN>
areas <NNS>
such <JJ>
as <IN>
the <DT>
Caribbean <NNP>
AP881104-0025 <DOCNO>
. <.>
An <DT>
early <JJ>
look <NN>
at <IN>
a <DT>
six-year <JJ>
study <NN>
of <IN>
the <DT>
health <NN>
effects <NNS>
of <IN>
radioactive <JJ>
fallout <IN>
shows <NNS>
`` <``>
no <DT>
strong <JJ>
evidence <NN>
'' <''>
of <IN>
a <DT>
link <NN>
between <IN>
exposure <NN>
and <CC>
leukemia <NN>
and <CC>
thyroid <VBD>
disorders <NNS>
, <,>
the <DT>
project <NN>
's <POS>
director <NN>
says <VBZ>
. <.>
The <DT>
$ <$>
7_million <CD>
study <NN>
, <,>
funded <VBD>
by <IN>
the <DT>
National_Cancer_Institute <NNP>
, <,>
is <VBZ>
intended <VBN>
to <TO>
determine <VB>
whether <IN>
people <NNS>
living <VBG>
downwind <NN>
of <IN>
above-ground_atomic <JJ>
bomb <NN>
tests <NNS>
in <IN>
Nevada <NNP>
in <IN>
the <DT>
1950s <CD>
and <CC>
1960s <CD>
suffered <VBD>
an <DT>
increased <VBN>
rate <NN>
of <IN>
cancer <NN>
. <.>
Because <IN>
all_the <DT>
data <NNS>
has <VBZ>
not <RB>
been_tabulated <VBN>
, <,>
it <PRP>
is <VBZ>
not <RB>
possible <JJ>
to <TO>
say <VB>
definitely <RB>
`` <``>
there <EX>
is <VBZ>
or <CC>
is <VBZ>
not <RB>
an <DT>
effect <NN>
, <,>
'' <''>
said <VBD>
Dr._Walter_Stevens <NNP>
, <,>
interim <JJ>
dean <NN>
of <IN>
the <DT>
University <NNP>
of <IN>
Utah_Medical_School <NNP>
and <CC>
director <NN>
of <IN>
the <DT>
study <NN>
. <.>
However <RB>
, <,>
he <PRP>
said <VBD>
Thursday <NNP>
there <RB>
is <VBZ>
`` <``>
no <DT>
strong <JJ>
evidence <NN>
that <IN>
would <MD>
convince <VB>
me <PRP>
... <:>
that <IN>
there <EX>
was <VBD>
a <DT>
relationship <NN>
'' <''>
between_fallout <IN>
and <CC>
disease <NN>
. <.>
Stevens <NNS>
emphasized <VBD>
that <IN>
epidemiological <JJ>
findings <NNS>
still <RB>
are <VBP>
being <VBG>
analyzed <VBN>
and <CC>
that <IN>
no <DT>
final <JJ>
conclusions <NNS>
would <MD>
be <VB>
drawn <VBN>
until <IN>
a <DT>
draft_report <NN>
had <VBD>
been_reviewed <VBN>
by <IN>
the <DT>
National_Cancer_Institute <NNP>
. <.>
The <DT>
draft <NN>
likely <JJ>
will <MD>
be <VB>
delivered <VBN>
to <TO>
NCI <NNP>
by <IN>
mid-November <NNP>
and <CC>
the <DT>
finished <JJ>
report <NN>
released <VBN>
next <JJ>
March <NNP>
, <,>
he <PRP>
said <VBD>
. <.>
For <IN>
years <NNS>
, <,>
people <NNS>
living <VBG>
in <IN>
southwestern <NN>
Utah <NNP>
, <,>
southeastern <JJ>
Nevada <NNP>
and <CC>
northeastern <VB>
Arizona <NNP>
have <VB>
feared <VBN>
that <IN>
exposure <NN>
to <TO>
about <IN>
80 <CD>
open-air <JJ>
tests <NNS>
at <IN>
the <DT>
Nevada_Test_Site <NNP>
had <VBD>
increased <VBN>
the <DT>
potential <JJ>
for <IN>
leukemia <NN>
and <CC>
thyroid <VBD>
cancers <NNS>
. <.>
In <IN>
1979 <CD>
, <,>
Dr._Joseph_L._Lyon <NNP>
, <,>
an <DT>
University <NNP>
of <IN>
Utah <NNP>
epidemiologist <NN>
who <WP>
is <VBZ>
working <VBG>
on <IN>
the <DT>
current <JJ>
study <NN>
, <,>
published <VBD>
a <DT>
paper <NN>
showing <VBG>
a <DT>
2.4-fold <JJ>
increase <NN>
in <IN>
childhood_leukemia <NN>
in <IN>
the <DT>
areas <NNS>
of <IN>
southern <NN>
Utah <NNP>
heavily <RB>
dusted <VBN>
by_fallout <IN>
. <.>
Meanwhile <RB>
, <,>
nearly <RB>
1 <CD>
, <,>
200 <CD>
people <NNS>
living <VBG>
downwind <NN>
of <IN>
the <DT>
tests <NNS>
sued <VBD>
the <DT>
federal <JJ>
government <NN>
, <,>
claiming <VBG>
that <IN>
exposure <NN>
to <TO>
fallout <VB>
caused <VBN>
sickness <NN>
and <CC>
death <NN>
. <.>
In <IN>
1982 <CD>
, <,>
U.S._District_Judge_Bruce_Jenkins <NNP>
ruled <VBD>
the <DT>
government <NN>
had <VBD>
failed <VBN>
to <TO>
warn <VB>
residents <NNS>
of <IN>
radiation <NN>
hazards <NNS>
. <.>
However <RB>
, <,>
the <DT>
10th <JJ>
U.S <NNS>
. <.>
Circuit <NN>
Court <NNP>
of <IN>
Appeals <NNPS>
overturned <VBN>
the <DT>
ruling <NN>
and <CC>
the <DT>
U.S._Supreme_Court <NNP>
concurred <VBD>
, <,>
saying <VBG>
the <DT>
government <NN>
was <VBD>
immune <JJ>
from <IN>
damages <NNS>
. <.>
The <DT>
latest <JJS>
study <NN>
was <VBD>
conducted <VBN>
in <IN>
two <CD>
parts <NNS>
_ <NNP>
one <CD>
for <IN>
leukemia <NN>
and <CC>
the <DT>
other <JJ>
for <IN>
thyroid <JJ>
disorders <NNS>
_ <NNP>
and <CC>
was <VBD>
designed <VBN>
as <IN>
the <DT>
most <RBS>
comprehensive <JJ>
undertaking <NN>
of <IN>
its <PRP$>
kind <NN>
. <.>
Researchers <NNS>
located <VBD>
the <DT>
names <NNS>
of <IN>
1 <CD>
, <,>
177 <CD>
people <NNS>
from <IN>
all <DT>
over <IN>
Utah <NNP>
who <WP>
had <VBD>
died <VBN>
of <IN>
leukemia <NN>
between <IN>
1952 <CD>
and <CC>
1966 <CD>
and <CC>
selected <VBN>
as <IN>
controls <NNS>
another <DT>
5 <CD>
, <,>
600 <CD>
people <NNS>
who <WP>
had <VBD>
died <VBN>
of <IN>
other <JJ>
causes <NNS>
. <.>
The <DT>
subjects <NNS>
were <VBD>
matched <VBN>
where <WRB>
possible <JJ>
in <IN>
age <NN>
, <,>
residence <NN>
, <,>
health <NN>
and <CC>
lifestyle <NN>
to <TO>
ensure <VB>
valid <JJ>
comparisons <NNS>
, <,>
Stevens <NNP>
said <VBD>
. <.>
In <IN>
the <DT>
thyroid <JJ>
study <NN>
, <,>
2 <CD>
, <,>
829 <CD>
subjects <NNS>
in <IN>
southern <NN>
Utah <NNP>
, <,>
southeastern <JJ>
Nevada <NNP>
and <CC>
southern <VB>
Arizona <NNP>
were <VBD>
identified <VBN>
as <IN>
having <NN>
been_exposed <VBN>
, <,>
and <CC>
about <IN>
280 <CD>
were <VBD>
found <VBN>
to <TO>
have <VB>
thyroid <JJ>
abnormalities <NNS>
. <.>
Scientists <NNS>
closely <RB>
researched <VBN>
production_distribution <NN>
and <CC>
consumption <NN>
of <IN>
milk <NN>
, <,>
thought <VBD>
to <TO>
be <VB>
one <CD>
of <IN>
the <DT>
primary <JJ>
ways_children <NNS>
might <MD>
have <VB>
ingested <VBN>
radioactive <JJ>
materials <NNS>
from_fallout <IN>
. <.>
Stevens <NNS>
said <VBD>
the <DT>
research <NN>
has <VBZ>
been <VBN>
greatly <RB>
aided <VBN>
by <IN>
the <DT>
release <NN>
of <IN>
previously <RB>
classified <VBN>
information <NN>
from <IN>
the <DT>
Department <NNP>
of <IN>
Energy <NNP>
on <IN>
the <DT>
amount <NN>
of <IN>
radiation <NN>
emitted <VBN>
by <IN>
the <DT>
tests <NNS>
. <.>
Stevens <NNS>
said <VBD>
the <DT>
study <NN>
could <MD>
prove <VB>
to <TO>
be <VB>
a <DT>
milestone <NN>
in <IN>
research <NN>
on <IN>
the <DT>
effects <NNS>
of <IN>
exposure <NN>
to <TO>
radiation <NN>
, <,>
with <IN>
particular <JJ>
significance <NN>
to <TO>
safety <NN>
concerns <NNS>
at <IN>
the <DT>
nation <NN>
's <POS>
nuclear <JJ>
production <NN>
plants <NNS>
AP880414-0254 <DOCNO>
. <.>
A <DT>
pharmaceutical <JJ>
company <NN>
said <VBD>
Thursday <NNP>
it <PRP>
has <VBZ>
begun <VBN>
selling <VBG>
a <DT>
new <JJ>
leukemia_drug <NN>
, <,>
the <DT>
fourth_new <JJ>
cancer_agent <NN>
since <IN>
1983 <CD>
and <CC>
the <DT>
third <JJ>
leukemia_drug <NN>
in <IN>
10 <CD>
years <NNS>
to <TO>
gain <VB>
federal <JJ>
approval <NN>
. <.>
Novantrone <NNP>
mitoxantrone_hydrochloride <NN>
is <VBZ>
to <TO>
be <VB>
used <VBN>
in <IN>
combination <NN>
with <IN>
other <JJ>
agents <NNS>
for <IN>
treating <VBG>
adults <NNS>
with <IN>
acute_nonlymphocytic <JJ>
leukemia <NN>
, <,>
Lederle <NNP>
Laboratories <NNPS>
said <VBD>
in <IN>
a <DT>
statement <NN>
. <.>
The <DT>
disease <NN>
strikes <VBZ>
about <IN>
8 <CD>
, <,>
000 <CD>
Americans <NNS>
a <DT>
year <NN>
, <,>
the <DT>
statement <NN>
said <VBD>
. <.>
The <DT>
drug <NN>
apparently <RB>
disrupts <VBZ>
the <DT>
functioning <NN>
of <IN>
genetic <JJ>
material <NN>
in <IN>
cancer <NN>
cells <NNS>
, <,>
the <DT>
company <NN>
said <VBD>
. <.>
Novantrone <NNP>
was <VBD>
approved <VBN>
by <IN>
the <DT>
Food <NNP>
and <CC>
Drug_Administration <NNP>
in <IN>
1987 <CD>
, <,>
but <CC>
the <DT>
agency <NN>
's <POS>
official_rating <NN>
of <IN>
the <DT>
drug <NN>
indicates <VBZ>
it <PRP>
represents <VBZ>
little <JJ>
or <CC>
no <DT>
advantage <NN>
over <IN>
other <JJ>
treatments <NNS>
. <.>
The <DT>
other <JJ>
three <CD>
new <JJ>
cancer <NN>
drugs <NNS>
approved <VBD>
in <IN>
the <DT>
past <JJ>
five <CD>
years <NNS>
are <VBP>
etoposide <JJ>
for <IN>
testicular <JJ>
cancer <NN>
, <,>
approved <VBD>
in <IN>
1983 <CD>
; <:>
leuprolide <JJ>
acetate <NN>
for <IN>
advanced <JJ>
prostate_cancer <NN>
, <,>
1985 <CD>
; <:>
and <CC>
interferon <NN>
, <,>
approved <VBD>
in <IN>
1986 <CD>
to <TO>
fight_hairy_cell_leukemia <NN>
, <,>
said <VBD>
Dr._John_Johnson <NNP>
of <IN>
the <DT>
FDA <NNP>
. <.>
Lederle <NNP>
is <VBZ>
a <DT>
division <NN>
of <IN>
American <JJ>
Cyanamid_Co <NNP>
AP900810-0046 <DOCNO>
. <.>
A <DT>
college_student <NN>
with <IN>
leukemia <NN>
whose <WP$>
search <NN>
for <IN>
a <DT>
compatible <JJ>
bone-marrow_donor <NN>
drew <VBD>
celebrity_support <NN>
and <CC>
50 <CD>
, <,>
000 <CD>
volunteers <NNS>
underwent <NN>
a <DT>
last-ditch <JJ>
transplant <NN>
using <VBG>
her <PRP>
mother's <VBZ>
marrow <NN>
. <.>
Allison_Atlas <NNP>
, <,>
20 <CD>
, <,>
opted <VBN>
for <IN>
the <DT>
surgery <NN>
Thursday <NNP>
although <IN>
her <PRP$>
mother <NN>
's <POS>
tissue <NN>
is <VBZ>
not <RB>
a <DT>
perfect_match <NN>
. <.>
She <PRP>
said <VBD>
she <PRP>
wanted <VBD>
to <TO>
try <VB>
the <DT>
life-saving <JJ>
procedure <NN>
while <IN>
she <PRP>
was <VBD>
still_relatively <RB>
strong <JJ>
. <.>
Her <PRP$>
condition_today <NN>
at <IN>
Fred_Hutchinson_Cancer_Research_Center <NNP>
was <VBD>
withheld <VBN>
at <IN>
the <DT>
family <NN>
's <POS>
request <NN>
, <,>
said <VBD>
hospital <JJ>
spokeswoman <NN>
Alice_Burgess <NNP>
. <.>
The <DT>
transplant_team <NN>
was <VBD>
headed <VBN>
Dr._Edward_Agura <NNP>
. <.>
The <DT>
marrow <NN>
from <IN>
her <PRP$>
54-year-old <JJ>
mother <NN>
, <,>
Arline_Atlas <NNP>
, <,>
matched <VBD>
only <RB>
four <CD>
of <IN>
six <CD>
antigens <NNS>
, <,>
or <CC>
cell <NN>
identifiers <NNS>
, <,>
from <IN>
her <PRP$>
daughter's <NNS>
marrow <NN>
. <.>
The <DT>
operation <NN>
could <MD>
work <VB>
if <IN>
Miss_Atlas <NNP>
' <POS>
body <NN>
does <VBZ>
not <RB>
reject <VB>
her <PRP$>
mother <NN>
's <POS>
tissue <NN>
. <.>
`` <``>
They <PRP>
're <VBP>
both <DT>
fighters <NNS>
, <,>
'' <''>
said <VBD>
Sy_Atlas <NNP>
, <,>
a <DT>
cousin <NN>
. <.>
`` <``>
They're <JJ>
both <DT>
people <NNS>
who <WP>
are <VBP>
determined <VBN>
to <TO>
beat <VB>
the <DT>
odds <NNS>
. <.>
Arline <NNP>
was <VBD>
excited <VBN>
to <TO>
be <VB>
the <DT>
donor <NN>
for <IN>
her <PRP$>
daughter <NN>
. <.>
'' <''>
Miss_Atlas <NNP>
, <,>
a <DT>
student <NN>
at <IN>
New_York_University <NNP>
when <WRB>
she <PRP>
became <VBD>
ill <RB>
last <JJ>
year <NN>
, <,>
heightened <VBN>
awareness <NN>
of <IN>
the <DT>
need <NN>
for <IN>
bone-marrow <JJ>
donors <NNS>
with <IN>
a <DT>
publicity_campaign <NN>
that <WDT>
drew <VBD>
50 <CD>
, <,>
000 <CD>
volunteers <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
and <CC>
Israel <NNP>
. <.>
Supporters <NNS>
raised <VBD>
$ <$>
3_million <CD>
, <,>
including <VBG>
a <DT>
six-figure <JJ>
check <NN>
from <IN>
actor <NN>
Dustin_Hoffman <NNP>
, <,>
to <TO>
process <NN>
the <DT>
50 <CD>
, <,>
000 <CD>
blood <NN>
tests <NNS>
. <.>
No <DT>
match <NN>
was <VBD>
found <VBN>
for <IN>
Miss_Atlas <NNP>
, <,>
but <CC>
10 <CD>
other <JJ>
leukemia <NN>
patients <NNS>
were <VBD>
matched <VBN>
with <IN>
donors <NNS>
. <.>
Bone_marrow <NN>
provides <VBZ>
necessary <JJ>
components <NNS>
of <IN>
the <DT>
human <JJ>
immune_system <NN>
, <,>
and <CC>
transplant <JJ>
patients <NNS>
are <VBP>
at <IN>
high <JJ>
risk <NN>
of <IN>
infection <NN>
for <IN>
three <CD>
weeks <NNS>
after <IN>
the <DT>
operation <NN>
until <IN>
the <DT>
new <JJ>
marrow <NN>
begins <NNS>
to <TO>
work <VB>
. <.>
Miss_Atlas <NNP>
, <,>
of <IN>
Bethesda <NNP>
, <,>
Md. <NNP>
, <,>
will <MD>
recuperate <VB>
in <IN>
a <DT>
sterile_environment <NN>
at <IN>
the <DT>
cancer_center <NN>
, <,>
where <WRB>
more <JJR>
than <IN>
3 <CD>
, <,>
000 <CD>
bone-marrow <NN>
transplants <NNS>
have <VBP>
been_performed <VBN>
, <,>
more <RBR>
than <IN>
any <DT>
other_clinic <JJ>
. <.>
Anatoly <RB>
Grishchenko <NNP>
, <,>
a <DT>
leukemia-stricken_Soviet <JJ>
helicopter_pilot <NN>
who <WP>
flew <NN>
firefighting <VBG>
missions <NNS>
over <IN>
the <DT>
damaged <JJ>
Chernobyl <NNP>
nuclear <JJ>
reactor <NN>
, <,>
underwent <NN>
a <DT>
bone_marrow_transplant <NN>
at <IN>
the <DT>
center <NN>
earlier <JJR>
this <DT>
year <NN>
. <.>
He <PRP>
died <VBD>
July <NNP>
3 <CD>
of <IN>
complications <NNS>
of <IN>
a <DT>
lung <JJ>
infection <NN>
that <WDT>
took <VBD>
hold <VBP>
during <IN>
the <DT>
period <NN>
when <WRB>
he <PRP>
had <VBD>
no <DT>
natural <JJ>
defenses <NNS>
. <.>
In <IN>
leukemia <NN>
, <,>
a <DT>
form <NN>
of <IN>
blood_cancer <NN>
, <,>
white <JJ>
blood <NN>
cells <NNS>
multiply <RB>
out_of <IN>
control <NN>
. <.>
Since <IN>
bone_marrow <NN>
produces <NNS>
blood <NN>
, <,>
doctors <NNS>
can <MD>
combat <VB>
leukemia <NN>
by <IN>
replacing <NN>
the <DT>
diseased <VBN>
marrow <NN>
with <IN>
healthy <JJ>
tissue <NN>
. <.>
Before <IN>
the <DT>
operation <NN>
, <,>
Miss_Atlas <NNP>
reassured <VBD>
her <PRP>
mother <RB>
with <IN>
humor <NN>
and <CC>
encouraged <VBD>
family <NN>
members <NNS>
. <.>
`` <``>
She <PRP>
was <VBD>
really <RB>
cool <JJ>
, <,>
'' <''>
Sy_Atlas <NNP>
said <VBD>
in <IN>
a <DT>
TV_interview <NN>
from <IN>
Washington <NNP>
, <,>
D.C. <NNP>
`` <``>
Last <JJ>
night <NN>
, <,>
talking <VBG>
with <IN>
her <PRP$>
mom <NN>
, <,>
she <PRP>
jokingly <RB>
said <VBD>
... <:>
`Mom <JJ>
, <,>
your <PRP$>
marrow_better <NN>
be <VB>
good <JJ>
for <IN>
me <PRP>
tomorrow <NN>
. <.>
' <POS>
'' <''>
`` <``>
She <PRP>
's <VBZ>
really <RB>
positive <JJ>
. <.>
With <IN>
that <DT>
kind <NN>
of <IN>
attitude <NN>
, <,>
we're <JJ>
confident <NN>
she <PRP>
's <VBZ>
going <VBG>
to <TO>
do <VB>
well <RB>
. <.>
AP880511-0277 <DOCNO>
'' <''>
A <DT>
biologist <NN>
said <VBD>
Wednesday <NNP>
that <IN>
a <DT>
newly <RB>
discovered <VBN>
herpes <NNS>
virus <RB>
spread <VB>
by <IN>
casual <JJ>
contact <NN>
might <MD>
be <VB>
a <DT>
sixth_cancer-causing <JJ>
virus <NN>
and <CC>
appears <VBZ>
to <TO>
work <VB>
with <IN>
the <DT>
AIDS <NNP>
virus <VBZ>
in <IN>
wiping <NN>
out <IN>
the <DT>
immune_system <NN>
of <IN>
AIDS <NNP>
victims <NNS>
. <.>
Robert_Gallo <NNP>
, <,>
the <DT>
National_Cancer_Institute <NNP>
's <POS>
chief <NN>
of <IN>
tumor-cell <NNP>
biology <NN>
, <,>
said <VBD>
more <JJR>
evidence <NN>
was <VBD>
needed <VBN>
before <IN>
the <DT>
highly <RB>
contagious <JJ>
Herpes <NNS>
6 <CD>
, <,>
or <CC>
human_B-lymphocyte <JJ>
virus <NN>
, <,>
could <MD>
be <VB>
blamed <VBN>
for <IN>
causing <NN>
certain <JJ>
types <NNS>
of <IN>
cancers <NNS>
. <.>
Gallo <NNP>
spoke <VBD>
at <IN>
the <DT>
annual <JJ>
meeting <NN>
of <IN>
the <DT>
American_Society <NNP>
for <IN>
Microbiology <NNP>
, <,>
which <WDT>
convened <VBN>
here <RB>
Sunday <NNP>
. <.>
Researchers <NNS>
have <VBP>
found <VBN>
a <DT>
high <JJ>
prevalence <NN>
of <IN>
antibodies <NNS>
to <TO>
the <DT>
Herpes <NNP>
6 <CD>
virus <NN>
in <IN>
people <NNS>
with <IN>
Hodgkin <NNP>
's <POS>
disease <NN>
, <,>
Burkitt's <VBZ>
lymphoma <NN>
, <,>
non-Hodgkin <JJ>
's <POS>
lymphoma <NN>
and <CC>
childhood_acute_leukemia <NN>
, <,>
Gallo <NNP>
said <VBD>
. <.>
`` <``>
One <NN>
could <MD>
argue <VB>
the <DT>
virus <NN>
must <MD>
be <VB>
playing <VBG>
a <DT>
role <NN>
to <TO>
be <VB>
detected <VBN>
so_readily <RB>
in <IN>
those <DT>
tumors <NNS>
, <,>
'' <''>
Gallo <NNP>
said <VBD>
. <.>
Currently <RB>
, <,>
five <CD>
other <JJ>
viruses <NNS>
are <VBP>
believed <VBN>
to <TO>
cause <VB>
cancer <NN>
. <.>
They <PRP>
are <VBP>
hepatitis <NNS>
B <NNP>
, <,>
which <WDT>
can <MD>
cause <VB>
liver <RB>
cancer <NN>
; <:>
Epstein-Barr <JJ>
, <,>
which <WDT>
can <MD>
cause <VB>
nasopharyngeal_cancer <NN>
; <:>
HTLV <NNP>
, <,>
which <WDT>
can <MD>
cause <VB>
leukemia <NN>
; <:>
papillomavirus <NN>
, <,>
which <WDT>
may <MD>
cause <VB>
cervical <JJ>
cancer <NN>
; <:>
and <CC>
cytomegalovirus <VBZ>
, <,>
linked <VBN>
to <TO>
prostate <VB>
cancer <NN>
. <.>
The <DT>
Herpes <NNP>
6 <CD>
virus <NN>
also <RB>
has <VBZ>
been_found <VBN>
alongside <NN>
the <DT>
AIDS <NNP>
virus <VBZ>
in <IN>
T-4 <-NONE->
cells <NNS>
, <,>
which <WDT>
mastermind <NN>
the <DT>
immune_system <NN>
and <CC>
are <VBP>
the <DT>
prime <JJ>
target <NN>
of <IN>
acquired <VBN>
immune_deficiency_syndrome <NN>
, <,>
Gallo <NNP>
said <VBD>
. <.>
Since <IN>
the <DT>
AIDS <NNP>
virus <VBZ>
kills <NNS>
only <RB>
a <DT>
small <JJ>
percentage <NN>
of <IN>
T-4 <-NONE->
cells <VBZ>
at <IN>
a <DT>
time <NN>
, <,>
Gallo <NNP>
said <VBD>
, <,>
the <DT>
new <JJ>
herpes <NNS>
virus <VBZ>
might <MD>
explain <VB>
the <DT>
total <JJ>
annihilation <NN>
of <IN>
T-4 <-NONE->
cells <VBZ>
in <IN>
AIDS <NNP>
patients <NNS>
. <.>
Tests <NNS>
to <TO>
detect <VB>
Herpes <NNS>
6 <CD>
have <VBP>
differed <VBN>
widely <RB>
on <IN>
its <PRP$>
prevalence <NN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
. <.>
One <CD>
test <NN>
indicated <VBD>
that <IN>
it <PRP>
is <VBZ>
carried <VBN>
by_between <IN>
5 <CD>
percent <NN>
and <CC>
30 <CD>
percent <NN>
of <IN>
the <DT>
population <NN>
; <:>
another <DT>
indicated <VBN>
between <IN>
70 <CD>
percent <NN>
and <CC>
90 <CD>
percent <NN>
AP900928-0040 <DOCNO>
. <.>
First <NNP>
a <DT>
patient <NN>
hears <NNS>
the <DT>
cancer_diagnosis <NN>
and <CC>
then <RB>
learns <VBZ>
that <IN>
the <DT>
needed <VBN>
chemotherapy <NN>
may <MD>
cause <VB>
temporary <JJ>
baldness <NN>
. <.>
For <IN>
many <JJ>
, <,>
the <DT>
loss <NN>
of <IN>
hair <NN>
is <VBZ>
a <DT>
huge <JJ>
cosmetic_burden <NN>
piled <VBD>
on <IN>
the <DT>
already <RB>
terrible_physical <JJ>
trauma <NN>
of <IN>
disease <NN>
. <.>
But <CC>
help <VBP>
may <MD>
be <VB>
on <IN>
the <DT>
way <NN>
, <,>
according <VBG>
to <TO>
a <DT>
study <NN>
published <VBN>
today <NN>
in <IN>
the <DT>
journal <NN>
Science <NNP>
. <.>
Dr._A.A._Yunis <NNP>
, <,>
of <IN>
the <DT>
University <NNP>
of <IN>
Miami_Jackson_Memorial_Hospital_Medical_Center <NNP>
, <,>
reports <VBZ>
that <IN>
he <PRP>
and <CC>
his <PRP$>
colleagues <NNS>
have <VBP>
discovered <VBN>
`` <``>
by <IN>
chance <NN>
'' <''>
that <WDT>
an <DT>
experimental <JJ>
cancer_drug <NN>
blocks <NNS>
hair_loss <NN>
in <IN>
laboratory <NN>
rats <NNS>
injected <VBD>
with <IN>
some <DT>
chemotherapy <NN>
agents <NNS>
. <.>
If <IN>
the <DT>
finding <NN>
can <MD>
be <VB>
translated <VBN>
into <IN>
drugs <NNS>
to <TO>
treat <VB>
humans <NNS>
, <,>
an <DT>
expert <NN>
said <VBD>
, <,>
`` <``>
it <PRP>
would <MD>
be <VB>
of <IN>
tremendous <JJ>
benefit <NN>
'' <''>
to <TO>
cancer <NN>
patients <NNS>
who <WP>
now <RB>
must <MD>
endure <VB>
the <DT>
characteristic <JJ>
mark <NN>
of <IN>
chemotherapy_baldness <NN>
. <.>
Yunis <NNP>
said <VBD>
his <PRP$>
team <NN>
made <VBD>
the <DT>
discovery <NN>
while <IN>
testing_cancer-fighting <NN>
drugs <NNS>
on <IN>
lab <NN>
rats <NNS>
that <WDT>
had <VBD>
been_injected <VBN>
with <IN>
leukemia <NN>
cells <NNS>
. <.>
Half <NNP>
of <IN>
the <DT>
rats <NNS>
were <VBD>
treated <VBN>
with <IN>
a <DT>
drug <NN>
called <VBN>
cytosine_arabinoside <NN>
, <,>
or <CC>
ARA-C <JJ>
. <.>
The <DT>
rest <NN>
were <VBD>
treated <VBN>
with <IN>
a <DT>
combination <NN>
of <IN>
ARA-C <JJ>
and <CC>
an <DT>
experimental <JJ>
drug <NN>
called <VBN>
ImuVert <NNP>
. <.>
`` <``>
We <PRP>
found <VBD>
, <,>
lo <NN>
and <CC>
behold <VBD>
, <,>
that <IN>
the <DT>
rats <NNS>
with <IN>
ARA-C <JJ>
only <RB>
became <VBD>
nude <NN>
. <.>
They <PRP>
lost <VBD>
all <PDT>
their <PRP$>
hair <NN>
, <,>
'' <''>
said <VBD>
Yunis <NNP>
. <.>
`` <``>
The <DT>
ones <NNS>
with <IN>
both <DT>
ARA-C <JJ>
and <CC>
ImuVert <NNP>
, <,>
however <RB>
, <,>
did <VBD>
not <RB>
lose <VB>
hair <JJ>
at <IN>
all <DT>
. <.>
'' <''>
Yunis <NNP>
said <VBD>
his <PRP$>
group <NN>
then <RB>
tested <VBN>
ImuVert <NNP>
with <IN>
another <DT>
common <JJ>
cancer_drug <NN>
, <,>
doxorubicin <NN>
, <,>
or <CC>
DX <NNP>
. <.>
He <PRP>
said <VBD>
they <PRP>
found <VBD>
that <IN>
rats <NNS>
with <IN>
the <DT>
DX-ImuVert <JJ>
combination <NN>
also <RB>
experienced <VBD>
no <DT>
hair_loss <NN>
, <,>
while <IN>
rats <NNS>
receiving <VBG>
only <RB>
the <DT>
DX <NNP>
lost <VBD>
hair <NN>
on <IN>
their <PRP$>
heads <NNS>
and <CC>
shoulders <NNS>
. <.>
ImuVert <NNP>
combined <VBD>
with <IN>
a <DT>
third <JJ>
cancer_drug <NN>
, <,>
cyclophosphamide <NN>
, <,>
however <RB>
, <,>
did <VBD>
not <RB>
prevent <VB>
hair <JJ>
loss <NN>
in <IN>
the <DT>
rats <NNS>
, <,>
said <VBD>
Yunis <NNP>
. <.>
Dr._Ed_Gelmann <NNP>
, <,>
chief <NN>
of <IN>
the <DT>
department <NN>
of <IN>
medical <JJ>
oncology <NN>
at <IN>
Georgetown_University <NNP>
in <IN>
Washington <NNP>
, <,>
said <VBD>
that_if <IN>
a <DT>
way <NN>
can <MD>
be <VB>
found <VBN>
to <TO>
prevent <VB>
hair_loss <NN>
`` <``>
patients <NNS>
will <MD>
feel <VB>
much <JJ>
better <RBR>
about <IN>
chemotherapy <NN>
. <.>
'' <''>
Chemotherapy <NNP>
baldness <NN>
is <VBZ>
nearly_always <RB>
temporary <JJ>
. <.>
The <DT>
hair <NN>
usually <RB>
grows <VBZ>
back <RB>
after <IN>
the <DT>
treatment_cycle <NN>
. <.>
Nonetheless <RB>
, <,>
said <VBD>
Gelmann <NNP>
: <:>
`` <``>
A <DT>
lot <NN>
of <IN>
patients <NNS>
focus <VBZ>
on <IN>
hair_loss <NN>
because <IN>
it <PRP>
is <VBZ>
so <RB>
apparent <JJ>
. <.>
It <PRP>
can <MD>
be <VB>
quite <RB>
a <DT>
stigma <NN>
. <.>
It <PRP>
would <MD>
be <VB>
a <DT>
tremendous <JJ>
benefit <NN>
to <TO>
eliminate <VB>
hair_loss <NN>
as <IN>
long <RB>
as <IN>
it <PRP>
did <VBD>
not <RB>
change <VB>
the <DT>
efficacy <NN>
of <IN>
the <DT>
cancer_chemotherapy <NN>
. <.>
'' <''>
Yunis <NNP>
said <VBD>
that <IN>
ImuVert <NNP>
appears <VBZ>
to <TO>
help <VB>
combat <JJ>
leukemia <NN>
while <IN>
it <PRP>
is <VBZ>
preventing <VBG>
chemotherapy_baldness <NN>
. <.>
He <PRP>
said <VBD>
the <DT>
drug <NN>
teamed <VBD>
with <IN>
ARA-C <JJ>
halted <VBN>
the <DT>
progression <NN>
of <IN>
leukemia <NN>
in <IN>
all <DT>
but <CC>
20 <CD>
percent <NN>
of <IN>
the <DT>
laboratory <NN>
rats <NNS>
tested <VBD>
. <.>
This <DT>
result <NN>
was <VBD>
better <RBR>
than_among <IN>
rats <NNS>
treated <VBN>
with <IN>
ARA-C <JJ>
alone <NN>
, <,>
he <PRP>
said <VBD>
. <.>
Dr._Gregory_Curt <NNP>
, <,>
director <NN>
of <IN>
the <DT>
clinical <JJ>
oncology_department <NN>
at <IN>
the <DT>
National_Cancer_Institute <NNP>
, <,>
said <VBD>
controlling <VBG>
hair_loss <NN>
during <IN>
chemotherapy <NN>
`` <``>
is <VBZ>
a <DT>
very <RB>
serious <JJ>
thing <NN>
for <IN>
patients <NNS>
. <.>
'' <''>
`` <``>
The <DT>
two <CD>
things <NNS>
that <WDT>
concern <NN>
patients <VBZ>
the <DT>
most <RBS>
about <IN>
chemotherapy <NN>
are <VBP>
nausea <NN>
and <CC>
that <IN>
some <DT>
people <NNS>
can <MD>
get <VB>
bald <VBN>
, <,>
'' <''>
he <PRP>
said <VBD>
. <.>
There <EX>
are <VBP>
drugs <NNS>
to <TO>
control <NN>
the <DT>
nausea <NN>
, <,>
but <CC>
there <EX>
is <VBZ>
no <DT>
pill <NN>
to <TO>
block <VB>
the <DT>
hair_loss <NN>
. <.>
`` <``>
For <IN>
both <DT>
men <NNS>
and <CC>
women <NNS>
, <,>
it <PRP>
is <VBZ>
one <CD>
of <IN>
the <DT>
side <NN>
effects <NNS>
that <WDT>
concerns_people <NNS>
the <DT>
most <JJS>
because <IN>
it <PRP>
changes <VBZ>
one <CD>
's <POS>
body_image <NN>
, <,>
'' <''>
said <VBD>
Curt <NNP>
. <.>
The <DT>
physician <JJ>
said <VBD>
he <PRP>
remembers <NNS>
at <IN>
least <JJS>
two <CD>
patients <NNS>
who <WP>
were <VBD>
so <RB>
concerned <VBN>
about <IN>
the <DT>
loss <NN>
of <IN>
hair <NN>
that <IN>
they <PRP>
actually <RB>
refused <VBD>
lifesaving <VBG>
chemotherapy <NN>
. <.>
ImuVert <NNP>
now <RB>
is <VBZ>
being <VBG>
tested <VBN>
as <IN>
a <DT>
chemotherapy_agent <NN>
against <IN>
brain_cancer <NN>
. <.>
Yunis <NNP>
said <VBD>
it <PRP>
could <MD>
be <VB>
several <JJ>
years <NNS>
before <IN>
it <PRP>
is <VBZ>
approved <VBN>
for <IN>
use <NN>
on <IN>
patients <NNS>
. <.>
He <PRP>
said <VBD>
the <DT>
discovery <NN>
also <RB>
gives <VBZ>
researchers <NNS>
a <DT>
clue <NN>
that <WDT>
may <MD>
help_find <VB>
even <RB>
more <RBR>
effective <JJ>
drugs <NNS>
to <TO>
block <VB>
hair_loss <NN>
among <IN>
chemotherapy <NN>
patients <NNS>
. <.>
He <PRP>
said <VBD>
ImuVert <NNP>
is <VBZ>
a <DT>
drug <NN>
known <VBN>
as <IN>
a <DT>
biological <JJ>
response_modifier <NN>
because <IN>
it <PRP>
alters <VBZ>
the <DT>
way <NN>
some <DT>
cells <NNS>
in <IN>
the <DT>
immune_system_act <NN>
. <.>
If <IN>
the <DT>
precise_effect <NN>
of <IN>
this <DT>
drug <NN>
on <IN>
the <DT>
hair <NN>
follicles <NNS>
could <MD>
be <VB>
identified <VBN>
, <,>
then <RB>
new <JJ>
drugs <NNS>
with <IN>
this <DT>
action <NN>
could <MD>
be <VB>
developed <VBN>
, <,>
said <VBD>
Yunis <NNP>
. <.>
Science <NN>
, <,>
which <WDT>
today <NN>
published <VBD>
the <DT>
University <NNP>
of <IN>
Miami <NNP>
research_report <NN>
, <,>
is <VBZ>
the <DT>
journal <NN>
of <IN>
the <DT>
American_Association <NNP>
for <IN>
the <DT>
Advancement <NNP>
of <IN>
Science <NNP>
. <.>
Coauthors <NNS>
of <IN>
the <DT>
paper <NN>
with <IN>
Yunis <NNP>
are <VBP>
Atif_M._Hussein <NNP>
and <CC>
Joaquin_J._Jimenez <NNP>
of <IN>
the <DT>
University <NNP>
of <IN>
Miami <NNP>
, <,>
and <CC>
Catherine_A._McCall <NNP>
of <IN>
Cell_Technology_Inc <NNP>
LA011590-0100 <DOCNO>
. <.>
Loss <NN>
of <IN>
genes <NNS>
that <WDT>
make <VBP>
interferon <RP>
, <,>
a <DT>
natural <JJ>
disease-fighting_substance <NN>
, <,>
has <VBZ>
been_linked <VBN>
with <IN>
development <NN>
of <IN>
a <DT>
form <NN>
of <IN>
leukemia <NN>
, <,>
researchers <NNS>
said <VBD>
. <.>
The <DT>
researchers <NNS>
speculate <VBP>
that <IN>
the <DT>
interferon <NN>
genes <NNS>
may <MD>
act <VB>
as <IN>
regulators <NNS>
that <IN>
stop <NN>
the <DT>
body <NN>
's <POS>
cells <NNS>
from <IN>
becoming <VBG>
cancerous <JJ>
. <.>
Researchers <NNS>
from <IN>
the <DT>
University <NNP>
of <IN>
Chicago <NNP>
found <VBD>
an <DT>
association <NN>
between <IN>
loss <NN>
of <IN>
the <DT>
genes <NNS>
and <CC>
development <NN>
of <IN>
acute <NN>
lymphoblastic <JJ>
leukemia <NN>
, <,>
a <DT>
blood_cancer <NN>
that <WDT>
is <VBZ>
the <DT>
most <RBS>
common <JJ>
form <NN>
of <IN>
childhood_leukemia <NN>
. <.>
They <PRP>
tested <VBD>
62 <CD>
patients <NNS>
with <IN>
this <DT>
kind <NN>
of <IN>
leukemia <NN>
and <CC>
found <VBD>
that <IN>
29 <CD>
% <NN>
of <IN>
them <PRP>
lacked <VBD>
the <DT>
interferon <NN>
genes <NNS>
. <.>
Their <PRP$>
work <NN>
, <,>
directed <VBD>
by <IN>
Dr._Manuel_O._Diaz <NNP>
, <,>
was <VBD>
published <VBN>
in <IN>
the <DT>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
. <.>
It <PRP>
adds <VBZ>
to <TO>
the <DT>
growing <VBG>
list <NN>
of <IN>
cancers <NNS>
that <WDT>
have <VBP>
been_associated <VBN>
with <IN>
the <DT>
presence <NN>
or <CC>
absence <NN>
of <IN>
particular <JJ>
genes <NNS>
. <.>
Interferon <NNP>
plays <VBZ>
a <DT>
variety <NN>
of <IN>
roles <NNS>
in <IN>
regulating <VBG>
the <DT>
body <NN>
's <POS>
immune <NN>
defenses <NNS>
and <CC>
controlling <VBG>
cell_growth <NN>
SJMN91-06307182 <DOCNO>
. <.>
Stem <NNP>
cells <NNS>
-- <:>
whose <WP$>
existence <NN>
had <VBD>
only <RB>
been_inferred <VBN>
until <IN>
now <RB>
-- <:>
are <VBP>
extremely <RB>
rare <JJ>
in <IN>
the <DT>
bone_marrow <NN>
, <,>
and <CC>
scientists <NNS>
believe <VBP>
a <DT>
single <JJ>
stem_cell <NN>
may <MD>
have <VB>
the <DT>
ability <NN>
to <TO>
rebuild <VB>
a <DT>
person <NN>
's <POS>
entire <JJ>
immune_system <NN>
. <.>
Given <RB>
that <IN>
extraordinary <JJ>
power <NN>
, <,>
the <DT>
search <NN>
for <IN>
the <DT>
bone_marrow_stem_cell <NN>
has <VBZ>
been_called <VBN>
the <DT>
Holy_Grail <NNP>
of <IN>
blood_research <NN>
. <.>
; <:>
If <IN>
borne <NN>
out_by <IN>
scientific <JJ>
data <NNS>
-- <:>
the <JJ>
researchers <NNS>
may <MD>
present <VB>
their <PRP$>
work <NN>
next <IN>
week <NN>
-- <:>
the <DT>
discovery <NN>
means <VBZ>
physicians <NNS>
would <MD>
soon <RB>
be <VB>
able <JJ>
to <TO>
restore <VB>
a <DT>
patient <NN>
's <POS>
blood <NN>
and <CC>
immune <NN>
systems <NNS>
when <WRB>
damaged <JJ>
by <IN>
radiation <NN>
, <,>
chemotherapy <NN>
or <CC>
disease <NN>
. <.>
; <:>
Great <NNP>
potential <NN>
; <:>
`` <``>
This <DT>
finding <NN>
is <VBZ>
extremely <RB>
exciting <VBG>
and <CC>
important <JJ>
, <,>
'' <''>
said <VBD>
Dr._Samuel_Broder <NNP>
, <,>
National_Cancer_Institute <NNP>
director <NN>
. <.>
; <:>
Dr._R._Michael_Blaese <NNP>
agreed <VBD>
. <.>
`` <``>
This <DT>
is <VBZ>
potentially_very <RB>
important <JJ>
for <IN>
gene_therapy <NN>
for <IN>
dozens <NNS>
of <IN>
diseases <NNS>
, <,>
'' <''>
said <VBD>
the <DT>
NCI <NNP>
immunologist <NN>
who <WP>
last <JJ>
year <NN>
became <VBD>
the <DT>
first <JJ>
physician <NN>
to <TO>
use <VB>
gene_therapy <NN>
to <TO>
treat <VB>
patients <NNS>
-- <:>
two <CD>
children <NNS>
suffering <VBG>
from <IN>
a <DT>
lethal <JJ>
immune_system_disease <NN>
known <VBN>
as <IN>
adenisine_deaminase_deficiency <NN>
. <.>
; <:>
The <DT>
discovery <NN>
of <IN>
the <DT>
stem_cell <NN>
also <RB>
promises <VBZ>
to <TO>
be <VB>
extremely <RB>
controversial <JJ>
. <.>
; <:>
It <PRP>
was <VBD>
not <RB>
announced <VBN>
in <IN>
a <DT>
scientific_journal <JJ>
but <CC>
by <IN>
a <DT>
for-profit <JJ>
company <NN>
that <WDT>
kept <VBD>
quiet <JJ>
about <IN>
its <PRP$>
work <NN>
until <IN>
it <PRP>
had <VBD>
obtained <VBN>
U.S. <NNP>
patents <NNS>
on <IN>
the <DT>
process <NN>
of <IN>
isolating <VBG>
the <DT>
stem_cell <NN>
and <CC>
on <IN>
the <DT>
cell <NN>
itself <PRP>
. <.>
; <:>
Patenting <NNP>
of <IN>
life <NN>
forms <NNS>
-- <:>
genes <NNS>
, <,>
cells <NNS>
, <,>
tissues <NNS>
, <,>
even <RB>
animals <NNS>
-- <:>
is <VBZ>
the <DT>
heart <NN>
of <IN>
the <DT>
burgeoning_biotechnology_industry <NN>
, <,>
but <CC>
the <DT>
idea <NN>
still <RB>
makes <VBZ>
many_uneasy <JJ>
. <.>
; <:>
Ethical <NNP>
questions <NNS>
; <:>
By <NNP>
patenting <NN>
the <DT>
bone_marrow_stem_cell <NN>
, <,>
Systemix <NNP>
`` <``>
introduces <NNS>
us <PRP>
into <IN>
a <DT>
new <JJ>
era <NN>
of <IN>
ethical <JJ>
problems <NNS>
in <IN>
medicine <NN>
, <,>
'' <''>
said <VBD>
Dr._Peter_Quesenberry <NNP>
, <,>
vice_president <NN>
of <IN>
medical <JJ>
and <CC>
scientific <JJ>
affairs <NNS>
of <IN>
the <DT>
Leukemia_Society <NNP>
of <IN>
America <NNP>
. <.>
`` <``>
The <DT>
idea <NN>
._._. <.>
you <PRP>
could <MD>
have <VB>
commercial <JJ>
restrictions <NNS>
on <IN>
the <DT>
use <NN>
of <IN>
such <JJ>
cells <NNS>
in <IN>
transplants <NNS>
would <MD>
be <VB>
very <RB>
disturbing <JJ>
. <.>
`` <``>
; <:>
Systemix <NNP>
plans <VBZ>
clinical <JJ>
trials <NNS>
to <TO>
test_bone_marrow_stem_cell_therapy <NN>
in <IN>
people <NNS>
early_next <JJ>
year <NN>
. <.>
The <DT>
first <JJ>
participants <NNS>
will <MD>
be <VB>
patients <NNS>
who <WP>
have_otherwise <VBP>
untreatable <JJ>
breast_cancer <NN>
, <,>
leukemia <NN>
and <CC>
neuroblastoma <NN>
, <,>
a <DT>
form <NN>
of <IN>
brain_cancer <NN>
AP891110-0134 <DOCNO>
. <.>
Increases <NNS>
in <IN>
leukemia <NN>
among <IN>
young <JJ>
people <NNS>
living <VBG>
near <IN>
nuclear <JJ>
plants <NNS>
are <VBP>
not <RB>
caused <VBN>
by <IN>
exposure <NN>
to <TO>
radiation <NN>
, <,>
said <VBD>
a <DT>
study <NN>
released <VBN>
Friday <NNP>
. <.>
Researchers <NNS>
found <VBD>
that <IN>
death <NN>
rates <NNS>
from <IN>
leukemia <NN>
and <CC>
Hodgkin's <VBZ>
disease <NN>
among <IN>
young <JJ>
people <NNS>
were <VBD>
about_as <IN>
high <JJ>
in <IN>
areas <NNS>
that <WDT>
were <VBD>
only <RB>
considered <VBN>
for <IN>
nuclear <JJ>
plants <NNS>
as_in <IN>
areas <NNS>
that <WDT>
actually <RB>
contained <VBD>
nuclear <JJ>
plants <NNS>
. <.>
Hodgkin <NNP>
's <POS>
disease <NN>
is <VBZ>
a <DT>
cancer <NN>
of <IN>
the <DT>
lymph <NN>
glands <NNS>
. <.>
Researchers <NNS>
said <VBD>
it <PRP>
has <VBZ>
never <RB>
been_linked <VBN>
to <TO>
radiation_exposure <NN>
. <.>
The <DT>
cause <NN>
of <IN>
heightened <VBN>
cancer <NN>
rates <NNS>
found <VBD>
in <IN>
the <DT>
study <NN>
remains <VBZ>
a <DT>
mystery <NN>
. <.>
But <CC>
the <DT>
researchers <NNS>
said <VBD>
their <PRP$>
findings <NNS>
indicate <VBP>
an <DT>
increased <VBN>
risk <NN>
of <IN>
leukemia <NN>
is <VBZ>
not <RB>
associated <VBN>
with <IN>
exposure <NN>
to <TO>
radiation <NN>
, <,>
with <IN>
the <DT>
possible <JJ>
exception <NN>
of <IN>
the <DT>
Sellafield <NNP>
nuclear <JJ>
reprocessing_plant <NN>
on <IN>
England <NNP>
's <POS>
northwest <JJS>
coast <NN>
. <.>
The <DT>
Sellafield <NNP>
plant <NN>
has <VBZ>
been_plagued <VBN>
by <IN>
radioactive <JJ>
leaks <NNS>
. <.>
Government <NNP>
studies <NNS>
have <VBP>
found <VBN>
a <DT>
10-fold <JJ>
increase <NN>
in <IN>
childhood_leukemia <NN>
a <DT>
mile <NN>
from <IN>
the <DT>
plant <NN>
, <,>
and <CC>
concluded <VBD>
the <DT>
plant <NN>
is <VBZ>
linked <VBN>
to <TO>
the <DT>
disease <NN>
. <.>
In <IN>
the <DT>
study <NN>
released <VBN>
Friday <NNP>
, <,>
researchers <NNS>
from <IN>
the <DT>
Medical <JJ>
Research_Council <NNP>
and <CC>
the <DT>
Imperial_Cancer_Research_Fund <NNP>
said <VBD>
the <DT>
new <JJ>
findings <NNS>
suggest <VBP>
that <IN>
areas <NNS>
near <IN>
existing <VBG>
and <CC>
potential_nuclear <JJ>
sites <NNS>
might <MD>
share <VB>
`` <``>
unrecognized <VBN>
risk <NN>
factors <NNS>
other <JJ>
than <IN>
environmental <JJ>
radiation_pollution <NN>
. <.>
'' <''>
Dr._Sarah_Darby <NNP>
of <IN>
the <DT>
Imperial_Cancer_Research_Fund <NNP>
said <VBD>
the <DT>
findings <NNS>
point <VBP>
to <TO>
something <NN>
possibly <RB>
`` <``>
in <IN>
the <DT>
lifestyle <NN>
of <IN>
the <DT>
young <JJ>
but <CC>
at <IN>
the <DT>
present_time <NN>
we <PRP>
do <VBP>
n't <RB>
have <VB>
a <DT>
great <JJ>
deal <NN>
of <IN>
handle <NN>
on <IN>
it <PRP>
. <.>
'' <''>
The <DT>
researchers <NNS>
investigated <VBD>
death <NN>
statistics <NNS>
in <IN>
400 <CD>
districts <NNS>
of <IN>
England <NNP>
and <CC>
Wales <NNP>
near <IN>
existing <VBG>
or <CC>
potential_nuclear <JJ>
sites <NNS>
. <.>
The <DT>
results <NNS>
were <VBD>
published <VBN>
in <IN>
the <DT>
The_Lancet <NNP>
, <,>
a <DT>
weekly_medical_journal <JJ>
. <.>
`` <``>
Excess <JJ>
mortality <NN>
due <JJ>
to <TO>
leukemia <VB>
and <CC>
Hodgkin <NNP>
's <POS>
disease <NN>
in <IN>
young <JJ>
people <NNS>
who <WP>
lived <VBN>
near <IN>
potential <JJ>
sites <NNS>
was <VBD>
similar <JJ>
to <TO>
that <DT>
in <IN>
young <JJ>
people <NNS>
who <WP>
lived <VBN>
near <IN>
existing <VBG>
sites <NNS>
, <,>
'' <''>
researchers <NNS>
wrote <VBD>
. <.>
Ms._Darby <NNP>
said <VBD>
: <:>
`` <``>
There <EX>
was <VBD>
a <DT>
16 <CD>
percent_increase <NN>
in <IN>
childhood_leukemia_mortality <NN>
in <IN>
areas <NNS>
near <IN>
nuclear <JJ>
installations <NNS>
compared <VBN>
with <IN>
the <DT>
rest <NN>
of <IN>
the <DT>
country <NN>
after <IN>
adjusting <VBG>
for <IN>
factors <NNS>
such <JJ>
as <IN>
urban-rural <JJ>
status <NN>
. <.>
When <WRB>
the <DT>
same <JJ>
analysis <NN>
was <VBD>
carried <VBN>
out <RP>
for <IN>
areas <NNS>
near <IN>
potential <JJ>
installations <NNS>
, <,>
there <EX>
was <VBD>
a <DT>
14 <CD>
percent_increase <NN>
. <.>
'' <''>
`` <``>
We <PRP>
carried <VBD>
out <RP>
this <DT>
study <NN>
because <IN>
estimates <NNS>
of <IN>
radiation <NN>
received <VBD>
by <IN>
children <NNS>
living <VBG>
near <IN>
nuclear <JJ>
installations <NNS>
are <VBP>
extremely <RB>
low <JJ>
, <,>
and <CC>
it <PRP>
has <VBZ>
been_suggested <VBN>
that <IN>
increases <NNS>
in <IN>
the <DT>
number <NN>
of <IN>
deaths <NNS>
are <VBP>
not <RB>
caused <VBN>
by <IN>
the <DT>
presence <NN>
of <IN>
the <DT>
installations <NNS>
, <,>
but <CC>
by <IN>
some <DT>
other <JJ>
feature <NN>
of <IN>
the <DT>
districts <NNS>
in <IN>
which <WDT>
they <PRP>
tend <VBP>
to <TO>
be <VB>
built <VBN>
, <,>
'' <''>
she <PRP>
said <VBD>
. <.>
The <DT>
new <JJ>
findings <NNS>
on <IN>
leukemia_bolster <NN>
this <DT>
hypothesis <NN>
, <,>
the <DT>
researchers <NNS>
wrote <VBD>
. <.>
Other_previous <JJ>
theories <NNS>
, <,>
such <JJ>
as <IN>
those <DT>
involving <VBG>
exposure <NN>
to <TO>
radon <VB>
gas <NN>
or <CC>
viruses <NNS>
, <,>
could <MD>
not <RB>
account <VB>
for <IN>
all <PDT>
the <DT>
excess <NN>
cancers <NNS>
in <IN>
young <JJ>
people <NNS>
, <,>
they <PRP>
said <VBD>
. <.>
Ms._Darby <NNP>
said <VBD>
the <DT>
study <NN>
also <RB>
would <MD>
disprove <VB>
stress <NN>
or <CC>
psychosomatic <JJ>
illness <NN>
being <VBG>
a <DT>
possible <JJ>
cause <NN>
since <IN>
most <JJS>
people <NNS>
living <VBG>
around <IN>
the <DT>
potential <NN>
sites <VBZ>
`` <``>
would <MD>
n't <RB>
have <VB>
been_worried <VBN>
about <IN>
it <PRP>
. <.>
'' <''>
She <PRP>
said <VBD>
the <DT>
main <JJ>
theory <NN>
that <WDT>
needs <VBZ>
investigation <NN>
is <VBZ>
`` <``>
that <IN>
people <NNS>
who <WP>
are <VBP>
exposed <VBN>
less <RBR>
frequently <RB>
to <TO>
infection <NN>
very <RB>
early <JJ>
in <IN>
life <NN>
are <VBP>
at <IN>
a <DT>
slightly <RB>
higher <JJR>
risk <NN>
of <IN>
leukemia <NN>
later <JJ>
on <IN>
. <.>
'' <''>
Mel_Greaves <NNP>
of <IN>
the <DT>
Leukemia_Research_Fund <NNP>
, <,>
who <WP>
originated <VBN>
the <DT>
theory <NN>
, <,>
`` <``>
has <VBZ>
biological <JJ>
reasons <NNS>
for <IN>
thinking <VBG>
that <IN>
is <VBZ>
the <DT>
case <NN>
, <,>
'' <''>
she <PRP>
said <VBD>
. <.>
`` <``>
Our <PRP$>
data <NNS>
support <NN>
that <IN>
, <,>
'' <''>
she <PRP>
said <VBD>
, <,>
explaining <NN>
that <IN>
areas <NNS>
with <IN>
a <DT>
higher <JJR>
proportion <NN>
of <IN>
people <NNS>
in <IN>
the <DT>
upper_social <JJ>
classes <NNS>
had <VBD>
a <DT>
slightly <RB>
higher <JJR>
risk <NN>
of <IN>
leukemia <NN>
than <IN>
people <NNS>
in <IN>
areas <NNS>
with <IN>
a <DT>
higher <JJR>
proportion <NN>
of <IN>
manual <JJ>
workers <NNS>
AP880505-0077 <DOCNO>
. <.>
A <DT>
mysterious <JJ>
paralyzing_disease <NN>
that <WDT>
occurs <VBZ>
in <IN>
tropical <JJ>
climates <NNS>
may <MD>
be <VB>
caused <VBN>
by <IN>
a <DT>
virus <NN>
that <WDT>
also <RB>
triggers <VBZ>
a <DT>
rare_form <NN>
of <IN>
blood_cancer <NN>
, <,>
according <VBG>
to <TO>
a <DT>
report_today <NN>
. <.>
The <DT>
virus <NN>
, <,>
first <JJ>
isolated <VBN>
in <IN>
1980 <CD>
, <,>
is <VBZ>
called <VBN>
human <NN>
T-cell_lymphoma-leukemia <NNP>
virus <VBZ>
Type <NNP>
1 <CD>
, <,>
or <CC>
HTLV-I <NNP>
. <.>
It <PRP>
causes <VBZ>
cancer <NN>
of <IN>
a <DT>
variety <NN>
of <IN>
white_blood <NN>
cells <NNS>
known <VBN>
as <IN>
T <NNP>
cells <NNS>
. <.>
Recently <RB>
, <,>
doctors <NNS>
have <VBP>
found <VBN>
that <IN>
people <NNS>
with <IN>
a <DT>
mysterious <JJ>
disease <NN>
called <VBN>
chronic_progressive_myelopathy <JJ>
, <,>
or <CC>
tropical_spastic <JJ>
paraparesis <NN>
, <,>
sometimes <RB>
show <VB>
signs <NNS>
in <IN>
their <PRP$>
blood <NN>
of <IN>
infection <NN>
with <IN>
HTLV-I <NNP>
. <.>
In <IN>
the <DT>
latest <JJS>
study <NN>
, <,>
doctors <NNS>
found <VBD>
direct <JJ>
evidence <NN>
of <IN>
the <DT>
virus <NN>
in <IN>
these <DT>
people <NNS>
, <,>
strengthening <VBG>
the <DT>
suspicion <NN>
that <IN>
HTLV-I <NNP>
can <MD>
be <VB>
one <CD>
cause <NN>
of <IN>
the <DT>
disease <NN>
. <.>
`` <``>
HTLV-I <JJ>
appears <NNS>
to <TO>
be <VB>
causally <RB>
associated <VBN>
with <IN>
many <JJ>
cases <NNS>
of <IN>
otherwise <NN>
unexplained <VBN>
myelopathy <JJ>
in <IN>
patients <NNS>
from <IN>
the <DT>
tropics <NNS>
, <,>
'' <''>
they <PRP>
wrote <VBD>
. <.>
The <DT>
research <NN>
was <VBD>
directed <VBN>
by <IN>
Dr._Satyakam_Bhagavati <NNP>
of <IN>
the <DT>
State_University <NNP>
of <IN>
New_York_Health_Science_Center <NNP>
in <IN>
Brooklyn <NNP>
. <.>
It <PRP>
was <VBD>
published <VBN>
in <IN>
the <DT>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
. <.>
Health <NNP>
experts <NNS>
say <VBP>
HTLV-I <JJ>
is <VBZ>
spreading <VBG>
among <IN>
drug <NN>
addicts <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
. <.>
Surveys <NNS>
estimate <VBP>
that_about <IN>
two <CD>
of <IN>
every <DT>
10 <CD>
, <,>
000 <CD>
units <NNS>
of <IN>
blood <NN>
used <VBN>
for <IN>
transfusions <NNS>
contain <VBP>
the <DT>
virus <NN>
. <.>
Blood <NNP>
bank <NN>
officials <NNS>
have <VBP>
said <VBN>
they <PRP>
will <MD>
start <VB>
checking <NN>
donations <NNS>
for <IN>
the <DT>
virus <NN>
when <WRB>
screening <VBG>
tests <NNS>
are <VBP>
available <JJ>
. <.>
Clusters <NNS>
of <IN>
chronic_progressive_myelopathy <JJ>
occur <NN>
in <IN>
tropical <JJ>
parts <NNS>
of <IN>
the <DT>
world <NN>
, <,>
including <VBG>
the <DT>
Caribbean <NNP>
, <,>
where <WRB>
the <DT>
virus <NN>
is <VBZ>
also_relatively <RB>
common <JJ>
. <.>
The <DT>
disease <NN>
results <NNS>
in <IN>
weakness <NN>
, <,>
numbness <NN>
and <CC>
gradual <JJ>
paralysis <NN>
of <IN>
the <DT>
legs <NNS>
. <.>
In <IN>
their <PRP$>
study <NN>
, <,>
doctors <NNS>
found <VBD>
direct <JJ>
evidence <NN>
of <IN>
the <DT>
virus <NN>
in <IN>
12 <CD>
patients <NNS>
who <WP>
also <RB>
had <VBD>
antibodies <NNS>
to <TO>
HTLV-I <NNP>
. <.>
In <IN>
an <DT>
accompanying_editorial <NN>
, <,>
Drs <NNP>
. <.>
Bruce_J <NNP>
. <.>
Brew <NNP>
and <CC>
Richard_W._Price <NNP>
of <IN>
Memorial <NNP>
Sloan-Kettering <JJ>
Cancer_Center <NNP>
in <IN>
New_York <NNP>
said <VBD>
it <PRP>
's <VBZ>
puzzling <VBG>
why <WRB>
the <DT>
disease <NN>
is <VBZ>
rare <JJ>
even <RB>
where <WRB>
the <DT>
virus <NN>
is <VBZ>
widespread <JJ>
. <.>
Even <RB>
though <IN>
there <EX>
are <VBP>
other <JJ>
examples <NNS>
of <IN>
low <JJ>
disease <NN>
rates <NNS>
from <IN>
common <JJ>
viruses <NNS>
, <,>
they <PRP>
wrote <VBD>
, <,>
`` <``>
it <PRP>
nonetheless_raises <VBZ>
the <DT>
question <NN>
of <IN>
what <WP>
other <JJ>
factors <NNS>
contribute <VBP>
to <TO>
the <DT>
development <NN>
of <IN>
the <DT>
disease <NN>
. <.>
LA022290-0150 <DOCNO>
'' <''>
Medical <JJ>
researchers <NNS>
unveiled <VBD>
new <JJ>
evidence <NN>
Wednesday <NNP>
showing <NN>
that <WDT>
doctors <NNS>
do <VBP>
n't <RB>
need <VB>
a <DT>
perfect_match <NN>
when <WRB>
they <PRP>
try <VBP>
to <TO>
transplant <VB>
bone_marrow <NN>
into <IN>
someone <NN>
whose <WP$>
blood-producing <JJ>
cells <NNS>
have <VBP>
been_damaged <VBN>
by <IN>
leukemia <NN>
or <CC>
another <DT>
deadly <RB>
illness <NN>
. <.>
Bone_marrow <NN>
transplants <NNS>
are <VBP>
usually <RB>
most <JJS>
successful <JJ>
when <WRB>
the <DT>
marrow <NN>
is <VBZ>
donated <VBN>
by <IN>
a <DT>
brother <NN>
or <CC>
sister <NN>
whose <WP$>
cells <NNS>
have <VBP>
the <DT>
same <JJ>
pattern <NN>
of <IN>
surface <NN>
proteins <NNS>
. <.>
When <WRB>
the <DT>
protein_pattern <NN>
matches <NNS>
, <,>
it <PRP>
reduces <VBZ>
the <DT>
likelihood <NN>
that <IN>
the <DT>
donated <JJ>
marrow <NN>
will <MD>
be <VB>
rejected <VBN>
or <CC>
produce <VB>
serious <JJ>
side <NN>
effects <NNS>
. <.>
But <CC>
researchers <NNS>
at <IN>
the <DT>
Medical_College <NNP>
of <IN>
Wisconsin <NNP>
, <,>
using <VBG>
special <JJ>
techniques <NNS>
to <TO>
cleanse <VB>
the <DT>
donated <VBN>
marrow <NN>
, <,>
found <VBD>
that <IN>
transplants <NNS>
can <MD>
be <VB>
successful <JJ>
when <WRB>
the <DT>
protein_pattern <NN>
in <IN>
the <DT>
donor <NN>
's <POS>
marrow <NN>
is <VBZ>
similar <JJ>
to <TO>
, <,>
but <CC>
not <RB>
identical <JJ>
to <TO>
, <,>
the <DT>
recipient <JJ>
's <POS>
. <.>
The <DT>
findings <NNS>
, <,>
reported <VBD>
in <IN>
the <DT>
current <JJ>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
, <,>
suggest <VBP>
that <IN>
`` <``>
we <PRP>
can <MD>
now <RB>
start <VB>
tapping <VBG>
into <IN>
the <DT>
enlarging_pool <NN>
of <IN>
volunteer_marrow <NN>
donors <NNS>
'' <''>
whose <WP$>
marrow <NN>
`` <``>
will <MD>
lead <VB>
to <TO>
satisfactory <JJ>
results <NNS>
for <IN>
many <JJ>
patients <NNS>
, <,>
'' <''>
said <VBD>
Dr._Robert_C._Ash <NNP>
, <,>
chief_author <NN>
of <IN>
the <DT>
study <NN>
. <.>
The <DT>
ability <NN>
to <TO>
use <VB>
marrow <NN>
from <IN>
unrelated <VBN>
donors <NNS>
is <VBZ>
important <JJ>
because <IN>
only <RB>
about <IN>
30 <CD>
% <NN>
of <IN>
patients <NNS>
who <WP>
might <MD>
benefit <VB>
from <IN>
a <DT>
bone_marrow_transplant <NN>
will <MD>
have <VB>
a <DT>
brother <NN>
or <CC>
sister <NN>
whose <WP$>
marrow <NN>
is <VBZ>
perfectly <RB>
matched <VBN>
, <,>
Ash <NNP>
said <VBD>
. <.>
This <DT>
issue <NN>
was <VBD>
dramatized <VBN>
last <JJ>
week <NN>
when <WRB>
a <DT>
43-year-old <JJ>
Walnut <NNP>
woman <NN>
disclosed <VBD>
that <IN>
she <PRP>
was <VBD>
having <VBG>
a <DT>
baby <NN>
in <IN>
the <DT>
hope <NN>
that <IN>
the <DT>
newborn <NN>
can <MD>
become <VB>
a <DT>
bone_marrow_donor <NN>
for <IN>
her <PRP$>
17-year-old <JJ>
daughter <NN>
, <,>
who <WP>
has <VBZ>
leukemia <VBP>
. <.>
Tests <NNS>
have <VBP>
shown <VBN>
that <IN>
the <DT>
fetus <NN>
's <POS>
bone_marrow <NN>
is <VBZ>
nearly <RB>
identical <JJ>
. <.>
The <DT>
birth <NN>
is <VBZ>
expected <VBN>
in <IN>
April <NNP>
. <.>
In <IN>
the <DT>
four-year <JJ>
study <NN>
of <IN>
55 <CD>
patients <NNS>
, <,>
the <DT>
transplants <NNS>
were <VBD>
successful <JJ>
in <IN>
48 <CD>
% <NN>
of <IN>
patientswith <NN>
early <RB>
leukemia <NN>
, <,>
32 <CD>
% <NN>
of <IN>
the <DT>
volunteers <NNS>
whose <WP$>
leukemia <NN>
had <VBD>
reached <VBN>
an <DT>
advanced <JJ>
stage <NN>
, <,>
and <CC>
63 <CD>
% <NN>
of <IN>
the <DT>
patients <NNS>
who <WP>
suffered <VBN>
from <IN>
diseases <NNS>
other <JJ>
than <IN>
leukemia <NN>
. <.>
In <IN>
all <DT>
, <,>
31 <CD>
of <IN>
the <DT>
55 <CD>
patients <NNS>
died <VBD>
, <,>
usually <RB>
from <IN>
infection <NN>
. <.>
Graft-versus-host <JJ>
disease <NN>
, <,>
a <DT>
potentially_deadly <RB>
reaction <NN>
that <IN>
appears <NNS>
when <WRB>
the <DT>
cells <NNS>
of <IN>
the <DT>
transplanted <VBN>
marrow_attack <NN>
the <DT>
body <NN>
, <,>
occurred <VBD>
in <IN>
nearly <RB>
half <NN>
the <DT>
patients <NNS>
. <.>
Ash <NNP>
and <CC>
his <PRP$>
colleagues <NNS>
characterized <VBD>
that <IN>
rate <NN>
as <IN>
relatively <RB>
low <JJ>
. <.>
To <TO>
reduce <VB>
the <DT>
risk <NN>
of <IN>
graftversus-host <JJ>
disease <NN>
, <,>
the <DT>
donated <VBN>
marrow <NN>
was <VBD>
initially <RB>
treatedwith <IN>
chemicals <NNS>
to <TO>
kill <VB>
white <JJ>
blood <NN>
cells <NNS>
that <WDT>
trigger <JJR>
an <DT>
immune_response <NN>
AP891128-0127 <DOCNO>
. <.>
The <DT>
Food <NNP>
and <CC>
Drug_Administration <NNP>
is <VBZ>
allowing <VBG>
wider_distribution <NN>
of <IN>
a <DT>
leukemia_drug <NN>
that <WDT>
has <VBZ>
been_shown <VBN>
effective <JJ>
in <IN>
patients <NNS>
who <WP>
are <VBP>
n't <RB>
helped <VBN>
by <IN>
other <JJ>
treatments <NNS>
, <,>
an <DT>
FDA <NNP>
spokesman <NN>
said <VBD>
Tuesday <NNP>
. <.>
The <DT>
drug <NN>
, <,>
fludarabine_phosphate <NN>
, <,>
is <VBZ>
being <VBG>
used <VBN>
to <TO>
treat <VB>
patients <NNS>
with <IN>
chronic_lymphocytic <JJ>
leukemia <NN>
, <,>
which <WDT>
is <VBZ>
the <DT>
most <RBS>
common <JJ>
form <NN>
of <IN>
adult_leukemia <NN>
. <.>
The <DT>
drug <NN>
is <VBZ>
believed <VBN>
to <TO>
slow <JJ>
or <CC>
interrupt <JJ>
reproduction <NN>
of <IN>
abnormal_white <JJ>
blood <NN>
cells <NNS>
that <WDT>
accumulate <NN>
in <IN>
the <DT>
bone_marrow <NN>
, <,>
blood <NN>
and <CC>
liver <NN>
of <IN>
people <NNS>
with <IN>
the <DT>
disease <NN>
. <.>
The <DT>
FDA <NNP>
has <VBZ>
approved <VBN>
wider_distribution <NN>
of <IN>
the <DT>
drug <NN>
under <IN>
a <DT>
`` <``>
treatment <NN>
IND <NNP>
, <,>
'' <''>
which <WDT>
is <VBZ>
shorthand <VBP>
for <IN>
treatment_use <NN>
of <IN>
an <DT>
investigational_new <JJ>
drug <NN>
, <,>
said <VBD>
FDA <NNP>
spokesman <NN>
Jeff_Nesbit <NNP>
. <.>
A <DT>
treatment <NN>
IND <NNP>
allows <VBZ>
patients <NNS>
with <IN>
serious <JJ>
or <CC>
immediately <RB>
life-threatening <JJ>
diseases <NNS>
to <TO>
get <VB>
an <DT>
experimental <JJ>
drug <NN>
while <IN>
controlled <JJ>
testing <NN>
in <IN>
human <NN>
clinical <JJ>
trials <NNS>
continues <VBZ>
. <.>
The <DT>
drug <NN>
was <VBD>
developed <VBN>
by <IN>
Triton_Biosciences_Inc. <NNP>
, <,>
a <DT>
Shell_Oil_Co. <NNP>
subsidiary <NN>
based <VBN>
in <IN>
Alameda <NNP>
, <,>
Calif. <NNP>
and <CC>
clinical <JJ>
trials <NNS>
are <VBP>
being <VBG>
conducted <VBN>
by <IN>
National_Cancer_Institute <NNP>
. <.>
Triton <NNP>
plans <VBP>
to <TO>
market <NN>
the <DT>
drug <NN>
under <IN>
the <DT>
trade_name <NN>
Fludara_I.V <NNP>
WSJ880909-0170 <DOCNO>
. <.>
Men <NNS>
who <WP>
smoke <NN>
heavily <RB>
are <VBP>
nearly <RB>
twice <NN>
as <IN>
likely <JJ>
as <IN>
nonsmokers <NNS>
to <TO>
die <VB>
from <IN>
a <DT>
common <JJ>
form <NN>
of <IN>
leukemia <NN>
, <,>
concludes <VBZ>
a <DT>
report <NN>
by <IN>
the <DT>
University <NNP>
of <IN>
Edinburgh <NNP>
. <.>
The <DT>
analysis <NN>
, <,>
based <VBN>
on <IN>
a <DT>
previous <JJ>
study <NN>
of <IN>
248 <CD>
, <,>
046 <CD>
U.S. <NNP>
veterans <NNS>
, <,>
offers <NNS>
the <DT>
firmest <JJS>
link <NN>
yet <RB>
between <IN>
cigarette_consumption <NN>
and <CC>
the <DT>
disease <NN>
. <.>
The <DT>
finding <NN>
could <MD>
add <VB>
leukemia <NN>
to <TO>
the <DT>
already <RB>
lengthy <JJ>
list <NN>
of <IN>
suspected <VBN>
health <NN>
risks <NNS>
from <IN>
smoking <VBG>
. <.>
The <DT>
report <NN>
in <IN>
tomorrow <NN>
's <POS>
British_Medical <JJ>
Journal <NNP>
`` <``>
may <MD>
well <RB>
have <VB>
an <DT>
emotional <JJ>
impact <NN>
on <IN>
some <DT>
people <NNS>
who <WP>
are <VBP>
vacillating <VBG>
'' <''>
about <IN>
quitting <VBG>
smoking <NN>
`` <``>
and <CC>
for <IN>
one <CD>
reason <NN>
or <CC>
another <DT>
have <VBP>
a <DT>
fear <NN>
of <IN>
leukemia <NN>
, <,>
'' <''>
suggested <VBD>
Nicholas_Wald <NNP>
, <,>
an <DT>
epidemiologist <NN>
at <IN>
the <DT>
Medical_College <NNP>
of <IN>
St._Bartholomew <NNP>
's <POS>
Hospital <NNP>
here <RB>
. <.>
`` <``>
The <DT>
balance <NN>
of <IN>
evidence <NN>
suggests <VBZ>
that <IN>
smoking <NN>
may <MD>
cause <VB>
leukemia <NN>
, <,>
'' <''>
Dr._Wald <NNP>
wrote <VBD>
in <IN>
an <DT>
accompanying_commentary <NN>
on <IN>
the <DT>
analysis <NN>
, <,>
which <WDT>
was <VBD>
conducted <VBN>
by <IN>
University <NNP>
of <IN>
Edinburgh <NNP>
epidemiologist <NN>
Leo_Kinlen <NNP>
. <.>
Dr._Kinlen <NNP>
, <,>
who <WP>
directs <NNS>
the <DT>
university <NN>
's <POS>
Cancer_Epidemiology_Unit <NNP>
, <,>
examined <VBD>
leukemia <NN>
deaths <NNS>
from <IN>
a <DT>
U.S. <NNP>
study <NN>
that <WDT>
had <VBD>
tracked <VBN>
veterans <NNS>
' <POS>
smoking <NN>
between <IN>
1954 <CD>
and <CC>
1969 <CD>
. <.>
The <DT>
earlier <JJR>
study <NN>
tallied <VBD>
overall <JJ>
deaths <NNS>
from <IN>
various <JJ>
causes <NNS>
, <,>
including <VBG>
723 <CD>
deaths <NNS>
due <JJ>
to <TO>
leukemia <VB>
. <.>
Dr._Kinlen <NNP>
found <VBD>
veterans <NNS>
who <WP>
had <VBD>
smoked <VBN>
more <JJR>
than <IN>
21 <CD>
cigarettes <NNS>
a <DT>
day <NN>
were <VBD>
the <DT>
most <JJS>
likely <JJ>
to <TO>
die <VB>
from <IN>
myeloid <JJ>
leukemia <NN>
, <,>
the <DT>
most <RBS>
common <JJ>
form <NN>
of <IN>
the <DT>
disease <NN>
in <IN>
middle-aged <JJ>
people <NNS>
. <.>
These <DT>
heavy <JJ>
smokers <NNS>
had <VBD>
a <DT>
93 <CD>
% <NN>
greater <JJR>
chance <NN>
of <IN>
developing <VBG>
fatal <JJ>
leukemia <NN>
than <IN>
the <DT>
veterans <NNS>
who <WP>
never <RB>
had <VBD>
smoked <VBN>
. <.>
For <IN>
those <DT>
smoking <VBG>
between <IN>
10 <CD>
and <CC>
20 <CD>
cigarettes <NNS>
a <DT>
day <NN>
, <,>
the <DT>
increased <VBN>
risk <NN>
was <VBD>
75 <CD>
% <NN>
. <.>
And <CC>
men <NNS>
using <VBG>
fewer <JJR>
than <IN>
10 <CD>
cigarettes <NNS>
daily <RB>
were <VBD>
31 <CD>
% <NN>
more <JJR>
likely <JJ>
to <TO>
die <VB>
from <IN>
leukemia <NN>
than <IN>
nonsmokers <NNS>
, <,>
according <VBG>
to <TO>
the <DT>
report <NN>
. <.>
Previous <JJ>
studies <NNS>
have <VBP>
observed <VBN>
higher <JJR>
death <NN>
rates <NNS>
from <IN>
leukemia <NN>
among <IN>
smokers <NNS>
, <,>
but <CC>
either <DT>
involved <VBN>
fewer <JJR>
patients <NNS>
or <CC>
did <VBD>
n't <RB>
compare <VB>
amounts <NNS>
smoked <VBN>
with <IN>
incidence <NN>
of <IN>
the <DT>
disease <NN>
. <.>
For <IN>
this <DT>
reason <NN>
, <,>
leukemia <NN>
`` <``>
has <VBZ>
in <IN>
general <JJ>
not <RB>
been_regarded <VBN>
as <IN>
a_a <DT>
malignancy <NN>
related <VBN>
to <TO>
smoking <NN>
, <,>
'' <''>
Dr._Kinlen <NNP>
wrote <VBD>
. <.>
The <DT>
latest <JJS>
analysis <NN>
does <VBZ>
n't <RB>
prove <VB>
a <DT>
causal_link <NN>
, <,>
Dr._Kinlen <NNP>
noted <VBD>
in <IN>
a <DT>
phone_interview <NN>
. <.>
But <CC>
`` <``>
it <PRP>
is <VBZ>
the <DT>
best <JJS>
evidence <NN>
to <TO>
date <NN>
that <IN>
the <DT>
relationship <NN>
is <VBZ>
genuine <JJ>
. <.>
`` <``>
If <IN>
the <DT>
link <NN>
is <VBZ>
causal <JJ>
, <,>
an <DT>
editorial <NN>
in <IN>
the <DT>
medical_journal <JJ>
said <VBD>
, <,>
`` <``>
then <RB>
smoking <VBG>
is <VBZ>
a <DT>
more <RBR>
important <JJ>
cause <NN>
of <IN>
leukemia <NN>
in <IN>
adults <NNS>
than <IN>
all <DT>
other <JJ>
known <VBN>
causes <NNS>
combined <VBN>
. <.>
`` <``>
Current <JJ>
known <NN>
causes <NNS>
include <VBP>
radiation <NN>
and <CC>
exposure <NN>
to <TO>
the <DT>
chemical <JJ>
benzene <NN>
. <.>
Leukemia <NNP>
is <VBZ>
fairly <RB>
rare <JJ>
. <.>
An <DT>
estimated <VBN>
18 <CD>
, <,>
100 <CD>
Americans <NNPS>
will <MD>
die <VB>
from <IN>
it <PRP>
this <DT>
year <NN>
, <,>
making <VBG>
the <DT>
disease <NN>
the <DT>
fifth-greatest <JJS>
cause <NN>
of <IN>
cancer <NN>
deaths <NNS>
. <.>
But <CC>
leukemia <IN>
represents <NNS>
the <DT>
third-leading <JJ>
cause <NN>
of <IN>
death <NN>
in <IN>
U.S. <NNP>
children <NNS>
, <,>
behind <IN>
accidents <NNS>
and <CC>
birth <JJ>
defects <NNS>
, <,>
according <VBG>
to <TO>
the <DT>
American_Cancer_Society <NNP>
AP900215-0131 <DOCNO>
. <.>
Here <RB>
are <VBP>
some <DT>
developments <NNS>
on <IN>
the <DT>
health_front <NN>
Thursday <NNP>
: <:>
Thirty-five <JJ>
million <NN>
Americans <NNS>
report <NN>
suffering <VBG>
from <IN>
arthritis <NNS>
and <CC>
6_million <CD>
admit <NN>
they <PRP>
have <VBP>
n't <RB>
seen <VBN>
a <DT>
doctor <NN>
about <IN>
it <PRP>
, <,>
according <VBG>
to <TO>
a <DT>
nationwide <JJ>
survey <NN>
released <VBN>
Thursday <NNP>
by <IN>
the <DT>
Centers <NNPS>
for <IN>
Disease_Control <NNP>
. <.>
`` <``>
People <NNS>
are <VBP>
seeing <VBG>
( <:>
pain-killer <JJ>
) <NN>
ads <NNS>
on <IN>
TV <NN>
and <CC>
treating <VBG>
their <PRP$>
arthritis <NNS>
themselves <PRP>
_ <NNP>
and <CC>
very_possibly <RB>
doing <VBG>
damage <NN>
to <TO>
themselves <PRP>
, <,>
'' <''>
said <VBD>
Steve_Erickson <NNP>
, <,>
spokesman <NN>
for <IN>
the <DT>
Arthritis_Foundation <NNP>
. <.>
The <DT>
problem <NN>
will <MD>
probably <RB>
get <VB>
worse <NN>
if <IN>
pain <NN>
relievers <NNS>
are <VBP>
the <DT>
only <JJ>
treatment <NN>
, <,>
he <PRP>
said <VBD>
. <.>
Erickson <NNP>
said <VBD>
too <RB>
few <JJ>
people <NNS>
are <VBP>
aware <JJ>
of <IN>
the <DT>
warning <NN>
signs <NNS>
of <IN>
arthritis <NNS>
, <,>
such <JJ>
as <IN>
joint <JJ>
swelling <NN>
, <,>
early <RB>
morning <VBG>
stiffness <NN>
, <,>
recurring <VBG>
joint <JJ>
pain <NN>
or <CC>
inability <NN>
to <TO>
move <VB>
a <DT>
joint <JJ>
that <IN>
lasts <NNS>
for <IN>
more <JJR>
than <IN>
two <CD>
weeks <NNS>
. <.>
At <IN>
least <JJS>
14 <CD>
deaths <NNS>
and <CC>
1 <CD>
, <,>
269 <CD>
cases <NNS>
of <IN>
a <DT>
rare <NN>
, <,>
painful <JJ>
blood_disorder <NN>
known <VBN>
as <IN>
eosinophilia-myalgia <NNP>
syndrome <NN>
have <VBP>
been_attributed <VBN>
to <TO>
the <DT>
health_food_supplement <NN>
L-tryptophan <JJ>
, <,>
the <DT>
Centers <NNPS>
for <IN>
Disease_Control <NNP>
reported <VBD>
Thursday <NNP>
. <.>
The <DT>
disorder <NN>
, <,>
marked <VBD>
by <IN>
an <DT>
abnormally <RB>
high <JJ>
number <NN>
of <IN>
white <JJ>
blood <NN>
cells <NNS>
, <,>
causes <NNS>
severe <RB>
muscle <JJ>
pain <NN>
and <CC>
can <MD>
cause <VB>
death <NN>
. <.>
The <DT>
median <JJ>
time <NN>
between <IN>
use <NN>
of <IN>
L-tryptophan <JJ>
and <CC>
the <DT>
onset <NN>
of <IN>
symptoms <NNS>
was <VBD>
152 <CD>
days <NNS>
. <.>
The <DT>
FDA <NNP>
issued <VBD>
a <DT>
recall_request <NN>
for <IN>
L-tryptophan <JJ>
on <IN>
Nov. <NNP>
17 <CD>
and <CC>
expanded <VBD>
it <PRP>
four <CD>
days <NNS>
later <JJ>
to <TO>
block <VB>
importation <NN>
of <IN>
the <DT>
product <NN>
, <,>
a <DT>
protein_component <NN>
widely <RB>
taken <VBN>
as <IN>
a <DT>
nutritional <JJ>
supplement <NN>
. <.>
Last <JJ>
month <NN>
, <,>
the <DT>
FDA <NNP>
cautioned <VBD>
consumers <NNS>
against <IN>
buying <VBG>
L-tryptophan <JJ>
products <NNS>
from <IN>
a <DT>
California <NNP>
company <NN>
that <WDT>
did <VBD>
not_comply <RB>
with <IN>
the <DT>
recall_request <NN>
. <.>
Researchers <NNS>
using <VBG>
an <DT>
intricate <JJ>
manipulation <NN>
of <IN>
genes <NNS>
and <CC>
transplantation <NN>
of <IN>
bone_marrow <NN>
have <VBP>
produced <VBN>
a <DT>
mouse <NN>
that <WDT>
suffers <NNS>
from <IN>
a <DT>
vicious <JJ>
form <NN>
of <IN>
human <JJ>
leukemia <NN>
, <,>
giving <VBG>
scientists <NNS>
a <DT>
new <JJ>
way <NN>
to <TO>
test <NN>
therapies <NNS>
against <IN>
the <DT>
killer_disease <NN>
. <.>
In <IN>
a <DT>
report <NN>
to <TO>
be <VB>
published <VBN>
Friday <NNP>
in <IN>
the <DT>
magazine <NN>
Science <NNP>
, <,>
researchers <NNS>
said <VBD>
they <PRP>
have <VBP>
discovered <VBN>
a <DT>
way <NN>
to <TO>
give <VB>
chronic_myelogenous <JJ>
leukemia <NN>
, <,>
CML <NNP>
, <,>
to <TO>
laboratory_mice <NN>
. <.>
CML <NNP>
is <VBZ>
a <DT>
form <NN>
of <IN>
leukemia <NN>
that <IN>
usually <RB>
attacks <VBZ>
adults <NNS>
and <CC>
is <VBZ>
only_rarely <RB>
cured <VBN>
. <.>
Lead <JJ>
researcher <NN>
George_Daley <NNP>
said <VBD>
the <DT>
study <NN>
also <RB>
proves <VBZ>
that <IN>
CML <NNP>
is <VBZ>
initiated <VBN>
by <IN>
the <DT>
fusion <NN>
of <IN>
parts <NNS>
from <IN>
two <CD>
broken <VBN>
chromosomes <NNS>
, <,>
a <DT>
finding <NN>
that <WDT>
had <VBD>
been_suggested <VBN>
by <IN>
earlier <JJR>
studies <NNS>
. <.>
Cells <NNS>
containing <VBG>
the <DT>
hybrid_gene_produce <NN>
a <DT>
protein <NN>
that <WDT>
changes <NNS>
healthy <VBP>
cells <NNS>
into <IN>
cancer <NN>
cells <NNS>
. <.>
Daley <NNP>
said <VBD>
it <PRP>
is <VBZ>
still_not <RB>
known <VBN>
precisely <RB>
what <WP>
causes <NNS>
the <DT>
two <CD>
chromosomes <NNS>
to <TO>
break <VB>
and <CC>
create <VB>
the <DT>
hybrid <JJ>
gene <NN>
, <,>
but <CC>
a <DT>
high <JJ>
exposure <NN>
to <TO>
radiation <NN>
is <VBZ>
thought <VBN>
to <TO>
be <VB>
a <DT>
factor <NN>
. <.>
A <DT>
study <NN>
of <IN>
airline-cabin <JJ>
environment <NN>
found <VBD>
that <IN>
, <,>
even <RB>
with <IN>
the <DT>
smoking_ban <NN>
that <WDT>
takes <VBZ>
effect <NN>
in <IN>
10 <CD>
days <NNS>
, <,>
passengers <NNS>
and <CC>
crew <VB>
still <RB>
face <VB>
a <DT>
health_risk <NN>
from <IN>
increased <VBN>
radiation <NN>
from <IN>
the <DT>
sun <NN>
and <CC>
stars <NNS>
. <.>
The <DT>
study <NN>
released <VBN>
Thursday <NNP>
by <IN>
the <DT>
Transportation_Department <NNP>
recommends <VBZ>
that <IN>
airlines <NNS>
schedule <VBP>
cabin <NN>
crews <NNS>
in <IN>
ways <NNS>
that <WDT>
will <MD>
reduce <VB>
their <PRP$>
risk <NN>
to <TO>
cosmic <JJ>
radiation <NN>
, <,>
especially <RB>
those <DT>
crews <NNS>
who <WP>
regularly_fly <RB>
near <IN>
the <DT>
North_Pole <NNP>
and <CC>
South_Pole <NNP>
or <CC>
at <IN>
higher <JJR>
altitudes <NNS>
. <.>
The <DT>
study <NN>
found <VBD>
the <DT>
risk <NN>
of <IN>
cancer_death <NN>
from <IN>
cosmic <JJ>
radiation <NN>
comparable <JJ>
to <TO>
the <DT>
risk <NN>
of <IN>
death <NN>
from <IN>
exposure <NN>
to <TO>
smoke-filled <JJ>
cabins <NNS>
, <,>
although <IN>
estimates <NNS>
of <IN>
cancer <NN>
caused <VBN>
by <IN>
cosmic <JJ>
rays <NNS>
had <VBD>
a <DT>
wider_range <NN>
because_of <IN>
uncertainty <NN>
over <IN>
the <DT>
effects <NNS>
of <IN>
low <JJ>
doses <NNS>
of <IN>
radiation <NN>
. <.>
It <PRP>
also <RB>
recommended <VBD>
a <DT>
total_smoking_ban <NN>
but <CC>
was <VBD>
superceded <VBN>
by <IN>
congressional <JJ>
action <NN>
banning <VBG>
smoking <NN>
on <IN>
all <DT>
flights <NNS>
of <IN>
six <CD>
hours <NNS>
or <CC>
less <JJR>
beginning <NN>
Feb. <NNP>
25 <CD>
AP900418-0106 <DOCNO>
. <.>
An <DT>
experimental <JJ>
cancer_drug <NN>
that <WDT>
works <VBZ>
after <IN>
a <DT>
single <JJ>
round <NN>
of <IN>
treatment <NN>
appears <VBZ>
to <TO>
be <VB>
the <DT>
most <JJS>
effective <JJ>
medicine <NN>
yet <RB>
for <IN>
a <DT>
rare_form <NN>
of <IN>
leukemia <NN>
, <,>
according <VBG>
to <TO>
a <DT>
study <NN>
. <.>
The <DT>
drug <NN>
_ <NNP>
called <VBD>
2-chlorodeoxyadenosine <CD>
, <,>
or <CC>
2-CdA <CD>
_ <NNP>
has <VBZ>
produced <VBN>
complete <JJ>
remissions <NNS>
in <IN>
almost <RB>
all <DT>
hairy_cell_leukemia <NN>
patients <NNS>
treated <VBD>
, <,>
and <CC>
none <NN>
has <VBZ>
relapsed <VBN>
so_far <RB>
. <.>
Researchers <NNS>
who <WP>
developed <VBD>
and <CC>
tested <VBN>
the <DT>
medicine_report <NN>
that <WDT>
it <PRP>
`` <``>
may <MD>
well <RB>
be <VB>
the <DT>
drug <NN>
of <IN>
choice <NN>
in <IN>
the <DT>
treatment <NN>
of <IN>
hairy_cell_leukemia <NN>
. <.>
'' <''>
The <DT>
drug <NN>
also <RB>
has <VBZ>
been_used <VBN>
successfully <RB>
against <IN>
chronic_lymphocytic <JJ>
leukemia <NN>
. <.>
It <PRP>
, <,>
like <IN>
hairy_cell_leukemia <NN>
, <,>
is <VBZ>
a <DT>
cancer <NN>
of <IN>
the <DT>
white <JJ>
blood <NN>
cells <NNS>
, <,>
which <WDT>
produce <NN>
disease-fighting <JJ>
antibodies <NNS>
. <.>
The <DT>
latest <JJS>
study <NN>
, <,>
published <VBD>
in <IN>
Thursday <NNP>
's <POS>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
, <,>
was <VBD>
directed <VBN>
by <IN>
Dr._Lawrence_D._Piro <NNP>
of <IN>
the <DT>
Scripps_Clinic <NNP>
and <CC>
Research_Foundation <NNP>
in <IN>
La_Jolla <NNP>
, <,>
Calif._Scripps <NNP>
recently <RB>
made <VBD>
an <DT>
agreement <NN>
with <IN>
Johnson <NNP>
& <CC>
amp <VB>
; <:>
Johnson <NNP>
's <POS>
Ortho <NNP>
Pharmaceuticals <NNPS>
to <TO>
produce <VB>
and <CC>
distribute <VB>
the <DT>
drug <NN>
once <RB>
it <PRP>
's <VBZ>
approved <VBN>
by <IN>
the <DT>
U.S._Food <NNP>
and <CC>
Drug_Administration <NNP>
. <.>
In <IN>
the <DT>
published <JJ>
work <NN>
, <,>
doctors <NNS>
gave <VBD>
the <DT>
drug <NN>
to <TO>
12 <CD>
patients <NNS>
as <IN>
far_back <RB>
as <IN>
four <CD>
years <NNS>
ago <RB>
. <.>
In <IN>
11 <CD>
, <,>
the <DT>
disease <NN>
disappeared <VBD>
and <CC>
they <PRP>
remain <VBP>
disease <NN>
free <JJ>
. <.>
In <IN>
all <DT>
, <,>
the <DT>
Scripps <NNP>
doctors <NNS>
have <VBP>
treated <VBN>
24 <CD>
patients <NNS>
with <IN>
almost <RB>
complete <JJ>
success <NN>
. <.>
However <RB>
, <,>
they <PRP>
caution <VBP>
that <IN>
longer <JJR>
follow <NN>
up <RB>
will <MD>
be <VB>
necessary <JJ>
before <IN>
they <PRP>
can <MD>
be <VB>
sure <JJ>
they <PRP>
have <VBP>
actually <RB>
cured <VBN>
the <DT>
disease <NN>
. <.>
Two <CD>
other <JJ>
treatments <NNS>
for <IN>
hairy_cell_leukemia <NN>
have <VBP>
been_developed <VBN>
in <IN>
recent <JJ>
years <NNS>
. <.>
They <PRP>
are <VBP>
interferon <RB>
and <CC>
deoxycoformycin <VB>
, <,>
a <DT>
drug <NN>
that <WDT>
is <VBZ>
similar <JJ>
to <TO>
2-CdA <CD>
. <.>
However <RB>
, <,>
interferon <NN>
is <VBZ>
less <JJR>
effective <JJ>
, <,>
and <CC>
both <DT>
of <IN>
those <DT>
treatments <NNS>
produce <VBP>
serious <JJ>
side <NN>
effects <NNS>
. <.>
By <IN>
contrast <NN>
, <,>
the <DT>
only_unwanted <JJ>
effect <NN>
of <IN>
2-CdA <CD>
was <VBD>
a <DT>
few <JJ>
days <NNS>
of <IN>
fever <NN>
. <.>
Patients <NNS>
experienced <VBD>
no <DT>
nausea <NN>
, <,>
hair_loss <NN>
, <,>
rashes <VBZ>
or <CC>
other <JJ>
symptoms <NNS>
typical <JJ>
of <IN>
cancer_therapy <NN>
. <.>
Also <RB>
unlike <VBP>
other <JJ>
treatments <NNS>
, <,>
this <DT>
one <CD>
appears <VBZ>
to <TO>
work <VB>
after <IN>
a <DT>
single <JJ>
seven-day_course <NN>
of <IN>
therapy <NN>
AP880429-0036 <DOCNO>
. <.>
The <DT>
American_Red_Cross <NNP>
is <VBZ>
`` <``>
right <RB>
on <IN>
target <NN>
'' <''>
with <IN>
plans <NNS>
to <TO>
start <VB>
testing <NN>
donated <VBN>
blood <NN>
for <IN>
a <DT>
rare_virus <NN>
linked <VBD>
to <TO>
a <DT>
vicious <JJ>
form <NN>
of <IN>
adult_leukemia <NN>
, <,>
says <VBZ>
the <DT>
National_Cancer_Institute <NNP>
researcher <NN>
who <WP>
first <RB>
discovered <VBD>
the <DT>
virus <NN>
. <.>
Dr._Robert_Gallo <NNP>
, <,>
a <DT>
scientist <NN>
credited <VBN>
with <IN>
discovering <NN>
the <DT>
human <NN>
T-lymphotropic <JJ>
virus_type <NN>
1 <CD>
, <,>
or <CC>
HTLV-1 <-NONE->
, <,>
said <VBD>
the <DT>
nation's <NNP>
blood_supply <NN>
should <MD>
be <VB>
tested <VBN>
to <TO>
protect <VB>
future <JJ>
generations <NNS>
from <IN>
the <DT>
slow-acting <JJ>
but <CC>
dangerous <JJ>
virus <NNS>
. <.>
In <IN>
a <DT>
Science <NNP>
magazine_report <NN>
published <VBD>
today <NN>
, <,>
Red_Cross <NNP>
scientist <NN>
recommended <VBD>
that <IN>
blood <NN>
donated <VBD>
across <IN>
the <DT>
country <NN>
should <MD>
be <VB>
tested <VBN>
for <IN>
the <DT>
HTLV-1 <-NONE->
virus <VBZ>
as <IN>
soon <RB>
as <IN>
a <DT>
practical <JJ>
test <NN>
be <VB>
developed <VBN>
. <.>
The <DT>
recommendation <NN>
was <VBD>
made <VBN>
after <IN>
a <DT>
Red_Cross <NNP>
survey <NN>
found <VBD>
10 <CD>
units <NNS>
infected <VBN>
with <IN>
the <DT>
virus <NNS>
out_of <IN>
39 <CD>
, <,>
898 <CD>
units <NNS>
tested <VBN>
. <.>
`` <``>
I <PRP>
think <VBP>
there <RB>
are <VBP>
as <IN>
many <JJ>
people <NNS>
infected <VBN>
with <IN>
this <DT>
virus <NN>
as <IN>
are <VBP>
infected <VBN>
with <IN>
the <DT>
AIDS <NNP>
virus <VBZ>
, <,>
'' <''>
Gallo <NNP>
said <VBD>
. <.>
Alan_E._Williams <NNP>
, <,>
a <DT>
research_scientist <NN>
at <IN>
the <DT>
Red_Cross <NNP>
laboratory <NN>
in <IN>
Rockville <NNP>
, <,>
Md. <NNP>
, <,>
said <VBD>
his <PRP$>
research_team <NN>
estimates <NNS>
that <WDT>
the <DT>
risk <NN>
of <IN>
becoming <VBG>
infected <VBN>
with <IN>
the <DT>
HTLV-1 <-NONE->
leukemia <NN>
virus_is <VBZ>
about <IN>
2 <CD>
, <,>
800 <CD>
in <IN>
12_million <CD>
, <,>
or <CC>
about <IN>
1 <CD>
chance <NN>
in <IN>
4 <CD>
, <,>
286 <CD>
for <IN>
every <DT>
unit <NN>
of <IN>
blood <NN>
transfused <VBN>
annually <RB>
. <.>
`` <``>
The <DT>
danger <NN>
is <VBZ>
minimal <JJ>
but <CC>
not <RB>
insignificant <JJ>
, <,>
'' <''>
Williams <NNP>
said <VBD>
. <.>
For <IN>
that <DT>
reason <NN>
, <,>
he <PRP>
said <VBD>
, <,>
the <DT>
Red_Cross <NNP>
`` <``>
wants <VBZ>
to <TO>
take <VB>
an <DT>
active <JJ>
stance <NN>
to <TO>
keep <VB>
the <DT>
situation <NN>
from <IN>
getting <VBG>
worse <NN>
, <,>
as <IN>
it <PRP>
possibly <RB>
could <MD>
. <.>
'' <''>
Williams <NNP>
said <VBD>
current <JJ>
methods <NNS>
of <IN>
testing <NN>
donated <VBN>
blood <NN>
for <IN>
the <DT>
virus_take <NN>
up <RP>
to <TO>
three <CD>
days <NNS>
and <CC>
a <DT>
more <RBR>
practical <JJ>
test <NN>
must <MD>
be <VB>
developed <VBN>
before <IN>
HTLV-1 <-NONE->
screening <VBG>
can <MD>
begin <VB>
. <.>
He <PRP>
said <VBD>
at <IN>
least <JJS>
three <CD>
drug <NN>
companies <NNS>
, <,>
which <WDT>
he <PRP>
declined <VBD>
to <TO>
name <VB>
, <,>
are <VBP>
trying <VBG>
to <TO>
develop <VB>
screening <NN>
tests <NNS>
, <,>
but <CC>
these <DT>
are <VBP>
months <NNS>
from <IN>
possible <JJ>
approval <NN>
by <IN>
the <DT>
Food <NNP>
and <CC>
Drug_Administration <NNP>
. <.>
The <DT>
NCI <NNP>
researcher <NN>
discovered <VBD>
and <CC>
identified <VBD>
the <DT>
HTLV-1 <-NONE->
virus <VBZ>
in <IN>
1978 <CD>
. <.>
Gallo <NNP>
said <VBD>
his <PRP$>
understanding <NN>
of <IN>
HTLV-1 <-NONE->
, <,>
a <DT>
retrovirus <NN>
that <WDT>
takes <VBZ>
over <IN>
genetic <JJ>
control <NN>
of <IN>
cells <NNS>
it <PRP>
attacks <VBZ>
, <,>
led <VBN>
him <PRP>
to <TO>
look <VB>
for <IN>
a <DT>
retrovirus <NN>
as <IN>
the <DT>
cause <NN>
of <IN>
AIDS <NNP>
. <.>
He <PRP>
is <VBZ>
credited <VBN>
as <RB>
co-discoverer <JJ>
of <IN>
the <DT>
HIV <NNP>
virus <VBZ>
that <IN>
causes_AIDS <NNS>
. <.>
Gallo <NNP>
said <VBD>
HTLV-1 <-NONE->
may <MD>
be <VB>
rare <JJ>
in <IN>
the <DT>
continental <JJ>
United <NNP>
States <NNPS>
, <,>
but <CC>
it <PRP>
is <VBZ>
endemic <JJ>
in <IN>
parts <NNS>
of <IN>
Europe <NNP>
, <,>
Alaska <NNP>
, <,>
Africa <NNP>
and <CC>
the <DT>
Orient <NNP>
. <.>
`` <``>
In <IN>
time <NN>
, <,>
due <JJ>
to <TO>
increased <VBN>
travel <NN>
and <CC>
increased <VBD>
sexual <JJ>
contact <NN>
, <,>
these <DT>
kinds <NNS>
of <IN>
virus <NN>
are <VBP>
all <DT>
increasing <VBG>
( <NN>
in <IN>
the <DT>
continental <JJ>
U.S._) <NNP>
, <,>
'' <''>
said <VBD>
Gallo <NNP>
. <.>
Because <IN>
HTLV-1 <-NONE->
has <VBZ>
a <DT>
long <JJ>
latent_period <NN>
before <IN>
it <PRP>
causes <VBZ>
disease <NN>
, <,>
he <PRP>
said <VBD>
, <,>
`` <``>
it <PRP>
is <VBZ>
not <RB>
as <IN>
readily <RB>
seen <VBN>
as <IN>
AIDS <NNP>
, <,>
but <CC>
our <PRP$>
children <NNS>
and <CC>
our <PRP$>
children <NNS>
's <POS>
children <NNS>
will <MD>
see <VB>
it <PRP>
if <IN>
we <PRP>
do <VBP>
n't <RB>
start <VB>
eliminating <VBG>
it <PRP>
from <IN>
the <DT>
blood_supply <NN>
. <.>
'' <''>
Gallo <NNP>
added <VBD>
, <,>
`` <``>
I <PRP>
'm <VBP>
very <RB>
glad <JJ>
to <TO>
see <VB>
the <DT>
way <NN>
the <DT>
Red_Cross <NNP>
has <VBZ>
responded <VBN>
. <.>
'' <''>
Dr._Edward_Murphy <NNP>
, <,>
a <DT>
National_Cancer_Institute <NNP>
researcher <NN>
who <WP>
has <VBZ>
studied <VBN>
the <DT>
HTLV-1 <-NONE->
virus <VBZ>
extensively <RB>
, <,>
said <VBD>
it <PRP>
is <VBZ>
linked <VBN>
to <TO>
adult <VB>
T-cell <JJ>
leukemia-lymphoma <NN>
, <,>
a <DT>
type <NN>
of <IN>
blood_cancer <NN>
usually <RB>
fatal <JJ>
within <IN>
six <CD>
months <NNS>
. <.>
Another <DT>
disease <NN>
closely <RB>
linked <VBN>
to <TO>
the <DT>
virus <NN>
, <,>
said <VBD>
Murphy <NNP>
, <,>
is <VBZ>
tropical_spastic <JJ>
paraparesis <NN>
, <,>
in <IN>
which <WDT>
the <DT>
virus <NN>
attacks <NNS>
nerve <VBP>
cells <NNS>
that <IN>
control <NN>
the <DT>
lower <JJR>
extremities <NNS>
and <CC>
causes <NNS>
paralysis <NN>
and <CC>
eventually <RB>
death <NN>
. <.>
The <DT>
incubation_period <NN>
for <IN>
expression <NN>
of <IN>
the <DT>
leukemia <NN>
is <VBZ>
thought <VBN>
to <TO>
be <VB>
30 <CD>
years <NNS>
or <CC>
more <JJR>
, <,>
but <CC>
people <NNS>
exposed <VBD>
to <TO>
the <DT>
virus_become <NN>
infectious <JJ>
within <IN>
two <CD>
weeks <NNS>
to <TO>
six <CD>
months <NNS>
, <,>
said <VBD>
Murphy <NNP>
. <.>
Incubation <NN>
for <IN>
paraparesis <NN>
is <VBZ>
slightly <RB>
shorter <JJR>
. <.>
The <DT>
virus <NN>
can <MD>
be <VB>
spread <VBN>
in <IN>
ways <NNS>
similar <JJ>
to <TO>
the <DT>
AIDS <NNP>
virus <VBZ>
: <:>
by <IN>
sexual <JJ>
contact <NN>
or <CC>
the <DT>
exchange <NN>
of <IN>
body <NN>
fluids <NNS>
such <JJ>
as_by <IN>
sharing_drug <NN>
needles <NNS>
. <.>
HTLV-1 <-NONE->
also <RB>
is <VBZ>
thought <VBN>
to <TO>
be <VB>
spread <VBN>
through <IN>
mother's <JJ>
milk <NN>
, <,>
said <VBD>
Murphy <NNP>
. <.>
Williams <NNP>
said <VBD>
the <DT>
Red_Cross <NNP>
survey <NN>
checked <VBD>
for <IN>
HTLV-1 <-NONE->
in <IN>
samples <NNS>
from <IN>
eight <CD>
different <JJ>
blood <NN>
banks <NNS>
. <.>
Blood <NNP>
donors <NNS>
who <WP>
tested <VBN>
positive <JJ>
for <IN>
the <DT>
virus <NN>
were <VBD>
found <VBN>
in <IN>
Atlanta <NNP>
, <,>
Washington <NNP>
, <,>
Birmingham <NNP>
, <,>
Ala. <NNP>
and <CC>
Los_Angeles <NNP>
. <.>
Blood <NNP>
also <RB>
was <VBD>
tested <VBN>
in <IN>
St._Paul <NNP>
, <,>
Minn. <NNP>
, <,>
Portland <NNP>
, <,>
Ore. <NNP>
, <,>
Baltimore <NNP>
and <CC>
Miami <NNP>
, <,>
but <CC>
no <DT>
HTLV-1 <-NONE->
was <VBD>
found <VBN>
. <.>
Though <IN>
the <DT>
positive <JJ>
tests <NNS>
totaled <VBD>
only <RB>
10 <CD>
out_of <IN>
more <JJR>
than <IN>
39 <CD>
, <,>
000 <CD>
samples <NNS>
tested <VBN>
, <,>
Williams <NNP>
said <VBD>
, <,>
`` <``>
a <DT>
highly <RB>
selective <JJ>
group <NN>
'' <''>
was <VBD>
used <VBN>
. <.>
`` <``>
They <PRP>
go <VBP>
through <IN>
several <JJ>
levels <NNS>
( <:>
of <IN>
screening <NN>
) <:>
before <IN>
the <DT>
blood <NN>
is <VBZ>
ever <RB>
drawn <VBN>
, <,>
'' <''>
he <PRP>
said <VBD>
AP901211-0040 <DOCNO>
. <.>
Cigarette <NNP>
smoking <NN>
appears <VBZ>
to <TO>
increase <VB>
the <DT>
risk <NN>
of <IN>
developing <VBG>
leukemia <NN>
, <,>
and <CC>
kicking <VBG>
the <DT>
habit <NN>
may <MD>
not <RB>
be <VB>
enough <RB>
to <TO>
dodge <VB>
the <DT>
dreaded <VBN>
blood_disease <NN>
, <,>
a <DT>
study <NN>
says <VBZ>
. <.>
Paul_K._Mills <NNP>
, <,>
a <DT>
professor <NN>
at <IN>
Loma_Linda_University <NNP>
and <CC>
the <DT>
principal_author <NN>
of <IN>
the <DT>
study <NN>
, <,>
said <VBD>
research <NN>
suggests <NNS>
that <WDT>
even <RB>
former <JJ>
smokers <NNS>
are <VBP>
at <IN>
high <JJ>
risk <NN>
. <.>
`` <``>
It <PRP>
's <VBZ>
very <RB>
discouraging <VBG>
, <,>
'' <''>
Mills <NNP>
said <VBD>
Monday <NNP>
. <.>
`` <``>
We <PRP>
saw <VBD>
a <DT>
strong <JJ>
association <NN>
between <IN>
prior <RB>
cigarette <JJ>
smoking <NN>
and <CC>
the <DT>
risk <NN>
of <IN>
developing <VBG>
leukemia <NN>
. <.>
'' <''>
The <DT>
study <NN>
's <POS>
results <NNS>
are <VBP>
being <VBG>
published <VBN>
this <DT>
month <NN>
in <IN>
the <DT>
Journal <NNP>
of <IN>
the <DT>
National_Cancer_Institute <NNP>
. <.>
Cigarette <NNP>
smoking <NN>
also <RB>
has <VBZ>
been_linked <VBN>
to <TO>
cancers <NNS>
of <IN>
the <DT>
lung <NN>
, <,>
bladder <NN>
, <,>
pancreas <VBZ>
, <,>
esophagus <VBZ>
, <,>
throat <JJ>
and <CC>
cervix <NN>
. <.>
The <DT>
study <NN>
is <VBZ>
part <NN>
of <IN>
the <DT>
Adventist_Health_Study <NNP>
, <,>
a <DT>
major_epidemiological <JJ>
investigation <NN>
of <IN>
the <DT>
causes <NNS>
of <IN>
various <JJ>
cancers <NNS>
among <IN>
California <NNP>
members <NNS>
of <IN>
the <DT>
Seventh-day <JJ>
Adventist_Church <NNP>
. <.>
About <IN>
34 <CD>
, <,>
000 <CD>
Adventists <NNS>
responded <VBD>
to <TO>
the <DT>
study <NN>
. <.>
Although <IN>
the <DT>
vast <JJ>
majority <NN>
of <IN>
Adventists <NNPS>
do <VBP>
not <RB>
smoke <VB>
by <IN>
church_proscription <NN>
, <,>
many <JJ>
are <VBP>
adult <VBN>
converts <NNS>
to <TO>
the <DT>
religion <NN>
who <WP>
smoked <VBN>
cigarettes <VBZ>
prior <RB>
to <TO>
their <PRP$>
baptism <NN>
into <IN>
the <DT>
church <NN>
. <.>
The <DT>
researchers <NNS>
found <VBD>
that <IN>
the <DT>
ex-smokers <NNS>
had <VBD>
twice <NN>
the <DT>
risk <NN>
of <IN>
developing <VBG>
leukemia <NN>
than <IN>
non-smokers <NNS>
. <.>
For <IN>
people <NNS>
who <WP>
regularly <RB>
smoked <VBD>
more <JJR>
than <IN>
25 <CD>
cigarettes <NNS>
a <DT>
day <NN>
, <,>
the <DT>
risk <NN>
of <IN>
developing <VBG>
leukemia <NN>
increased <VBD>
threefold <NN>
. <.>
The <DT>
Adventists <NNPS>
who <WP>
had <VBD>
smoked <VBN>
for <IN>
more <JJR>
than <IN>
15 <CD>
years <NNS>
had <VBD>
a <DT>
2_{ <CD>
-fold <JJ>
increased <VBN>
leukemia_risk <NN>
. <.>
Leukemia <NNP>
is <VBZ>
a <DT>
bone_marrow_cancer <NN>
in <IN>
which <WDT>
the <DT>
marrow <NN>
is <VBZ>
replaced <VBN>
by <IN>
immature <NN>
, <,>
abnormal_white <JJ>
blood <NN>
cells <NNS>
. <.>
The <DT>
disease <NN>
kills <NNS>
18 <CD>
, <,>
000 <CD>
people <NNS>
a <DT>
year <NN>
in <IN>
the <DT>
United <NNP>
States <NNPS>
. <.>
Dr._Clark_Heath_Jr. <NNP>
of <IN>
the <DT>
American_Cancer_Society <NNP>
said <VBD>
the <DT>
causes <NNS>
of <IN>
leukemia <NN>
are <VBP>
largely <RB>
unknown <VBN>
. <.>
But <CC>
several <JJ>
studies <NNS>
in <IN>
recent <JJ>
years <NNS>
, <,>
including <VBG>
a <DT>
large <JJ>
study <NN>
of <IN>
U.S. <NNP>
military <JJ>
veterans <NNS>
, <,>
have <VBP>
suggested <VBN>
smoking <VBG>
as <IN>
a <DT>
cause <NN>
, <,>
he <PRP>
said <VBD>
. <.>
The <DT>
Loma_Linda <NNP>
study <NN>
estimates <VBZ>
that_about <IN>
20 <CD>
percent <NN>
of <IN>
leukemia <NN>
cases <NNS>
were <VBD>
linked <VBN>
to <TO>
smoking <NN>
AP900814-0015 <DOCNO>
. <.>
In <IN>
a <DT>
medical_first <JJ>
, <,>
five <CD>
tablespoons <NNS>
of <IN>
umbilical <JJ>
cord_blood <NN>
saved <VBD>
after <IN>
the <DT>
birth <NN>
of <IN>
a <DT>
baby <NN>
were <VBD>
given <VBN>
to <TO>
her <PRP$>
4-year-old <JJ>
brother <NN>
in <IN>
hopes <NNS>
it <PRP>
will <MD>
help <VB>
him <PRP>
form <VB>
new <JJ>
bone_marrow <NN>
and <CC>
beat <VB>
fast-acting <JJ>
leukemia <NN>
. <.>
Michael_Sancilio <NNP>
received <VBD>
the <DT>
transfusion <NN>
at <IN>
Johns_Hopkins_Oncology_Center <NNP>
on <IN>
Monday <NNP>
. <.>
His <PRP$>
3-month-old <JJ>
sister <NN>
, <,>
Christina <NNP>
, <,>
is <VBZ>
too <RB>
young <JJ>
to <TO>
donate <VB>
bone_marrow <NN>
, <,>
the <DT>
usual <JJ>
treatment <NN>
for <IN>
Michael <NNP>
's <POS>
form <NN>
of <IN>
leukemia <NN>
, <,>
and <CC>
doctors <NNS>
were <VBD>
afraid <VBN>
he <PRP>
would <MD>
n't <RB>
survive <VB>
the <DT>
three-month <JJ>
wait <NN>
before <IN>
his <PRP$>
sister <NN>
became <VBD>
old <JJ>
enough <RB>
. <.>
`` <``>
We <PRP>
did <VBD>
n't <RB>
have <VB>
any <DT>
other <JJ>
choice <NN>
, <,>
'' <''>
said <VBD>
the <DT>
youngsters' <NNP>
mother <NN>
, <,>
Denise_Sancilio <NNP>
. <.>
`` <``>
We <PRP>
could <MD>
n't <RB>
put <VB>
our <PRP$>
baby <NN>
through <IN>
a <DT>
bone_marrow_aspiration <NN>
. <.>
It <PRP>
's <VBZ>
very <RB>
dangerous <JJ>
for <IN>
her <PRP>
. <.>
We <PRP>
were <VBD>
in <IN>
a <DT>
situation <NN>
where <WRB>
we <PRP>
had <VBD>
to <TO>
do <VB>
it <PRP>
. <.>
'' <''>
It <PRP>
was <VBD>
the <DT>
first <JJ>
time <NN>
the <DT>
rare_operation <NN>
was <VBD>
undertaken <VBN>
to <TO>
treat <VB>
leukemia <NN>
, <,>
an <DT>
often <RB>
fatal <JJ>
blood_cancer <NN>
. <.>
It <PRP>
has <VBZ>
been_performed <VBN>
three <CD>
other <JJ>
times <NNS>
, <,>
once <RB>
in <IN>
Cincinnati <NNP>
and <CC>
twice <NN>
in <IN>
France <NNP>
, <,>
to <TO>
treat <VB>
a <DT>
different <JJ>
disease <NN>
, <,>
Fanconi <NNP>
's <POS>
anemia <NN>
. <.>
Umbilical <JJ>
cord_blood <NN>
is <VBZ>
rich <JJ>
in <IN>
stem <NN>
cells <NNS>
, <,>
used <VBN>
by <IN>
the <DT>
recipient <JJ>
to <TO>
form_marrow <NN>
. <.>
Doctors <NNS>
said <VBD>
they <PRP>
will <MD>
know <VB>
in_about <IN>
three <CD>
weeks <NNS>
whether <IN>
the <DT>
operation <NN>
worked <VBD>
. <.>
Michael <NNP>
, <,>
who <WP>
has <VBZ>
juvenile_chronic_myelogenous <JJ>
leukemia <NN>
, <,>
is <VBZ>
at <IN>
extreme_risk <NN>
of <IN>
infection <NN>
in <IN>
the <DT>
meantime <NN>
because <IN>
his <PRP$>
cancerous <JJ>
bone_marrow <NN>
had <VBD>
to <TO>
be <VB>
destroyed <VBN>
as <IN>
part <NN>
of <IN>
the <DT>
treatment <NN>
. <.>
Marrow <NNP>
is <VBZ>
critical <JJ>
to <TO>
the <DT>
immune_system <NN>
. <.>
`` <``>
He <PRP>
's <VBZ>
been <VBN>
on <IN>
and <CC>
off <IN>
sleeping <VBG>
all <DT>
day <NN>
, <,>
'' <''>
Michael <NNP>
's <POS>
father <NN>
, <,>
Tony <NNP>
, <,>
said <VBD>
Monday <NNP>
night <NN>
. <.>
`` <``>
This <DT>
afternoon <NN>
he <PRP>
got <VBD>
up <RP>
and <CC>
walked <VBD>
down <RP>
the <DT>
hall <NN>
and <CC>
to <TO>
the <DT>
children <NNS>
's <POS>
playroom <NN>
. <.>
He <PRP>
's <VBZ>
up <RP>
and <CC>
alert <NN>
. <.>
A <DT>
little <RB>
groggy <NN>
but <CC>
holding <VBG>
his <PRP$>
own <JJ>
. <.>
'' <''>
Mrs._Sancilio <NNP>
said <VBD>
she <PRP>
was <VBD>
7_{ <CD>
months <NNS>
pregnant <JJ>
with <IN>
Christina <NNP>
when <WRB>
she <PRP>
learned <VBD>
Michael <NNP>
had <VBD>
a <DT>
form <NN>
of <IN>
leukemia <NN>
that <IN>
can <MD>
not <RB>
be <VB>
controlled <VBN>
with <IN>
drugs <NNS>
and <CC>
usually <RB>
kills <VBZ>
within <IN>
a <DT>
year <NN>
of <IN>
diagnosis <NN>
. <.>
The <DT>
umbilical <JJ>
cord_blood <NN>
was <VBD>
frozen <VBN>
when <WRB>
Christina <NNP>
was <VBD>
born <VBN>
May <NNP>
1 <CD>
. <.>
A <DT>
total <NN>
of <IN>
2.7 <CD>
ounces <NNS>
were <VBD>
given <VBN>
to <TO>
Michael <NNP>
after <IN>
chemotherapy <NN>
to <TO>
destroy <VB>
his <PRP$>
cancerous <JJ>
marrow <NN>
. <.>
The <DT>
transplant <NN>
carries <VBZ>
the <DT>
same <JJ>
risk <NN>
as <IN>
a <DT>
bone-marrow_transplant <NN>
. <.>
Besides <IN>
the <DT>
risk <NN>
of <IN>
infection <NN>
, <,>
the <DT>
body <NN>
often <RB>
rejects <VBZ>
foreign <JJ>
cells <NNS>
. <.>
Michael <NNP>
's <POS>
blood_type <NN>
does <VBZ>
not <RB>
match <VB>
his <PRP$>
sister <NN>
's <POS>
, <,>
but <CC>
doctors <NNS>
found <VBD>
that <IN>
he <PRP>
was <VBD>
not_overly <RB>
likely <JJ>
to <TO>
reject <VB>
the <DT>
umbilical <JJ>
cord_blood <NN>
. <.>
Tests <NNS>
on <IN>
Michael <NNP>
's <POS>
parents <NNS>
and <CC>
his <PRP$>
7-year-old <JJ>
brother <NN>
, <,>
also <RB>
named <VBD>
Tony <NNP>
, <,>
showed <VBD>
they <PRP>
were <VBD>
not <RB>
compatible <JJ>
marrow <NN>
donors <NNS>
. <.>
The <DT>
family <NN>
lives <VBZ>
in <IN>
Virginia_Beach <NNP>
, <,>
Va. <NNP>
`` <``>
The <NNP>
odds <NNS>
were <VBD>
we <PRP>
thought <VBD>
he <PRP>
had <VBD>
the <DT>
chance <NN>
of <IN>
surviving <VBG>
for <IN>
a <DT>
couple <NN>
of <IN>
months <NNS>
, <,>
but <CC>
it <PRP>
was <VBD>
unknown <VBN>
when <WRB>
the <DT>
disease <NN>
would <MD>
accelerate <VB>
and <CC>
become <VB>
life-threatening <JJ>
, <,>
'' <''>
said <VBD>
Dr._John_Wagner <NNP>
. <.>
`` <``>
We <PRP>
decided <VBD>
to <TO>
go <VB>
ahead <RB>
and <CC>
take <VB>
the <DT>
chance <NN>
on <IN>
the <DT>
cord_blood <NN>
rather <RB>
than <IN>
waiting <VBG>
until <IN>
the <DT>
donor <NN>
was <VBD>
old <JJ>
enough <RB>
. <.>
'' <''>
If <IN>
the <DT>
transfusion <NN>
works <VBZ>
, <,>
it <PRP>
could <MD>
lead <VB>
to <TO>
creation <NN>
of <IN>
a <DT>
bank <NN>
of <IN>
umbilical <JJ>
cord_blood <NN>
to <TO>
aid <NN>
similarly <RB>
afflicted <VBN>
youngsters <NNS>
, <,>
doctors <NNS>
said <VBD>
. <.>
The <DT>
transfusion <NN>
can <MD>
be <VB>
performed <VBN>
only <RB>
on <IN>
young <JJ>
children <NNS>
because <IN>
not_enough <RB>
blood <NN>
is <VBZ>
in <IN>
the <DT>
umbilical <JJ>
cord <NN>
for <IN>
use <NN>
with <IN>
adults <NNS>
, <,>
said <VBD>
Dr._Richard_Champlin <NNP>
, <,>
chief <NN>
of <IN>
the <DT>
bone-marrow <JJ>
transplant_program <NN>
at <IN>
M.D <JJ>
. <.>
Anderson_Cancer_Center <NNP>
in <IN>
Houston <NNP>
. <.>
`` <``>
In <IN>
the <DT>
long <JJ>
run <NN>
it <PRP>
could <MD>
provide <VB>
the <DT>
potential <JJ>
to <TO>
protect <VB>
and <CC>
store <VB>
umbilical <JJ>
blood <NN>
from <IN>
every <DT>
baby <NN>
and <CC>
create <VB>
a <DT>
bank <NN>
of <IN>
cells <NNS>
for <IN>
transplantation <NN>
that <WDT>
could <MD>
be <VB>
used <VBN>
if <IN>
a <DT>
patient <NN>
did <VBD>
n't <RB>
have <VB>
a <DT>
donor <NN>
within <IN>
the <DT>
family <NN>
, <,>
'' <''>
he <PRP>
said <VBD>
AP900802-0028 <DOCNO>
. <.>
Scientists <NNS>
today <NN>
reported <VBD>
finding <VBG>
the <DT>
first <JJ>
treatment <NN>
capable <JJ>
of <IN>
relieving <NN>
and <CC>
even <RB>
curing <VBG>
chronic <JJ>
hepatitis <NNS>
B <NNP>
, <,>
one <CD>
of <IN>
the <DT>
world <NN>
's <POS>
biggest <JJS>
killers <NNS>
. <.>
A <DT>
study <NN>
in <IN>
the <DT>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
indicates <VBZ>
that <IN>
shots <NNS>
of <IN>
a <DT>
synthetic <JJ>
form <NN>
of <IN>
the <DT>
natural <JJ>
protein_interferon <NN>
can <MD>
prevent <VB>
the <DT>
virus <NN>
from <IN>
destroying <VBG>
the <DT>
liver <NN>
in <IN>
nearly <RB>
half <NN>
the <DT>
people <NNS>
chronically <RB>
infected <VBN>
. <.>
One <CD>
in <IN>
10 <CD>
victims <NNS>
can <MD>
be <VB>
cured <VBN>
, <,>
while <IN>
the <DT>
drug <NN>
had <VBD>
no <DT>
benefits <NNS>
for <IN>
60 <CD>
percent <NN>
of <IN>
the <DT>
169 <CD>
people <NNS>
studied <VBN>
in <IN>
clinical <JJ>
trials <NNS>
, <,>
researchers <NNS>
said <VBD>
. <.>
Hepatitis_B <NNP>
is <VBZ>
the <DT>
chief <NN>
underlying <VBG>
cause <NN>
of <IN>
liver_cancer <NN>
and <CC>
cirrhosis <NN>
and <CC>
the <DT>
world <NN>
's <POS>
ninth-leading <JJ>
cause <NN>
of <IN>
death <NN>
, <,>
just <RB>
behind <IN>
lung <JJ>
disease <NN>
and <CC>
well_ahead <RB>
of <IN>
AIDS <NNP>
, <,>
according <VBG>
to <TO>
the <DT>
World_Health_Organization <NNP>
. <.>
An <DT>
estimated <VBN>
1_million <CD>
to <TO>
1.5_million <CD>
people <NNS>
in <IN>
the <DT>
United <NNP>
States <NNPS>
are <VBP>
long-term <JJ>
carriers <NNS>
of <IN>
the <DT>
hepatitis <NNS>
B <NNP>
virus <NN>
. <.>
At <IN>
least <JJS>
half <NN>
of <IN>
them <PRP>
have <VBP>
liver <RB>
disease <VB>
. <.>
Worldwide <NNP>
, <,>
300_million <CD>
people <NNS>
, <,>
or <CC>
5 <CD>
percent <NN>
of <IN>
the <DT>
world <NN>
's <POS>
population <NN>
, <,>
are <VBP>
chronically <RB>
infected <VBN>
. <.>
Until <IN>
now <RB>
, <,>
there <EX>
has <VBZ>
been <VBN>
no <DT>
treatment <NN>
or <CC>
cure <NN>
for <IN>
the <DT>
virus <NN>
. <.>
`` <``>
This <DT>
is <VBZ>
an <DT>
encouraging <VBG>
result <NN>
. <.>
All <DT>
of <IN>
us <PRP>
would <MD>
feel <VB>
a <DT>
lot_happier <NN>
if <IN>
we <PRP>
had <VBD>
a <DT>
better <JJR>
treatment <NN>
. <.>
This <DT>
spurs <NNS>
us <PRP>
on <IN>
to <TO>
find <VB>
that <IN>
, <,>
'' <''>
said <VBD>
Dr._Baruch_S._Blumberg <NNP>
of <IN>
the <DT>
Fox_Chase_Cancer_Center <NNP>
in <IN>
Philadelphia <NNP>
. <.>
Blumberg <NNP>
won <VBD>
the <DT>
Nobel_Prize <NNP>
in <IN>
medicine <NN>
in <IN>
1976 <CD>
for <IN>
identifying <NN>
the <DT>
virus <NN>
. <.>
The <DT>
latest <JJS>
research <NN>
, <,>
which <WDT>
involved <VBN>
169 <CD>
people <NNS>
at <IN>
12 <CD>
hospitals <NNS>
, <,>
confirms <NNS>
several <JJ>
smaller <JJR>
studies <NNS>
suggesting <VBG>
that <IN>
interferon <NN>
works <NNS>
. <.>
Other <JJ>
studies <NNS>
have <VBP>
also <RB>
shown <VBN>
that <IN>
interferon <NN>
works <NNS>
against <IN>
hepatitis <NNS>
C <NNP>
, <,>
another <DT>
serious <JJ>
but <CC>
less <JJR>
common <JJ>
variety <NN>
of <IN>
the <DT>
virus <NN>
. <.>
Although <IN>
the <DT>
Food <NNP>
and <CC>
Drug_Administration <NNP>
has <VBZ>
not_yet <RB>
recommended <VBD>
interferon <NN>
for <IN>
hepatitis <NNS>
B <NNP>
, <,>
physicians <VBZ>
can <MD>
use <VB>
it <PRP>
any <DT>
way <NN>
they <PRP>
choose <VBP>
, <,>
and <CC>
Blumberg <NNP>
said <VBD>
some <DT>
doctors <NNS>
have <VBP>
already <RB>
begun <VBN>
prescribing <VBG>
it <PRP>
for <IN>
this <DT>
disease <NN>
. <.>
Doctors <NNS>
said <VBD>
the <DT>
latest <JJS>
study <NN>
is <VBZ>
big <JJ>
enough_so <RB>
physicians <NNS>
can <MD>
use <VB>
the <DT>
results <NNS>
to <TO>
predict <VB>
how <WRB>
interferon <NN>
will <MD>
affect <VB>
their <PRP$>
patients <NNS>
if <IN>
_ <NNP>
as <IN>
seems <NNS>
likely <JJ>
_ <NNP>
it <PRP>
becomes <VBZ>
the <DT>
standard <JJ>
medicine <NN>
for <IN>
hepatitis <NNS>
B <NNP>
. <.>
`` <``>
We <PRP>
can <MD>
be <VB>
relatively <RB>
sure <JJ>
what <WP>
doctors <NNS>
will <MD>
find <VB>
in <IN>
practice <NN>
: <:>
Ten <NNP>
percent <NN>
will <MD>
be <VB>
cured <VBN>
and <CC>
40 <CD>
or <CC>
50 <CD>
percent <NN>
will <MD>
be <VB>
made <VBN>
better <JJR>
and <CC>
their <PRP$>
liver_disease <NN>
will <MD>
be <VB>
stopped <VBN>
in <IN>
its <PRP$>
tracks <NNS>
, <,>
'' <''>
said <VBD>
Dr._Robert_P._Perrillo <NNP>
of <IN>
the <DT>
St._Louis_Veterans_Affairs_Medical_Center <NNP>
, <,>
the <DT>
principal <JJ>
author <NN>
of <IN>
the <DT>
study <NN>
. <.>
He <PRP>
defined <VBD>
a <DT>
cure <NN>
as <IN>
the <DT>
complete <JJ>
disappearance <NN>
of <IN>
the <DT>
virus <NN>
. <.>
Experts <NNS>
cautioned <VBD>
the <DT>
treatment <NN>
should <MD>
be <VB>
used <VBN>
only <RB>
for <IN>
those <DT>
with <IN>
chronic <JJ>
infections <NNS>
who <WP>
show <NN>
signs <VBZ>
of <IN>
liver <JJR>
damage <NN>
. <.>
The <DT>
results <NNS>
were <VBD>
published <VBN>
along_with <IN>
an <DT>
editorial <NN>
by <IN>
Dr._Jay_H._Hoofnagle <NNP>
of <IN>
the <DT>
National_Institute <NNP>
of <IN>
Diabetes <NNPS>
and <CC>
Digestive <NNP>
and <CC>
Kidney_Diseases <NNP>
. <.>
`` <``>
For <IN>
now <RB>
, <,>
interferon_alpha <NN>
offers <NNS>
the <DT>
best <JJS>
hope <NN>
'' <''>
for <IN>
treating <VBG>
chronic <JJ>
hepatitis <NNS>
B <NNP>
, <,>
Hoofnagle <NNP>
wrote <VBD>
. <.>
Hepatitis <NNP>
is <VBZ>
likely <JJ>
to <TO>
become <VB>
the <DT>
first_major <JJ>
use <NN>
for <IN>
interferon <NN>
. <.>
Isolating <VBG>
the <DT>
natural <JJ>
disease-fighting_substance <NN>
was <VBD>
one <CD>
of <IN>
the <DT>
early <JJ>
goals <NNS>
of <IN>
genetic <JJ>
engineering <NN>
. <.>
In <IN>
a <DT>
decade <NN>
of <IN>
testing <NN>
, <,>
interferon <NN>
has <VBZ>
turned <VBN>
out <RP>
to <TO>
be <VB>
useful <JJ>
against <IN>
a <DT>
variety <NN>
of <IN>
diseases <NNS>
, <,>
none <NN>
as <IN>
common <JJ>
as <IN>
hepatitis <NNS>
. <.>
The <DT>
FDA <NNP>
has <VBZ>
approved <VBN>
use <NN>
of <IN>
the <DT>
drug <NN>
for <IN>
hairy-cell <JJ>
leukemia <NN>
, <,>
AIDS-related <JJ>
Kaposi <NNP>
's <POS>
sarcoma <NN>
and <CC>
genital <JJ>
warts <NNS>
. <.>
In <IN>
hepatitis <NN>
B <NNP>
, <,>
Perrillo <NNP>
said <VBD>
the <DT>
treatment <NN>
appears <VBZ>
to <TO>
offer <VB>
the <DT>
best <JJS>
chance <NN>
of <IN>
a <DT>
cure <NN>
if <IN>
given <VBN>
during <IN>
the <DT>
first <JJ>
two <CD>
years <NNS>
of <IN>
infection <NN>
WSJ870722-0113 <DOCNO>
. <.>
A <DT>
new <JJ>
class <NN>
of <IN>
drugs <NNS>
that <WDT>
may <MD>
aid <VB>
in <IN>
fighting_cancer <NN>
, <,>
AIDS <NNP>
and <CC>
other <JJ>
diseases <NNS>
is <VBZ>
moving <VBG>
onto <IN>
biotechnology <NN>
's <POS>
center_stage <NN>
. <.>
The <DT>
experimental <JJ>
drugs <NNS>
are <VBP>
called <VBN>
blood-cell <-NONE->
colony <NN>
stimulating <VBG>
factors <NNS>
, <,>
or <CC>
CSFs <NNP>
. <.>
In <IN>
animal <JJ>
and <CC>
early <RB>
human <JJ>
tests <NNS>
, <,>
the <DT>
drugs <NNS>
have <VBP>
boosted_depressed <VBN>
numbers <NNS>
of <IN>
infection-fighting_white <JJ>
blood <NN>
cells <NNS>
to <TO>
normal <JJ>
and <CC>
even <RB>
above-normal <JJ>
levels <NNS>
. <.>
`` <``>
For <IN>
the <DT>
first <JJ>
time <NN>
, <,>
we <PRP>
are <VBP>
able <JJ>
to <TO>
regulate <VB>
blood <NN>
cells <NNS>
, <,>
'' <''>
says <VBZ>
David_Golde <NNP>
, <,>
a <DT>
researcher <NN>
at <IN>
the <DT>
University <NNP>
of <IN>
California <NNP>
in <IN>
Los_Angeles <NNP>
. <.>
`` <``>
That <DT>
is <VBZ>
a <DT>
revolutionary <JJ>
thing <NN>
. <.>
`` <``>
CSFs <NNS>
are <VBP>
n't <RB>
expected <VBN>
to <TO>
cure <VB>
cancer <NN>
or <CC>
acquired <VBN>
immune <JJ>
deficiency_syndrome <NN>
. <.>
But <CC>
they <PRP>
may <MD>
help <VB>
patients <NNS>
with <IN>
such <JJ>
diseases <NNS>
fight <MD>
off <VB>
potentially <RB>
fatal <JJ>
infections <NNS>
that <WDT>
take <VB>
advantage <NN>
of <IN>
their <PRP$>
weakened <VBN>
immune <NN>
systems <NNS>
. <.>
Scientists <NNS>
caution <NN>
that <IN>
the <DT>
CSFs <NNP>
' <POS>
benefits <NNS>
to <TO>
patients <NNS>
have <VBP>
n't <RB>
been_established <VBN>
, <,>
and <CC>
doing <VBG>
so <RB>
may <MD>
take <VB>
years <NNS>
. <.>
But <CC>
preliminary <JJ>
reports <NNS>
on <IN>
the <DT>
drugs <NNS>
, <,>
including <VBG>
one <CD>
expected <VBN>
to <TO>
appear <VB>
soon <RB>
in <IN>
the <DT>
New_England_Journal <NNP>
of <IN>
Medicine <NNP>
, <,>
show <NN>
they <PRP>
bolster <VBP>
certain <JJ>
kinds <NNS>
of <IN>
white <JJ>
blood <NN>
cells <NNS>
with <IN>
remarkable <JJ>
consistency <NN>
. <.>
That <DT>
has <VBZ>
created <VBN>
a <DT>
groundswell <NN>
of <IN>
optimism <NN>
among <IN>
medical <JJ>
researchers <NNS>
, <,>
who <WP>
hope <NN>
the <DT>
drugs <NNS>
will <MD>
enable <VB>
them <PRP>
to <TO>
`` <``>
dial <JJ>
up <IN>
'' <''>
blood-cell <NNP>
levels <NNS>
in <IN>
patients <NNS>
as_if <IN>
they <PRP>
were <VBD>
turning <VBG>
up <RP>
the <DT>
volume <NN>
on <IN>
a <DT>
radio <NN>
. <.>
Jerome_Groopman <NNP>
, <,>
a <DT>
researcher <NN>
at <IN>
New_England_Deaconess_Hospital <NNP>
in <IN>
Boston <NNP>
, <,>
says <VBZ>
, <,>
`` <``>
Preliminary <NNP>
trials <NNS>
indicate <VBP>
that <IN>
the <DT>
CSFs <NNP>
are <VBP>
the <DT>
most <RBS>
exciting <JJ>
and <CC>
promising <JJ>
'' <''>
of <IN>
biotechnology <NN>
's <POS>
immune-system <JJ>
modifiers <NNS>
, <,>
which <WDT>
include <VBP>
much-touted <JJ>
drugs <NNS>
like <IN>
interferon <NN>
and <CC>
interleukin-2 <-NONE->
. <.>
CSFs <NNS>
also <RB>
are <VBP>
winning <VBG>
acclaim <NN>
among <IN>
analysts <NNS>
, <,>
who <WP>
note <NN>
that <IN>
the <DT>
drugs <NNS>
are <VBP>
aimed <VBN>
at <IN>
well-defined <JJ>
markets <NNS>
. <.>
And <CC>
compared <VBN>
with <IN>
drugs <NNS>
like <IN>
interferon <NN>
, <,>
which <WDT>
have <VBP>
broad <VBN>
actions <NNS>
that <IN>
are <VBP>
difficult <JJ>
to <TO>
register <NN>
, <,>
`` <``>
CSFs <NNP>
have <VBP>
very <RB>
direct <JJ>
effects <NNS>
that <WDT>
make <VBP>
it <PRP>
easy <JJ>
to <TO>
devise <VB>
clinical <JJ>
trials <NNS>
needed <VBN>
to <TO>
get <VB>
them <PRP>
approved <VBD>
'' <''>
for <IN>
marketing <NN>
, <,>
says <VBZ>
Stuart_Weisbrod <NNP>
, <,>
an <DT>
analyst <NN>
with <IN>
Prudential-Bache <NNP>
Securities <NNPS>
Inc._Two <NNP>
of <IN>
the <DT>
new <JJ>
drugs <NNS>
are <VBP>
in <IN>
clinical <JJ>
trials <NNS>
: <:>
GM-CSF <JJ>
, <,>
made <VBN>
by <IN>
both <DT>
Genetics_Institute_Inc. <NNP>
and <CC>
Immunex_Corp. <NNP>
, <,>
which <WDT>
promotes <VBZ>
infection-fighting <JJ>
cells <NNS>
called <VBN>
granulocytes <NNS>
and <CC>
macrophages <NNS>
; <:>
and <CC>
GCSF <NNP>
, <,>
made <VBD>
by <IN>
Amgen_Corp. <NNP>
, <,>
which <WDT>
boosts <NNS>
granulocytes <VBZ>
. <.>
Scientists <NNS>
often <RB>
mention <NN>
a <DT>
closely <RB>
related <VBN>
substance <NN>
, <,>
erythropoietin <NN>
, <,>
or <CC>
EPO <NNP>
, <,>
in <IN>
the <DT>
same <JJ>
breath <NN>
with <IN>
CSFs <NNP>
. <.>
EPO <NNP>
, <,>
made <VBD>
by <IN>
both <DT>
Amgen <NNP>
and <CC>
Genetics_Institute <NNP>
, <,>
boosts <VBZ>
oxygen-carrying <JJ>
red <VBN>
blood <NN>
cells <NNS>
and <CC>
also <RB>
has <VBZ>
proved <VBN>
very <RB>
promising <JJ>
in <IN>
early_clinical <JJ>
trials <NNS>
. <.>
Scientists <NNS>
working <VBG>
with <IN>
CSFs <NNP>
emphasize <NN>
that <WDT>
the <DT>
benefits <NNS>
of <IN>
higher <JJR>
white-blood-cell <JJ>
counts <NNS>
induced <VBN>
by <IN>
the <DT>
drugs <NNS>
remain <VBP>
to <TO>
be <VB>
shown <VBN>
. <.>
But <CC>
many <JJ>
researchers <NNS>
say <VBP>
they <PRP>
believe <VBP>
the <DT>
drugs <NNS>
will <MD>
help <VB>
fight <NN>
diseases <NNS>
, <,>
citing <VBG>
the <DT>
well-established <JJ>
fact <NN>
that <IN>
patients <NNS>
with <IN>
very <RB>
low_white-blood-cell <JJ>
counts <NNS>
are <VBP>
prone <VBN>
to <TO>
infections <NNS>
. <.>
In <IN>
fact <NN>
, <,>
patients <NNS>
taking <VBG>
anti-cancer <NN>
drugs <NNS>
-- <:>
which <IN>
can <MD>
almost <RB>
knock <VB>
out <RP>
the <DT>
immune_system <NN>
-- <:>
sometimes <RB>
die <VB>
of <IN>
pneumonia <NN>
and <CC>
other_infectious <JJ>
diseases <NNS>
rather <RB>
than <IN>
cancer <NN>
. <.>
Sadly <RB>
, <,>
such <JJ>
patients <NNS>
often <RB>
have <VBP>
cancers <NNS>
that <IN>
might <MD>
be <VB>
arrested <VBN>
. <.>
Indeed <RB>
, <,>
doctors <NNS>
are <VBP>
more <RBR>
willing <JJ>
to <TO>
risk <VB>
giving <VBG>
heavy <JJ>
doses <NNS>
of <IN>
anti-cancer <JJ>
drugs <NNS>
to <TO>
patients <NNS>
they <PRP>
might <MD>
save <VB>
than <IN>
to <TO>
those <DT>
with <IN>
untreatable <JJ>
tumors <NNS>
. <.>
If <IN>
CSFs <NNP>
can <MD>
prevent <VB>
infections <NNS>
, <,>
physicians <NNS>
may <MD>
be <VB>
able <JJ>
to <TO>
prescribe <VB>
larger <JJR>
and <CC>
more <JJR>
frequent_chemotherapy <NN>
doses <NNS>
-- <:>
perhaps <RB>
extending <VBG>
cancer <NN>
victims <NNS>
' <POS>
lives <NNS>
by <IN>
years <NNS>
. <.>
Thus <RB>
, <,>
CSFs <NNP>
may <MD>
turn <VB>
out <RP>
to <TO>
be <VB>
potent <JJ>
weapons <NNS>
in <IN>
the <DT>
anti-cancer <NN>
arsenal <JJ>
-- <:>
without <IN>
having <NN>
to <TO>
pass <VB>
muster <NN>
in <IN>
long <JJ>
, <,>
expensive <JJ>
anti-cancer <NN>
tests <NNS>
. <.>
To <TO>
get <VB>
marketing_approval <NN>
for <IN>
the <DT>
drugs <NNS>
, <,>
`` <``>
I <PRP>
think <VBP>
it <PRP>
will <MD>
only <RB>
be <VB>
necessary <JJ>
to <TO>
show <VB>
reduced <VBN>
morbidity <NN>
from <IN>
infections <NNS>
rather <RB>
than_from <IN>
cancer <NN>
, <,>
'' <''>
says <VBZ>
Jordan_Gutterman <NNP>
, <,>
a <DT>
cancer_researcher_testing_GM-CSF <NN>
at <IN>
Houston <NNP>
's <POS>
M.D <JJ>
. <.>
Anderson_Hospital <NNP>
. <.>
A <DT>
spokesman <NN>
for <IN>
the <DT>
Food <NNP>
and <CC>
Drug_Administration <NNP>
says <VBZ>
it <PRP>
's <VBZ>
too <RB>
early <JJ>
to <TO>
comment <NN>
on <IN>
possible <JJ>
standards <NNS>
to <TO>
be <VB>
applied <VBN>
to <TO>
CSFs <NNP>
. <.>
Scientists <NNS>
also <RB>
are <VBP>
testing <VBG>
GM-CSF <JJ>
in <IN>
AIDS <NNP>
patients <NNS>
. <.>
The <DT>
AIDS <NNP>
virus <VBZ>
mainly <RB>
bludgeons <NNS>
immune <VBP>
cells <NNS>
that <IN>
GM-CSF <JJ>
is <VBZ>
n't <RB>
expected <VBN>
to <TO>
revive <VB>
. <.>
But <CC>
researchers <NNS>
hope <VBP>
that_by <IN>
revving <NN>
up <IN>
other <JJ>
immune <NN>
cells <NNS>
with <IN>
GM-CSF <JJ>
, <,>
they <PRP>
can <MD>
ward <VB>
off <RP>
`` <``>
opportunistic <JJ>
'' <''>
infections <NNS>
in <IN>
AIDS <NNP>
patients <NNS>
caused <VBD>
by <IN>
bacteria <NN>
, <,>
fungi <NN>
and <CC>
other <JJ>
microbes <NNS>
. <.>
The <DT>
drug <NN>
also <RB>
may <MD>
offset <VB>
immune_suppression <NN>
caused <VBD>
by <IN>
antibiotics <NNS>
and <CC>
AZT <NNP>
, <,>
the <DT>
only <JJ>
drug <NN>
approved <VBD>
so_far <RB>
to <TO>
treat <VB>
AIDS <NNP>
. <.>
According <VBG>
to <TO>
early <JJ>
reports <NNS>
, <,>
CSFs <NNP>
cause <NN>
only <RB>
minor_flu-like <JJ>
side <NN>
effects <NNS>
, <,>
such <JJ>
as <IN>
fever <NN>
, <,>
chills <NNS>
and <CC>
body <NN>
aches <NNS>
. <.>
Ironically <RB>
, <,>
three <CD>
of <IN>
18 <CD>
patients <NNS>
in <IN>
an <DT>
AIDS <NNP>
study <NN>
reported <VBD>
in <IN>
May <NNP>
developed <VBD>
signs <NNS>
of <IN>
infection <NN>
by <IN>
a <DT>
tuberculosis-like <JJ>
bacteria <NN>
after <IN>
taking <VBG>
GM-CSF <JJ>
. <.>
Boston <NNP>
's <POS>
Dr._Groopman <NNP>
, <,>
who <WP>
codirected <VBN>
the <DT>
study <NN>
, <,>
says <VBZ>
the <DT>
patients <NNS>
apparently <RB>
had <VBD>
been <VBN>
harboring <VBG>
the <DT>
bug <NN>
without <IN>
showing <NN>
it <PRP>
. <.>
He <PRP>
explains <VBZ>
that_before <IN>
they <PRP>
took <VBD>
GM-CSF <JJ>
their <PRP$>
immune <NN>
systems <NNS>
were <VBD>
too <RB>
depressed <VBN>
to <TO>
mount <VB>
normal <JJ>
responses <NNS>
to <TO>
the <DT>
bacteria <NN>
-- <:>
such <JJ>
as <IN>
fever <NN>
, <,>
a <DT>
sign <NN>
that <IN>
the <DT>
body <NN>
is <VBZ>
fighting <VBG>
back <RB>
. <.>
If <IN>
CSFs <NNP>
are <VBP>
approved <VBN>
for <IN>
marketing <NN>
, <,>
their <PRP$>
uses <NNS>
could <MD>
expand <VB>
rapidly <RB>
-- <:>
especially <RB>
if <IN>
larger <JJR>
clinical <JJ>
trials <NNS>
support <NN>
the <DT>
conclusion <NN>
that <IN>
they <PRP>
have <VBP>
few <JJ>
side <NN>
effects <NNS>
. <.>
The <DT>
drugs <NNS>
might <MD>
be <VB>
used <VBN>
, <,>
for <IN>
example <NN>
, <,>
to <TO>
push <VB>
normal <JJ>
immune <NN>
systems <NNS>
into <IN>
overdrive <JJ>
as <IN>
a <DT>
preventive <JJ>
measure <NN>
in <IN>
frail <NN>
, <,>
older <NN>
patients <NNS>
hospitalized <VBD>
for <IN>
broken <VBN>
bones <NNS>
. <.>
`` <``>
A <DT>
lot <NN>
of <IN>
people <NNS>
die <VB>
of <IN>
pneumonia <NN>
, <,>
'' <''>
says <VBZ>
Dr._Golde <NNP>
, <,>
the <DT>
UCLA <NNP>
researcher <NN>
, <,>
who <WP>
is <VBZ>
working <VBG>
with <IN>
GM-CSF <JJ>
. <.>
`` <``>
I <PRP>
would <MD>
like <VB>
to <TO>
ask <VB>
whether <IN>
we <PRP>
could <MD>
reduce <VB>
that <IN>
death_rate <NN>
. <.>
`` <``>
Scientists <NNS>
' <POS>
excitement <NN>
about <IN>
CSFs <NNP>
stems <NNS>
partly <RB>
from <IN>
the <DT>
light <JJ>
they <PRP>
are <VBP>
shedding <VBG>
on <IN>
the <DT>
immune_system <NN>
, <,>
a <DT>
complex <JJ>
system <NN>
whose <WP$>
actions <NNS>
are <VBP>
controlled <VBN>
by <IN>
messenger <NN>
molecules <NNS>
such <JJ>
as <IN>
CSFs <NNP>
. <.>
Last <JJ>
year <NN>
, <,>
for <IN>
example <NN>
, <,>
Genetics_Institute <NNP>
scientists <NNS>
identified <VBD>
a <DT>
new <JJ>
member <NN>
of <IN>
the <DT>
CSF <NNP>
family <NN>
called <VBN>
interleukin-3 <-NONE->
, <,>
or <CC>
IL-3 <-NONE->
, <,>
which <WDT>
apparently <RB>
affects <VBZ>
a <DT>
broad <JJ>
range <NN>
of <IN>
cells <NNS>
and <CC>
may <MD>
amplify <VB>
effects <NNS>
of <IN>
other <JJ>
CSFs <NNS>
. <.>
Moreover <RB>
, <,>
researchers <NNS>
are <VBP>
finding <VBG>
that <IN>
CSFs <NNP>
have <VBP>
other <JJ>
roles <NNS>
besides <VBZ>
increasing <VBG>
blood-cell <NN>
counts <NNS>
. <.>
`` <``>
When <WRB>
granulocytes <NNS>
sense <VBP>
bacteria <NNS>
, <,>
they <PRP>
get <VBP>
very <RB>
angry <JJ>
and <CC>
dump <VB>
out <RP>
a <DT>
toxic <JJ>
substance <NN>
that <WDT>
's <VBZ>
essentially <RB>
like <IN>
bleach <NN>
, <,>
'' <''>
says <VBZ>
Robert_Kamen <NNP>
, <,>
Genetics_Institute <NNP>
's <POS>
senior <JJ>
vice_president <NN>
, <,>
scientific <JJ>
affairs <NNS>
. <.>
`` <``>
Their <PRP$>
ability <NN>
to <TO>
be <VB>
angered <VBN>
is <VBZ>
increased <VBN>
by <IN>
GM-CSF <JJ>
, <,>
so <RB>
with <IN>
the <DT>
drug <NN>
, <,>
we <PRP>
can <MD>
both <DT>
increase_granulocyte <NN>
numbers <NNS>
and <CC>
prime <JJ>
them <PRP>
for <IN>
action <NN>
. <.>
`` <``>
And <CC>
G-CSF <JJ>
may <MD>
prove <VB>
directly <RB>
useful <JJ>
as <IN>
a <DT>
treatment <NN>
for <IN>
certain <JJ>
kinds <NNS>
of <IN>
leukemia <NN>
, <,>
or <CC>
blood-cell <NNP>
cancers <NNS>
. <.>
In <IN>
test-tube <JJ>
studies <NNS>
, <,>
the <DT>
drug <NN>
has <VBZ>
converted <VBN>
leukemia_cancer <NN>
cells <NNS>
that <WDT>
are <VBP>
multiplying <VBG>
out <RP>
of <IN>
control <NN>
into <IN>
normal <JJ>
cells <NNS>
, <,>
says <VBZ>
Philip_Whitcome <NNP>
, <,>
Amgen <NNP>
's <POS>
director <NN>
of <IN>
strategic <JJ>
planning <NN>
. <.>
Ultimately <RB>
, <,>
researchers <NNS>
hope <VBP>
to <TO>
use <VB>
combinations <NNS>
of <IN>
CSFs <NNP>
, <,>
perhaps <RB>
with <IN>
other_immune-system <JJ>
hormones <NNS>
, <,>
to <TO>
manipulate <VB>
the <DT>
immune_system <NN>
with <IN>
even <RB>
more <JJR>
power <NN>
and <CC>
precision <NN>
. <.>
Immunex <NNP>
, <,>
for <IN>
example <NN>
, <,>
recently <RB>
reported <VBD>
that <IN>
CSFs <NNP>
appear <VBP>
to <TO>
work <VB>
synergistically <RB>
with <IN>
interleukin-1 <-NONE->
, <,>
another <DT>
immune_messenger <NN>
, <,>
to <TO>
boost <VB>
white <JJ>
blood <NN>
cells <NNS>
. <.>
Christopher_Henney <NNP>
, <,>
Immunex <NNP>
's <POS>
scientific <JJ>
director <NN>
, <,>
says <VBZ>
the <DT>
company <NN>
hopes <VBZ>
the <DT>
combination <NN>
will <MD>
help_offset <VB>
cancer <NN>
patients <NNS>
' <POS>
immune_suppression <NN>
from <IN>
radiation <NN>
treatments <NNS>
AP901119-0032 <DOCNO>
. <.>
A <DT>
4-year-old <JJ>
with <IN>
a <DT>
rare <JJ>
form <NN>
of <IN>
leukemia <NN>
once <RB>
considered <VBN>
incurable <JJ>
has <VBZ>
apparently <RB>
beaten <VBN>
the <DT>
disease <NN>
after <IN>
being <VBG>
given <VBN>
a <DT>
transfusion <NN>
of <IN>
umbilical <JJ>
cord_blood <NN>
from <IN>
his <PRP$>
baby_sister <NN>
, <,>
doctors <NNS>
say <VBP>
. <.>
Michael_Sancilio <NNP>
of <IN>
Virginia_Beach <NNP>
left <VBD>
Johns_Hopkins_Hospital <NNP>
in <IN>
Baltimore <NNP>
on <IN>
Saturday <NNP>
three <CD>
months <NNS>
after <IN>
becoming <VBG>
the <DT>
first <JJ>
leukemia_patient <NN>
to <TO>
undergo <VB>
the <DT>
experimental <JJ>
transplant <NN>
. <.>
`` <``>
Although <IN>
doctors <NNS>
are <VBP>
reluctant <JJ>
to <TO>
say <VB>
Michael <NNP>
is <VBZ>
cured <VBN>
, <,>
Michael <NNP>
appears <VBZ>
to <TO>
have <VB>
defeated <VBN>
a <DT>
rare_form <NN>
of <IN>
leukemia <NN>
for <IN>
which <WDT>
previously <RB>
existed <VBD>
no <DT>
known_cure <NN>
, <,>
'' <''>
Virginia_BEach_General_Hospital <NNP>
said <VBD>
in <IN>
a <DT>
statement <NN>
. <.>
Doctors <NNS>
there <EX>
had <VBD>
collected <VBN>
so-called <JJ>
stem <NN>
cells <NNS>
from <IN>
his <PRP$>
sister <NN>
's <POS>
umbilical <JJ>
cord <NN>
for <IN>
transplant <NN>
in <IN>
Baltimore <NNP>
. <.>
Umbilical <JJ>
blood <NN>
, <,>
usually <RB>
discarded <VBD>
at <IN>
birth <JJ>
, <,>
is <VBZ>
rich <JJ>
in <IN>
stem <NN>
cells <NNS>
, <,>
which <WDT>
multiply_rapidly <RB>
to <TO>
form_bone_marrow <NN>
. <.>
Doctors <NNS>
gave <VBD>
Michael <NNP>
five <CD>
tablespoons <NNS>
of <IN>
the <DT>
blood <NN>
. <.>
Within <NNP>
one <CD>
month <NN>
, <,>
he <PRP>
began <VBD>
producing <VBG>
healthy <JJ>
bone_marrow <NN>
, <,>
doctors <NNS>
said <VBD>
. <.>
`` <``>
What <WP>
we <PRP>
are <VBP>
viewing <VBG>
this <DT>
afternoon <NN>
is <VBZ>
nothing <NN>
short <RB>
of <IN>
a <DT>
miracle <NN>
, <,>
'' <''>
Dr._Leslie_Wasserman_Jr. <NNP>
said <VBD>
Sunday <NNP>
. <.>
`` <``>
God <NNP>
deserves <VBZ>
all_the <DT>
credit <NN>
, <,>
'' <''>
said <VBD>
Michael <NNP>
's <POS>
grandmother <NN>
, <,>
Rachel_Sancilio <NNP>
. <.>
`` <``>
I <PRP>
prayed <VBD>
for <IN>
a <DT>
miracle <NN>
. <.>
It <PRP>
was <VBD>
the <DT>
most <JJS>
devastating <VBG>
thing <NN>
. <.>
My <PRP$>
heart <NN>
goes <VBZ>
out <RP>
to <TO>
any <DT>
family <NN>
that <IN>
has <VBZ>
to <TO>
go <VB>
through <RP>
something <NN>
like <IN>
this <DT>
. <.>
'' <''>
Umbilical <NNP>
cord_blood <NN>
transplants <NNS>
have <VBP>
been_performed <VBN>
three <CD>
other <JJ>
times <NNS>
, <,>
once <RB>
in <IN>
Cincinnati <NNP>
and <CC>
twice <NN>
in <IN>
France <NNP>
, <,>
to <TO>
treat <VB>
a <DT>
different <JJ>
disease <NN>
, <,>
Fanconi <NNP>
's <POS>
anemia <NN>
. <.>
Leukemia <NNP>
is <VBZ>
a <DT>
cancer <NN>
of <IN>
the <DT>
blood <NN>
and <CC>
bone_marrow <NN>
. <.>
Eight <NNP>
months <NNS>
ago <RB>
, <,>
Michael <NNP>
was <VBD>
diagnosed <VBN>
with <IN>
a <DT>
form <NN>
known <VBN>
as <RB>
chronic_myelogenous <JJ>
leukemia <NN>
, <,>
which <WDT>
can <MD>
not <RB>
be <VB>
controlled <VBN>
with <IN>
drugs <NNS>
and <CC>
usually <RB>
kills <VBZ>
within <IN>
a <DT>
year <NN>
of <IN>
diagnosis <NN>
. <.>
The <DT>
boy <NN>
's <POS>
sister <NN>
, <,>
Christina <NNP>
, <,>
was <VBD>
born <VBN>
May <NNP>
1 <CD>
. <.>
Michael <NNP>
's <POS>
blood_type <NN>
did <VBD>
not <RB>
match <VB>
hers <NNS>
, <,>
but <CC>
the <DT>
siblings <NNS>
were <VBD>
otherwise <RB>
compatible <JJ>
, <,>
and <CC>
doctors <NNS>
found <VBD>
that <IN>
he <PRP>
was <VBD>
not_overly <RB>
likely <JJ>
to <TO>
reject <VB>
the <DT>
umbilical <JJ>
cord_blood <NN>
. <.>
Because_of <IN>
the <DT>
procedure <NN>
, <,>
Michael <NNP>
has <VBZ>
`` <``>
another <DT>
chance <NN>
at <IN>
life <NN>
'' <''>
- <:>
and <CC>
a <DT>
new <JJ>
blood_type <NN>
, <,>
the <DT>
hospital <NN>
said <VBD>
. <.>
Doctors <NNS>
will <MD>
not <RB>
know <VB>
for_about <IN>
two <CD>
years <NNS>
whether <IN>
the <DT>
boy <NN>
is <VBZ>
cured <VBN>
. <.>
Christina <NNP>
is <VBZ>
healthy <JJ>
. <.>
